Page 1

NATIONAL QUALITY FORUM

+ + + + +

POPULATION HEALTH ENDORSEMENT MAINTENANCE

PHASE II STEERING COMMITTEE MEETING

+ + + + +

THURSDAY MAY 31, 2012

+ + + + +

The Steering Committee met at the National Quality Forum, 9th Floor Conference Room, 1030 15th Street, N.W., Washington, D.C., at 8:30 a.m., Paul Jarris and Kurt Stange, Co-Chairs, presiding.

PRESENT:

PAUL JARRIS, MD, MPH, Co-Chair KURT STANGE, MD, MPH, Co-Chair RON BIALEK

MADELINE NAEGLE ROBERT PESTRONK SUE PICKENS AMIR QASEEM SARAH SAMPSEL JASON SPANGLER MATT STIEFEL

MICHAEL STOTO

NQF STAFF: HELEN BURSTIN, MD, MPH KRISTIN CHANDLER, Project Analyst ELISA MUNTHALI, MPH, Senior Project Manager for Population Health ROBYN NISHIMI, NQF Consultant

Page 2

ALSO PRESENT:

PETER BRISS, CDC*

IAN CORBRIDGE, HRSA*

PEGGY HONORE, Office of the Assistant

Secretary

for Health, HHS

DAWN JACOBSON, Public Health Institute*

LORRAINE MAINO-FIKE, Moderator

NEIL MAIZLISH, California Department of Public

Health*

*Participating via teleconference

Pa	ge	3
C-O-N-T-E-N-T-S		
Welcome, Recap of Day 1	.4	
Recap of Recent Call for Measures	.6	
Perspectives on Increasing Response to Future		
Call for Population Health Measures	33	
Recommendations from the		
Commission Paper	78	
NQF Member/Public Comment	83	

	Page 4
1	P-R-O-C-E-E-D-I-N-G-S
2	8:39 a.m.
3	CO-CHAIR JARRIS: Good morning,
4	everyone, to Day 2 of our Population Health
5	Work Group Meeting. And we had a long and
6	tedious and productive day yesterday. In many
7	ways, I think it really laid out a lot of the
8	issues we want to discuss in depth today. And
9	today we'll have, first of all, a little bit
10	of review, a recap that Elisa can do of
11	yesterday. And I think it should be actually
12	a fairly interesting and engaging day today.
13	We have a facilitated conversation to look
14	around some of these issues, to look at:
15	What have we done to date?
16	What's going well?
17	What hasn't gone well?
18	We'll hear from a couple of
19	representatives of the measures community to
20	talk about why they think we got the response
21	we got and not a different response, how is
22	that field in terms of their receptivity to an

Page 5 NOF process as well as their readiness for it. 1 2 And from that, hopefully we'll be able to develop some common sense of a path forward; 3 recommendations, what can we do to improve the 4 5 field, improve the response to the call to 6 measures and also consider some more about 7 what some people raise as a round peg in a 8 square hole or a square peg in a round hole, 9 however that goes, and, you know, whether the 10 peg is right and the hole is right. So, how we can modify that process. 11 12 So, I think it should be an interesting day and really get us back to the 13 reason lots of us here is to try to develop 14 this field of population health measures that 15 can be applicable and ultimately drive 16 improvements in the health of the population 17 that are being served. 18 19 So, anyone else want to make any 20 opening comments? Okay. 21 Elisa, did you --22 MS. MUNTHALI: Thank you, and

	Page
1	welcome back.
2	I just wanted to remind everyone
3	that, you know, the meeting is being taped and
4	transcribed so please remember to speak into
5	the microphones.
6	Before we start our discussion
7	today we wanted to recap what happened
8	yesterday. And, as you know, the Steering
9	Committee evaluated and voted on nine
10	measures. There were four endorsed BMI
11	measures, some clinical BMI measures and five
12	newly submitted measures, one of which was
13	clinical BMI measure. And of those, the
14	Steering Committee has recommended three.
15	The first measure is Measure 1999
16	which is the late HIV diagnosis. It's a CDC
17	measure. It's a newly submitted measure to
18	the project.
19	The second measure is Measure 0029
20	counseling on physical activity in older
21	adults. It's a two part measure. The first
22	part is discussing physical activity and the

	Page 7
1	second part is advising on physical activity.
2	It's an NCQA measure which was previously
3	endorsed.
4	And the final measure is 0421
5	preventative care and screening: BMI
б	screening and follow-up. A CMS measure also
7	previously endorsed.
8	There were five measures that were
9	not recommended for endorsement.
10	The first one is 2014 place of
11	birth, a CDC newly submitted measure.
12	The second is 2018 year of arrival
13	to the U.S. for the foreign born. Also CDC
14	newly submitted measure.
15	0023 is a BMI measure for adults
16	18 and older from the City of New York,
17	Department of Health and Mental Hygiene. That
18	was also previously endorsed.
19	1690 is adult BMI assessment, NCQA
20	a newly submitted measure.
21	And 0024 BMI for children age 2 to
22	18 years of age. That was a previously

Page 8 1 endorsed measure from NCOA. 2 The Committee has held voting on a 3 newly submitted CDC measure. I'm sorry. 4 MEMBER SPANGLER: Elisa, I thought 5 0024 was passed yesterday. 6 MS. MUNTHALI: Okay. Sorry about 7 that. 8 MEMBER SPANGLER: Okay. 9 MS. MUNTHALI: So just a correction. 0024, the BMI measure for 10 11 children age 2 to 18 was passed. That was 12 recommended by the Steering Committee. This 13 is an NCQA measure that was previously 14 endorsed. 15 The Committee has held voting on 16 2020. This is adult current smoking 17 prevalence. It's a CDC newly submitted 18 measure. They had several questions for the 19 developer who was unable to attend. Staff has 20 been trying to reach them and we can't get a 21 hold of them. And so we do have some concerns 22 with this measure.

	Page 9
1	We wanted to share with the
2	Committee that just prior to this meeting just
3	last week the developer the staff developer
4	at Legacy left. And so I think some of this
5	turnover is probably indicative of them not
6	being able to attend the meeting yesterday.
7	So we will let you know what we can do in a
8	way of working with Legacy. We've spoken with
9	Ron and Ron is going to help us as well to
10	reach out to them.
11	So before we start the facilitated
12	discussion on trying to improve future
13	response to call for population health
14	measures, we want to give you some background
15	information on the recent call for measures.
16	This discussion was to take place yesterday,
17	but we ran out of time. So, we won't take too
18	long but much of this information you've heard
19	before.
20	The call for measures, as you
21	know, was developed by the Committee with
22	input from NQF staff. What we tried to do

i	
	Page 10
1	with the call is integrate priority areas for
2	healthy living and well-being from the NQS and
3	the NPP with a focus on community
4	interventions that result in improvement of
5	social, economic and environmental factors and
6	interventions that result in adoption of
7	health lifestyle behaviors across the life
8	span.
9	The call was also informed by the
10	Commission Paper on Population Health. Sorry.
11	MEMBER STOTO: I'll ask you what
12	NQS and NPP are.
13	MS. MUNTHALI: The National
14	Quality Strategy and the National Priorities
15	Partnership.
16	MEMBER STOTO: Okay.
17	MS. MUNTHALI: Sorry about that.
18	I'm so used to acronyms.
19	So the call was also informed by
20	the Commission Paper on Population Health
21	which was written by the Los Angeles
22	Department of Public Health and the Public

	Page 11
1	Health Institute. And in that paper the
2	authors presented an environmental scan on
3	existing population health measures and
4	provided gap analysis, but they also provides
5	conceptual frameworks for measuring population
6	health, the determinants of health and
7	improvement activities.
8	It took several months to finalize
9	the call, and this was due in part to the
10	delay in the paper development. But we felt
11	that it was important to wait for this work
12	because it was informative to developing the
13	call. And since this was the first time that
14	NQF had put out a call on population level
15	measures we wanted to make sure that we
16	received input and suggestions for refinement
17	throughout the entire development process.
18	And so we got input from our Consensus
19	Standards Approval Committee, which is a
20	standing committee of our Board. So the call
21	was finally posted in early April for 30 days.
22	Outreach was conducted prior to

	Page 12
1	and during the call for measures. The
2	Committee played an important role in our
3	outreach efforts. Just prior to posting the
4	call the Co-Chairs forwarded the draft call
5	for measures to external partners to gauge
6	their thoughts about the call: Did it make
7	sense, was it relevant to their work?
8	Committee members also arranged meetings with
9	potential submitters like Ron arranged a
10	meeting with us and Legacy.
11	They also put in a plug at your
12	individual meetings, during external webinars
13	and other fora.
14	As we do with our other consensus
15	development projects, particularly in new
16	areas like population health, NQF made sure
17	that the word got out about the call through
18	monthly webinars, developer webinars, our
19	member Council meetings, member communications
20	like our member blasts and alerts, one-in-one
21	calls that we had with developers in meetings
22	and our leadership. Helen and Janet met with

Page 13 1 our external partners to tell them that this 2 call was coming up. 3 And with regards to the response, we had several calls and many email exchanges 4 5 with potential submitters. There was a lot of 6 interest and enthusiasm, a lot of people 7 thought we were moving in the right direction 8 putting out this call for population health 9 measures. But as you know, we received just five measures and one of which was a clinical 10 BMI measure. But we've been very fortunate 11 12 through this process that potential developers 13 have been extremely forthcoming with the 14 reasons why they didn't submit. And these 15 included concerns about their testing completeness uncertainty, about testing 16 17 requirements. And where we heard this we made sure that we held calls with our 18 19 methodologists on staff with the developers to 20 determine whether or not they had the testing 21 requirements. 22 Many of them cited a lack of

Page 14 It could have been with their own 1 resources. 2 staffing or the time to gather information, or 3 to complete the submission form, or a testing And then some of them cited 4 of their measure. 5 competing priorities. 6 I mean, there are some that wanted 7 to submit to the project but perhaps were 8 thinking they could submit their proposal or 9 their measure for publication. 10 And so I think you have the outreach document. Kristin is going to share 11 12 that with you, but it was included in your briefing materials for this meeting. 13 And we 14 just wanted you to look at that. 15 We've been noting all of the communication that we've had with developers 16 17 and so you can get a sense of who we've talked 18 to, some of the reasons that they've cited in 19 greater detail. 20 And so that's it for me. We're 21 waiting for our facilitator. 22 DR. BURSTIN: She's parking.

	Page 15
1	MS. MUNTHALI: Okay. Great.
2	CO-CHAIR JARRIS: Any questions or
3	comments? Ron?
4	MEMBER BIALEK: I do have one
5	question, which is the implication of us not
6	endorsing the measure, especially a measure
7	that had previously been endorsed is there any
8	implication?
9	DR. BURSTIN: We do it all the
10	time.
11	MEMBER BIALEK: Okay.
12	DR. BURSTIN: So we do it all the
13	time. In fact, as we've raised the bar on
14	endorsement many of the measures endorsed
15	three, four, five years ago are not being re-
16	upped for endorsement. The implications are
17	sometimes if they're a national reporting
18	programs, they need to be eventually pulled
19	out of those programs, retired; that usually
20	happens over a period of time. But beyond
21	that, no.
22	CO-CHAIR JARRIS: And also is can

	Page 16
1	you explain the appeals process? Because the
2	NQS folks yesterday indicated they may appeal
3	our decision on the BMI, which is fine because
4	we don't have the full perspective of all
5	these measures and I think that's what an
6	appeals process is for.
7	DR. BURSTIN: Right. So there's
8	two kinds of appeals, one of which is a
9	measure makes it all the way through, at the
10	end of the process anybody can appeal saying
11	"Hey, one more time," as just happened with
12	our hospital wide all cause readmission
13	measures, the bane of our existence for the
14	last six months, just got appealed. So at the
15	end of the process anybody can say still I
16	don't agree with the process, it should have
17	been no.
18	On the other hand if it's during
19	the course of a project and the Steering
20	Committee does not recommend a measure, they
21	have the option of getting a second opinion
22	from the CSAC, which is what they'll do where

	Page 17
1	they're review the process, review what the
2	ratings and criteria were. They rarely
3	overturn what Steering Committees do. They
4	don't like to redo Steering Committee
5	business. They really just make sure their
6	process was followed, the criteria were
7	appropriately met or not met.
8	CO-CHAIR JARRIS: Other questions?
9	Perhaps we could, two options. We
10	could just take a minute to look over this
11	measure of developer outreach if people
12	haven't digested that. The other thing we
13	could do is just get started with Peter and
14	Neil.
15	Peter and Neil, are you on the
16	line?
17	Operator, could you check if Peter
18	Briss and Neil Maizlish are on the line?
19	OPERATOR: And that is Peter -
20	DR. BURSTIN: Peter Briss and Neil
21	Maizlish.
22	OPERATOR: Okay, thank you.

	Page 18
1	CO-CHAIR JARRIS: While we're
2	checking on that, Peggy did you want to at all
3	address the group about some of the work
4	you're doing with CMMI? We're putting you on
5	the spot, so if you're not ready, that's okay.
6	So Peggy Honore is going to come
7	up from Health and Human Services the Offices
8	of the Assistant Secretary for Health and talk
9	a little bit about the work that she is doing
10	as she has detailed some of her time to CMMI,
11	Center for Medicare and Medicaid Innovation.
12	DR. BRISS: Hi. This is Petter
13	Briss. I just wanted to let you know that I'm
14	here.
15	CO-CHAIR JARRIS: Okay. Peter,
16	we'll get to you right after Peggy then.
17	Thank you. And you and Neil, thanks.
18	MS. HONORE: Thank you, Paul, for
19	inviting me to speak tot he group this
20	morning.
21	Yes, I am working in the
22	population health arm of the Innovation Center

	Page 19
1	in CMMI. The population health work is really
2	in its infancy at this point in time. We are
3	beginning to look at population health
4	measures. But I can tell you one of the
5	biggest barriers that I see, and others also,
6	is for the clinical side of healthcare to
7	really embrace and understand the concept of
8	population health. It's been very difficult
9	at times articulating and coming to a common
10	or consensus on exactly what is population
11	health and how it actually relates to the work
12	of clinicians. That's something that they are
13	rigorously working on by having a series of
14	webinars and listening sessions, especially
15	with the group of pioneers at CMS. So, it's
16	just going to be a process that,
17	unfortunately, we're going to have to go
18	through that impacts probably the low response
19	rate that we see here with this call for
20	measures.
21	You know, there's even confusion
22	over whether or not it's even a legitimate

1	
	Page 20
1	concept of population health, believe it or
2	not. Those of us who work with this all the
3	time understand it and the leadership at CMS
4	certainly understands it as well, but it's
5	pushing that out and getting others to embrace
6	the usefulness of this.
7	So, that's an overview.
8	CO-CHAIR JARRIS: I understand the
9	work on population health measures is at this
10	point, sort of in limbo and on hold. Can you
11	let us know the status of what that is?
12	MS. HONORE: Well, it's not
13	because there isn't strong interest, but it's
14	because you know there's so many other
15	initiatives going on in the Innovation Center
16	such as, you know, the challenge grants and
17	some of the grants that will be coming out
18	soon. I'm really not at liberty to talk in
19	detail about those, but there will be some
20	things coming out. So it's just that the
21	attention has been split in so many
22	directions. And it isn't that work has

	Page 21
1	totally stopped, but those of us who have been
2	working on population health have been busy
3	looking at some other things.
4	So I would expect in the short
5	term that work will pick up again on that, and
б	perhaps I can even suggest to Jim Hester that,
7	you know a visit with this group or
8	conversation with this group could be helpful.
9	I know Matt Stiefel has provided
10	tremendous input that has been very well
11	received by CMS. So, that's one way that this
12	group has had involvement and engagement, but
13	I think perhaps you know I could suggest to
14	Jim that a broader conversation of this group
15	as well.
16	MEMBER STOTO: I just wanted to
17	clarify. You were talking about population
18	health measures within the CMS Innovation
19	Center, is that
20	CO-CHAIR JARRIS: Correct.
21	MEMBER STOTO: Okay. Thank you.
22	CO-CHAIR JARRIS: As a measure

Page 221developer. Since we're not a measure2developer, we're a measure endorser, or not.3CO-CHAIR STANGE: Peggy, is there4anything interesting happening talking about5the denominator for accountable health6organizations and looking at accountable to7who and any work looking at ACOs actually8having accountability for the health of a9local community?10MS. HONORE: I'm not intimately11involved with the ACO activity. There is, you12know a lot of ongoing continuing dialogue. I13couldn't tell you specifically to answer your14point. But there is a lot of dialogue and I15would suspect that that will continue.16CO-CHAIR JARRIS: Any other17questions for Peggy?18Peter and Neil, if we could hold19you one more minute.20Facilitator, are you21OPERATOR: To ask a question press22star and the number one on your telephone key		
2 developer, we're a measure endorser, or not. 3 CO-CHAIR STANGE: Peggy, is there 4 anything interesting happening talking about 5 the denominator for accountable health 6 organizations and looking at accountable to 7 who and any work looking at ACOs actually 8 having accountability for the health of a 9 local community? 10 MS. HONORE: I'm not intimately 11 involved with the ACO activity. There is, you 12 know a lot of ongoing continuing dialogue. I 13 couldn't tell you specifically to answer your 14 point. But there is a lot of dialogue and I 15 would suspect that that will continue. 16 CO-CHAIR JARRIS: Any other 17 questions for Peggy? 18 Peter and Neil, if we could hold 19 you one more minute. 20 Facilitator, are you 21 OPERATOR: To ask a question press		Page 22
3 CO-CHAIR STANGE: Peggy, is there 4 anything interesting happening talking about 5 the denominator for accountable health 6 organizations and looking at accountable to 7 who and any work looking at ACOs actually 8 having accountability for the health of a 9 local community? 10 MS. HONORE: I'm not intimately 11 involved with the ACO activity. There is, you 12 know a lot of ongoing continuing dialogue. I 13 couldn't tell you specifically to answer your 14 point. But there is a lot of dialogue and I 15 would suspect that that will continue. 16 CO-CHAIR JARRIS: Any other 17 questions for Peggy? 18 Peter and Neil, if we could hold 19 you one more minute. 20 Facilitator, are you 21 OPERATOR: To ask a question press	1	developer. Since we're not a measure
4anything interesting happening talking about5the denominator for accountable health6organizations and looking at accountable to7who and any work looking at ACOs actually8having accountability for the health of a9local community?10MS. HONORE: I'm not intimately11involved with the ACO activity. There is, you12know a lot of ongoing continuing dialogue. I13couldn't tell you specifically to answer your14point. But there is a lot of dialogue and I15would suspect that that will continue.16CO-CHAIR JARRIS: Any other17questions for Peggy?18Peter and Neil, if we could hold19you one more minute.20Facilitator, are you21OPERATOR: To ask a question press	2	developer, we're a measure endorser, or not.
5 the denominator for accountable health 6 organizations and looking at accountable to 7 who and any work looking at ACOs actually 8 having accountability for the health of a 9 local community? 10 MS. HONORE: I'm not intimately 11 involved with the ACO activity. There is, you 12 know a lot of ongoing continuing dialogue. I 13 couldn't tell you specifically to answer your 14 point. But there is a lot of dialogue and I 15 would suspect that that will continue. 16 CO-CHAIR JARRIS: Any other 17 questions for Peggy? 18 Peter and Neil, if we could hold 19 you one more minute. 20 Facilitator, are you 21 OPERATOR: To ask a question press	3	CO-CHAIR STANGE: Peggy, is there
 organizations and looking at accountable to who and any work looking at ACOs actually having accountability for the health of a local community? MS. HONORE: I'm not intimately involved with the ACO activity. There is, you know a lot of ongoing continuing dialogue. I couldn't tell you specifically to answer your point. But there is a lot of dialogue and I would suspect that that will continue. CO-CHAIR JARRIS: Any other questions for Peggy? Peter and Neil, if we could hold you one more minute. DERATOR: To ask a question press 	4	anything interesting happening talking about
 who and any work looking at ACOs actually having accountability for the health of a local community? MS. HONORE: I'm not intimately involved with the ACO activity. There is, you know a lot of ongoing continuing dialogue. I couldn't tell you specifically to answer your point. But there is a lot of dialogue and I would suspect that that will continue. CO-CHAIR JARRIS: Any other questions for Peggy? Peter and Neil, if we could hold you one more minute. Facilitator, are you OPERATOR: To ask a question press 	5	the denominator for accountable health
 having accountability for the health of a local community? MS. HONORE: I'm not intimately involved with the ACO activity. There is, you know a lot of ongoing continuing dialogue. I couldn't tell you specifically to answer your point. But there is a lot of dialogue and I would suspect that that will continue. CO-CHAIR JARRIS: Any other questions for Peggy? Peter and Neil, if we could hold you one more minute. Facilitator, are you OPERATOR: To ask a question press 	6	organizations and looking at accountable to
9 local community? 10 MS. HONORE: I'm not intimately 11 involved with the ACO activity. There is, you 12 know a lot of ongoing continuing dialogue. I 13 couldn't tell you specifically to answer your 14 point. But there is a lot of dialogue and I 15 would suspect that that will continue. 16 CO-CHAIR JARRIS: Any other 17 questions for Peggy? 18 Peter and Neil, if we could hold 19 you one more minute. 20 Facilitator, are you 21 OPERATOR: To ask a question press	7	who and any work looking at ACOs actually
 MS. HONORE: I'm not intimately involved with the ACO activity. There is, you know a lot of ongoing continuing dialogue. I couldn't tell you specifically to answer your point. But there is a lot of dialogue and I would suspect that that will continue. CO-CHAIR JARRIS: Any other questions for Peggy? Peter and Neil, if we could hold you one more minute. Facilitator, are you OPERATOR: To ask a question press 	8	having accountability for the health of a
 involved with the ACO activity. There is, you know a lot of ongoing continuing dialogue. I couldn't tell you specifically to answer your point. But there is a lot of dialogue and I would suspect that that will continue. CO-CHAIR JARRIS: Any other questions for Peggy? Peter and Neil, if we could hold you one more minute. Facilitator, are you OPERATOR: To ask a question press 	9	local community?
12 know a lot of ongoing continuing dialogue. I 13 couldn't tell you specifically to answer your 14 point. But there is a lot of dialogue and I 15 would suspect that that will continue. 16 CO-CHAIR JARRIS: Any other 17 questions for Peggy? 18 Peter and Neil, if we could hold 19 you one more minute. 20 Facilitator, are you 21 OPERATOR: To ask a question press	10	MS. HONORE: I'm not intimately
<pre>13 couldn't tell you specifically to answer your 14 point. But there is a lot of dialogue and I 15 would suspect that that will continue. 16 CO-CHAIR JARRIS: Any other 17 questions for Peggy? 18 Peter and Neil, if we could hold 19 you one more minute. 20 Facilitator, are you 21 OPERATOR: To ask a question press</pre>	11	involved with the ACO activity. There is, you
14 point. But there is a lot of dialogue and I 15 would suspect that that will continue. 16 CO-CHAIR JARRIS: Any other 17 questions for Peggy? 18 Peter and Neil, if we could hold 19 you one more minute. 20 Facilitator, are you 21 OPERATOR: To ask a question press	12	know a lot of ongoing continuing dialogue. I
15 would suspect that that will continue. 16 CO-CHAIR JARRIS: Any other 17 questions for Peggy? 18 Peter and Neil, if we could hold 19 you one more minute. 20 Facilitator, are you 21 OPERATOR: To ask a question press	13	couldn't tell you specifically to answer your
<pre>16 CO-CHAIR JARRIS: Any other 17 questions for Peggy? 18 Peter and Neil, if we could hold 19 you one more minute. 20 Facilitator, are you 21 OPERATOR: To ask a question press</pre>	14	point. But there is a lot of dialogue and I
<pre>17 questions for Peggy? 18 Peter and Neil, if we could hold 19 you one more minute. 20 Facilitator, are you 21 OPERATOR: To ask a question press</pre>	15	would suspect that that will continue.
Peter and Neil, if we could hold you one more minute. Facilitator, are you OPERATOR: To ask a question press	16	CO-CHAIR JARRIS: Any other
<pre>19 you one more minute. 20 Facilitator, are you 21 OPERATOR: To ask a question press</pre>	17	questions for Peggy?
20 Facilitator, are you 21 OPERATOR: To ask a question press	18	Peter and Neil, if we could hold
21 OPERATOR: To ask a question press	19	you one more minute.
	20	Facilitator, are you
22 star and the number one on your telephone key	21	OPERATOR: To ask a question press
	22	star and the number one on your telephone key

	Page 23
1	pad.
2	CO-CHAIR JARRIS: I'm sorry,
3	Operator. We actually weren't asking for
4	public input at this point. We were just
5	discussing with our facilitator whether she
6	was ready.
7	Peggy, do you have any advice or
8	feedback for this group based on what you've
9	been observing?
10	MS. HONORE: I've been very
11	impressed with what I've seen the last two
12	days that I've sat through the meetings. You
13	know, I would just like to say that you know
14	I know that there was a low response rate, but
15	I think that this barrier with getting people
16	to understand the concept of public health
17	I mean of population health is probably a
18	bigger barrier than anyone here probably
19	initially realized. But the concept of
20	population health is so new, so outside of the
21	way in a traditional healthcare setting that
22	people think about healthcare that it's just

Page 24 1 going to take some time to get over that 2 hurdle. 3 CO-CHAIR STANGE: Peggy, are you 4 able to say anything about the HHS Director's 5 Office interest in any ongoing supporting 6 initiative like this within NOF? 7 MS. HONORE: I can certainly 8 explore that if you could define it for me 9 better. Not now, but that could be explored. 10 DR. BURSTIN: And I think part of the goal of today is to actually think about 11 12 what are the logical next steps, particularly what can NQF help validate to this discussion. 13 14 So that may be helpful and we may get a good 15 sense of that through the course of this discussion. 16 17 MS. HONORE: Okay. 18 MEMBER QASEEM: In your opinion, 19 primary care physicians do you think they're 20 more open, that there is a need for 21 essentially something like performance 22 measures in this arena? Because it's such a

	Page 25
1	new field, like you were saying, and do you
2	have any opinion on that? Where does the
3	primary care clinicians or where do they
4	stand? And I'm just asking because, I'm
5	sorry, I came in late. I don't know what's
6	your background, but you're involved with them
7	or not.
8	MS. HONORE: I really would not be
9	the appropriate person to make a blanket
10	statement about what primary care physicians
11	thinks or the way they behave. But I can say
12	that I can see interest in population health,
13	population health measurement. I can see it
14	growing and people beginning to understand the
15	value of it.
16	MEMBER QASEEM: So this interest,
17	where is it coming from? You're saying there
18	is interest, would you be able to tell there
19	is interest from who?
20	MS. HONORE: Well, I think any
21	time the government, you know initiates a
22	program and there's funding to support that

	Page 26
1	program that it provides an incentive for
2	people to become engaged and involved. And
3	some of the work that is going on at the
4	Innovation Center I think is going to promote
5	that over time. They have a very worthwhile
6	agenda and I think over time that it is
7	resonating.
8	CO-CHAIR JARRIS: Okay. Very
9	good. Thank you, Peggy.
10	One of the things you might
11	consider is an innovation grant to develop
12	measures because this takes support and there
13	is no support for it right now.
14	Amir, did you
15	MEMBER QASEEM: So this question
16	is for the whole Committee. I'm just curious
17	do you guys have an answer of where this
18	primary care stands in terms of this?
19	CO-CHAIR STANGE: This is Kurt.
20	There's a special issue, a
21	combined issue of American Journal of
22	Preventive Medicine and American Journal of

	Page 27
1	Public Health coming out very soon that will
2	have a lot of papers to address that. One of
3	the papers is actually from a student of mine
4	who spent time interviewing various policy
5	people in Washington and found a tremendous
6	interest. And I think that anybody that is
7	able to step back, anybody in primary care is
8	able to step back from the hamster wheel of
9	day-to-day life and look at where things are
10	going, where the need is sees the strong need
11	for primary care to be much more integrated
12	with community and population and public
13	health approaches. And there are various
14	pilots that are going on around the country
15	that are exploring that.
16	And if you look at the historical
17	roots of primary care, if you look at the
18	definition of primary care it really includes
19	a population health focus practiced in the
20	context of family and community. So that is
21	the roots.
22	What has happened over the last

	Page 28
1	decade, in part actually because of the
2	plethora of disease specific quality measures
3	is that primary care has started to lose touch
4	with that root and has come to think of
5	quality as just doing a good job one disease
6	at a time where it really is the integrating
7	prioritizing personalizing functions of
8	primary care that are the source of the added
9	benefit that it is what provides meaning to
10	practitioners, provides value to patients and
11	value to society. So we're actually squeezing
12	this out. It is a core root thing.
13	So if you talk to people on the
14	front lines they're just barely trying to get
15	through the days right now. Anybody who gets
16	a chance to step back really sees the value of
17	this and it's what they would like in their
18	hearts and at the root to do. And it's what
19	I think anyone that looks at what our health
20	care system needs recognizes that we need a
21	better integration of primary care and public
22	and community health.

	Page 29
1	CO-CHAIR JARRIS: There are also
2	some thoughtful people in emergency medicine,
3	because in many ways ER absorbs the failures
4	of our society whereas violence, drugs, you
5	know uninsurance, unemployment. And again,
6	when they can step back there's some real
7	interesting thoughts among ER physicians about
8	what really would need to happen in the
9	community to prevent the failures that they
10	end up dealing with.
11	DR. BURSTIN: It'll also be
12	interesting to see as the emergence of the
13	medical home continues to move forward, maybe
14	we're waiting to see medical home, the CAHPS
15	for example. I don't know whether it will deal
16	with some of these whole health population
17	kinds of issues. It'll be interesting to see.
18	CO-CHAIR JARRIS: Matt?
19	MEMBER STIEFEL: I think another
20	important development to watch is the
21	Community Health Needs Assessments that are
22	driven by the Affordable Care Act, and that's

	Page 30
1	causing hospital systems and large health
2	systems in the country to really think a lot
3	more actively about these kinds of measures.
4	Paul Stange, are you any relation?
5	CO-CHAIR STANGE: No.
6	MEMBER STIEFEL: At CDC has been
7	working to try to develop a consistent and
8	coordinated framework for those Community
9	Health Need Assessments. And I think that's
10	a very significant opportunity.
11	CO-CHAIR JARRIS: There is
12	potential. Bobby and I have been working a
13	lot with American Hospital Association,
14	Catholic Hospital Association and others
15	trying to bring public health together with
16	that. And I'd say that there's a spectrum of
17	possibilities out there.
18	One end you have a strict
19	compliance with the 990 form, your accountant
20	will get you through this process. On the
21	other hand, there are some real innovators
22	looking at how hospitals and health systems

Page 31 1 can improve the health of the community and 2 there's everything in between. And I think we have to go through a -- if we're going to get 3 4 more people moving down that spectrum to a 5 meaningful engagement with the community and 6 what's going on, we have to go through a long 7 change process. And then there's also much 8 more comfort with the notion of engaging the 9 community and others in the assessment than there is comfort with engaging the community 10 and others in the actual plan or activity to 11 12 improve the health. Because that creates a 13 level of accountability that many people don't 14 want to go to in the hospital community. 15 So, it's an interesting time of trying to define what the full potential of 16 17 that is, which is incredible. But then it's going to be a long change process to make it 18 19 happen. 20 Mike? 21 MEMBER STOTO: I want to agree 22 with both of those points. And I think it's

Page 32 1 really important that we think through what 2 are the potential uses of these measures, 3 including the second part that you said. Because I don't think that we -- for two 4 5 reasons. 6 One is that at the moment I don't 7 think the developers have incentives to do it 8 because they don't know about how they'll be 9 used. The other thing is I think that when we 10 think about the uses, that'll help us to think through some of the criteria: What would make 11 12 a good measure and what should be included as well. 13 The other thing I'd like to add is 14 15 that the accreditation standards also call for 16 using different words to saying two things: Community Health Needs Assessments and the 17 18 Improvement Plans. 19 Yes, Bobby's can CO-CHAIR JARRIS: 20 talk about that for a long time. That's part 21 of what our interest here is requirements on 22 the public health community which are the same

	Page 33
1	requirements on the nonprofit hospitals and
2	why couldn't we put this process together. And
3	some get that and some I've seen some very
4	interesting letters about how this is an
5	attempt by public health to co-op the
6	hospital's resources to their own means. So,
7	yes, everywhere from this is you know sort
8	of war to what a good idea and we have a big
9	change process in front of us.
10	Why don't we take an opportunity
11	to Elisa, would you like to do some
12	introductions and then Peter and Neil, we'll
13	get to you next.
14	MS. MAINO-FIKE: Thank you.
15	Hi. I'm Lorraine Maino-Fike. As
16	you can see if you're here in the room, I am
17	your facilitator for the rest of the morning
18	in this conversation.
19	I've had some positive experience
20	with NQF and our organization has worked with
21	NQF in arranging and facilitating meetings
22	before. So I am somewhat familiar with the

Page 34 organization and happy to be here. 1 2 My role is simply as facilitator in this discussion trying to work you through 3 what are some of the causes of the low 4 5 response rate in this call for measures and what you can do about that. 6 7 I am trying to make sure that we 8 also hear from the contributors that we have 9 remotely on the phone. Peter Briss from the CDC and Neil Maizlish who is from the 10 California Department of Public Health. So 11 12 we'll make sure to get their participation and feedback in the course of the morning 13 14 conversation. 15 CO-CHAIR JARRIS: Thanks, 16 Lorraine. 17 I would say certainly we want to get to some of the -- you know, it's important 18 19 to look at the response rate and figure out 20 sort of the engineering of that process and 21 how it can be re-engineered. But I think we 22 also want to go way beyond that to look at

	Page 35
1	what is the purpose of this group, what is the
2	readiness of the field in general and how do
3	we facilitate development of this concept in
4	the field as well as how do we facilitate the
5	NQF process so those things can come together.
6	So although we want to get to some of the duct
7	tape and hard wiring, it's the bigger issue I
8	think we also need to get to.
9	MS. MAINO-FIKE: Well, I'm more
10	comfortable with standing next to the flip
11	chart. Part of what I think the benefit of
12	having a facilitator for a meeting like this
13	is that I can try to capture visually here on
14	the flip chart, you know low tech old
15	fashioned flip chart what some of the themes
16	of the conversation are.
17	Now, can the folks who are on the
18	phone hear me if I step away from this mic.
19	MS. MUNTHALI: If you're using the
20	microphone.
21	MS. MAINO-FIKE: Okay. Perfect.
22	All right.

	Page 36
1	So, as you said, thank you. We
2	want to look at the narrow focus of what are
3	some of the things that we think contributed
4	to or you all think contributed to the lower
5	than desired response rate. I think as we
6	said earlier, if you spend a little time
7	looking at or clarifying the uses and
8	objectives of the measures, then that might
9	drive your conversation around what those
10	measures might be or the criteria for them.
11	And then we can hear from our colleagues on
12	the phone regarding what might entice them or
13	what is in it for them in terms of responding
14	so we can get their perspective.
15	That conversation begs the larger
16	question, as you said, of then and we can
17	entertain this conversation as well: What
18	might be next? Might there be any role in
19	marrying measures with this population health?
20	And it seems as though now is the time to look
21	at what leverages among different
22	organizations might be out there for you all

ſ
	Page 37
1	to take advantage of.
2	So if I might first have you all
3	start with I know you did a little work
4	yesterday regarding what some of the
5	improvement opportunities were. What were
6	some of the themes that came out of that if
7	you want to capture them for the folks that
8	weren't a part of that?
9	For folks on the phone, we're
10	going to be pulling up some of the ideas that
11	were captured yesterday regarding what could
12	improve the response rate from support these
13	quality measures. However, we also want to
14	just bring you up to speed on what the initial
15	concerns or thoughts were there.
16	CO-CHAIR STANGE: The other
17	things, we're also looking at the larger
18	opportunity. I think many of us joined this
19	Committee with the idea that there is
20	something potentially transformative about
21	measuring the health and health determinants
22	of a population of a community. And that what

Page 38 1 gets measured tends to be what gets paid 2 attention to, so there's something very helpful in measuring that. So there's a large 3 opportunity and it is a frame shift for the 4 NOF that's been focused on clinical measures. 5 6 Healthcare is certainly a health 7 determinant, but it's also the big sucking 8 sound in our society that's pulling resources away from some of the social and environmental 9 determinants of health. So there is that 10 larger frame for what we're doing and part of 11 12 the frame shift that we're looking at starting 13 with a process and a system that's really very 14 healthcare focused in trying to shift the 15 frame of reference to how we might focus on 16 measuring what's important to advance the 17 health of the population as opposed to improve 18 the quality of the healthcare of a population. 19 So that's a little bit bigger frame for the 20 question. 21 CO-CHAIR JARRIS: Mike? 22 MEMBER STOTO: Another idea from

Page 39 yesterday I wanted to bring back is the one 1 2 that we've talked about -- about a population, 3 may be the population covered by an ACO or some other healthcare unit. And population 4 5 measurements that are not just outcomes, but measures -- okay. So we need measures that are 6 7 not just health outcomes, but measures that 8 really relate to processes and, for instance 9 that relate to those kinds of units. 10 So for instance, rather than 11 measuring immunization among the people who 12 happen to have come in for care during a given 13 year, you look at immunization coverage among 14 everybody who is a member of that population. CO-CHAIR JARRIS: Or even the 15 16 outbreak of vaccine-preventable diseases like 17 pertussis in a community. 18 MEMBER STOTO: Sure. 19 CO-CHAIR JARRIS: Or measles that 20 we're seeing now. 21 MEMBER STOTO: But the point here 22 is that I think that there are process

Page 40 measures within the covered populations as 1 2 opposed to geographical populations that those measures are different if you think about the 3 4 population as opposed to the quality of care 5 provided to the people who happen to come in. MS. MAINO-FIKE: Right. So if we 6 7 look at the measures that this group thinks 8 would be helpful moving forward, I hear what 9 you said. Both outcome based measures as well 10 as process based measures. Are there other categories that we 11 12 want to make sure to capture in terms of what would make good measures? 13 14 CO-CHAIR JARRIS: Go ahead, Bobby. 15 There is another MEMBER PESTRONK: set of dimensions which I think Mike 16 17 referenced we talked about yesterday that have 18 to do with a geographic catchment area versus an organizational catchment area. Having to 19 20 do with the political catchment area or some 21 other community-based catchment area. There's 22 another dimension that has to do with what

	Page 41
1	types of populations are we looking at,
2	specific racial and ethnic groups or people of
3	color or not. So in thinking about measuring
4	population health there are multiple
5	dimensions I think need to be considered.
6	MS. MAINO-FIKE: Right.
7	MEMBER PESTRONK: And we have to I
8	think clearly define for the purposes of NQF
9	what the communities of interests are because
10	I think we stumbled around that yesterday in
11	trying to figure out, okay, is this an
12	appropriate measure for this group to consider
13	or should that be considered in another group.
14	MS. MAINO-FIKE: Yes. So with this
15	notion of measures there are outcome type
16	measures, process type measures, different
17	populations that you want to make sure to
18	address and the measures for those different
19	categories might look different. So
20	MEMBER PESTRONK: One other one,
21	if I can say. This group, and I mean it's
22	reasonable that we do, we see health as an

Page 42 1 outcome and so we're looking at the social 2 determinants as processes or inputs to effect that outcome. An interesting guestion to 3 explore is whether this group also ought to be 4 5 looking at the world as those who are in the 6 social determinant world look at health. For 7 them health is an input to their output, which 8 could be education or justice, or housing, or 9 transportation, or other social determinants. 10 And so an interesting way to push the envelop potentially in NQF is to say why are we only 11 12 focused on measures that have to do with 13 health outcomes for populations? Could we 14 potentially be interested, could NQF 15 potentially be interested in the outputs that others are looking for but that we see as 16 inputs, if that makes sense? 17 18 MS. MAINO-FIKE: Yes. 19 CO-CHAIR JARRIS: Matt, and then 20 Ron and then Sue. 21 MEMBER STIEFEL: Which then become 22 inputs to health, by the way. You know it's

1	Page 43 a cycle.
2	We started our work with a bunch
4	we started our work with a bunch
3	of fun discussions about frameworks, and had
4	lots of frameworks. But all of those
5	frameworks converged and I think we've kind of
6	lost the connection with the background paper,
7	which I think laid out a very nice organizing
8	framework for our work, and it's probably
9	useful to recall it.
10	As Don was reminding us throughout
11	the day yesterday, they had this simple
12	construct of improvement activities,
13	determinants, and outcomes. And we spent
14	almost all of the day on improvement
15	activities, and it was just that that was what
16	we had in front of us. We got improvement
17	activities, by in large.
18	And that created lots of messiness
19	in that causal chain of evidence between
20	assessing BMI and weight and then the
21	downstream consequences of weight.
22	And so I think it's useful to sort

1	
	Page 44
1	of bring that framework back up. And in most
2	of the frameworks there were these common
3	denominators of something about the social and
4	physical environment. You know, it's high
5	school graduation rates, crime, food deserts,
6	parks; that kind of thing. Behaviors:
7	Smoking, eating, drinking, exercise. And
8	those are ones that are actually easier to
9	draw the casual chain to outcomes.
10	Physiology, like BMI measures of
11	BMI are blood pressure, cholesterol, disease
12	and injury, which are pretty clear. Health
13	and functional status which, you know we're a
14	long way from with the measures that we have.
15	And then measures of death, which
16	are pretty fundamentally important population
17	health outcomes.
18	And then as Bobby talked about,
19	those then are can be means to broader
20	population goals of quality of life and other
21	factors which then become part of the social
22	and physical environmental determinants of

	Page 45
1	health.
2	I mean, so we've got a good
3	framework. We just didn't get in the call for
4	measures, measures in those categories. But
5	it seems like that's a useful framing to
6	continue to use.
7	MS. MAINO-FIKE: So in summarizing
8	what you're suggesting, the call for measures
9	addressed some improvement activities, and you
10	did get response on that. But there are some
11	other areas that could be addressed. You'd
12	like to get more data from your contributors
13	on. And that might suggest a second call for
14	measures with an updated survey, maybe
15	different kinds of questions or different ways
16	to frame the questions in a second survey. Is
17	that what you're saying?
18	MEMBER STIEFEL: And perhaps more
19	explicitly use these frameworks to call for
20	measures in those broad categories. Because
21	we ended up with health improvement activity
22	measures and not determinants or outcomes.

	Page 46
1	MS. MAINO-FIKE: Yes.
2	MEMBER STOTO: I think that Matt
3	is right, is that the background paper and our
4	discussions sort of laid it all out. But it's
5	not clear to me that the people who were
6	potentially proposing measures really were
7	aware of all that and had been thinking about
8	the kind of uses that we were just talking
9	about this morning. And I think there's been
10	a disconnect between our thinking about these
11	issues and we probably haven't clearly
12	communicated that.
13	CO-CHAIR JARRIS: It calls into
14	question how well did the call for measures
15	capture the concepts that we were trying to
16	get at.
17	Ron?
18	MEMBER BIALEK: I have a variety
19	of thoughts. And you know, Paul, you had
20	mentioned about fitting the square peg into
21	the round hole. And I think at times the hole
22	is round and at times it was triangular, at

Page 47 1 times it was even square. I mean, so there 2 were some pieces there that were laid out and understandable from the population 3 perspective, like the general criteria. 4 But 5 then when you got to the work sheet, for 6 instance, the questions focused on something 7 different. And so now you had the square peg 8 in the square hole in terms of the criteria, 9 and now you have the rectangular hole. And so I think it kept changing. 10 And if I may just talk for a 11 12 moment about my conversations with Legacy. Because I thought that tobacco measures, at 13 14 least one, would be low-hanging fruit. Ι mean, there's a lot of research, a lot of 15 16 evidence on these types of measures. 17 And so I think we have two things 18 here. One is where there are existing 19 measures, the low-hanging fruit, how do we get 20 those brought here? And then the second is 21 for measure developers how do we encourage 22 measure development in a way that can really

Page 48 1 fit with this? 2 So let's go back to the measures 3 that already exist. What the Legacy folks first had in my initial conversation is why. 4 5 Why would we want to submit something to NOF? 6 What is NOF? What's the relevance to what it 7 is we do? And that was a considerable 8 discussion back and forth, and I think the NOF 9 staff helped to clarify that on a call. But 10 that took a bit of time to understand, and I'm still not sure it's fully understood what the 11 12 benefit is to an organization like NQF for having a tobacco -- I'm sorry. By Legacy to 13 14 have a tobacco measure approved by NQF. 15 Second was the work load and time 16 frame, I know that's been brought up. That 17 they just didn't have enough time to do it well because from the announcement to 18 19 contacting them, to discussions about the 20 benefits, to what the measures could be that 21 gave them, let's say a week or less from the time they finally decided which measure and 22

then submitting. 1 2 There are lack of examples, good examples of -- you know often this isn't well 3 understood, no matter how well we describe it 4 5 in the background paper that was developed and other papers, seeing some examples even if 6 7 they are fictional examples of what this might 8 be or what might fit, would help. 9 Suggestions from the Steering 10 Committee. So, you know we talked with Legacy about prevalence, about taxation, about indoor 11 12 air. Well, is there a preference from the Steering Committee about which types of 13 14 measures might resonant the best, might be the ones to bring forward initially? 15 That is -- let's see. Yes. 16 I'11 17 just come back again to the work sheet where 18 it didn't necessarily provide the guidance 19 that was desirable for that. 20 MS. MAINO-FIKE: This seems like 21 the perfect entree to actually touch base with 22 our developers, contributors that are on the

Page 50 1 phone and ask them for their feedback as to 2 what were the reasons that they were not able 3 to participate. We know some of that was resource. But also what benefits could they 4 5 see for themselves, kind of a what's in it for 6 them around what would they like to see in 7 measures? Do they see some leverage in 8 submitting information to an organization such 9 as NQF? 10 So, with that I'm going to ask --Can I just --11 CO-CHAIR JARRIS: 12 Sue, did you see something? Did you have your 13 card up? 14 MEMBER PICKENS: Yes. 15 CO-CHAIR JARRIS: Okay. All right. 16 MEMBER PICKENS: Actually, they covered it. 17 18 CO-CHAIR JARRIS: All right. 19 MEMBER PICKENS: How far upstream 20 did we want to go because we did all that work 21 on the model. 22 CO-CHAIR JARRIS: All right. Can

	Page 51
1	I say something? One thing I want to
2	reenforce you said, Ron, because in a sense
3	you brought up the NCQA branding issue NQF
4	branding issue. And, you now, NQF would have
5	to rebrand to make itself of value to the
б	population health, public health community.
7	That assumption was there that the public
8	health community would understand that. And
9	I think what we learned is they didn't, you
10	know. Xerox makes copies, right? And Xerox
11	also runs most of the E-ZPass toll booths in
12	this country. You never would have thought
13	about that.
14	So, I don't know that NQF
15	appreciated the rebranding process here.
16	And then if I could add one more
17	thing that came up, I think, yesterday was
18	that you know a lot of these measures were
19	one-on-one clinical measures which is useful,
20	but that's largely I mean, I guess that's
21	part of tier 1 in this group. But then you
22	have the issue of, okay, so you measure does

i	
	Page 52
1	the doctor give the right vaccine measure of
2	BMI. But it's a separate measure to say, okay,
3	then what is the vaccination rate among this
4	whole clinical population served by this
5	health group? We have less those types of
6	measures.
7	And then you take another step:
8	What is the vaccination rate in the community
9	served by that hospital outside of their
10	direct patients? We didn't get anything like
11	that.
12	You could take a step further more
13	outcome to say, okay. what is the rate of
14	vaccine preventable disease outbreak in this
15	community, which is still another step
16	further.
17	And then what we didn't get, which
18	I think we talked about in the NPP process in
19	here, is that's still a disease or deficit
20	model. We never got to anything that measures
21	the well-being of the population and the
22	community.

Page 531And so there's a long way to go2down that spectrum and we're still very much3on the first step about doctor/patient4interaction. We haven't even gone to a5population approach for that clinical study.6We did one exception of that HIV measure I7think, which is a very good first measure for8us to approve.9Mike?10MEMBER STOTO: You know, I think11one of the things is that NQF has been around12for a while and serves a very important13purpose, but I don't think we've been very14explicit about what that purpose is or why15people in the clinical world see value in NQF.16And maybe if we could sort of lay that out and17then think how does that translate.18I imagine it's because you need to19have NQF endorsed measures for certain20purposes. For accreditation or pay-for-21performance, or something like that. There's22some value in having NQF endorsement, but I'm		
2down that spectrum and we're still very much3on the first step about doctor/patient4interaction. We haven't even gone to a5population approach for that clinical study.6We did one exception of that HIV measure I7think, which is a very good first measure for8us to approve.9Mike?10MEMBER STOTO: You know, I think11one of the things is that NQF has been around12for a while and serves a very important13purpose, but I don't think we've been very14explicit about what that purpose is or why15people in the clinical world see value in NQF.16And maybe if we could sort of lay that out and17then think how does that translate.18I imagine it's because you need to19have NQF endorsed measures for certain20purposes. For accreditation or pay-for-21performance, or something like that. There's		Page 53
3 on the first step about doctor/patient 4 interaction. We haven't even gone to a 5 population approach for that clinical study. 6 We did one exception of that HIV measure I 7 think, which is a very good first measure for 8 us to approve. 9 Mike? 10 MEMBER STOTO: You know, I think 11 one of the things is that NQF has been around 12 for a while and serves a very important 13 purpose, but I don't think we've been very 14 explicit about what that purpose is or why 15 people in the clinical world see value in NQF. 16 And maybe if we could sort of lay that out and 17 then think how does that translate. 18 I imagine it's because you need to 19 have NQF endorsed measures for certain 10 purposes. For accreditation or pay-for- 11 purposes. For accreditation or pay-for- 12 performance, or something like that. There's	1	And so there's a long way to go
 interaction. We haven't even gone to a population approach for that clinical study. We did one exception of that HIV measure I think, which is a very good first measure for us to approve. Mike? MEMBER STOTO: You know, I think one of the things is that NQF has been around for a while and serves a very important purpose, but I don't think we've been very explicit about what that purpose is or why people in the clinical world see value in NQF. And maybe if we could sort of lay that out and then think how does that translate. I imagine it's because you need to have NQF endorsed measures for certain purposes. For accreditation or pay-for- performance, or something like that. There's 	2	down that spectrum and we're still very much
 population approach for that clinical study. We did one exception of that HIV measure I think, which is a very good first measure for us to approve. Mike? MEMBER STOTO: You know, I think one of the things is that NQF has been around for a while and serves a very important purpose, but I don't think we've been very explicit about what that purpose is or why people in the clinical world see value in NQF. And maybe if we could sort of lay that out and then think how does that translate. I imagine it's because you need to have NQF endorsed measures for certain purposes. For accreditation or pay-for- performance, or something like that. There's 	3	on the first step about doctor/patient
 We did one exception of that HIV measure I think, which is a very good first measure for us to approve. Mike? MEMBER STOTO: You know, I think one of the things is that NQF has been around for a while and serves a very important purpose, but I don't think we've been very explicit about what that purpose is or why people in the clinical world see value in NQF. And maybe if we could sort of lay that out and then think how does that translate. I imagine it's because you need to have NQF endorsed measures for certain purposes. For accreditation or pay-for- performance, or something like that. There's 	4	interaction. We haven't even gone to a
 think, which is a very good first measure for us to approve. Mike? MEMBER STOTO: You know, I think one of the things is that NQF has been around for a while and serves a very important purpose, but I don't think we've been very explicit about what that purpose is or why people in the clinical world see value in NQF. And maybe if we could sort of lay that out and then think how does that translate. I imagine it's because you need to have NQF endorsed measures for certain purposes. For accreditation or pay-for- performance, or something like that. There's 	5	population approach for that clinical study.
 8 us to approve. 9 Mike? 10 MEMBER STOTO: You know, I think 11 one of the things is that NQF has been around 12 for a while and serves a very important 13 purpose, but I don't think we've been very 14 explicit about what that purpose is or why 15 people in the clinical world see value in NQF. 16 And maybe if we could sort of lay that out and 17 then think how does that translate. 18 I imagine it's because you need to 19 have NQF endorsed measures for certain 20 purposes. For accreditation or pay-for- 21 performance, or something like that. There's 	6	We did one exception of that HIV measure I
9 Mike? 10 MEMBER STOTO: You know, I think 11 one of the things is that NQF has been around 12 for a while and serves a very important 13 purpose, but I don't think we've been very 14 explicit about what that purpose is or why 15 people in the clinical world see value in NQF. 16 And maybe if we could sort of lay that out and 17 then think how does that translate. 18 I imagine it's because you need to 19 have NQF endorsed measures for certain 20 purposes. For accreditation or pay-for- 21 performance, or something like that. There's	7	think, which is a very good first measure for
10MEMBER STOTO: You know, I think11one of the things is that NQF has been around12for a while and serves a very important13purpose, but I don't think we've been very14explicit about what that purpose is or why15people in the clinical world see value in NQF.16And maybe if we could sort of lay that out and17then think how does that translate.18I imagine it's because you need to19have NQF endorsed measures for certain20purposes. For accreditation or pay-for-21performance, or something like that. There's	8	us to approve.
one of the things is that NQF has been around for a while and serves a very important purpose, but I don't think we've been very explicit about what that purpose is or why people in the clinical world see value in NQF. And maybe if we could sort of lay that out and then think how does that translate. I imagine it's because you need to have NQF endorsed measures for certain purposes. For accreditation or pay-for- performance, or something like that. There's	9	Mike?
12 for a while and serves a very important 13 purpose, but I don't think we've been very 14 explicit about what that purpose is or why 15 people in the clinical world see value in NQF. 16 And maybe if we could sort of lay that out and 17 then think how does that translate. 18 I imagine it's because you need to 19 have NQF endorsed measures for certain 20 purposes. For accreditation or pay-for- 21 performance, or something like that. There's	10	MEMBER STOTO: You know, I think
13 purpose, but I don't think we've been very 14 explicit about what that purpose is or why 15 people in the clinical world see value in NQF. 16 And maybe if we could sort of lay that out and 17 then think how does that translate. 18 I imagine it's because you need to 19 have NQF endorsed measures for certain 20 purposes. For accreditation or pay-for- 21 performance, or something like that. There's	11	one of the things is that NQF has been around
<pre>14 explicit about what that purpose is or why 15 people in the clinical world see value in NQF. 16 And maybe if we could sort of lay that out and 17 then think how does that translate. 18 I imagine it's because you need to 19 have NQF endorsed measures for certain 20 purposes. For accreditation or pay-for- 21 performance, or something like that. There's</pre>	12	for a while and serves a very important
15 people in the clinical world see value in NQF. 16 And maybe if we could sort of lay that out and 17 then think how does that translate. 18 I imagine it's because you need to 19 have NQF endorsed measures for certain 20 purposes. For accreditation or pay-for- 21 performance, or something like that. There's	13	purpose, but I don't think we've been very
And maybe if we could sort of lay that out and then think how does that translate. I imagine it's because you need to have NQF endorsed measures for certain purposes. For accreditation or pay-for- performance, or something like that. There's	14	explicit about what that purpose is or why
17 then think how does that translate. 18 I imagine it's because you need to 19 have NQF endorsed measures for certain 20 purposes. For accreditation or pay-for- 21 performance, or something like that. There's	15	people in the clinical world see value in NQF.
18 I imagine it's because you need to 19 have NQF endorsed measures for certain 20 purposes. For accreditation or pay-for- 21 performance, or something like that. There's	16	And maybe if we could sort of lay that out and
19 have NQF endorsed measures for certain 20 purposes. For accreditation or pay-for- 21 performance, or something like that. There's	17	then think how does that translate.
20 purposes. For accreditation or pay-for- 21 performance, or something like that. There's	18	I imagine it's because you need to
21 performance, or something like that. There's	19	have NQF endorsed measures for certain
	20	purposes. For accreditation or pay-for-
22 some value in having NQF endorsement, but I'm	21	performance, or something like that. There's
	22	some value in having NQF endorsement, but I'm

	Page 54
1	not sure that the public health world
2	understands what those are.
3	CO-CHAIR JARRIS: You should
4	understand what the value is because as
5	occurred to me yesterday, I mean who does
б	submit a measure to NQF and who is it a value
7	to? NCQA would be because then they had some
8	credibility to their measure when they go to
9	health plans. I think CMS the same thing;
10	they're going out to hold ACOs accountability
11	just as a measure of credibility.
12	Do doctors and clinicians actually
13	care? Do they even know? And then why would
14	the public health people care when NCQA is
15	core to their business to get this
16	endorsement?
17	MEMBER STOTO: Right.
18	CO-CHAIR JARRIS: And CMS is core
19	to their business. In what way is this
20	accreditation core or meaningful, or
21	beneficial to someone in the population health
22	world, or are they being asked to do something

	Page 55
1	for someone else's benefit?
2	MEMBER STOTO: So if IRS said you
3	need to have NQF endorsed measures for your
4	Community Health Needs Assessment, well then
5	it would pay attention to it?
6	CO-CHAIR JARRIS: Yes.
7	DR. BURSTIN: It's very analogous.
8	If hospitals need to have endorsed measures
9	you know if all these different pay-for-
10	performance programs, purchasing, public
11	reporting programs need NQF measures, then
12	those developers are going to make a march to
13	NQF to bring those forward because they want
14	those done.
15	The other thing is though on the
16	side of the clinicians and the providers, and
17	I'd be curious some of the folks in the room,
18	the biggest thing we hear is that in some ways
19	it removes the noise in the debate. If an NQF $$
20	endorsed measure comes forward to a hospital
21	and says let's use this one, they sort of feel
22	like they could dispense with the evidence and

Page 56

1 a lot of the stuff has already been taken care 2 of as part of the process, and they just kind 3 of eliminate a lot of the angst and just move 4 forward with it and focus on measurement and 5 improvement.

So, I mean but again I think the 6 7 issue -- I think you're absolutely right. We 8 haven't really dealt with this. What's the 9 benefit to the public? And again, I think this whole issue of all the terms we've used 10 interchangeably through the course of this 11 12 project are still very confusing, at least to me at least in terms of what is public health, 13 14 population health, community health and then you know how tethered should it be ultimately 15 back to the health care system? 16 I mean there's some very different models in terms of 17 18 looking at rates of community vaccination, I 19 think is still pretty close because it's still 20 directly relevant to a health care system or 21 an ACO to understand what's out there. There 22 are some things that go further and further

	Page 57
1	layers out without that tether back, and I
2	think that's where we really need to think
3	about how relevant those are and whether the
4	public health community sees any value in
5	bringing those forward to NQF.
6	MS. MAINO-FIKE: Right. And we
7	can brainstorm what some of those values might
8	be.
9	I'm sorry, did I interrupt you?
10	MEMBER PICKENS: I'm sorry. I'm
11	working very hard with our region on a new
12	1115 waiver for Texas. The entire category 4
13	is all NQF measures, mostly around the
14	potentially avoidable and admissions and
15	readmissions. But the immunizations are there
16	and some utilization measures are there. But
17	they're all of value to the state of Texas
18	because that's for the entire state.
19	MEMBER STIEFEL: I think we should
20	think of this marketing strategy not just to
21	the public health community, but I think it's
22	important in marketing to health care delivery

	Page 58
1	systems to expand their thinking to think of
2	upstream determinants of health. And there is
3	a closer relationship with NQF already built
4	into the health care delivery system, and I
5	think that that's an important driver of this
6	change. I think we're trying to we're at
7	this boundary between public health and health
8	care delivery or clinical health.
9	And, you know a very modest step
10	would be if we have just moved upstream a step
11	to behaviors. If we had smoking, eating,
12	drinking and exercise as measures for health
13	care delivery systems, that would be an
14	enormous step and move us closer to the
15	upstream determinants.
16	CO-CHAIR JARRIS: Matt, it raises
17	the question, you know NQF wants to enter this
18	field. Have they made that decision? You now,
19	before Starbucks would open a new product line
20	their Board of Directors would really weigh do
21	they want to go down that product line. And
22	how seriously has the Board considered that or

	Page 59
1	is this just the work of one temporary work
2	group or has this fundamentally been endorsed
3	and understood by the Board?
4	And to the extent we're struggling
5	with it, I would almost guarantee you the
б	Board can't understand any better than we do.
7	DR. BURSTIN: I think depending on
8	the rings of how far outside of health care
9	you're going, you're going to get less and
10	less agreement. I think, you know the
11	measures we talk about that are clearly more
12	at a population level but somehow still have
13	a connection back to sort of health care
14	system measures, you know that Matt and Sue
15	just talked about, I don't think there's any
16	debate at all. Everybody gets the ACO,
17	everybody understands the movement towards
18	that. NPP's been very clear about that.
19	I think what is less and less
20	clear are things where there may be measures
21	for which the accountability, shared though it
22	may be, to the health care system is more

	Page 60
1	tenuous. And so, for example, some of the
2	measures we talked about: Taxation rates for
3	smoking. I think that may be a place you'd
4	start to see some discomfort on the part of
5	some typical sort of leaders within NQF,
б	whereas I think understanding your community
7	smoking rates, no brainier. It's incredibly
8	useful, it's useful information to you as a
9	health care system and a provider to have that
10	information to move and make improvement. And
11	I think it's when they feel slightly further
12	and further out of those circles that I think
13	you get into more debate.
14	MS. MAINO-FIKE: And again, for
15	your own information I want to give our remote
16	folks who are the contributor population, if
17	you will, the opportunity to share their
18	thoughts on what would they see as value to
19	participating in a measurement survey such as
20	this, what are the challenges that they face.
21	With that, I will just ask our CDC
22	representative, Peter.

Page 611DR. BRISS: Good morning. I'm2Peter Briss. Can you hear me?3MS. MAINO-FIKE: Yes, Peter.4MEMBER QASEEM: Just one second. I5want to call up something that Paul started6saying, because I think it's extremely7important.8In my mind I think that's exactly9the issue with population health measures.10You're applying the same concept that we've11been using for the disease-based measures now12on a population level.13I was just thinking that the14movement to have guidelines, for example,15comorbid conditions because we have been16issuing these guidelines just for COPD or for17diabetes, you know the thing about it. But18you're treating this patient who comes with19multiple conditions, right?20The goal of population health21measures is to improve the health of the whole22population. But now we're taking these		
2 Peter Briss. Can you hear me? 3 MS. MAINO-FIKE: Yes, Peter. 4 MEMBER QASEEM: Just one second. I 5 want to call up something that Paul started 6 saying, because I think it's extremely 7 important. 8 In my mind I think that's exactly 9 the issue with population health measures. 10 You're applying the same concept that we've 11 been using for the disease-based measures now 12 on a population level. 13 I was just thinking that the 14 movement to have guidelines, for example, 15 comorbid conditions because we have been 16 issuing these guidelines just for COPD or for 17 diabetes, you know the thing about it. But 18 you're treating this patient who comes with 19 multiple conditions, right? 20 The goal of population health 21 The goal of population health		Page 61
 MS. MAINO-FIKE: Yes, Peter. MEMBER QASEEM: Just one second. I want to call up something that Paul started saying, because I think it's extremely important. In my mind I think that's exactly the issue with population health measures. You're applying the same concept that we've been using for the disease-based measures now on a population level. I was just thinking that the movement to have guidelines, for example, comorbid conditions because we have been issuing these guidelines just for COPD or for diabetes, you know the thing about it. But you're treating this patient who comes with multiple conditions, right? The goal of population health measures is to improve the health of the whole 	1	DR. BRISS: Good morning. I'm
4MEMBER QASEEM: Just one second. I5want to call up something that Paul started6saying, because I think it's extremely7important.8In my mind I think that's exactly9the issue with population health measures.10You're applying the same concept that we've11been using for the disease-based measures now12on a population level.13I was just thinking that the14movement to have guidelines, for example,15comorbid conditions because we have been16issuing these guidelines just for COPD or for17diabetes, you know the thing about it. But18you're treating this patient who comes with19multiple conditions, right?20The goal of population health21measures is to improve the health of the whole	2	Peter Briss. Can you hear me?
 want to call up something that Paul started saying, because I think it's extremely important. In my mind I think that's exactly the issue with population health measures. You're applying the same concept that we've been using for the disease-based measures now on a population level. I was just thinking that the movement to have guidelines, for example, comorbid conditions because we have been issuing these guidelines just for COPD or for diabetes, you know the thing about it. But you're treating this patient who comes with multiple conditions, right? The goal of population health measures is to improve the health of the whole 	3	MS. MAINO-FIKE: Yes, Peter.
 saying, because I think it's extremely important. In my mind I think that's exactly the issue with population health measures. You're applying the same concept that we've been using for the disease-based measures now on a population level. I was just thinking that the movement to have guidelines, for example, comorbid conditions because we have been issuing these guidelines just for COPD or for diabetes, you know the thing about it. But you're treating this patient who comes with multiple conditions, right? The goal of population health measures is to improve the health of the whole 	4	MEMBER QASEEM: Just one second. I
<pre>7 important. 8 In my mind I think that's exactly 9 the issue with population health measures. 10 You're applying the same concept that we've 11 been using for the disease-based measures now 12 on a population level. 13 I was just thinking that the 14 movement to have guidelines, for example, 15 comorbid conditions because we have been 16 issuing these guidelines just for COPD or for 17 diabetes, you know the thing about it. But 18 you're treating this patient who comes with 19 multiple conditions, right? 20 The goal of population health 21 measures is to improve the health of the whole</pre>	5	want to call up something that Paul started
8 In my mind I think that's exactly 9 the issue with population health measures. 10 You're applying the same concept that we've 11 been using for the disease-based measures now 12 on a population level. 13 I was just thinking that the 14 movement to have guidelines, for example, 15 comorbid conditions because we have been 16 issuing these guidelines just for COPD or for 17 diabetes, you know the thing about it. But 18 you're treating this patient who comes with 19 multiple conditions, right? 20 The goal of population health 21 measures is to improve the health of the whole	6	saying, because I think it's extremely
 9 the issue with population health measures. 10 You're applying the same concept that we've 11 been using for the disease-based measures now 12 on a population level. 13 I was just thinking that the 14 movement to have guidelines, for example, 15 comorbid conditions because we have been 16 issuing these guidelines just for COPD or for 17 diabetes, you know the thing about it. But 18 you're treating this patient who comes with 19 multiple conditions, right? 20 The goal of population health 21 measures is to improve the health of the whole 	7	important.
You're applying the same concept that we've been using for the disease-based measures now on a population level. I was just thinking that the movement to have guidelines, for example, comorbid conditions because we have been issuing these guidelines just for COPD or for diabetes, you know the thing about it. But you're treating this patient who comes with multiple conditions, right? The goal of population health measures is to improve the health of the whole	8	In my mind I think that's exactly
11 been using for the disease-based measures now 12 on a population level. 13 I was just thinking that the 14 movement to have guidelines, for example, 15 comorbid conditions because we have been 16 issuing these guidelines just for COPD or for 17 diabetes, you know the thing about it. But 18 you're treating this patient who comes with 19 multiple conditions, right? 20 The goal of population health 21 measures is to improve the health of the whole	9	the issue with population health measures.
12 on a population level. 13 I was just thinking that the 14 movement to have guidelines, for example, 15 comorbid conditions because we have been 16 issuing these guidelines just for COPD or for 17 diabetes, you know the thing about it. But 18 you're treating this patient who comes with 19 multiple conditions, right? 20 The goal of population health 21 measures is to improve the health of the whole	10	You're applying the same concept that we've
I was just thinking that the movement to have guidelines, for example, comorbid conditions because we have been issuing these guidelines just for COPD or for diabetes, you know the thing about it. But you're treating this patient who comes with multiple conditions, right? The goal of population health measures is to improve the health of the whole	11	been using for the disease-based measures now
14 movement to have guidelines, for example, 15 comorbid conditions because we have been 16 issuing these guidelines just for COPD or for 17 diabetes, you know the thing about it. But 18 you're treating this patient who comes with 19 multiple conditions, right? 20 The goal of population health 21 measures is to improve the health of the whole	12	on a population level.
15 comorbid conditions because we have been 16 issuing these guidelines just for COPD or for 17 diabetes, you know the thing about it. But 18 you're treating this patient who comes with 19 multiple conditions, right? 20 The goal of population health 21 measures is to improve the health of the whole	13	I was just thinking that the
16 issuing these guidelines just for COPD or for 17 diabetes, you know the thing about it. But 18 you're treating this patient who comes with 19 multiple conditions, right? 20 The goal of population health 21 measures is to improve the health of the whole	14	movement to have guidelines, for example,
17 diabetes, you know the thing about it. But 18 you're treating this patient who comes with 19 multiple conditions, right? 20 The goal of population health 21 measures is to improve the health of the whole	15	comorbid conditions because we have been
<pre>18 you're treating this patient who comes with 19 multiple conditions, right? 20 The goal of population health 21 measures is to improve the health of the whole</pre>	16	issuing these guidelines just for COPD or for
<pre>19 multiple conditions, right? 20 The goal of population health 21 measures is to improve the health of the whole</pre>	17	diabetes, you know the thing about it. But
20 The goal of population health 21 measures is to improve the health of the whole	18	you're treating this patient who comes with
21 measures is to improve the health of the whole	19	multiple conditions, right?
-	20	The goal of population health
22 population. But now we're taking these	21	measures is to improve the health of the whole
	22	population. But now we're taking these

Page 62 individual measures that are based on these 1 2 guidelines, disease focused guidelines which it may improve how to measure for that 3 particular -- if it's applied or however it 4 5 gets applied, but it is not going to increase the overall health of the population. 6 7 And I think NQF is in a very good 8 position. This is a new field we are starting 9 on. And I think we need to maybe first take a 10 step back and think about maybe NQF maybe may not be the forum, that what do we need to do 11 12 to improve the quality of the population? What sort of measures do we really need? 13 14 I think we're really isolating. Ι 15 mean yesterday if you think about it what measures did we review? We're looking at 16 17 three or four disease conditions, right? Ι 18 feel that there is a huge disconnect, that's 19 not going to lead to -- because we're 20 separating so many other factors that go with 21 the population. I think in terms of what's 22 going on with the population. And I think we

	Page 63
1	need to think of it all as a collective format
2	and then do a lot of measures.
3	And then there is some work that
4	has been done in this arena. Again, I am not
5	the biggest expert in it. But I know that some
б	folks have written about this specific issue,
7	as well as Paul. So I just want to bring this
8	up that I think what you raise is extremely
9	important and maybe we need to really look
10	into that.
11	MS. MAINO-FIKE: Thank you, Amir.
12	The notion here of casting your
13	net wide, looking at some broader upstream
14	kinds of determinants for what would impact or
15	how to measure population health.
16	And again, I want to get back to
17	our remote partners and give them an
18	opportunity to contribute.
19	DR. BRISS: Hi. This is Peter
20	Briss. Can you hear me?
21	MS. MAINO-FIKE: Yes.
22	DR. BRISS: Okay. So I'm Peter

Page 64 1 Briss. I'm from CDC. 2 I have spoken with many of the people at CDC who are sort of working in this 3 general area, so this is to some extent a 4 5 synthesized view. I don't pretend that this completely reflects all 15,000 people at CDC. 6 7 So first we agree with Kurt and 8 others that there's an enormous amount of interest now inside and outside of government 9 10 at sort of working at the clinical and community interface and in better linking what 11 12 health care systems and community health systems are doing. So there's an enormous 13 14 amount of interest and support for your work. And on the private side things like the 15 National Priorities Partnership Population 16 Health Working Group, which I on behalf of CDC 17 have been helping to Co-Chair, for example. 18 19 And there are scads of governmental examples, 20 community health needs, work that Paul is 21 doing that you've given already. The CMMI's 22 brand new health care innovation challenge is

	Page 65
1	to some extent very population health focused.
2	I'm really excited about it.
3	HHS' Million Hearts Initiative is
4	a very nice example of pulling together
5	clinical and community work.
6	So, there's an enormous amount of
7	support and enthusiasm for the kind of work
8	you're trying to move forward.
9	The second point would be that we
10	think that there's no strong technical reason
11	that the sorts of evaluation criteria that NQF
12	uses about impact and validity and usability
13	and feasibility couldn't be applied to
14	population health kinds of measures and
15	topics, perhaps sometimes with some tweaking.
16	A third major point, and this is
17	probably the most important point, is I think
18	it was Mike Stoto who said the collective "we"
19	on the Committee and in public health more
20	generally haven't made a convincing case to
21	answer the why are we doing this, how will
22	these measures be used, what's the value added

	Page 66
1	of NQF endorsement in this context? We think
2	that the fairly thin response that you've
3	gotten primarily reflect our lack of making a
4	convincing case about how these measures will
5	be used. And probably without us making a
6	much crisper case about what are the proposed
7	uses, it seems unlikely to use that we're
8	going to make major steps forward in this
9	area.
10	And perhaps to echo what Helen was
11	just saying, the case gets harder to make for
12	the farther you get away from clinical care.
13	So it's not obvious at this point I'm going
14	to speak for Peter and I'm not speaking for
15	CDC or the wider world. But it's never been
16	apparent to me that people who are working on
17	social and environmental drivers of health are
18	necessarily looking to NQF for endorsement of
19	measures.
20	And I guess the final thing I
21	would raise in this category of work is I
22	think we need to think really carefully about

Page 67 whether building in NOF endorsement sort of 1 2 into measurement and payment kind of systems might have unwanted negative effect. 3 It would be a shame I would think, for example, for a 4 5 Community Health Needs Assessment if we built requirements for NQF endorsement that had the 6 7 unintended effect that I think is negative of 8 pushing us to only looking at sort of clinical 9 measures, of which there are now 700 plus and 10 pushing us away from using sort of more geographic population health measures which 11 12 are likely to be much more under represented. And then finally given everybody 13 on the -- Helen and others who are very 14 15 involved in the NQF process knows that many measure developers feel that the NQF process 16 17 can be arduous. And given a lot of 18 uncertainty about how the measures are likely 19 to be used, it's very hard for people to make 20 the return on investment case at the moment in 21 their home organizations that the upside of 22 NQF endorsement today is worth the significant

	Page 68
1	investment in getting measures endorsed.
2	CO-CHAIR JARRIS: Peter, is there
3	another process that exists and if it does, is
4	it more relevant than NQF, for example CDC
5	folks creating population health measures?
6	What is the process, for example, of
7	standardizing across if there is one,
8	across surveys so that the same questions
9	asked on the YRBS as the BRFSS and other CDC
10	related surveys out there? Or, does each
11	program come up with their own measures and
12	validate their own measures independently
13	without any process for developing common
14	measures across programmatic areas?
15	DR. BRISS: Yes. I can start on
16	this topic. There are likely to be several
17	people around the real and virtual table up
18	there that know as much or more about this
19	than I do.
20	So I would say that public health
21	has not been perfect about sort of aligning
22	measures and making them coherent across

8

	Page
1	surveys and programs. And to be fair to public
2	health, Helen and others up there know that
3	the clinical world hasn't been perfect about
4	that either. All of us are trying to work on
5	that.
6	There's a fair amount of inside
7	intergovernmental conversation about those
8	kinds of points. And within agencies, across
9	agencies and with cross governmental groups
10	like OMB, but it's not perfect as it stands.
11	I don't think that there's a
12	current external kind of Good Housekeeping
13	Seal of Approval that would do what you're
14	talking about, Paul. And if there were such
15	a group, we'd probably have to be that
16	would certainly have both costs and benefits
17	and we'd be having a conversation I suspect
18	much like this one about needing to very
19	cleanly make the case that the upside exceeds
20	the potential downsides.
21	DR. BURSTIN: Peter, just a
22	follow-up question. This is Helen.

69

	Page 70
1	This is very helpful. Just one
2	thought as you talked about the surveys,
3	standardizing the surveys for example, I think
4	one place where there would be huge benefits
5	would be if the measures used by the health
6	care systems, the clinicians and others in
7	fact standardized the approach to asking about
8	some of those health behaviors that you
9	already do in all your surveys in the same
10	ways? You could in fact say: "My health
11	system is falling down within our community,
12	within our state in a way that we can't do now
13	because is nothing is sort of harmonized in a
14	way that makes any sense."
15	DR. BRISS: I agree with that,
16	Helen. And in addition to that that also sort
17	of links a little bit to the last point that
18	you were making about a starting point where
19	the inner most concentric circle were NQF
20	endorsements and help from NQF in sort of
21	standardizing or aligning, or making as
22	consistent as possible some of the survey work

	Page 71
1	and some of the quality measures, the health
2	care quality measurement work would allow all
3	of us to do more sort of rolling up and down
4	measurement efforts from the individual
5	provider level to the health care system
6	level, to the community level to something
7	like the state or national level. And that
8	would be a really important that may not be
9	all we want to do in population health, but
10	that would be a really important practical
11	step forward, I think.
12	CO-CHAIR JARRIS: Peter, Howard
13	Koh announced around the time that Healthy
14	People 2020 measures came out that HHS had
15	developed a common set of measures for surveys
16	on health equity. And I don't know if you or
17	Peggy know anymore about that, but that's the
18	first I've heard about that being done across
19	HHS. It's a very important area, and it's an
20	area that we got nothing on. So, are you
21	familiar with that, or Peggy?
22	DR. BRISS: I think that's closer

	Page 72
1	to Peggy's wheelhouse than it's likely to be
2	to mine.
3	MS. MAINO-FIKE: We're just making
4	sure you can hear Peggy. We're giving her a
5	microphone.
6	MS. HONORE: I think there's
7	probably two reports that it could possibly
8	be. And, Paul, you're familiar with the NPA.
9	I don't think they may touch some on that,
10	but also the HHS wide health equity plan, and
11	I may not have the title of the report, that
12	may not be the exact title of the report, but
13	perhaps that's what he was referring to.
14	CO-CHAIR JARRIS: I recall it
15	being specifically measures and how HHS was
16	going to measure across different surveys, or
17	maybe "measures" is the wrong word. How
18	they're going to there's common language to
19	be used in the surveys around health equity.
20	DR. BURSTIN: It's not just the
21	OMB category, it's to categorize race
22	ethnicity

2
	Page 73
1	MS. HONORE: Maybe that's what it
2	is. In the Affordable Care Act, and I forget
3	which exact section it was, but there was a
4	mandate that work be done to explicitly define
5	certain categories race and ethnicity but also
6	that there be reporting requirements that
7	people report under those specific categories.
8	So that's probably what he was talking about.
9	And that's being done in stages, like they've
10	done stage 1 and I think that may include some
11	specific sort of surveys that are currently
12	being done. And then they're going to roll it
13	out and develop those definitions for other
14	types of data collection efforts as well.
15	I can get you some information on
16	that.
17	MS. MAINO-FIKE: Just in a summary
18	capacity here, what I've begun to do,
19	particularly for those folks on the phone, is
20	to organize or structure the comments that
21	people are making in terms of future steps of
22	needs, things that could be looked at and

	Page 74
1	might require future work, and then another
2	category is measures; the kinds of things we
3	want to or you want to include in measures.
4	Things like outcome-based, process-based.
5	So the kinds of things I put under
6	future steps or needs are not necessarily that
7	you all as a group or NQF has agreed to pursue
8	them, but rather items that have come up as a
9	result of this discussion that could be
10	pursued should this group and NQF choose to do
11	so. So things like standardization that we've
12	been talking about most recently across
13	organizations. Standardization of definition.
14	Standardization of measures. And there are a
15	lot of work or organizations to leverage off
16	of, like HHS, like even with IRS if they're
17	through ACA developing common survey
18	definitions.
19	Things like marketing or making
20	the case for how these measures could be used.
21	Things like over here on this side
22	why the benefits to developers for

Page 75 1 responding to NOF. So kind of a 2 branding/marketing opportunity for NQF as a whole if they choose to do so in terms of 3 taking a role in moving this conversation 4 5 forward. 6 So as you're talking, I'm kind of 7 looking at trying to capture the ideas that 8 you have so that we don't lose them in terms 9 of potential action items to move forward. 10 Just one comment. DR. BURSTIN: I'm not so sure it's a branding exercise for 11 12 NQF. I think it's less about NQF. I think 13 it's more about what's the value case for 14 bringing these measures to NQF? What are the 15 benefits to the developers? What are the 16 benefits to the broader system? 17 MS. MAINO-FIKE: Yes. DR. BURSTIN: And I think that's 18 19 the piece that I'd like us to noodle a bit 20 more. 21 MS. MAINO-FIKE: Yes. And I do 22 have that written down, too. So I apologize

	Page 76
1	for saying specifically branding, although
2	that was one small piece of the pie.
3	DR. BURSTIN: We can say we're
4	perfectly interested in it. We say we embrace
5	population health. But if the community still
6	doesn't see a value case for doing it, it
7	doesn't really matter.
8	CO-CHAIR JARRIS: But I would
9	explicitly use branding because the question
10	for me is, and I just may be ignorant, is does
11	the NQF Board really understand this area and
12	are they really willing to address it in a
13	meaningful way even if that means changing the
14	way NQF does business and changing the
15	outreach that they do, which would frankly
16	mean everything from changing the makeup to
17	their Board, to changing the way business is
18	done, perhaps even changing the organization.
19	Because currently it's structured for clinical
20	measures, it's not structured for population
21	health measures.
22	So, is there truly commitment to

1this? Because if there isn't, I just think2it's just not going to happen.3DR. BURSTIN: I think there is.4But I think a lot of it is people are waiting5to see what came in and trying to understand6where are the boundaries is what I think we7would have hit debate on as opposed to I think8some of the kind of things. I mean, I don't9think anybody would blink about the HIV10measure yesterday. No one would blink on the11Board or anywhere. That was a great measure.12It's incredibly useful at lots of different13levels, including the health care system.14I think when you start to get out15to measures that have no tether back or not as16easy a tether back, I think that's where17you'll hit a snag.18DR. BRISS: And this is Peter.19MS. MAINO-FIKE: Yes.20DR. BRISS: And so, Paul, this is		
2it's just not going to happen.3DR. BURSTIN: I think there is.4But I think a lot of it is people are waiting5to see what came in and trying to understand6where are the boundaries is what I think we7would have hit debate on as opposed to I think8some of the kind of things. I mean, I don't9think anybody would blink about the HIV10measure yesterday. No one would blink on the11Board or anywhere. That was a great measure.12It's incredibly useful at lots of different13levels, including the health care system.14I think when you start to get out15to measures that have no tether back or not as16easy a tether back, I think that's where17you'll hit a snag.18DR. BRISS: And this is Peter.19MS. MAINO-FIKE: Yes.20NS. MAINO-FIKE: Yes.21DR. BRISS: And so, Paul, this is		Page 77
3 DR. BURSTIN: I think there is. 4 But I think a lot of it is people are waiting 5 to see what came in and trying to understand 6 where are the boundaries is what I think we 7 would have hit debate on as opposed to I think 8 some of the kind of things. I mean, I don't 9 think anybody would blink about the HIV 10 measure yesterday. No one would blink on the 11 Board or anywhere. That was a great measure. 12 It's incredibly useful at lots of different 13 levels, including the health care system. 14 I think when you start to get out 15 to measures that have no tether back or not as 16 easy a tether back, I think that's where 17 you'll hit a snag. 18 DR. BRISS: And this is Peter. 19 Can I comment on that as well? 20 MS. MAINO-FIKE: Yes. 21 DR. BRISS: And so, Paul, this is	1	this? Because if there isn't, I just think
4But I think a lot of it is people are waiting5to see what came in and trying to understand6where are the boundaries is what I think we7would have hit debate on as opposed to I think8some of the kind of things. I mean, I don't9think anybody would blink about the HIV10measure yesterday. No one would blink on the11Board or anywhere. That was a great measure.12It's incredibly useful at lots of different13levels, including the health care system.14I think when you start to get out15to measures that have no tether back or not as16easy a tether back, I think that's where17you'll hit a snag.18DR. BRISS: And this is Peter.19MS. MAINO-FIKE: Yes.20DR. BRISS: And so, Paul, this is	2	it's just not going to happen.
5to see what came in and trying to understand6where are the boundaries is what I think we7would have hit debate on as opposed to I think8some of the kind of things. I mean, I don't9think anybody would blink about the HIV10measure yesterday. No one would blink on the11Board or anywhere. That was a great measure.12It's incredibly useful at lots of different13levels, including the health care system.14I think when you start to get out15to measures that have no tether back or not as16easy a tether back, I think that's where17you'll hit a snag.18DR. BRISS: And this is Peter.19MS. MAINO-FIKE: Yes.20DR. BRISS: And so, Paul, this is	3	DR. BURSTIN: I think there is.
 where are the boundaries is what I think we would have hit debate on as opposed to I think some of the kind of things. I mean, I don't think anybody would blink about the HIV measure yesterday. No one would blink on the Board or anywhere. That was a great measure. It's incredibly useful at lots of different levels, including the health care system. I think when you start to get out to measures that have no tether back or not as easy a tether back, I think that's where you'll hit a snag. DR. BRISS: And this is Peter. Can I comment on that as well? DR. BRISS: And so, Paul, this is 	4	But I think a lot of it is people are waiting
 would have hit debate on as opposed to I think some of the kind of things. I mean, I don't think anybody would blink about the HIV measure yesterday. No one would blink on the Board or anywhere. That was a great measure. It's incredibly useful at lots of different levels, including the health care system. I think when you start to get out to measures that have no tether back or not as easy a tether back, I think that's where you'll hit a snag. DR. BRISS: And this is Peter. Can I comment on that as well? DR. BRISS: And so, Paul, this is 	5	to see what came in and trying to understand
 some of the kind of things. I mean, I don't think anybody would blink about the HIV measure yesterday. No one would blink on the Board or anywhere. That was a great measure. It's incredibly useful at lots of different levels, including the health care system. I think when you start to get out to measures that have no tether back or not as easy a tether back, I think that's where you'll hit a snag. DR. BRISS: And this is Peter. Can I comment on that as well? DR. BRISS: And so, Paul, this is 	6	where are the boundaries is what I think we
 9 think anybody would blink about the HIV 10 measure yesterday. No one would blink on the 11 Board or anywhere. That was a great measure. 12 It's incredibly useful at lots of different 13 levels, including the health care system. 14 I think when you start to get out 15 to measures that have no tether back or not as 16 easy a tether back, I think that's where 17 you'll hit a snag. 18 DR. BRISS: And this is Peter. 19 MS. MAINO-FIKE: Yes. 20 MS. BRISS: And so, Paul, this is 	7	would have hit debate on as opposed to I think
 measure yesterday. No one would blink on the Board or anywhere. That was a great measure. It's incredibly useful at lots of different levels, including the health care system. I think when you start to get out to measures that have no tether back or not as easy a tether back, I think that's where you'll hit a snag. DR. BRISS: And this is Peter. Can I comment on that as well? MS. MAINO-FIKE: Yes. DR. BRISS: And so, Paul, this is 	8	some of the kind of things. I mean, I don't
 Board or anywhere. That was a great measure. It's incredibly useful at lots of different levels, including the health care system. I think when you start to get out to measures that have no tether back or not as easy a tether back, I think that's where you'll hit a snag. DR. BRISS: And this is Peter. Can I comment on that as well? DR. BRISS: And so, Paul, this is 	9	think anybody would blink about the HIV
12 It's incredibly useful at lots of different 13 levels, including the health care system. 14 I think when you start to get out 15 to measures that have no tether back or not as 16 easy a tether back, I think that's where 17 you'll hit a snag. 18 DR. BRISS: And this is Peter. 19 Can I comment on that as well? 20 MS. MAINO-FIKE: Yes. 21 DR. BRISS: And so, Paul, this is	10	measure yesterday. No one would blink on the
 levels, including the health care system. I think when you start to get out to measures that have no tether back or not as easy a tether back, I think that's where you'll hit a snag. DR. BRISS: And this is Peter. Can I comment on that as well? MS. MAINO-FIKE: Yes. DR. BRISS: And so, Paul, this is 	11	Board or anywhere. That was a great measure.
14I think when you start to get out15to measures that have no tether back or not as16easy a tether back, I think that's where17you'll hit a snag.18DR. BRISS: And this is Peter.19Can I comment on that as well?20MS. MAINO-FIKE: Yes.21DR. BRISS: And so, Paul, this is	12	It's incredibly useful at lots of different
 to measures that have no tether back or not as easy a tether back, I think that's where you'll hit a snag. DR. BRISS: And this is Peter. Can I comment on that as well? MS. MAINO-FIKE: Yes. DR. BRISS: And so, Paul, this is 	13	levels, including the health care system.
<pre>16 easy a tether back, I think that's where 17 you'll hit a snag. 18 DR. BRISS: And this is Peter. 19 Can I comment on that as well? 20 MS. MAINO-FIKE: Yes. 21 DR. BRISS: And so, Paul, this is</pre>	14	I think when you start to get out
 17 you'll hit a snag. 18 DR. BRISS: And this is Peter. 19 Can I comment on that as well? 20 MS. MAINO-FIKE: Yes. 21 DR. BRISS: And so, Paul, this is 	15	to measures that have no tether back or not as
18DR. BRISS: And this is Peter.19Can I comment on that as well?20MS. MAINO-FIKE: Yes.21DR. BRISS: And so, Paul, this is	16	easy a tether back, I think that's where
<pre>19 Can I comment on that as well? 20 MS. MAINO-FIKE: Yes. 21 DR. BRISS: And so, Paul, this is</pre>	17	you'll hit a snag.
20 MS. MAINO-FIKE: Yes. 21 DR. BRISS: And so, Paul, this is	18	DR. BRISS: And this is Peter.
21 DR. BRISS: And so, Paul, this is	19	Can I comment on that as well?
	20	MS. MAINO-FIKE: Yes.
	21	DR. BRISS: And so, Paul, this is
22 Peter. I represent CDC on the Board and I	22	Peter. I represent CDC on the Board and I

Page 78 1 thought I'd comment on that as well. 2 I think that my quess is that 3 especially as we get further away from the health care system that we're going to have 4 5 the same case making issues for the Board that 6 we sort of seem to have with the public health 7 community. I think that having the Board 8 discussion first might actually be a cart before the horse thing. I think that if we 9 can make a crisp case for what the value case 10 is, then we can sell it. If we can't make a 11 12 crisp case, then we won't be able to sell it 13 either to the Board or to the community. 14 MS. MAINO-FIKE: Good point. 15 Thank you. 16 Yes, I'm just wondering about our other remote participants. Neil, like to make 17 18 sure you get an opportunity to share your 19 thoughts. 20 DR. MAIZLISH: Sure. Can you hear 21 me okay? 22 MS. MAINO-FIKE: Yes.

	Page 79
1	DR. MAIZLISH: Okay. Great.
2	First of all, I want to thank you
3	for inviting me to participate. It's been a
4	pretty interesting conversation so far.
5	I suspect unlike many of my
6	colleagues in public health I actually know
7	about NQF. I've known about it for over ten
8	years, partly because of my background. I
9	helped the Consortium of Community Clinics in
10	the Bay Area establish a quantitative clinical
11	quality improvement program. So I actually
12	know about NQF from that study because I was
13	looking at non-HEDIS measures for some of the
14	activities that our clinic system implemented.
15	I'd like to just address the
16	social determinants of health, part of what
17	you are interested in. I mean, that's where
18	my work now in the California Department of
19	Public Health resides. And I just want to
20	say, I mean I was listening before talking
21	about the readiness of various communities to
22	embrace especially determinative health types

	Page 80
1	of indicators upstream indicators. And it's
2	just to say that many health departments or
3	local health departments in California, this
4	paradigm has shifted, discussion isn't so much
5	about whether there's evidence for it.
6	There's a framework that are now being adopted
7	that explicitly look at very upstream
8	conditions and presents an entire continuum
9	from institutional power and structural
10	racism, and how those things, the economic
11	activities influence basic living conditions
12	of populations and how those things influence
13	individual behaviors and behavioral risk
14	factors, and then onward towards actualization
15	of morbidity and mortality. And people are
16	very clear about where the points of
17	intervention are as far as the primary care,
18	the practitioners, health care systems, public
19	health departments and then going further
20	upstream to the organizations and the
21	institutions in society that has their hand on
22	the throttle more so than the health folks.

_	Page 81
1	Also in California there's the
2	sustainability movement which is driven by
3	climate change concerns and population growth
4	concerns. They've recognized that health is
5	a partner. Part of it is that public health
6	pushing its way to the table and when it's not
7	explicitly asked, but we see the connections
8	to these upstream determinants. So in that
9	sense the institutional climate in California,
10	at least, is definitely receptive. And it
11	also extends to the party who might be tied to
12	interventions outside of public health, like
13	municipal governments, regional planning
14	agencies, state agencies. And they see that
15	they need help as a partner in this process
16	and the credibility that health brings to the
17	discussions about these social determinants
18	that you can't under estimate how important
19	that really is when the public health
20	department joins with a regional planning
21	agency to say that, yes, we need to increase
22	biking and walking as part of our

	Page 82
1	transportation plan because it's going to have
2	a big impact on population health or physical
3	activity. That really does resonate.
4	And I just want to emphasize that
5	while there is a debate in the room about the
6	readiness of the various parties, some of it
7	has already happened. And I guess I'll use a
8	metaphor that, you know addressing why you may
9	have had a low response rate.
10	You know in a sense it feels like
11	you've invited people to a party that started
12	over 25 years ago for some of the
13	participants. And I'm talking about
14	communities like Jacksonville, Florida or
15	Santa Cruz in California where they've had
16	community indicator projects looking at many
17	of the things that people have suggested as
18	social determinants of health in the arena of
19	housing, education, economic development,
20	social cohesion. Many have had projects going
21	on for over 25 years in some cases, and some
22	of them are incredibly elaborate projects

Page 83 1 where they engage private social survey 2 companies to interview thousands of residents to determine everything from how city services 3 and municipal services are provided to whether 4 5 you think the board of education is doing a good job. So you have a sort of kind of 6 7 granularity there, but you also have total 8 chaos in the sense that there are hundreds and 9 hundreds of these kinds of projects already 10 going on. You know, some of them like the Jacksonville project, the Boston indicators 11 12 project are just examples of things that have a real longevity. And I doubt people would 13 14 just keep on doing it and invest the resources they invest. I mean, it's part of the 15 16 continuous quality improvement movement that 17 they see that they're tied into. I think our interest in California 18 19 in part is that we know we're going to go 20 ahead with the indicators on the social 21 determinants of health, but how do you rein in 22 this chaos or this great need for

Page 84

1 standardization that we see? And this is 2 where there's a logical connection to NQF 3 because we want to make sure that whatever 4 we're doing is harmonized with what other 5 organizations are doing and that they see 6 value in that.

7 You know, why at this time we weren't able to submit a rubic of indicators 8 9 is partly due to timing. We are lucky to have 10 a small research and development grant from the Strategic Growth Council, which is an 11 12 entity that represents the large state agencies working on green house gas mitigation 13 and sustainability in California. And they 14 have a Health Policy Task Force composed of 18 15 state agencies that basically created a series 16 of aspirational goals to which -- I mean, this 17 I think has been circulated among the 18 19 Committee, your Committee. But it's a series 20 of aspirational goals that had a tremendous 21 amount of community input as well. So it's not 22 just, you know high level directors or deputy

Page 85 1 directors of large state agencies, but this is 2 taken around the state and a number of communities for us to get input from community 3 members and local health departments, from 4 5 community-based organizations, from environmental justice groups. So it's a 6 7 pretty wide ranging group of folks who had 8 input. So this is a numbered approach to 9 getting -- you're setting up aspirational 10 goals, deconstructing them into indicators and then trying to address that from that 11 12 standpoint. So the process is really top down and bottom up in our situation. 13 14 Now some of the challenges, as I mentioned, we have this research and 15 16 development grant from the Strategic Growth 17 Council to work on its task force aspirational 18 goals, to turn them into indicators. And we 19 just started the project, so it's just a matter of timing. If the call had come out a 20 21 year from now, we'd probably be in a much 22 better position to actually provide much of

	Page 86
1	the information that would support the
2	criteria.
3	We don't particularly have an
4	issue with the rigor, the issues around
5	validity and precision that generally
б	indicator development. I think we will have
7	a challenge with the evidence-base. It won't
8	be based on clinical trials as many of the
9	clinical measures ideally are. So I think
10	there's going to be a certain I don't know
11	if it will be uneasiness maybe in the clinical
12	world to see the level of what's considered
13	evidence and validity might be visited. That
14	it may be a series of is it syllogisms that
15	this is related to that, which is related to
16	B and C and D and that we see a casual chain
17	here, but we can't through either hierarchical
18	modeling or other things demonstrate what the
19	population attributable risk is to any
20	individual factor that may be considered way
21	upstream. But we will try to get that
22	evidence and try to create some kind of

	Page 87
1	framework for evaluating that.
2	So we're not put off by that
3	piece, which I think some organizations may
4	not have the resources to do that.
5	One more challenge is the
6	geographic downscaling. That's one of our
7	missions. And I know that may be perhaps at
8	odds with some of the materials in the
9	background paper where a premium is going to
10	be put on measures that can have a national
11	scope. And that relies often on data that are
12	survey-based. And when you get to sub-county
13	levels the stability of those measures
14	basically breaks down.
15	I know there's been a lot of work
16	in modeling of some of those things. But I can
17	tell you from working directly with lots of
18	epidemiologists and local health departments
19	there's a certain queasiness about model data
20	for the purpose of monitoring performance.
21	They're less queasy about it being used in
22	predictive models for things that might be

	Page 88
1	happening 20 or 30 years from now. So, this
2	is a real challenge, which means that in some
3	cases local data sets will have more value or
4	get a higher priority.
5	The other challenges that I think
6	we have is just the administrative
7	arrangements with some of the data owners.
8	Where it's public domain data, there's not
9	going to be a problem. But one of the values
10	that we as a state agency California offers
11	that we can leverage our position in the state
12	to work with other state agencies that might
13	be data owners. Actually, very little of the
14	data that's on our preliminary draft list is
15	data that the California Department of Public
16	Health owns. There's a few items that are
17	behavioral risk factors, like smoking
18	prevalence and production of fresh fruits and
19	vegetables, and levels of physical activity
20	through our California Health Interview
21	Survey. But many of the data are owned by
22	other agencies, whether it's the Department of

Page 89 1 Education or the Department of Agriculture, or 2 Economic Development and we will need to broker administrative arrangements that those 3 agencies, and they have confidentiality 4 5 arrangements with some of the participants in 6 their surveys that may prevent them from 7 sharing individual identifiers, arranging 8 aggregations through third parties or some 9 arrangement is going to be a challenge for us 10 to get some that data. These are some of the --11 12 MS. MAINO-FIKE: What about the 13 confidentiality piece? Nobody's brought that 14 up, but that is a good point regarding what might make people hesitant in responding. 15 DR. MAIZLISH: 16 Yes. 17 So maybe I'll just leave it at 18 that, I mean as far as addressing some of the 19 specific reasons why we didn't move further 20 than we have on submitting something. But we 21 did see the value of standardization and I'm 22 pretty sure that organizations like NQF will

	Page 90
1	have in seeing that these measures are adopted
2	and it feeds into a accreditation processes
3	for the health departments, local health
4	departments. So there's some business reasons
5	on our end that we see the value to having a
6	standard rubic of indicators of the social
7	determinants of health that will be very
8	useful.
9	There are many business processes
10	within local health departments, many of them
11	do health status reports periodically that go
12	beyond the vital statistics of, you know,
13	birth and death data. And these kinds of
14	indicators and their underlying data will
15	advance their ability to do more sophisticated
16	health status reports that integrate both the
17	health side and the social determinant side.
18	So what is now an exception for a few large
19	health departments for Alameda County, Los
20	Angeles County and a few others will be
21	routine activity. And so that's hopefully
22	where this will go. And so I'll just leave it

	Page 91
1	at that just so that other people can
2	participate.
3	CO-CHAIR JARRIS: You know, that
4	was very helpful and I think your point that
5	there's a lot of, I guess noise out there is
6	partly departmental in the field, but it also
7	as you say raises the issue that it would be
8	very helpful to create some way of decreasing
9	that noise or standardizing some of these
10	measures.
11	You mentioned organizations like
12	the NQF. Are there others that are
13	potentially in this space that could
14	DR. MAIZLISH: Oh, my gosh. You
15	bet. I've been in touch with some of them.
16	There is ICLEI, which is an
17	organization of municipalities that is
18	creating a, it's called STAR, S-T-A-R, and it
19	is a rating system. And they are including
20	indicators indicators of social
21	determinants of health for municipal
22	governments. And this is in part part of the

	Page 92
1	stateability movement around the country. So
2	I've been in touch with them.
3	MS. MAINO-FIKE: Excuse me. What
4	was the name of that organization again?
5	DR. MAIZLISH: It's ICLEI, I-C-L-
6	E-I. And it's I can't remember if it's the
7	international league of communities something.
8	It started out as sort of an environmental
9	based organization but they've branched out
10	quite a bit. It's a membership organization
11	that has several hundred communities around
12	the United States that are participating.
13	They have a data group, and I participated.
14	Actually, Vickie Boothe at CDC was one of the
15	representatives from CDC. I don't know if Paul
16	knows CDC, it's a large organization and
17	you actually had CDC people helping with that
18	effort.
19	There's a sustainable
20	transportation organization. I can send your
21	Committee some of the specifics, because I had
22	my antenna out there for all the many

	Page 93
1	different organizations that are doing
2	indicator projects on the social determinants
3	of health just to see where they're at and
4	what they're doing.
5	Many of these organizations
6	actually have a business model where they're
7	going to be doing these ratings, in part for
8	identifying interventions, specific
9	interventions that they can do. And when they
10	do contracting to various entities for
11	whatever, public works, that they actually
12	will have some of these indicators written in
13	that is per the contractual arrangement that
14	they're still going to somehow contribute to
15	the indicators.
16	So, there's actually a business
17	reason why some of these communities are doing
18	it. Much of it is influenced by the LEED, the
19	leadership in environmental design folks. So
20	there's other organizations I found out about
21	as well. But I can send those to the
22	Committee afterwards.

	Page 94
1	CO-CHAIR JARRIS: That's very
2	helpful. In fact, that's something that NQF
3	might want to consider is that competitive
4	analysis of who else is in this space that can
5	be collaborators or competitors.
6	Sarah, you are on the line and
7	wanted to say something. And so, Operator, if
8	Sarah Linde-Feucht's line is not open, can you
9	open it?
10	OPERATOR: One moment.
11	CO-CHAIR JARRIS: Perhaps while
12	we're waiting, we'll go Bobby, Ron and Matt.
13	MEMBER PESTRONK: I was trying to
14	figure out what problem we're trying to solve.
15	OPERATOR: Sarah, press star 1.
16	MEMBER PESTRONK: Because before
17	Neil's presentation it seemed to me that we
18	were focused on three or four different
19	problems and that it would be helpful for us
20	to pick one and then continuous quality
21	improvement jargon do a fishbone diagram and
22	ask ourselves what's contributing to the

Г

	Page 95
1	problem. And ask ourselves if NQF will go
2	forward in this space, what's our
3	MR. CORBRIDGE: Thank you.
4	Ian Corbridge, can you hear me?
5	CO-CHAIR JARRIS: Yes. Who is
6	that, please?
7	MR. CORBRIDGE: This is Ian
8	Corbridge with HRSA. Apologize, Sarah Linde-
9	Feucht had to step off the phone, but she
10	asked me to speak in her stead. I don't know
11	if now is a good time to follow-up on some of
12	that or if you want to kind of reserve that
13	conversation until later on.
14	CO-CHAIR JARRIS: Why don't we let
15	Bobby finish and then ask you to speak.
16	MR. CORBRIDGE: All right.
17	Wonderful. I'll stay on the phone.
18	MEMBER PESTRONK: The four
19	potential problems, the four problems that I
20	heard were that we didn't get a sufficient
21	number of measures submitted; that's one
22	problem.

Page 96 1 The second is that the measures 2 that were submitted were of poor quality, and 3 that had to do with that they were more clinically focused or that they were not 4 5 social determinant focused. 6 The third problem is that there 7 was some confusion in the evaluation of the 8 submitted measures; that we had some confusion. 9 10 And then the fourth problem was 11 the ability to get measures accepted by the 12 NQF Board. 13 So those, there were comments 14 about each of those. And those are very 15 different problems. 16 MS. MAINO-FIKE: May I interrupt for just one second? 17 18 MEMBER PESTRONK: Yes. 19 MS. MAINO-FIKE: And ask you, I 20 want to make sure that we get those four 21 categories you've created. What was the 22 third?

Page 971MEMBER PESTRONK: The third was2confusion around how to evaluate the measures,3both on the part of submitters and on the part4of us as a Committee.5MS. MAINO-FIKE: Okay.6MEMBER PESTRONK: And so my7thinking is that if we were clear about what8problem we were trying to solve, then we would9do a better job of solving it.10MS. MAINO-FIKE: Right.11CO-CHAIR JARRIS: Our colleague12from HRSA, did you want to speak now? And13could you identify yourself again because14there was some breaking up of the phone there.15MR. CORBRIDGE: Yes. I apologize.16Can you guys hear me clear now?17CO-CHAIR JARRIS: Yes.18MR. CORBRIDGE: All right. So19this is Ian Corbridge with the Health20in for Captain Sarah Linde-Feucht. She21apologizes. She had to step off the phone,		
confusion around how to evaluate the measures, both on the part of submitters and on the part of us as a Committee. MS. MAINO-FIKE: Okay. MEMBER PESTRONK: And so my thinking is that if we were clear about what problem we were trying to solve, then we would do a better job of solving it. MS. MAINO-FIKE: Right. CO-CHAIR JARRIS: Our colleague from HRSA, did you want to speak now? And could you identify yourself again because there was some breaking up of the phone there. MR. CORBRIDGE: Yes. I apologize. Can you guys hear me clear now? MR. CORBRIDGE: All right. So this is Ian Corbridge with the Health Resources and Services Administration filling in for Captain Sarah Linde-Feucht. She		Page 97
 both on the part of submitters and on the part of us as a Committee. MS. MAINO-FIKE: Okay. MEMBER PESTRONK: And so my thinking is that if we were clear about what problem we were trying to solve, then we would do a better job of solving it. MS. MAINO-FIKE: Right. CO-CHAIR JARRIS: Our colleague from HRSA, did you want to speak now? And could you identify yourself again because there was some breaking up of the phone there. MR. CORBRIDGE: Yes. I apologize. Can you guys hear me clear now? CO-CHAIR JARRIS: Yes. MR. CORBRIDGE: All right. So this is Ian Corbridge with the Health Resources and Services Administration filling in for Captain Sarah Linde-Feucht. She 	1	MEMBER PESTRONK: The third was
4 of us as a Committee. 5 MS. MAINO-FIKE: Okay. 6 MEMBER PESTRONK: And so my 7 thinking is that if we were clear about what 8 problem we were trying to solve, then we would 9 do a better job of solving it. 10 MS. MAINO-FIKE: Right. 11 CO-CHAIR JARRIS: Our colleague 12 from HRSA, did you want to speak now? And 13 could you identify yourself again because 14 there was some breaking up of the phone there. 15 MR. CORBRIDGE: Yes. I apologize. 16 Can you guys hear me clear now? 17 CO-CHAIR JARRIS: Yes. 18 MR. CORBRIDGE: All right. So 19 this is Ian Corbridge with the Health 20 this is Ian Corbridge with the Health 21 in for Captain Sarah Linde-Feucht. She	2	confusion around how to evaluate the measures,
5MS. MAINO-FIKE: Okay.6MEMBER PESTRONK: And so my7thinking is that if we were clear about what8problem we were trying to solve, then we would9do a better job of solving it.10MS. MAINO-FIKE: Right.11CO-CHAIR JARRIS: Our colleague12from HRSA, did you want to speak now? And13could you identify yourself again because14there was some breaking up of the phone there.15MR. CORBRIDGE: Yes. I apologize.16Can you guys hear me clear now?17CO-CHAIR JARRIS: Yes.18MR. CORBRIDGE: All right. So19this is Ian Corbridge with the Health20Resources and Services Administration filling21in for Captain Sarah Linde-Feucht. She	3	both on the part of submitters and on the part
 MEMBER PESTRONK: And so my thinking is that if we were clear about what problem we were trying to solve, then we would do a better job of solving it. MS. MAINO-FIKE: Right. CO-CHAIR JARRIS: Our colleague from HRSA, did you want to speak now? And could you identify yourself again because there was some breaking up of the phone there. MR. CORBRIDGE: Yes. I apologize. Can you guys hear me clear now? CO-CHAIR JARRIS: Yes. MR. CORBRIDGE: All right. So this is Ian Corbridge with the Health Resources and Services Administration filling in for Captain Sarah Linde-Feucht. She 	4	of us as a Committee.
 thinking is that if we were clear about what problem we were trying to solve, then we would do a better job of solving it. MS. MAINO-FIKE: Right. CO-CHAIR JARRIS: Our colleague from HRSA, did you want to speak now? And could you identify yourself again because there was some breaking up of the phone there. MR. CORBRIDGE: Yes. I apologize. Can you guys hear me clear now? CO-CHAIR JARRIS: Yes. MR. CORBRIDGE: All right. So this is Ian Corbridge with the Health Resources and Services Administration filling in for Captain Sarah Linde-Feucht. She 	5	MS. MAINO-FIKE: Okay.
 problem we were trying to solve, then we would do a better job of solving it. MS. MAINO-FIKE: Right. CO-CHAIR JARRIS: Our colleague from HRSA, did you want to speak now? And could you identify yourself again because there was some breaking up of the phone there. MR. CORBRIDGE: Yes. I apologize. Can you guys hear me clear now? CO-CHAIR JARRIS: Yes. MR. CORBRIDGE: All right. So this is Ian Corbridge with the Health Resources and Services Administration filling in for Captain Sarah Linde-Feucht. She 	6	MEMBER PESTRONK: And so my
9 do a better job of solving it. 10 MS. MAINO-FIKE: Right. 11 CO-CHAIR JARRIS: Our colleague 12 from HRSA, did you want to speak now? And 13 could you identify yourself again because 14 there was some breaking up of the phone there. 15 MR. CORBRIDGE: Yes. I apologize. 16 Can you guys hear me clear now? 17 CO-CHAIR JARRIS: Yes. 18 MR. CORBRIDGE: All right. So 19 this is Ian Corbridge with the Health 20 Resources and Services Administration filling 21 in for Captain Sarah Linde-Feucht. She	7	thinking is that if we were clear about what
 MS. MAINO-FIKE: Right. CO-CHAIR JARRIS: Our colleague from HRSA, did you want to speak now? And could you identify yourself again because there was some breaking up of the phone there. MR. CORBRIDGE: Yes. I apologize. Can you guys hear me clear now? CO-CHAIR JARRIS: Yes. MR. CORBRIDGE: All right. So this is Ian Corbridge with the Health Resources and Services Administration filling in for Captain Sarah Linde-Feucht. She 	8	problem we were trying to solve, then we would
11CO-CHAIR JARRIS: Our colleague12from HRSA, did you want to speak now? And13could you identify yourself again because14there was some breaking up of the phone there.15MR. CORBRIDGE: Yes. I apologize.16Can you guys hear me clear now?17CO-CHAIR JARRIS: Yes.18MR. CORBRIDGE: All right. So19this is Ian Corbridge with the Health20Resources and Services Administration filling21in for Captain Sarah Linde-Feucht. She	9	do a better job of solving it.
12 from HRSA, did you want to speak now? And 13 could you identify yourself again because 14 there was some breaking up of the phone there. 15 MR. CORBRIDGE: Yes. I apologize. 16 Can you guys hear me clear now? 17 CO-CHAIR JARRIS: Yes. 18 MR. CORBRIDGE: All right. So 19 this is Ian Corbridge with the Health 20 Resources and Services Administration filling 21 in for Captain Sarah Linde-Feucht. She	10	MS. MAINO-FIKE: Right.
13 could you identify yourself again because 14 there was some breaking up of the phone there. 15 MR. CORBRIDGE: Yes. I apologize. 16 Can you guys hear me clear now? 17 CO-CHAIR JARRIS: Yes. 18 MR. CORBRIDGE: All right. So 19 this is Ian Corbridge with the Health 20 Resources and Services Administration filling 21 in for Captain Sarah Linde-Feucht. She	11	CO-CHAIR JARRIS: Our colleague
14there was some breaking up of the phone there.15MR. CORBRIDGE: Yes. I apologize.16Can you guys hear me clear now?17CO-CHAIR JARRIS: Yes.18MR. CORBRIDGE: All right. So19this is Ian Corbridge with the Health20Resources and Services Administration filling21in for Captain Sarah Linde-Feucht. She	12	from HRSA, did you want to speak now? And
 MR. CORBRIDGE: Yes. I apologize. Can you guys hear me clear now? CO-CHAIR JARRIS: Yes. MR. CORBRIDGE: All right. So this is Ian Corbridge with the Health Resources and Services Administration filling in for Captain Sarah Linde-Feucht. She 	13	could you identify yourself again because
 16 Can you guys hear me clear now? 17 CO-CHAIR JARRIS: Yes. 18 MR. CORBRIDGE: All right. So 19 this is Ian Corbridge with the Health 20 Resources and Services Administration filling 21 in for Captain Sarah Linde-Feucht. She 	14	there was some breaking up of the phone there.
17 CO-CHAIR JARRIS: Yes. 18 MR. CORBRIDGE: All right. So 19 this is Ian Corbridge with the Health 20 Resources and Services Administration filling 21 in for Captain Sarah Linde-Feucht. She	15	MR. CORBRIDGE: Yes. I apologize.
18 MR. CORBRIDGE: All right. So 19 this is Ian Corbridge with the Health 20 Resources and Services Administration filling 21 in for Captain Sarah Linde-Feucht. She	16	Can you guys hear me clear now?
19 this is Ian Corbridge with the Health 20 Resources and Services Administration filling 21 in for Captain Sarah Linde-Feucht. She	17	CO-CHAIR JARRIS: Yes.
 20 Resources and Services Administration filling 21 in for Captain Sarah Linde-Feucht. She 	18	MR. CORBRIDGE: All right. So
21 in for Captain Sarah Linde-Feucht. She	19	this is Ian Corbridge with the Health
	20	Resources and Services Administration filling
22 apologizes. She had to step off the phone,	21	in for Captain Sarah Linde-Feucht. She
	22	apologizes. She had to step off the phone,

	Page 98
1	but has been listening into the discussion
2	this morning.
3	And I think, Paul, with respect to
4	your question yesterday, I wanted to follow-up
5	on a couple of points where I guess you
6	pointedly asked why maybe more measures from
7	HRSA didn't come into this project. So,
8	having spoken with Sarah, I really wanted to
9	touch on two points that I think tie into
10	today's larger discussion really looking at
11	the commitments and investments into the NQF
12	process from HRSA and HHS' standpoint, and
13	then also I think hoping to touch on probably
14	the low response rate, specifically from
15	HRSA's perspective.
16	So kind of on the larger view it
17	is HRSA Administrator Dr. Wakefield's priority
18	not only to align measures and actual
19	specifications within the agency, but also to
20	make sure that we're doing it at the federal
21	level. And that's really tying into this
22	larger drive from the National Quality

	Page 99
1	Strategy. And so as that trickles down it
2	really is a priority of HRSA's Administrator
3	to make sure that all the bureaus and offices
4	within the agency are using nationally
5	recognized measures and really has moved us to
6	making sure that when we are using measures
7	within HRSA programs that we are using or
8	moving towards NQF endorsed measures. And so
9	that set us somewhat on a different trajectory
10	and has caused us to change some of the way
11	that we're doing business or thinking about
12	development and moving forward.
13	So, I think that is kind of a
14	strong commitment. And I would say that
15	probably resounds across HHS and really moving
16	towards the NQF process, more to I think
17	specifically decide probably the lack of
18	response rate, specifically from HRSA's end.
19	And I think this goes to issues that have
20	already been touched on, but I hope it kind of
21	provided a perspective from HRSA in the safety
22	net community. It's really an issue of timing

Page 100

and resources.

1

2	I think we've already touched on
3	the timing to some degree, but given the
4	current NQF process and a cycle of every three
5	years of when the different measurement
6	projects come up, depending upon when an
7	agency or an entity has a measure ready and
8	depending on when that cycle starts, you may
9	have a measure that's ready but maybe you
10	haven't completed your testing or validation,
11	et cetera. However, if that project has
12	already started and you're not ready to
13	submit, you kind of lose out. You may have to
14	wait another three years. So I think there's
15	really an issue of timing.
16	With respect to this specific
17	project, I know there were entities or bureaus
18	and offices within HRSA who had intended to or
19	were interested in submitting measures to this
20	project. One of them specifically was HRSA's
21	Maternal and Child Health Bureau. However
22	their measures weren't tested and validated at

Page 101
this time, and so they weren't able to submit
measures.
Another bureau that was interested
was HRSA's HIV/AIDS Bureau, but given the
actual kind of specifications and target of
their measures, they were encouraged to submit
their measures to the NQF Infectious Disease
Project which is coming up in a couple of
months.
So, those were the two bureaus
that actually had measures that were of
interest to this project, and I think wanted
to participate. One due to timing issues and
one due to a priority of their measures would
fit better in a different project. So it was
really due to a lack of response rate on
HRSA's end.
I will say that I think one
challenge is that the framework that the
Committee put out and the turnaround time
frame by which the measure development
committee had time to react to that was

i	
	Page 102
1	relatively short. And I think when we looked
2	at the broader spectrum of measure
3	development, the field didn't really have the
4	time necessary I think to adequately pull
5	together something that would be of value for
6	the Committee to review.
7	So, I think from our end as we
8	looked at that framework I think it had a lot
9	of value to the agency and give us a lot of
10	direction of where we need to go. I would
11	imagine in a couple of years there would be a
12	point at which we would be ready to probably
13	move population health measures through.
14	That being said, I know I had a
15	conversation yesterday with respect to the HHS
16	Home Visiting Program which HRSA is helping to
17	run. And they have a wide variety of measures
18	that actually get to the health determinant
19	level that a representative from HRSA was
20	interested in moving through the NQF
21	endorsement process or having that discussion.
22	So, I know this project has already passed,

	Page 103
1	but I think at a later date when the
2	opportunity arises, we'd be very interested in
3	trying to move some of those more population
4	level measures through the NQF process.
5	That was some of the key points
6	that Sarah wanted me to speak on. I don't
7	know if there's any questions, or if that was
8	helpful to the conversation. But thank you
9	for the opportunity to speak.
10	CO-CHAIR JARRIS: Thank you. That
11	was very helpful.
12	From your point of view what could
13	be done to help HRSA by NQF in terms of
14	preparing as an agency or parts of the agency
15	to develop and submit measures?
16	MR. CORBRIDGE: Again, I think one
17	of the challenge on HRSA's end is that we have
18	very limited expertise in terms of actual
19	measure developers within the agency itself
20	and really try to leverage off of already
21	developed and endorsed measures. That being
22	said, we really do look to develop measures

Page 104 1 when there are gaps, when we have identified 2 gaps. And one thing that I think we 3 would find helpful, I know these conversations 4 5 are already taking place, is looking to 6 somewhat revamp or restructure the current NQF 7 endorsement process. And I don't know, maybe 8 Helen or others from the NOF staff in the room 9 can speak on that issue. So really trying to 10 make it a much more nimble process that can respond to change in guidelines or best 11 12 practices within the field. 13 I will say having recently had a 14 discussion with the NOF staff around the NOF 15 Infectious Disease Project, we found it very helpful in that NQF staff actually took the 16 17 time about an hour and a half and they sat down with the actual developers within HRSA 18 19 and some of the team that I work with and 20 really went through all the steps within the 21 NQF endorsement process, were very detailed in 22 helping us to think through some of the

	Page 105
1	testing requirements, that we had our testing
2	data in order to submit to NQF. So, I think
3	that process was invaluable for us and I think
4	that that's something that hopefully the rest
5	of the measure development community can
6	really take advantage of.
7	DR. BURSTIN: Just briefly to
8	respond to what Ian is referring to. We are
9	actually moving towards our pilot, just
10	approved yesterday actually, a two stage
11	endorsement process. And some of this is to
12	try to make our work align better with the
13	work of measure development. So that we're
14	going to be moving forward, probably in 2013,
15	across all projects with a process whereby
16	measures would come forward as a concept first
17	and really just get a look at importance to
18	measure and report. So really looking at the
19	impact, where there's a gap, the underlying
20	evidence and really the concept without the
21	requirements for the full testing and the full
22	specifications. If that's approved, the

Page 106 1 developer can then come back with fully 2 specified tested measures. 3 So in the instance that Ian just mentioned that there are measures out of MCHB 4 5 that might have been very appropriate but were not tested, that would be an opportunity for 6 7 them to at least get an early read by a 8 Committee as to say whether they are important 9 enough to keep moving forward, and then bring 10 them back when they're tested. So try to make it more nimble. 11 12 We're also going to move to having we hope more regular submissions, at least on 13 14 an annual basis across all the different 15 topical areas. 16 DR. MAIZLISH: Hi. This is Neil 17 Maizlish again. I have maybe two questions which 18 19 are related. One is, you know The Robert Wood 20 Johnson University of Wisconsin County Health 21 Rankings has come out. Are folks aware of 22 that project?

	Page 107
1	CO-CHAIR JARRIS: Yes, we are.
2	DR. MAIZLISH: Oh, okay. And I
3	don't know, did you have contact with them?
4	Because to me they seem to have a development
5	process that meets many of the criteria and
6	rigor that NQF has stated for developers. So,
7	that's one thing.
8	The other is has NQF ever
9	facilitated contacts between developers that
10	might advance the field in some way?
11	DR. BURSTIN: We routinely do
12	outreach. In fact, we did outreach to all
13	those groups, including Wisconsin. Again, I
14	think it was just an issue of people being
15	ready.
16	It is actually very helpful that
17	some of you may know Barb Rudolph, who has
18	been a measure developer of Leapfrog for
19	years. Barbara just joined David Kindig's
20	team. So I think having somebody on site
21	DR. MAIZLISH: Okay.
22	DR. BURSTIN: who is very

	Page 108
1	familiar with development and NQF submission
2	actually will be very helpful as well.
3	DR. MAIZLISH: Okay.
4	MEMBER BIALEK: Just a quick
5	response to that last comment. Gets back to
6	again, you know what's in it for the
7	organization to propose the measure?
8	I know that we had with the
9	Community Health Status Indicators, we had a
10	whole process, evidence-based indicators.
11	Some of those indicators, county health
12	rankings. And we thought about, you know why
13	would we want to go through the process and
14	also do we have the resources to go through
15	the process. That second part was no, the
16	second question.
17	I fully support what Bobby
18	suggested is that we decide on which problem
19	to address. And I'd like to suggest that we
20	address the problem of too few measures. And
21	that we look at the root causes around that.
22	We identify then what it is that this
Page 109 Committee and staff control and influence and 1 2 work on that. At the same time, we identify what 3 4 other players may control or influence that may be important. I think we can only address 5 6 what it is that we have the authority and the 7 ability to address. And so refining what 8 we're talking about and getting to the root 9 cause, and working that through I think would 10 be helpful. Just one last item. 11 Just a 12 question. Has the Institute for Health Care 13 Improvement submitted measures? They have. 14 Okay. Because I think about a lot of the 15 process types of measures that we might 16 ultimately look at from the public health 17 community that IHI has some process measures 18 that are clearly tied to health care, and we 19 can have process measures that clearly can tie 20 to health. 21 DR. BURSTIN: It's actually 22 interesting. IHI, HRSA, CDC all submit

Page 110 measures to NQF but they're just clinical. 1 Ι 2 mean, they are just much more -- not so much clinical, but health care system focused. 3 So they're used to submitting, just not in this 4 5 area. MEMBER STOTO: On that last point, 6 7 IHI of course has their Triple Aim activity 8 and it would seem to be the population health 9 leg of that tripod would be the right one to work on. 10 But I wanted to pick up on the 11 12 last comment that was made on the phone about the possibility of providing technical 13 14 support. I think it goes beyond what you were 15 responding to -- your response, Helen. 16 I mean, it strikes me that a lot 17 of people in the public health world are not 18 used to this measurement process, measure 19 development process that we're now used to in 20 the health care world. And that maybe a kind 21 of training session, you know what exactly is 22 involved? What are we talking about here?

	D 111
	Page 111
1	How do you show that it works and so on and so
2	forth would be a useful thing to do.
3	MEMBER QASEEM: Okay. So I was
4	just sitting over here again with the
5	population health measures, I was trying to
6	figure out how we can differentiate a little
7	bit. In my mind, I don't think this is just
8	structured process outcome measures, and I was
9	just trying to list some of them from the top
10	of my head what I remembered over the years.
11	So population health measures fall
12	in the category of process, outcome, access,
13	structure of course is there, population
14	experience, population management, population
15	costs and population services.
16	And I don't think that we can have
17	them, we can separate them out, sort of linked
18	to what I was trying to say earlier as all the
19	population needs to be looked as a whole.
20	So, for example, we'll take an
21	example of smoking. We talked about some of
22	the process and outcome measures, but we can't

	Page 112
1	separate out for example population experience
2	which I think is whether the population has
3	seen ads on TV or ads in papers regarding
4	anti-smoking.
5	Population access would be access
6	to smoking cessation programs. Costs, of
7	course, we all know. And then population
8	services is going to be whether the population
9	is using those services.
10	And again, I think that maybe NQF
11	when we go out and make the call for measures,
12	I think we need to be really looking at all of
13	them together. We just cannot be getting
14	measures getting measures that are talking
15	about population process and population
16	outcomes if we are not really talking about
17	the rest of these categories. Because again,
18	it goes back to the if you're talking about
19	improving the care and outcomes for the
20	population level, if you're addressing just
21	two out of whatever, seven or eight, then very
22	bright people have done work on this, it's not

1	
	Page 113
1	going to improve the health of the population
2	unless we take them altogether and come up
3	with the measures that sort of it goes back
4	to sort of a composite measure sort of thing.
5	But it's difficult, but I think this is where
6	NQF can play a leadership role in terms of
7	specifically asking that it may be better to
8	just have a performance measures on smoking
9	cessation that addresses some of these
10	categories rather than having 20 measures that
11	are just talking about one here and one there.
12	MEMBER STIEFEL: Sorry this is a
13	little disjointed. My card went up when Peter
14	was talking.
15	But along the way, just in
16	response to Mike's comment, I serve on the IHI
17	Triple Aim Faculty for Measurement and have
18	developed the population health measures for
19	the Triple Aim. Those have been submitted to
20	Health Affairs, including the framework that
21	I developed and that's the status of that
22	work.

	Page 114
1	I would say in general it's not so
2	much IHI's philosophy to have the same level
3	of rigor for the measurement work, especially
4	for quality improvement that are established
5	for NQF endorsed measures.
6	The comment, I have sort of an
7	observation and specific recommendation. The
8	observation is based on the interchange
9	between Peter and Helen in talking about the
10	potential value of standardization and
11	harmonization. And I think that the sweet
12	spot for this work and for NQF is at the
13	intersection between health care delivery and
14	public health and not too far out in the
15	middle of the public health, but at that
16	intersection. And I think that the sweet spot
17	for that intersection is in the measures of
18	health behaviors. Again, back to smoking,
19	eating, drinking and exercise.
20	There's mutual benefit in the
21	public health world. The problem is that
22	those are assessed in small random sample

Page 115 1 surveys that are getting worse and worse over 2 time because of response rates and people not having forms and all that. And those measures 3 are not useful to the health care delivery 4 5 The county health rankings are not system. very useful to the health care delivery system 6 7 because they're not discrete enough; they 8 don't go down to the level where improvement 9 happens. But those measures are increasingly, 10 routinely collected, gathered in the health care delivery system and by health plans. 11 12 And so it's interesting. The 13 clinical care delivery system has 14 subpopulation level data of entire subpopulations whereas the public health 15 system has these small random sample surveys. 16 17 So if measures in those domains, 18 and just take those four behaviors, were 19 standardized or harmonized such that the 20 measures that the clinical care delivery 21 system is gathering for subpopulations are the 22 same measures with the same specifications as

	Page 11
1	the public health measures, then we can move
2	toward rolling up those subpopulation measures
3	to get at least approximations of total
4	population measures. And with that I think
5	that will drive I think the behavior that
6	we're interested in. I think that there's a
7	positive feedback, a synergy in that having
8	better information on those healthy behaviors
9	in the public health world will drive
10	improvement activities probably upstream in
11	social and environmental determinants. It
12	will drive improvement activities in the
13	health care delivery system because the health
14	care delivery system is, at least my
15	organization and I'm sure Sarah's as well, get
16	it that smoking and drinking and eating and
17	exercise are profound determinants of
18	subsequent utilization in costs and outcomes.
19	So it will drive the improvement activities in
20	the kinds of things that we were talking about
21	yesterday about assessment and then follow-up.
22	So by focusing on that sweet spot

6

	[
	Page 117
1	I think that we will generate activity in this
2	positive feedback loop in both public health
3	and the clinical care delivery system, and it
4	seems like a very appropriate role for NQF to
5	focus on defining clearly in harmonizing the
6	measures used in public health and clinical
7	health.
8	You can then go beyond the health
9	behaviors. I mean, we've got great
10	information on disease status with our disease
11	registries. That could be rolled up to
12	population level measures. Or even self-
13	perceived health down the road. We routinely
14	collect that information now. If that's
15	measured in the standard way and there's an
16	easy way to standardize that, that also could
17	be rolled up from the subpopulation.
18	So it's just the point is that
19	it's at that intersection. And I think that
20	a modest first step would be to focus on those
21	four healthy behaviors and do a call for
22	measures, specifically for those. And I think

	Page 118
1	make the case that there's mutual benefit to
2	public health and health care delivery.
3	CO-CHAIR JARRIS: Kurt?
4	CO-CHAIR STANGE: This is really
5	just a minor point, but just s reaction to
6	Mike's comment. I actually like the idea of
7	an educational thing that NQF could do on
8	population health measures. And the addendum
9	I want to make of that is to think of it as a
10	two-way learning street. Because I think one
11	small hook might be the idea that people
12	getting that education could actually help
13	frame, influence NQF's thinking in this area.
14	I mean, when people are too busy to really
15	come up with the measures, it might not be
16	enough of a motivation. But for some it might
17	be a little bit of a motivation, particularly
18	for things that are I mean clearly the role
19	I think we're hearing for NQF is really at the
20	interface with the clinical care measures.
21	And I agree with Matt that the healthy
22	behaviors are a nice way to frame it. But

	Page 119
1	just think about an educational thing as a
2	two-way street and that would be a good frame.
3	MEMBER STOTO: Yes, I think that's
4	right. And I think that over the last,
5	whatever decade or so that NQF has been
6	around, that has all happened. But it hasn't
7	happened with the public health community.
8	And we have to short-circuit that.
9	CO-CHAIR JARRIS: So I just wanted
10	to add one thing to just put it on the list
11	and it doesn't even have to be addressed
12	today. But the notion of evidence and what is
13	considered evidence within this NQF process.
14	And I think it's largely been a biomedical
15	model. And yet when you get out into the
16	population public health world, you're talking
17	about a collection of different sciences.
18	There clearly are some biomedical science
19	components, but there are many social sciences
20	whether it's political sciences,
21	communications, economics, behavioral sciences
22	that have different types of evidence

	Page 120
1	gathering and different notions of what
2	evidence is. And I think that's going to be
3	a tremendously difficult thing as we start
4	moving away from purely clinical measures into
5	public health and population interventions to
6	decide what is adequate evidence. Because if
7	we use the random double-blinded controlled
8	study, we're going to get nothing. It just
9	does not apply in that world. So somehow we
10	need to figure that out and come up with an
11	acceptable level of what constitutes evidence.
12	So, I guess, Kurt, you were going
13	to say something and then let's take a break.
14	CO-CHAIR STANGE: I don't know if
15	Peter's still on, but certainly piggyback onto
16	the work that the Community Guide folks have
17	done and having to think about that makes
18	sense.
19	CO-CHAIR JARRIS: But even the
20	Community Guide, by the time you get into
21	Community Guide you're ten years into a
22	process because it has to collect so much. I

	Page 121
1	mean, you can't drive innovation with a
2	Community Guide. You're driving
3	retrospectively.
4	DR. BURSTIN: One last point. We
5	did some work on an evidence task force about
6	a year and a half ago or so and had a very
7	nice report some experts did for us on how to
8	assess evidence. We don't require double-
9	blind RCTs. It's very clearly that we ask to
10	look at the quality and the quantity and the
11	consistency of evidence. So there could be a
12	very new single study that's really innovative
13	and really important and there's no evidence
14	of inconsistency, and that can move things
15	forward. I mean if you look at the work we
16	just did on cultural competency or care
17	coordination, I'm not convinced it's that
18	different than the evidence base for some of
19	these public health interventions. They're
20	actually we had lots of discussions about
21	squishiness of what's really there, but they
22	still moved forward because everybody agreed

Page 122 1 that those were important enough. And we 2 actually have an evidence exception. Ιf 3 something is so important that everybody in 4 the Committee completely agrees that this 5 would drive significant improvement and the evidence just isn't there, it's not that the 6 7 evidence is there and it's negative, it just isn't there at all, the Committee can still 8 9 move it forward. And we've done that, for 10 example, some work on spirituality in palliative care. Again, not something you're 11 12 going to see a ton of research on, but then why would anybody say don't move something 13 14 like that forward when it's so intuitive that that would be useful for patients? 15 I agree. 16 MEMBER STIEFEL: You know, I think science is science. And I think 17 it applies more broadly, especially if you 18 19 don't necessarily require specifically 20 clinical trials. 21 Where we stumbled yesterday was 22 evidence base associated with these

Page 123 assessments that -- because it's a long way 1 2 causal pathway between assessing something and 3 the outcome. But for BMI, for example, so assessment of BMI it was troublesome, in fact 4 5 we rejected them yesterday. But if the measure was BMI, that causal pathway is very 6 7 clear between BMI and outcomes. I don't think 8 we would have had any trouble at all of making 9 the association and thinking that the evidence was there. 10 11 MS. MAINO-FIKE: I think that 12 sounds good. So let's take a ten minute break 13 14 because what that usually means is it's a 15 minute break. So let's take ten minutes and 15 16 get back at five of and we can wrap up our discussion and we'll be done at 11:45. 17 (Whereupon, the above-entitled 18 19 matter went off the record at 10:41 a.m. and 20 resumed 11:04 p.m.) 21 MS. MAINO-FIKE: So let's 22 summarize what we've accomplished thus far

Page 124

1 this morning.

2	It seems that there was a lot of
3	energy in having a broad discussion on not
4	just why we had a low response to the call for
5	measures, but on some larger issues as well.
б	So, we spent a good amount of time gathering
7	very important observations and feedback
8	regarding not just the call for measures, but
9	a possible role for NQF in moving forward with
10	not just clinical measures, but public and
11	population measures and the need for some
12	consistent standardization in that area. And
13	it seems like this is really a point in time
14	where the health field has evolved to where
15	you're looking at putting some more rigorous
16	and standardized measures and bringing that
17	out into the population or public health care
18	forum.
19	What seemed to me in listening to
20	the discussion was that three categories
21	seemed to emerge around your conversation.
22	One category was simply why was the response

	Page 125
1	low? What were the determining factors in
2	those responses so low? And I've identified
3	and captured some of the comments under No. 1
4	for that.
5	The second category of broad
6	comments seemed to be what are some future
7	steps or needs that NQF, perhaps this group,
8	might want to look at? Not that there are
9	decision points there. Some of those possible
10	future steps are small, some of them might be
11	larger and broader in scope.
12	And then the third category of
13	comments seemed to be around the measures
14	themselves. Okay. And I've captured those
15	under category No. 3.
16	Someone asked, obviously my
17	chicken scratch is exactly that; chicken
18	scratch, hard to understand. I've tried to
19	post things in terms of category 1, category
20	2, category 3. However, one of the outcomes
21	of this meeting is that each of you will get
22	not just the meeting minutes, but the lists of

	Page 126
1	the comments and suggestions in each of those
2	categories so that we don't lose them.
3	What we thought it might be good
4	to do now in the remaining 45 minutes or so is
5	to bring the conversation down to a more
6	concrete level given all of the excellent
7	input and discussion we've had up to this
8	point. So what we'd like to do is a fishbone
9	diagram. I don't know, some of you may have
10	used that format in the past regarding
11	bringing it to the original purpose for the
12	morning, which is we want to frame it in a
13	more positive way. Not why, you know was the
14	response so low. But assuming that we're
15	going to reissue this call for measures, what
16	should we would we do differently? So
17	let's keep it on a more positive frame of
18	mind.
19	So, here's our assumption that we
20	will reissue this call for measures. What
21	would we do differently?
22	Some of you have come up earlier

Page 127 1 this morning with some categories or areas 2 around what you might do different, and that's fine if you want to identify categories. 3 Ι think we can kind of brainstorm some of these. 4 5 And if I'm not clear on what the connections are, you can certainly correct me so that 6 7 they're reflected appropriately on the 8 fishbone diagram. And then that might lead us 9 just very naturally into a conversation which 10 you'll see next on the agenda, the working lunch regarding measures. 11 12 So, assuming we are going to reissue this call for measures, what would we 13 14 do differently? 15 I'm sorry. I can't see the name tags being flipped up, I apologize, when I'm 16 over there. 17 Matt? 18 MEMBER STIEFEL: That's okay, I 19 was just waiting for permission. 20 MS. MAINO-FIKE: Maybe we can do 21 the hand raise thing because it's easier to 22 see from up there.

Page 128 MEMBER STIEFEL: Well, I think I 1 2 might challenge your premise. 3 MS. MAINO-FIKE: Okay. 4 MEMBER STIEFEL: If we were to do 5 another call for measures, what would we do differently? 6 7 MS. MAINO-FIKE: Yes. 8 MEMBER STIEFEL: Maybe take out 9 the front part of that, just what would we do differently. 10 11 MS. MAINO-FIKE: Yes. 12 MEMBER STIEFEL: Because I think 13 part of the problem was in relying on luck of 14 the draw about whoever happened to submit 15 measures. 16 MS. MAINO-FIKE: Yes. 17 MEMBER STIEFEL: And it turned out there was a handful of clinical improvement 18 19 measures that we got. So it seems like we 20 shouldn't rely, at least at the front end, on 21 a call for measures but instead Helen and I were talking a little bit on the break about 22

	Page 129
1	doing an exercise of finding going out now
2	and finding all of the sources and pick a
3	subset. You know, pick behaviors is my
4	suggestion. But do an analysis of all of the
5	public health measures for those health
6	behaviors, all of the measures used within the
7	clinical care delivery system, and they are in
8	HEDIS and other sources. And do a kind of
9	harmonization exercise and maybe even I
10	don't know if it's a white paper or whatever,
11	but come up with some recommendations. And
12	then from that, perhaps, go and solicit. And
13	maybe that's the call for measures part. But
14	you'd be soliciting to particular developers,
15	say here's our framework, we would like you to
16	submit a measure in this area.
17	The second part is, Jason and I
18	were talking at the break also about there are
19	a lot of population or potential population
20	health measures currently in the NCQA and NQF
21	portfolios. They're just not labeled
22	population health measures. But it would be

Page 130 an interesting exercise just to assemble all 1 2 of those into a compendium or a collection of potential population health measures. 3 And again start from there to do a more informed 4 5 targeting. And maybe it's a different type of 6 call that's done for measures when that 7 groundwork is done. 8 MS. MAINO-FIKE: Okay. So what I 9 have here is this bone, if you will, of identifying sources, recommendations and 10 basically solicit targeted developers rather 11 12 than just sort of throwing it out there to 13 anyone and everyone. So, one might be to 14 solicit targeted developers. 15 And then the other is to survey 16 population health measures that are already 17 out there and compile them in some sort of a 18 list so that you don't have to reinvent the 19 wheel. 20 MEMBER STIEFEL: Before 21 solicitation, though, I think that's an 22 important piece of it; that's the analysis of

Page 131 1 the existing measures that are already out 2 there and where there are similarities and 3 differences. And so that's an important analytic piece that I think could be done now 4 5 and would be valuable. 6 MS. MAINO-FIKE: And help me. Am 7 I not capturing that properly here? Identify 8 resources, recommendations in order to solicit 9 targeted developers and then survey population 10 health measures and compile them? Is the second step analysis of that? 11 12 MEMBER STIEFEL: The first step is to kind of assess the state of measurement in 13 14 targeted domains. 15 MS. MAINO-FIKE: Okay. 16 MS. NISHIMI: I just want the 17 Committee to be aware that actually as part of the discussion for this afternoon that this is 18 19 bleeding into, the staff did look through the 20 existing portfolio and have identified the 21 "population health measures." And so that is 22 available and we can tee that up for everyone

Page 132 1 to take a look at. 2 MS. MAINO-FIKE: Good. 3 What else should show up on that fishbone diagram? Yes? 4 5 MEMBER BIALEK: I'd like to offer a few broader categories and then some 6 7 specifics underneath at least one of them. 8 MS. MAINO-FIKE: Okay. 9 MEMBER BIALEK: I think we need to refine the guidance that's provided to those 10 we wish to submit measures. 11 12 We need to reduce the burden for 13 those who wish to submit measures. And we need to demonstrate the 14 value to those who wish to submit measures. 15 16 Under refined guidance --17 MS. MAINO-FIKE: I'm sorry. One 18 thing. 19 MEMBER BIALEK: Yes. 20 MS. MAINO-FIKE: So refine 21 guidance, reduce the burden for those 22 developers --

	Page 133
1	MEMBER BIALEK: And demonstrate
2	value.
3	MS. MAINO-FIKE: Demonstrate
4	value.
5	MEMBER BIALEK: Yes.
6	Under the guidance, I'd like to
7	suggest that the work sheet be reworked to
8	incorporate the specific population health
9	measure language that we came up with during
10	one of our earlier meetings. Well, the
11	language that's on the what are these
12	called? The criteria, right. That it
13	actually use the language versus the health
14	care language.
15	Second, that to the extent
16	feasible we provide some examples of completed
17	work sheets to help people see the types of
18	information that's desired.
19	And then third, I think a couple
20	of folks mentioned that education, webinars,
21	whatever it might take to help engage people
22	in a dialogue to help build some

Г

Page 134 1 understanding. 2 The last piece I'll mention has to do with the burden. I think part of the 3 burden was the time frame, not just the time 4 5 it took but how much time people had that they 6 could devote to this within -- you know, to 7 get the measure submitted. And so I think --8 MS. MAINO-FIKE: Deadline for 9 responding? 10 MEMBER BIALEK: Yes, right. So, I think increasing the time frame, the 11 12 responding that's under that. 13 MS. MAINO-FIKE: Yes. 14 MEMBER BIALEK: And I'll stop. 15 MS. MAINO-FIKE: Okay. Well, what 16 I've added up here is refine our guidance; that's something that we can do differently 17 whenever we issue a call, let's put it that 18 19 way. 20 We can revise the work sheet to 21 use the recommended language that's indicated. 22 Provide examples for our

Page 135 1 developers. 2 And provide some sort of training or education for developers to allow them to 3 have a more informed dialogue on this, and see 4 5 what the value might be of participating. 6 The other thing you said was to 7 reduce the burden for our developers. And one 8 way to do that is to increase the time that 9 they have that they have to meet the deadline 10 to respond. Okay. And then the other thing that you 11 12 said was we need some way to demonstrate the 13 value and it's the value to our developers of 14 responding. 15 MEMBER STOTO: I'd like to develop that a little bit further. I mean, I don't 16 17 think it's so much demonstrating it. I think we have to be clear what it is. I don't think 18 19 that we know what the value proposition really 20 is here. 21 MS. MAINO-FIKE: Yes. 22 MEMBER STOTO: I mean, it's kind

r		
	Page 1	L36
1	of evolved over time for the health care world	
2	in NQF	
3	MS. MAINO-FIKE: Yes.	
4	MEMBER STOTO: but in the	
5	population health world I mean it seems to me	
6	we have to begin to by thinking about what are	
7	the potential users and uses of these	
8	measures. And the ones that have been on the	
9	table are the IRS community benefits, the	
10	accreditation standards, the accountable care	
11	organizations and things like that. And that	
12	I think that if we thought through what are	
13	the potential uses, and then I'm sure there	
14	are more than those. The IHI Triple Aim is	
15	another one that we put in there. That would	
16	lead to more clearer thinking about what is	
17	the potential value of having IHI what do	
18	you call this organization? NQF endorsement.	
19	Excuse me. I'm sorry. NQF endorsement.	
20	MS. MAINO-FIKE: Right.	
21	MEMBER STOTO: And it seems to me	
22	that there are two possible values with that.	

	Page 137
1	One is the harmonization that
2	comes from that process, and the other one is
3	the sense that these are good measures. I
4	think that those things may play out
5	differently in public health than in the
6	health care world, population health.
7	MS. MAINO-FIKE: Okay. So let me
8	just tell you what I've captured. So not only
9	do we want to demonstrate the value, but we
10	need to actually create what that value
11	proposition is or articulate it. And then we
12	can demonstrate it or communicate it, or try
13	to engage people in getting on board with what
14	that value proposition is.
15	And you put forth two pieces of
16	MEMBER STOTO: And I guess what I
17	would say is that in order to do that we have
18	to consider what are the potential uses and
19	users
20	MS. MAINO-FIKE: Yes.
21	MEMBER STOTO: of NQF endorsed
22	population health measures.

	Page 138
1	MS. MAINO-FIKE: Okay. Including
2	uses and users potential. All right. Very
3	good. Very good.
4	I know someone over here yes?
5	Matt?
6	MEMBER STIEFEL: And I think that
7	value proposition to public health is with
8	harmonized data available from the health care
9	delivery system it would dramatically improve
10	the public health surveillance system that
11	relies currently on these small dwindling
12	random sample surveys. That's it. And I'm
13	not sure if that message is clearly made or
14	understood, but it seems potentially
15	enormously valuable. I don't think public
16	health has any idea about it.
17	MS. MAINO-FIKE: So let me put
18	this in some sort of an equation. So you said
19	harmonized standards from your health care
20	delivery systems results in improved you
21	said "surveillance of public health." Is that
22	the best word?

i	
	Page 139
1	MEMBER STIEFEL: I would say so.
2	MEMBER STOTO: I would say
3	assessment; that's one of the three core
4	public health functions that includes all this
5	stuff.
6	MS. MAINO-FIKE: Okay.
7	MEMBER STIEFEL: Because it's a
8	much richer data source.
9	MS. MAINO-FIKE: Okay. So that's
10	one possible value equation. There might be
11	others that you choose to use as well.
12	I want to ask some folks who have
13	not put forth some ideas. I want to make sure
14	everybody gets a chance to participate.
15	MEMBER STOTO: Okay.
16	CO-CHAIR JARRIS: So there's two
17	things I want to say. One is that Helen
18	mentioned a two step process, perhaps, and
19	maybe this would be an excellent place to
20	start to basically say have a phase of this
21	where you could put forth a concept. Is this
22	what you're thinking of? Is this what you're

Page 140 1 talking about? And then to sort of work that 2 through so people can then decide whether or not it's something that they should go back 3 4 and work on or perhaps it gets referred into 5 another group of NOF. 6 I think it would be very helpful 7 since people don't quite know what we're 8 asking for, and sometimes I think we don't 9 quite know what we're asking for based on what 10 we put out. And then the other thing, I think 11 12 we should build out. I don't really think 13 that this is just a matter of educating 14 people, and I mean education and training are components to it, but I think we have to have 15 16 a much more interactive process to support the 17 learning and development in this area. So, I 18 think it would be very interesting. 19 Remember, we heard basically we 20 don't have the time, we don't have the 21 resources to do this; that's a problem. So 22 how do we support that? And part of that

Page 141 could be to look for seed funding to help 1 2 certain developers develop these measures if there is no other funding out there. 3 But part of that also is to create some kind of 4 5 community of learning whether that's through periodic calls or SharePoint sites or 6 7 something where we could bring together people 8 in the field to ask questions about well 9 here's the direction we're going in, what do 10 you think. 11 MS. MAINO-FIKE: Right. 12 CO-CHAIR JARRIS: And other developers and other people in this area could 13 14 say, "Well, have you considered this, have you considered that, we tried that, didn't work," 15 16 whatever. 17 So, create a much more active 18 learning community. 19 MS. MAINO-FIKE: Yes. 20 CO-CHAIR JARRIS: Because it 21 sounds like we have to do a lot of development 22 here.

1	
	Page 142
1	MS. MAINO-FIKE: A community of
2	practice is how I've heard that referred to.
3	DR. BURSTIN: And actually,
4	building on that I was actually going to say
5	something similar.
6	One of the things that really
7	struck me as well is I think there's a real
8	opportunity as well to work with the measure
9	developers who understand how to do this and
10	know NQF in a different way.
11	So, for example, I was struck by
12	the measures that we talked about yesterday
13	about physical activity. Granted, they were
14	inside the box, but start thinking about how
15	you take out some of those layers. If you
16	took out the requirement that they been seen
17	once a year, that gets a little bit further.
18	If you take out the requirement that they
19	you know have to talk to a physician, that
20	gets it a little bit further. I mean, there
21	are ways to work with the current developers
22	I think as well to change their mindset.

Page 143 1 Because they know how to do this. 2 And interestingly, you know NCQA has been doing just as one example a lot of 3 the work developing the measures for Medicaid. 4 5 So they're out there developing, the same 6 folks who have been developing measures 7 traditionally in the health plan world are now 8 developing measures that have really no direct 9 connection back but are for Medicaid plans. 10 So, I think there's an opportunity there to really build that community that's 11 12 the current measure developers with the folks 13 in the population health space and see if 14 there's some shared learning and opportunities for a little marriage --15 16 MS. MAINO-FIKE: And does that tie 17 into your initial thought around throwing a 18 concept out there for developers to react to? 19 When you said that --20 CO-CHAIR JARRIS: Well, there's 21 two sides. Yes, we could do that. We could 22 put out concepts, that would be very helpful.

	Page 144
1	But I also think we ought to have an
2	opportunity for developers to throw a concept
3	in to say is this the type of thing that would
4	work.
5	But I just want to do one little
6	tweaking though here. This is not a matter of
7	just going to the public health folks and
8	population health folks and saying, "Wait a
9	minute, you guys don't get this. Let's help
10	you get it." This isn't gotten at all on the
11	clinical side, so we have to work there also
12	and somehow bring these things to and I
13	would agree with something you said earlier,
14	Matt. Probably the first place to work on is
15	the overlap of those two. The overlap may not
16	be appreciated by either side as much as it
17	needs to be.
18	MEMBER STOTO: If I could just add
19	one little point to this. I mean, I was
20	struck, I was saying to Ron during the break,
21	that here we're talking about measure
22	developers. If you want to an APHA meeting
	Page 145
----	--
1	and said we're going to have a reception for
2	all the measure developers, you'd have an
3	empty room because people just don't think of
4	themselves in that category. And I think
5	we've got to sort of build an identity in a
6	way.
7	MS. MAINO-FIKE: Yes. Good point.
8	Sue, are you
9	MEMBER PICKENS: A couple of
10	things I wanted to bring up and I don't know
11	if this is an appropriate time or not.
12	One is we talked earlier about
13	what else is going out there in the field, who
14	else is developing all these measures, as Neil
15	talked about, there's lots of competition in
16	the field and suggested gathering that data,
17	who else is doing all those.
18	And then the other is is the
19	unusual partners that are out there doing this
20	work now. The Federal Reserve is going all
21	around the country doing the intersection of
22	health and economic and economic development.

	Page 146
1	They have had all these national conversations
2	going on.
3	And United Ways are getting really
4	involved in health improvement at the local
5	level. In our area they have a huge childhood
6	obesity initiative that they've involved the
7	entire community, all the health systems,
8	everybody involved.
9	CO-CHAIR JARRIS: The CIA tracks
10	comparative data between U.S. health and other
11	nations. I mean, it's amazing. That
12	competitive analysis is something I think we
13	should have.
14	MS. MAINO-FIKE: Yes. And I think
15	the competitive analysis that you're referring
16	to is a little bit different than developing
17	that community of interest.
18	CO-CHAIR JARRIS: Maybe we should
19	call it collaborative analysis or something
20	like that.
21	MS. MAINO-FIKE: Yes, yes.
22	Because, you know these aren't necessarily

	Page 147
1	your competitors. These are other folks that
2	might be operating in the space that NQF could
3	be in terms of interest in gathering measures.
4	So let's call it tell me what you had said,
5	the terminology?
6	CO-CHAIR JARRIS: The
7	collaborative analysis. I don't know.
8	MEMBER PESTRONK: Actually,
9	they're offering up the potential for measures
10	that could appeal to that space where public
11	health and clinical care overlap. And there's
12	no reason to go through the development
13	process, I think that's the whole point.
14	There's every reason for NQF to claim those
15	measures. There's no reason for NQF to have to
16	develop them all over again.
17	MS. MAINO-FIKE: Right.
18	MEMBER PESTRONK: Or to suggest
19	that they be developed. So it's creative
20	stealing for the purpose that NQF has been
21	asked to work in the population space.
22	MS. MAINO-FIKE: Right. And most

	Page 148
1	organizations would not view it as stealing or
2	competitive in anyway because it's furthering
3	something that they've already worked on. And
4	I think most organizations would view that,
5	would view the whole standardization issue as
6	you all have, as something that would be
7	positive.
8	Yes?
9	MEMBER STIEFEL: Well, a specific
10	suggestion about that, you know I think that
11	there's a lot of resonance about finding this
12	intersection or sweet spot between clinical
13	care and public health. I don't think this
14	may not be consistent with NQF's philosophy,
15	but it would be I think quite interesting,
16	perhaps, to convene a group of I don't
17	know. In public health I guess you don't call
18	them measure developers. but whatever they're
19	called in public health. And from clinical
20	care.
21	MS. MAINO-FIKE: Yes.
22	MEMBER STIEFEL: To get together

1	
	Page 149
1	and focus on a few measures, and maybe it's
2	the health behavior measures, and that there
3	would be a background paper that would say
4	here are all the measures out there in public
5	health and clinical care. And the charge would
6	be to come up with a set of harmonized
7	measures that could be used in both domains
8	and to make the case for doing that.
9	So, it wouldn't be a call for
10	measures. It would be something different.
11	And I don't know if NQF does that, but it
12	would be an interesting exercise, I think.
13	CO-CHAIR JARRIS: Like a
14	datapalooza?
15	MS. MAINO-FIKE: Measurepalooza?
16	MEMBER STOTO: Yes. I think that
17	makes a lot of sense, and I would sort of
18	harken back to the discussion we had about the
19	smoking measures yesterday is that there's a
20	lot of people interested in smoking and
21	tobacco, different parts of CDC for different
22	surveys. If you look at the county health

	Page 150
1	rankings, they've got tobacco use in there and
2	so on. And I think that getting all of these
3	folks together with the people in the clinical
4	world who are interested in these topics to
5	kind of think through, you know, what is the
6	point of intersection and the way that the
7	measures are all out there, at least the
8	survey questions are all out there that we can
9	do a better job of harmonizing and things like
10	that would be a very useful exercise.
11	MS. MAINO-FIKE: Helen, is yours
12	up? It was just up from the last time. Okay.
13	Paul?
14	CO-CHAIR JARRIS: Well, part of it
15	would be convening is helpful, but the other
16	thing is outreach. I mean, you first got to
17	go to other people's table before you invite
18	them to your table. And that would be part of
19	this. Again, it's part of that collaborative
20	analysis. Who is out there in this world that
21	we should touch base with. And, you know,
22	there's certainly the APHA meetings which we

i	
	Page 151
1	can give presentations and a workshop added on
2	to.
3	I think CSTE is Council for
4	State and Territorial Epidemiologists. If you
5	tweak them, they will fight you to the death
6	so you've got to make sure that you get in
7	with them the right way so they support this.
8	If you tweak them, in other words,
9	you know politically any group that's been
10	enlisted will be your ally. If they feel like
11	you are stepping on their toes, they are not
12	your ally. And with all due respect, the
13	epidemiologists they can argue to death on
14	anything if you want. But they're also
15	phenomenally powerful if we engage them. So we
16	should think about that as part of this
17	collaborative analysis: Who do we need to get
18	to, to talk, to enlist their help and support?
19	DR. BURSTIN: Right. So can we
20	continue that list? It would be actually
21	really useful just for the people in the room
22	just to throw out some of those organizations.

Page 152 1 We engage the rest of the --2 MS. MAINO-FIKE: Fine. Let's take it aside. We'll do like a little break from 3 the fishbone exercise, okay, to just 4 5 brainstorm quickly in a couple of minutes who 6 off the top of your head or what some of those 7 organizations are out there that you might want to include in this collaborative 8 analysis. Okay. 9 I can write them down here. 10 11 Maybe. Okay. 12 So we'll say collaborative 13 analysis, these are potential partners. Okay. 14 CO-CHAIR JARRIS: I'll qive you 15 three: There's academic partners, funding 16 partners and practice partners will be three 17 main categories. 18 And I think funding partners just 19 might be the type of thing that RWJ would be 20 interested in. CDC should be interested. 21 AHRQ should be interested in it. So there's 22 a number of -- we heard that HRSA might be.

Page 153 1 There's a number of groups like that that we 2 need to get to. Some of those are also 3 practice partners. But FHA is one, CSTE, which is the 4 epidemiologists is one. I think the HIV 5 6 Association is one. 7 MEMBER STOTO: Well, focusing on 8 behaviors there's a group that deals with that 9 among the state health organizations. I forget what that's called. 10 CO-CHAIR JARRIS: Yes. There's one 11 12 that deals with --13 MEMBER STOTO: Chronic disease 14 probably is the --15 CO-CHAIR JARRIS: Yes, chronic 16 disease. 17 MEMBER STOTO: Yes. CO-CHAIR JARRIS: We convened that 18 19 group of 20 organizations on a quarterly 20 basis, so we could get you to all of them. 21 Some are going to be more powerful than 22 others.

	Page 154
1	I mean, then NACCHO has got to be
2	one of them, and you would have a world.
3	And I think maybe we should do
4	we could do the email also, I mean to list
5	now.
6	MS. MAINO-FIKE: And brainstorm
7	this list via email? Okay. I mean, you don't
8	necessarily have to be together to do that.
9	All right. Let me ask you for
10	your third category.
11	CO-CHAIR JARRIS: Practice
12	partners. People actually in the field doing
13	the work, using the measures. They would come
14	in each of those levels, but under funding
15	they'd clearly be there's government and
16	philanthropic.
17	MS. MAINO-FIKE: You disagree,
18	agree; what are you thinking? Okay.
19	MEMBER STIEFEL: So, CDC, where
20	would CDC fit in?
21	CO-CHAIR JARRIS: Well, I would
22	hope they would be a funding partner, but they

	Page 155
1	also have many components of it that are in
2	the business and the practice.
3	MS. MAINO-FIKE: And that's an
4	example of an organization or a potential
5	partner that could fall under several of these
6	categories.
7	CO-CHAIR JARRIS: Right.
8	MS. MAINO-FIKE: I don't think
9	there's anything wrong with having
10	MEMBER STIEFEL: There's a
11	category missing of I mean, they do a lot
12	of work in measure development which doesn't
13	fit neatly in one of those. What about
14	measure developers?
15	CO-CHAIR JARRIS: We've lumped
16	them in one of the practice group, but they're
17	also in academics and I mean, they're also
18	I mean government or do we want to add
19	explicitly measure developers? But they do
20	actually fall in most of those categories. I
21	don't know what the word
22	MEMBER PESTRONK: What's an

	Page 156
1	example that was just in your head about
2	someone in that category?
3	MEMBER STIEFEL: CDC and NCQA.
4	It's not only about public sector. I mean,
5	we're talking about the convergence, I think.
6	MEMBER BIALEK: I'm thinking a
7	group like RAND would not fit in any of those
8	three. So I don't know if it's academic or
9	research. Is that what you're thinking, more
10	research than
11	CO-CHAIR JARRIS: Okay. Let's add
12	the category. Let's call them practice
13	developers then, for that matter.
14	MEMBER STIEFEL: Or just
15	brainstorm and then they fit the categories
16	after.
17	MS. MAINO-FIKE: I like "Other."
18	It leaves it broad. Okay.
19	MEMBER STOTO: But I would imagine
20	things like the folks of Wisconsin who do the
21	county health rankings and the Legacy
22	Foundation for the tobacco related things.

	-
	Page 157
1	MS. MAINO-FIKE: Okay. So I'll
2	just put a few examples under each of these.
3	What's an example of an academic?
4	MEMBER STOTO: I would put
5	Wisconsin there.
6	MS. MAINO-FIKE: Oh, Wisconsin.
7	MEMBER SPANGLER: You can't
8	separate Wisconsin from RWJ. It's RWJ. It
9	just happens to be that the people that do the
10	work are Wisconsin. I mean, that's an RWJ
11	project now.
12	MEMBER STOTO: Yes. Sure. But we
13	really want the people who are doing the
14	collection work.
15	MEMBER SPANGLER: True. True. So
16	the reason I'm bringing that up is there may
17	be other people at RWJ that aren't affiliated
18	with the county health rankings that may also
19	be people we want to talk to.
20	MEMBER STOTO: Okay.
21	MS. MAINO-FIKE: Good point. Keep
22	your partners as broad as possible. I think

Page 158 1 that's a good point. 2 MEMBER SPANGLER: We were talking about before, and maybe we need to approach 3 them, but Healthy People. And I don't know 4 5 where they would -- no, that's ODPHP. 6 MEMBER SAMPSEL: But I also want 7 to throw out there when you're dealing with 8 Healthy People, when you're dealing with 9 Wisconsin, when you're dealing with -- or you think about United does America's Health 10 Rankings and the Kaiser Foundation and all of 11 12 that, they're not developing measures. 13 They're using measures, you know because 14 county health rankings are using BRFSS for the 15 most part, right? So they can't submit those 16 measures. 17 MEMBER SPANGLER: They're developing, they're indicators. But you can 18 19 easily make measures from indicators and 20 indices, I think. 21 MEMBER SAMPSEL: Yes, but they're 22 not really --

	Page 159
1	CO-CHAIR JARRIS: It sounds like
2	they're using publicly available data.
3	MEMBER SAMPSEL: I guess my point
4	is that they're using data from the CDC for
5	the most part. So they can't submit those
6	unless they do develop them into a measure.
7	MEMBER STIEFEL: I don't think we
8	should worry about categorization so much,
9	though as just getting the list of
10	organizations.
11	MS. MAINO-FIKE: Yes. Because you
12	may not at this moment in time see the obvious
13	tie-in or a direct tie-in for a potential
14	partner. But as you outreach to these people,
15	these organizations regardless of what their
16	role is, the ways to partner might become more
17	clear. So, I agree. Have this be a
18	brainstorming exercise for yourselves more
19	than anything else.
20	MEMBER SPANGLER: It seems like,
21	Sarah, though you weren't talking about
22	categorization, you were talking about should

	Page 160
1	they even be on the list, right?
2	MEMBER SAMPSEL: Yes. I mean, you
3	know to me some of the folks that were I
4	mean, I guess it all depends on what's the
5	use. You know, what is the purpose of the
6	list? If the purpose of the list is twofold:
7	one to engage the users of such measures, then
8	those folks fit. But if it's to engage people
9	to submit measures, they can't submit measures
10	they didn't develop or aren't measures in the
11	first place.
12	MS. MAINO-FIKE: And perhaps it's
13	both.
14	Ron, you had a comment?
15	MEMBER BIALEK: Yes. I'm not
16	really clear on the it. You know, we're
17	coming up with a list to do what?
18	MS. MAINO-FIKE: Okay. Well, this
19	is
20	MEMBER BIALEK: Well, if I may, I
21	think if we try to do if whatever it is is
22	too broad and you list every conceivable

	Page 161
1	partner, nothing is going to get accomplished
2	and I would suggest that if there is a follow-
3	up, that one really narrow and look for some
4	type of an early win.
5	So if we look at every potential
6	opportunity for healthcare in public health,
7	we work together and to overlap. I mean,
8	there have been efforts in public health
9	initiatives and they've gone too far. And so
10	I'm just suggesting that maybe we
11	MS. MAINO-FIKE: Well, here's a
12	question, a process question, because that was
13	a very goo question. So based on that a
14	process question for this group and this
15	Steering Committee.
16	So this exercise of identifying
17	potential partners in this collaborative
18	analysis or putting an initial list together
19	of potential partners; could be users, could
20	be developers well, you have a choice. We
21	can do a brainstorming here and use this time
22	here while you're together to do that. And

	Page 162
1	then perhaps a second step would be some
2	analysis to your point, Sarah and Ron, about
3	let's focus on some organizations that have
4	some clear solid links where we can possibly
5	develop some initial partnerships.
6	We can do that here using this
7	time, or that can be something that you choose
8	to do via email post-meeting. Remember, it's
9	one item on this fishbone diagram of what to
10	do differently when we are issuing a call for
11	measures, or whatever.
12	MEMBER PESTRONK: I thought it was
13	actually one of five potential in strategic
14	map language, strategic priorities that are
15	potentially available to address the problem
16	of two few measures were submitted. And the
17	broad category was identifying other measures
18	and use. And these are sources, these are
19	potential places where other measures are in
20	use now and it would be useful to ask them or
21	for someone to determine what measures do they
22	have in use that relate to the population

	Page 163
1	health work that NQF is doing.
2	CO-CHAIR JARRIS: I think you're
3	sort of talking about surveying the field for
4	what's out there. But as I stated at a
5	different level, I was thinking who are the
6	opinion leaders you want to enlist in terms of
7	collaboration or at least support who either
8	fund, develop or use measures. Because what
9	you don't want to do is ignore an important
10	group that then comes back and argues with you
11	or fights. I was talking about how do you get
12	the movement started.
13	MS. MAINO-FIKE: I was thinking of
14	your definition as opinion leaders as a part
15	of developing that community of practice. At
16	least I wrote that down as something as
17	something different from doing sort of what I
18	call an environmental survey of who is out
19	there that might have some standards in place,
20	more to your definition, you know the level of
21	partnership could be very different. So I see
22	those as two potentially different lists or

Page 164 1 groups of organizations for you. 2 This is more an environmental 3 survey of what's out there versus your community of practice, which are those key 4 5 partners and opinion leaders that you want to 6 make sure to involve. 7 MEMBER STOTO: Can I just report 8 that I'm scanning my emails and I got one from 9 another CDC oriented measuring project I'm 10 involved in all about an ASPE health systems measurement project that has a population 11 12 health component, that has weight, smoking, all sorts of good stuff in it. 13 14 MS. MAINO-FIKE: There you go. 15 There are other -- yes. Others out there. So let's do this: Let's define 16 17 these two separate things. One is developing or creating your community of practice. All 18 19 right. Those opinion leaders. And then the 20 other is doing a, we don't want to call it 21 competitive analysis, but an environmental 22 analysis if you will. So maybe we shouldn't

1	
	Page 165
1	call it potential partners.
2	Do you want to look at just what's
3	out there already that we can use and build
4	on?
5	MEMBER PESTRONK: Go back to
6	what's the problem we're trying to solve. I
7	mean, are we trying to create a community of
8	practice and get a lot of other people working
9	in this area or are we trying to help NQF get
10	good measures submitted so that their
11	portfolio of measures is increased?
12	DR. BURSTIN: Just as follow-up
13	on, I actually wrote down what Paul said
14	because I found that incredibly helpful. So
15	if we think about sort of building on Matt's
16	idea of saying let's focus on a few of the big
17	ticket health behaviors, bringing together all
18	of the various entities in the clinical
19	community, in the development community,
20	public health community and what Paul said
21	which really resonated with me was you have to
22	outreach to other people's tables. And so to

	Page 166
1	me the question was who is out there who is
2	doing this work in the public health field who
3	we have probably never even talked to. We
4	talked to CDC, but I've certainly never talked
5	to CSCE or some of these other groups.
б	So, the thing for me was this was
7	this question of who is out there in this
8	space that if we were going to try to think
9	about convening like this, we want to make
10	sure we include so we don't wind up at the end
11	having missed a really important player in
12	this space.
13	MEMBER STOTO: Can I just add one
14	to that, the AcademyHealth, particularly the
15	public health systems research interest group.
16	I'm currently the Chair of that and we're just
17	beginning a project with RWJ funding about
18	translation about public health systems
19	research. I think it would be very
20	MS. MAINO-FIKE: So who's out
21	there if we define this list? Who's out there
22	for us to partner with? And these broad

	Page 167
1 categories,	academic, funding, practice
2 partners and	d other. It seems like there's
3 energy aroun	nd brainstorming who and where
4 those partne	ers might be. So is it something
5 you want to	do now or do you want to do via
6 email later	2
7	Helen, you think we're okay now?
8 Okay.	
9	MEMBER QASEEM: So while we're
10 brainstormin	ng this list of partners and
11 everything,	and we love reinventing the wheel
12 in the U.S.	, there's been a lot of good work
13 that has been	en done in Europe. I'm sure many of
14 you are away	re of it. In the United Kingdom
15 they impleme	ented quality and QF framework,
16 I forget what	at
17	MEMBER PESTRONK: Quality Outcomes
18 Framework?	
19	MEMBER QASEEM: That's what it is.
20 And it happe	ened and in fact they've been using
21 it for four	or five years now. And they're
22 actually sta	arted seeing some negative

Page 168 1 consequences at this point. 2 What started happening over there was that the clinicians started focusing on 3 some of these measures and outcomes were from 4 5 some other performance measures, the other 6 things that should have been done that started 7 getting ignored. 8 And I'm not going to call them 9 partners or anything. And so in Germany, AZQ 10 have been doing some very good work in this arena, has gone for a very long time and 11 12 they're way ahead of us. 13 And somehow I wonder if -- I don't 14 know how will this work, but I think if we can 15 engage some of these folks, at least learn from their lessons, I think that would be more 16 17 helpful aside from what we're going to be doing in the U.S. So rather than us being in 18 19 five years just going where they are at, maybe 20 we can take a little bit of a head start here. 21 MS. MAINO-FIKE: Very good. Good 22 point. Okay.

	Page 169
1	I'm looking at a time frame.
2	We're supposed to be breaking for lunch two
3	minutes ago. So we'll use ten more minutes.
4	So to kind of better define what
5	we're trying to come up with here, what are
6	the organizations that are out there that we
7	can richly partner with to get some quick
8	hits? A couple of under academic. Any others
9	under funding? I have CDC.
10	MEMBER BIALEK: Not necessarily
11	category, but folks who have thought about
12	this, the Community Indicators Consortium.
13	They look at broad community indicators, some
14	of which impact health, some of which impact
15	urban planning. It's a variety of approaches.
16	And I think they're Florida based. Well, I
17	know that some folks actually at NACCHO have
18	dealt with Community Indicators Consortium.
19	We've dealt with them.
20	MS. MAINO-FIKE: Any others you
21	can think of under practice partners?
22	MEMBER PICKENS: Outside the box

	Page 170
1	kind of partners like the Federal Reserve that
2	are trying to use this data in conversations
3	around the country and the United Way that are
4	developing projects and things. And doing
5	needs assessments all around the country.
6	MS. MAINO-FIKE: Any others?
7	MEMBER SPANGLER: I just had a
8	quick comment on what Ron sorry, I just
9	looked them up because I had never heard of
10	them. They have a integrating community
11	indicators and performance measures project.
12	MS. MAINO-FIKE: Oh.
13	MEMBER SPANGLER: So they're
14	trying to do what they do with performance
15	measures.
16	MS. MAINO-FIKE: Yes. So it
17	sounds like very similar objectives there.
18	Okay.
19	So let's record these as at least
20	an initial start to some partners that we'd
21	like to reach out to and see what they have,
22	what results they might already be doing.

Page 171 Just to give you 1 MEMBER PESTRONK: 2 an example, the group that Ron has just talked about, the Community Indicators Project. 3 they've got a list of probably 300 communities 4 5 and organizations that have indicators as part of their work. 6 7 MS. MAINO-FIKE: Yes. So to your 8 earlier point, there might be a lot of work 9 out there that does not require reinventing the wheel on NQF's part? 10 11 MEMBER PESTRONK: Yes. 12 MEMBER BIALEK: The problem could be that their indicators tend to be what we've 13 14 been referring to as the stretch indicators, if you will. 15 MS. MAINO-FIKE: Right. 16 17 MEMBER BIALEK: That might not be 18 the ones that NQF would initially wish to 19 endorse. And so that's part of the rub. 20 What I thought Matt was suggesting 21 was starting with somewhere, it's maybe a 22 little bit more obvious how health care --

	Page 172
1	MS. MAINO-FIKE: Yes. Okay.
2	MEMBER BIALEK: Yes. Yes.
3	MEMBER PESTRONK: In the framework
4	that you were helping us develop, that's a
5	second of the strategic priorities which have
6	to do with refining the guidance and the
7	definitions. Really refining so what's the
8	project about right now? What's this work at
9	NQF all about right now?
10	And so we just did a deep dive
11	into one strategic priority that were listed
12	under some of the other ones, a number of
13	ideas. What someone has to decide is which of
14	the strategic priorities is going to be a
15	focus first or is there some sequence in which
16	some order of prioritization?
17	MS. MAINO-FIKE: Right.
18	MEMBER PESTRONK: And then what
19	are their resources within NRQ to do, because
20	we're not going to be able to do that work.
21	We've all got full time jobs somewhere else.
22	MS. MAINO-FIKE: Right. But if we

Page 173 take these as the strategic priorities that 1 2 you're talking about, then -- and Helen, check 3 me if I'm wrong here, but we're gathering this 4 information, then there are some choice points 5 for NQF to look at. Do we want to pursue some of these things? If so, how and in what 6 7 order? 8 MEMBER PESTRONK: So the five, as 9 an example, just the way that I was keeping my own notes about this. The five, and these are 10 11 in no particular order but they're --12 MS. MAINO-FIKE: Excuse me one 13 second. 14 MEMBER PESTRONK: Yes. 15 MS. MAINO-FIKE: I just want to 16 make sure that you're going to be recording the five, the five items that --17 18 COURT REPORTER: I'm recording everything. 19 20 So identifying MEMBER PESTRONK: 21 other measures in use or other partners, 22 that's the one we just got through talking

	Page 174
1	about.
2	A second potential priority is
3	refining the guidance and the definitions for
4	the project and for NQF. And under that just
5	revising the work sheet or giving examples,
6	providing technical assistance. Those are,
7	you know one level down from refining the
8	guidance and the definitions.
9	A third potential area is reducing
10	the burden for people that have to submit. So
11	increasing time or finding funding to support
12	developers, or making it fun for developers to
13	submit would be things that could be done
14	under there.
15	A fourth is describing the NQF
16	value preposition so that people understand
17	the potential users and uses, as that's the
18	way it was described earlier.
19	And a fifth is simply raising the
20	brand awareness of NQF, and that has to do
21	with outreach into specific places and to help
22	people understand what NQF is all about.

1	
	Page 175
1	So if those are five different
2	areas of work and we've got examples, we've
3	described ways in which each of those could be
4	flushed out at the next level. Now somebody
5	has to decide what's the best one to focus on
6	first, or the best ones to focus on first and
7	what kinds of resources are there available to
8	get that kind of work of done? What would it
9	take to get that work done?
10	MS. MAINO-FIKE: Okay.
11	MEMBER PESTRONK: That's the way
12	my head is processing the conversation.
13	Whether that works for anybody else
14	MS. MAINO-FIKE: Right.
15	MEMBER PESTRONK: I don't know.
16	MS. MAINO-FIKE: No. That makes
17	perfect sense in that the five strategic areas
18	that you're describing are sort of the scale
19	or the bones of the fish diagram and some of
20	the particulars off of them. As you said, we
21	kind of did a deep dive into who's out there
22	doing an environmental analysis for partners.

	Page 176
1	Are there any other things or
2	strategic areas that we would do differently
3	other than those five? Can anybody think of
4	anything else? Helen?
5	DR. BURSTIN: I just would love to
6	have this group actually help us talk through
7	the value proposition. I mean, we keep saying
8	we need one, but I think it would be actually
9	really helpful if we have the time to actually
10	walk through what would make other folks want
11	to bring those measures forward to NQF and/or
12	what would make developers like NCQA
13	potentially think about a different approach
14	to bringing measures that are closer to what
15	you actually want.
16	MS. MAINO-FIKE: Yes.
17	DR. BURSTIN: And need.
18	MS. MAINO-FIKE: Well I see being
19	able to carve out the time. We were planning
20	on a working lunch anyway. So maybe we can
21	take a deep dive, if you will, into
22	articulating that value proposition.

	Page 177
1	MEMBER PESTRONK: Can I make a
2	suggestion, Helen, on that point? Who here at
3	NQF now could characterize the value
4	proposition for your current customers, the
5	people who are making use of what you
6	typically generate? Because rather than
7	trying to develop something de novo, couldn't
8	we see what you think the value proposition is
9	now for them and adapt it?
10	DR. BURSTIN: And I can do that
11	easily and I'm happy to do that after we'll
12	get food. And perhaps if you want to talk
13	about that if that's useful. It's just not
14	clear to me. I understand how it works in
15	sort of the spheres that Sarah and I live in
16	to a certain extent, and Amir. I'm not sure
17	I understand how that translates to a public
18	health agency and would they see the value if
19	their measures don't need to be endorsed to be
20	picked up for accreditation.
21	MS. MAINO-FIKE: Yes.
22	DR. BURSTIN: If their measures
	_

	Page 178
1	don't need to be endorsed to be picked for
2	whatever purposes we're discussing.
3	I mean, the harmonization piece I
4	got, the linked piece I get. But it's the
5	concentric circles out that is harder for me.
6	CO-CHAIR JARRIS: How well do you
7	understand how NCQA and other groups that
8	already submit measures to you would value
9	this, or do they value it? NCQA came
10	yesterday with a measure of did a doctor
11	assess a BMI or provider assess a BMI. They
12	could have withheld plan data, come with a
13	measure that says what is the average BMI in
14	the population served by this insurer? Very
15	different. Or what is the rate of obesity in
16	the population insured? They didn't go there.
17	They still stuck with a one-on-one clinical
18	approach. So why didn't they go there? They
19	really could, it'd be a leader here, but are
20	they working on it?
21	DR. BURSTIN: I think they're
22	working on it. I mean, again this

	Page 179
1	unfortunate. The issues of resources. I
2	mean, they're working on it, they're getting
3	funding to do new Medicaid measures that do
4	some of that. These are traditional HEDIS
5	measures, Sarah can probably speak to this
6	better than anybody here having worked on
7	them, where they need to have a set of
8	measures they can use to accredit health plans
9	which at least traditional have been about the
10	patient interaction.
11	Do you want to speak to that,
12	Sarah, more than me?
13	MEMBER SAMPSEL: Yes. I mean, some
14	ways you know to answer the question why did
15	NCQA bring what they brought, it's what they
16	have. You know, so we also had this
17	discussion a couple of times yesterday is
18	that, you know this group is making a
19	distinction between clinical measures and
20	population health measures, and we probably
21	should have looked at those measures in phase
22	I. But they were held, you know and we were

	Page 180
1	told last fall that they were going to be
2	held, the BMI measures because we thought we'd
3	get more population health type measures.
4	You know, I don't think NCQA has
5	historically pushed nor has, you know AMA
6	PCPI, nor has CMS to look at broader
7	categories that aren't visit-based measures.
8	You know, it's just something that their
9	audience is, you know health plans. You know,
10	they're looking at what are large employers
11	requiring of health plans. And they also have
12	to develop measures based on the data
13	available through health plan data.
14	But to broaden that yes, you're
15	going to start seeing some very different
16	measures come out of NCQA. They just had a
17	call for measures that closed Tuesday for that
18	Medicaid project. So looking for the core set
19	of child paternal health measures. But in all
20	honesty, very similar to a HEDIS measure
21	except adapted for a Medicaid population.
22	They just haven't been pushed.
	Page 181
----	--
1	MS. MAINO-FIKE: So let's do this
2	sorry. Ron?
3	MEMBER BIALEK: Is anybody pushing
4	when it comes to the accountable care
5	organizations? You'd think that there would
6	be a different set of measures needed when you
7	get because that's not all individual
8	patient focused.
9	MEMBER SAMPSEL: Yes. So, and I
10	don't know how much Kaiser is doing any of
11	this. But when you look at our portfolio of
12	metrics whether it's ACO or some of the stuff
13	that we're doing to incentivize providers by
14	paying them for quality, we're still using
15	HEDIS indicators and adapting them for use in
16	those models. But that's part of the value
17	part, it comes back to the value proposition.
18	As a plan, we don't like to create our own
19	measures. It's a lot of work, it's time
20	intensive. So then we come back to, okay,
21	what does NQF have out there that they
22	endorsed? You know, it's a vicious

	Page 182
1	CO-CHAIR JARRIS: Part of this is
2	that the market isn't driving what we'd like
3	it to drive. And so one of the strategic
4	questions is how do you change the market?
5	I mean, when we were a health
б	plan, GE came to us and said "You get
7	accreditation, we're talking our business away
8	from you." All of a sudden we had a reason to
9	do it, and we did it. And then, you know they
10	would come and basically say "I want you to
11	jump," and it would be "How high?" So, who is
12	saying jump?
13	Because I do think an employer,
14	like as sophisticated as GE was when they were
15	looking at combining they were just looking
16	at productivity and absenteeism completely and
17	wanted to combine their health care with their
18	disability, with their worker's compensation.
19	They were hugely sophisticated. So wouldn't
20	GE get the fact that we want you to look at
21	our entire insured population to ensure
22	they're healthy? Not just that the doctor

Page 183 1 gave the shot at the visit. 2 MEMBER SAMPSEL: And I would say most plans are doing that for large groups 3 like that. You know, for the national 4 5 accounts we're able to take data from them or 6 they're taking data from us. we're all sharing 7 data and doing that. But, you know who's 8 wagging the tail right now is CMS with the 9 Medicare STARS program. 10 You know, we'd love to see -- and on the Medicaid side it's just still so 11 12 disorganized in dealing with state by state by state by state requirements of performance 13 14 guarantees. Do, yes, that's what's driving it still is CMS and large employers. 15 CO-CHAIR JARRIS: So one other 16 stakeholder group to consider, at least going 17 to for ideas, would be like the medical 18 19 director of GE. They are so phenomenally --20 the way they think about health was way behind 21 anything we could ever deliver. And the 22 difference is in the private sector -- in the

	Page 184
1	public sector you're going to have to process
2	everything to death, whereas GE could just
3	come and say you'd say "Well why do you
4	want us to do that" and they'd say "Because we
5	said so."
6	MEMBER PESTRONK: And that's a
7	piece of the value proposition, Helen, that I
8	think you're trying to create. The value
9	proposition, this is an example from my own
10	practice in a community.
11	I was asked to develop a system
12	which provided primary care to everybody in
13	the community who didn't have access, didn't
14	have insurance or was under insured. And what
15	occurred to me and we did the business plan
16	and we did. What occurred to me as I was
17	doing that was if I could have enough if I
18	could capture enough people in that health
19	plan, I could influence the practice of
20	medicine in the community.
21	So, the value proposition
22	that's one statement.

	Page 185
1	The second statement is I assumed,
2	and maybe incorrectly, that the value
3	proposition for me working with you here was
4	that if NQF adopted the right population
5	measures, that the customers who used those
6	measures, Medicare, potentially Medicaid,
7	businesses and others would say "Well, wait a
8	second," you know. "That's actually a better
9	set of measures than the ones that we've been
10	asking the plans and the physicians and other
11	folks to work on."
12	So for people in the practice of
13	public health, the third place of this, my
14	early epiphany in my practice of public health
15	was I walked out of a clinic that we ran in
16	the local community and I looked across the
17	street and there was a school and there was
18	another organization. And I said to myself,
19	you know as the local health official in my
20	community if I can improve health status in
21	the community, I would have done it a long
22	time ago. I needed a range of other partners

Page 186

1 to get that done.

2	So the third piece of this is if
3	you've got that leverage at NQF to make those
4	things happen that I just described and you
5	can say to the public health practice partners
6	we have that leverage if you can help us get
7	the right indicators, your job of improving
8	health in the community will be much easier
9	because we are your partner. You didn't know
10	that, but we are. And here's what we can do
11	for you, which is always a sales job, it's
12	always the value proposition. It's not
13	you're telling somebody else what you can do
14	for them. That's the real value proposition
15	that attracts the people in public health in
16	who are on the cutting edge of trying to get
17	something done in their community other than
18	the direct delivery of services which they're
19	no longer getting funded to do.
20	MS. MAINO-FIKE: And I think
21	that's a perfect spot for us to take a break.
22	Lunch is here I'm told. Okay. Okay.

	Page 187
1	We are planning to have a working
2	lunch, but let's take until quarter after
3	12:00 at least to just get ourselves some
4	lunch, take care of whatever our needs are and
5	then we can reconvene.
6	All right. Thanks.
7	(Whereupon, the above-entitled
8	matter went off the record at 12:07 p.m. and
9	resumed at 12:52 p.m.)
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
I	Neal P. Grogg & Co. Ing

	Page 188
1	A-F-T-E-R-N-O-O-N S-E-S-S-I-O-N
2	12:53 p.m.
3	MS. MAINO-FIKE: All right.
4	Everybody, let's reconvene. I will not take
5	offense if you're finishing up your lunch.
6	What we did while we were on break
7	is to go ahead and capture on the screen here
8	those five fish bones, if you will, or five
9	strategic activities in order to improve our
10	results when whether we resubmit the call for
11	measures or put out any call for measures what
12	we would want to do differently.
13	First of all, I'd like to take and
14	make sure that this captures what we were
15	saying appropriately. Then what we're going
16	to do: We took a deep dive into No. 1
17	identifying our partners and who those folks
18	could be. We had a conversation, I'm not
19	quite sure we're done with that conversation
20	around NQF's value proposition. So we're
21	going to finish that up. And then what we can
22	do once we have agreement on those five key

Page 189 1 things to moving forward is to have some 2 discussion about next steps in each of these five areas. 3 So I think what Robert summarized 4 5 very nicely that was on the flip charts that 6 nobody could see were the five strategies that 7 we want to use to improving our data call response. 8 9 So what we said it's important 10 that we identify partners: We want to solicit targeted 11 12 developers; 13 We want to establish some sort of 14 community practice or key partners and do some 15 collaborative analysis, and; Who's out there that might have 16 17 information? And we said we categorize them under academic, funding, practice or others. 18 19 And we have some initial examples of some of 20 those organizations. 21 And then we also said we needed to 22 refine guidance, and that includes:

	Page 190
1	Revising the work sheet, including
2	some examples of completed measures;
3	Providing some technical support,
4	and;
5	Providing some training or
6	education for developers as well.
7	We also said we wanted to reduce
8	the burden to submit for our developers. And
9	that might mean increasing the length of time
10	they have to meet their deadline.
11	And utilize this two stage process
12	to introduce the measure concepts. And so
13	that might make it easier for them.
14	We also said we needed to describe
15	NQF's value proposition if we reach out to a
16	broader constituency, and how would we do
17	that? Explaining to people that harmonizing
18	standards from the health care delivery
19	results in improved surveillance or assessment
20	of public health.
21	We also said establish measure
22	developers from clinical care and public

Page 191 health, bring them together in some kind of 1 2 forum to develop draft measures that could be used in both domains. That had to do with. 3 you know where is that sweet spot where both 4 5 domains overlap and can we get some measure 6 developers from each of those areas to kind of 7 put their heads together and come up with some 8 sample measures. And then we also said another 9 10 thing we needed to do was raise the brand awareness of NQF, meaning there raise NQF's 11 12 recognition, if you will, out there with a 13 broader constituency base and what role they 14 may be able to play in standard of measures 15 beyond just the clinical arena. 16 Does that capture what we had 17 discussed earlier before the lunch break? CO-CHAIR JARRIS: Could I offer 18 19 some modifications? Kristin, do you mind 20 going down? 21 So I think the community practice 22 and partners for me I consider that under part

	Page 192
1	of the cluster of technical assistance,
2	training and education. To actually put
3	together a group of people who work on these
4	things who can inform and educate people and
5	support each other. So, I was just dropping
6	that down.
7	And then making collaborative
8	analysis, which is B. That is an activity in
9	and of itself as opposed to being under
10	community practice. So I'd drop that
11	community practice down as an E, perhaps, or
12	something or other under two.
13	MS. MAINO-FIKE: Under Refining
14	Guidance?
15	CO-CHAIR JARRIS: Yes, it could be
16	under that or Reduce the Burden to Submit,
17	either one of those really.
18	And the issue of brand awareness
19	of NQF, I do think that's very important but
20	MS. MAINO-FIKE: It's not a
21	Strategic Objective?
22	CO-CHAIR JARRIS: It's not the

	Page 193
1	responsibility of this group. Now we might
2	have a responsibility to be representatives
3	about talking about NQF's relevance to the
4	public health community if we define that
5	value proposition. But the branding of NQF is
6	NQF's issue.
7	And I also by brand, it's not a
8	let's go tell everyone NQF is important about
9	this. To me that's a much more complex
10	construct which includes NQF looking at who it
11	is and deciding whether this is part of what
12	NQF is, and if it is, restructuring itself to
13	do this kind of business and that is an
14	organizational development process for NQF.
15	A brand is what comes to people's mind when
16	they think of NQF; that's pretty far
17	downstream.
18	MEMBER STOTO: I think really this
19	is related to the value proposition thing.
20	CO-CHAIR JARRIS: Yes.
21	MEMBER STOTO: And it's whatever
22	NQF's brand is is making the public health

Page 194 1 community understand how that might be 2 relevant to them. CO-CHAIR JARRIS: 3 Yes. 4 MS. MAINO-FIKE: So, yes. Okay. 5 That makes sense to me. Raising the 6 awareness. 7 And I'll come back to you, Robert. 8 Was there something around the fifth strategic 9 objective that we did not capture? 10 MEMBER PESTRONK: You mean why I 11 had it as a separate priority? 12 MS. MAINO-FIKE: Yes, or if you're 13 comfortable. We want to make sure everybody's 14 comfortable with the way we're looking at 15 something. So, are you comfortable with the 16 way it is now? Is there something else that 17 you would see going under the fifth strategic 18 objective? 19 MEMBER PESTRONK: Glad you didn't 20 capture the "um." 21 I think now it's a question of 22 sort of lumping and splitting.

	Page 195
1	CO-CHAIR JARRIS: Yes.
2	MEMBER PESTRONK: So, I'm
3	comfortable.
4	MS. MAINO-FIKE: Okay. Fine.
5	MEMBER PESTRONK: The reason why I
6	included raising brand awareness as a separate
7	issue was because I wasn't thinking
8	specifically about the work of this particular
9	group, and I was thinking about us as helping
10	the population health staff at NQF frame their
11	presentation to the NQF Board, for example,
12	and that what we were doing here was serving,
13	if you will, as a Board of Directors
14	appropriately or not for Helen and her staff
15	as they're trying to think through their role
16	within NQF. And so that was why I had it as
17	a separate strategic priority, but I mean I
18	don't care.
19	CO-CHAIR JARRIS: I think there's
20	something there, but I think I kind of feel
21	like the blind man feeling the elephant
22	because is there a populational staff in NQF?

	Page 19
1	We have NPP, National Priorities Partnership
2	which has staff working on this. We have this
3	group. And then I don't know where the MAP
4	process exists I don't know a lot about it
5	in NQF, the Measure Applications Partnership.
6	Because they are starting, apparently, to look
7	at population health in something that I just
8	learned about today. So there's all this
9	stuff going on. I have no idea whether there
10	is a well, we have not been introduced to
11	the notion about whether there is a strategic
12	vision and strategic process NQF is doing or
13	whether these are random things going on. And
14	I feel like we're working for an intelligence
15	agency where we don't know what the other
16	cells are doing. But what's going on? How do
17	we fit together?
18	MEMBER PESTRONK: Yes, I don't
19	know any of that and so I assume that there is
20	a population health staff and we've been
21	working with them.
22	DR. BURSTIN: I mean, in general

6

Page 197 there have been a set of activities that are 1 2 actually guite connected. I mean, Wendy Vernon was here the entire morning listening 3 from NPP. National Priorities Partnership has 4 5 been staffing the work group that you and Peter have been working on. 6 7 The MAP is just sort of in its 8 preconceptual phase of thinking about creating 9 these families of measures, this idea of sort 10 of cascading up and down. And one of the topics on the list for the future is 11 12 population health as being something considered. 13 14 There's nothing else happening at These activities are all about 15 the moment. how do we sort of move this field forward. 16 Our role in this are there measures out there 17 18 to bring forward? NPP is setting sort of the 19 broader vision and the MAP is trying to work 20 on alignment across the public and private 21 sectors. So there are different pieces of the 22 puzzle, but I think the issue really is I

	Page 198
1	think particularly because we're guided by the
2	National Quality Strategy. That's how we kind
3	of do our work. They could not have made it
4	more clear that population health is front and
5	center and a high priority. So, it is a higher
6	priority for NQF. I think the only issue is
7	how do we operationalize that I think is the
8	issue that's still not completely clear.
9	MEMBER SPANGLER: Helen, a quick
10	question. Did someone replace Bonnie's
11	position or that position was eliminated?
12	DR. BURSTIN: No, we have not
13	brought in content specific people. I mean,
14	Robyn does her work on disparities, has done
15	a lot of work in this field. And Elisa has
16	been doing this work for us assigned to this
17	space. But no.
18	MEMBER PESTRONK: So in the
19	context of the conversation this morning could
20	you have asked the other in the call for
21	population health measures could other
22	sections of NQF itself have responded to those

	Page 199
1	call for measures because there are this other
2	work going within NQF or
3	DR. BURSTIN: NQF never develops
4	measures. That's a hard line for us. So no
5	one else within NQF is developing measures.
6	And, in fact, we did have the NPP folks weigh
7	in on our call for measures and were actually
8	quite helpful. But, no, there is no measure
9	development within NQF.
10	MEMBER PESTRONK: Is there a set
11	of customers or partners for the other
12	population health work at NQF
13	DR. BURSTIN: No.
14	MEMBER PESTRONK: that could
15	have extended outreach?
16	DR. BURSTIN: Yes, and we work
17	closely with Karen and Wendy to see who those
18	people were. Yes, and we did.
19	MEMBER PESTRONK: And you work
20	closely with them? Okay.
21	DR. BURSTIN: Yes. And the MAP
22	stuff is really pre-contemplative, so there's

	Page 200
1	nobody to work with there yet.
2	MEMBER PESTRONK: I had in mind
3	under the raise brand awareness as a fifth
4	area outreach into specific places that might
5	be helpful or might be able to suggest
6	measures since that's where we were focused.
7	MS. MAINO-FIKE: I noticed, Matt,
8	you have a comment.
9	MEMBER STIEFEL: 4b, I was
10	originally thinking that not so much as an
11	activity describing NQF's value proposition,
12	but actually jump-starting the measure
13	development process or creating a use case or
14	being a very important first step. That may
15	push NQF up against that bright line of
16	measure development, and one I'm not sure how
17	you navigate. But if it's a convener role of
18	measure developers, then maybe that's all
19	right. But I see that as fundamentally
20	different then describing the value
21	proposition. It's jump-starting the
22	population health measure development process

Page 2011by doing it, or at least convening this group2of stakeholders and in so doing I think3demonstrating the value, the mutual benefit.4And I hope we get to actually do5what you asked, Helen, is to talk a little6more about the value proposition before we're7done.8MS. MAINO-FIKE: Yes. Yes. That is9definitely the next step. What I wanted to do10was get some agreement that what we have here11kind of captures the key strategies, if you12will.13So I'm going to say, you know14perhaps I hear what you're saying. It's15not part of NQF's value proposition. It might16be more around NQF's potential role in17bringing disparate parties to jump-start the18measure process. Would you see that20MEMBER STOTO: I think it very21much is the value proposition, but it's not22describing it. It's creating it.		
2 of stakeholders and in so doing I think 3 demonstrating the value, the mutual benefit. 4 And I hope we get to actually do 5 what you asked, Helen, is to talk a little 6 more about the value proposition before we're 7 done. 8 MS. MAINO-FIKE: Yes. Yes. That is 9 definitely the next step. What I wanted to do 10 was get some agreement that what we have here 11 kind of captures the key strategies, if you 12 will. 13 So I'm going to say, you know 14 perhaps I hear what you're saying. It's 15 not part of NQF's value proposition. It might 16 be more around NQF's potential role in 17 bringing disparate parties together or 18 convening different parties to jump-start the 19 measure process. Would you see that 20 MEMBER STOTO: I think it very 21 much is the value proposition, but it's not		Page 201
 demonstrating the value, the mutual benefit. And I hope we get to actually do what you asked, Helen, is to talk a little more about the value proposition before we're done. MS. MAINO-FIKE: Yes. Yes. That is definitely the next step. What I wanted to do was get some agreement that what we have here kind of captures the key strategies, if you will. So I'm going to say, you know perhaps I hear what you're saying. It's not part of NQF's value proposition. It might be more around NQF's potential role in bringing disparate parties together or convening different parties to jump-start the measure process. Would you see that MEMBER STOTO: I think it very much is the value proposition, but it's not 	1	by doing it, or at least convening this group
And I hope we get to actually do what you asked, Helen, is to talk a little more about the value proposition before we're done. MS. MAINO-FIKE: Yes. Yes. That is definitely the next step. What I wanted to do was get some agreement that what we have here kind of captures the key strategies, if you will. So I'm going to say, you know perhaps I hear what you're saying. It's not part of NQF's value proposition. It might be more around NQF's potential role in bringing disparate parties to jump-start the measure process. Would you see that MEMBER STOTO: I think it very much is the value proposition, but it's not	2	of stakeholders and in so doing I think
5 what you asked, Helen, is to talk a little 6 more about the value proposition before we're 7 done. 8 MS. MAINO-FIKE: Yes. Yes. That is 9 definitely the next step. What I wanted to do 10 was get some agreement that what we have here 11 kind of captures the key strategies, if you 12 will. 13 So I'm going to say, you know 14 perhaps I hear what you're saying. It's 15 not part of NQF's value proposition. It might 16 be more around NQF's potential role in 17 bringing disparate parties together or 18 convening different parties to jump-start the 19 measure process. Would you see that 20 MEMBER STOTO: I think it very 21 much is the value proposition, but it's not <td>3</td> <td>demonstrating the value, the mutual benefit.</td>	3	demonstrating the value, the mutual benefit.
 more about the value proposition before we're done. MS. MAINO-FIKE: Yes. Yes. That is definitely the next step. What I wanted to do was get some agreement that what we have here kind of captures the key strategies, if you will. So I'm going to say, you know perhaps I hear what you're saying. It's not part of NQF's value proposition. It might be more around NQF's potential role in bringing disparate parties together or convening different parties to jump-start the measure process. Would you see that MEMBER STOTO: I think it very much is the value proposition, but it's not 	4	And I hope we get to actually do
7done.8MS. MAINO-FIKE: Yes. Yes. That is9definitely the next step. What I wanted to do10was get some agreement that what we have here11kind of captures the key strategies, if you12will.13So I'm going to say, you know14perhaps I hear what you're saying. It's15not part of NQF's value proposition. It might16be more around NQF's potential role in17bringing disparate parties together or18convening different parties to jump-start the19measure process. Would you see that20MEMBER STOTO: I think it very21much is the value proposition, but it's not	5	what you asked, Helen, is to talk a little
8MS. MAINO-FIKE: Yes. Yes. That is9definitely the next step. What I wanted to do10was get some agreement that what we have here11kind of captures the key strategies, if you12will.13So I'm going to say, you know14perhaps I hear what you're saying. It's15not part of NQF's value proposition. It might16be more around NQF's potential role in17bringing disparate parties together or18convening different parties to jump-start the19measure process. Would you see that20MEMBER STOTO: I think it very21much is the value proposition, but it's not	6	more about the value proposition before we're
9 definitely the next step. What I wanted to do was get some agreement that what we have here kind of captures the key strategies, if you will. 12 will. 13 So I'm going to say, you know 14 perhaps I hear what you're saying. It's 15 not part of NQF's value proposition. It might 16 be more around NQF's potential role in 17 bringing disparate parties together or 18 convening different parties to jump-start the 19 measure process. Would you see that 20 MEMBER STOTO: I think it very 21 much is the value proposition, but it's not	7	done.
10 was get some agreement that what we have here 11 kind of captures the key strategies, if you will. 12 will. 13 So I'm going to say, you know 14 perhaps I hear what you're saying. It's 15 not part of NQF's value proposition. It might 16 be more around NQF's potential role in 17 bringing disparate parties together or 18 convening different parties to jump-start the 19 measure process. Would you see that 20 MEMBER STOTO: I think it very 21 much is the value proposition, but it's not	8	MS. MAINO-FIKE: Yes. Yes. That is
11 kind of captures the key strategies, if you 12 will. 13 So I'm going to say, you know 14 perhaps I hear what you're saying. It's 15 not part of NQF's value proposition. It might 16 be more around NQF's potential role in 17 bringing disparate parties together or 18 convening different parties to jump-start the 19 measure process. Would you see that 20 MEMBER STOTO: I think it very 21 much is the value proposition, but it's not	9	definitely the next step. What I wanted to do
12 will. 13 So I'm going to say, you know 14 perhaps I hear what you're saying. It's 15 not part of NQF's value proposition. It might 16 be more around NQF's potential role in 17 bringing disparate parties together or 18 convening different parties to jump-start the 19 measure process. Would you see that 20 MEMBER STOTO: I think it very 21 much is the value proposition, but it's not	10	was get some agreement that what we have here
13So I'm going to say, you know14perhaps I hear what you're saying. It's15not part of NQF's value proposition. It might16be more around NQF's potential role in17bringing disparate parties together or18convening different parties to jump-start the19measure process. Would you see that20MEMBER STOTO: I think it very21much is the value proposition, but it's not	11	kind of captures the key strategies, if you
14perhaps I hear what you're saying. It's15not part of NQF's value proposition. It might16be more around NQF's potential role in17bringing disparate parties together or18convening different parties to jump-start the19measure process. Would you see that20MEMBER STOTO: I think it very21much is the value proposition, but it's not	12	will.
not part of NQF's value proposition. It might be more around NQF's potential role in bringing disparate parties together or convening different parties to jump-start the measure process. Would you see that MEMBER STOTO: I think it very much is the value proposition, but it's not	13	So I'm going to say, you know
16 be more around NQF's potential role in 17 bringing disparate parties together or 18 convening different parties to jump-start the 19 measure process. Would you see that 20 MEMBER STOTO: I think it very 21 much is the value proposition, but it's not	14	perhaps I hear what you're saying. It's
<pre>17 bringing disparate parties together or 18 convening different parties to jump-start the 19 measure process. Would you see that 20 MEMBER STOTO: I think it very 21 much is the value proposition, but it's not</pre>	15	not part of NQF's value proposition. It might
<pre>18 convening different parties to jump-start the 19 measure process. Would you see that 20 MEMBER STOTO: I think it very 21 much is the value proposition, but it's not</pre>	16	be more around NQF's potential role in
<pre>19 measure process. Would you see that 20 MEMBER STOTO: I think it very 21 much is the value proposition, but it's not</pre>	17	bringing disparate parties together or
20 MEMBER STOTO: I think it very 21 much is the value proposition, but it's not	18	convening different parties to jump-start the
21 much is the value proposition, but it's not	19	measure process. Would you see that
	20	MEMBER STOTO: I think it very
22 describing it. It's creating it.	21	much is the value proposition, but it's not
	22	describing it. It's creating it.

	Page 202
1	MS. MAINO-FIKE: Right. Right.
2	MEMBER STOTO: And in this new
3	realm that NQF has not done that much business
4	in.
5	MS. MAINO-FIKE: And so maybe we
6	could put it under value proposition but just
7	in terms of what is
8	MEMBER STOTO: But the other thing
9	I'd like to add about that is that another
10	important step there is this identifying the
11	potential users and uses of NQF-endorsed
12	measures in this space. Because I think that
13	helps to figure out what the value proposition
14	is as well.
15	MS. MAINO-FIKE: Right. So C
16	might be a list of potential users and uses?
17	Would you see that as C under the value
18	proposition, a list of potential uses and
19	users?
20	CO-CHAIR JARRIS: How much is the
21	issue here that value proposition has to be
22	created for NQF endorsement, which is what NQF

	Page 201
1	does, versus a value proposition has to be
2	created for population health measures?
3	Because NQF is like the last step in this
4	where they endorse a measure that someone else
5	has developed. But if we're really talking
6	about this being developmental all the way
7	from we're having conceptual problems to
8	practical problems, to who would use it
9	anyway, to why would anyone want one that's
10	way before an endorsement process. So I'm
11	wondering, and part of the question is who
12	should be playing in this field either as a
13	partner of NQF or rather in advance of NQF?
14	Because I mean a lot of this smells like if
15	anyone has an extra million bucks an IOM type
16	study.
17	MEMBER STOTO: So that's why I
18	wanted to put in identify the users and uses
19	because that really creates the value
20	proposition, or at least helps to clarify the
21	value proposition with respect to population
22	health measures. And then the question is if

3

	Page 204
1	we're going to have those, what can NQF add to
2	that?
3	MS. MAINO-FIKE: Right.
4	MEMBER STIEFEL: I mean, it
5	depends on your diagnosis of the problem.
6	I don't know that we have a
7	significant shortage of measures. We maybe
8	have an over abundance of measures. I think
9	there's probably a shortage on the very top of
10	HealthyPeople healthy life expectancy where we
11	don't do that as well as other countries. But
12	below that, there are busloads, truckloads of
13	thousands and thousands, and so that the value
14	proposition may well be in the endorsement as
15	opposed to the development, and especially if
16	that endorsement bridges this gap that we've
17	talked about between clinical and community by
18	having a consistent set of measures used for
19	performance improvement that also can be used
20	for assessment.
21	MS. MAINO-FIKE: Right. I think
22	you're bringing up a good point which is, you
	Nool P. Grogg & Co. Ing

	Page 205
1	know kind of a discussion of what comes first,
2	the chicken or the egg. Does NQF want to look
3	at in their efforts to look at measures, do
4	they want to expand their role to include
5	creating forums to convene groups so there's
6	a choice point about a role there that is good
7	to highlight, it's just a choice point. So
8	NQF could play a role.
9	In an area where it's a new area
10	where does the public and the one-on-one
11	clinical areas oversect to assess health?
12	That's kind of a new area. We've got a lot of
13	stuff going on, but no standardization. So,
14	NQF has a choice point to broaden their role
15	a little bit and see if they want to be or
16	take on convening so that then they're further
17	along in standardization and measures and
18	would be able to then fall back into their
19	normal role of endorsement.
20	So, yes, Ron?
21	MEMBER BIALEK: I'm also thinking
22	that any of the elements within the value

	Page 206
1	proposition are choice points for NQF in that
2	we can sit around and come up what we think
3	the value proposition is. It really is the
4	Board that needs to say we agree or disagree.
5	MS. MAINO-FIKE: Correct.
6	MEMBER BIALEK: You know, so
7	before one would go out and tell folks this is
8	the value proposition, the Board needs to say
9	we agree
10	MS. MAINO-FIKE: Right.
11	MEMBER BIALEK: or here's how
12	we modify it.
13	MS. MAINO-FIKE: Right. And
14	that's a really good point because one of the
15	benefits of getting a group like this together
16	is to come up with thorough recommendations
17	that, you know Ron to your point, then the
18	Board has to make some choices regarding what
19	they want to pursue, what they agree with,
20	what they don't agree with. So the value of
21	this group coming together one of the
22	values of this group coming together is to

	Page 20
1	give them some ideas. The benefit of your
2	opinions, and that's what I think this is.
3	If we want to move forward, you
4	know here are some ways that we can do it.
5	So if we're okay with the way we
6	sort of organized, I don't want to over assess
7	how we've organized each of these steps and
8	not get to taking some action on them. So if
9	we're okay, if you're comfortable with how
10	things are reflected and organized here in
11	these four areas, then the next thing that we
12	want to do is circle that yes, Helen?
13	DR. BURSTIN: I'm still
14	struggling, and I understand Paul's point
15	about the value proposition and the branding
16	being about NQF. But I'm struggling about
17	whether and I think this is a question for
18	the highest levels of this group and NQF, and
19	whatever. How far out in those concentric
20	circles do we go?
21	I have no doubt that it is
22	directly relevant when a measure clearly has

7

	Page 208
1	some linkage back and influences what happens
2	in a health plan, in a health care system, et
3	cetera. For example, we endorsed the measure
4	last year that looked at number of days kids
5	missed from school. No brainer. Incredibly
6	useful. I think it's a population health
7	measure. I think you'd agree. But it's
8	incredibly useful. You can see how the health
9	system or Kaiser would love to have a
10	standardize way to track something like that
11	for their kids with asthma in their health
12	system.
13	I think the question is how far
14	out does this group think is logical for NQF
15	to go. Because I think we have to bring a set
16	of questions like that to the Board, which we
17	haven't yet.
18	CO-CHAIR JARRIS: I think it's a
19	developmental process and it'll change over
20	time. But the clinical world will go out so
21	far, there will be some overlap with public
22	health which will go out further. But we have

	Page 209
1	this debate in public health all the time
2	also. You know, should we be having somebody
3	full time sitting in on the Transportation
4	Commission meetings?
5	So, I think public health will go
6	further than NQF can go. And so when we
7	developed those three parts in the NPP the
8	reason we plugged in there at clinical
9	provided services was just to do that bridge
10	to the clinical world to say okay, that can be
11	measured at a patient population level, so
12	we'll call that population health. At least
13	some of us choked that down realizing it was
14	a developmental thing we had to do to bridge
15	to clinical medicine.
16	MEMBER PESTRONK: It is just to
17	some extent another one of those strategic
18	choices. Because what Neil told us this
19	morning in his presentation was there are
20	other organizations and groups going out to
21	the other space already. And so if they're out
22	there, something's going to happen out there

Page 210 1 where people are going to turn to them if 2 they're successful when they're looking for the measures to be used. And the question for 3 NOF is to what extent is their business model 4 5 potentially -- I mean, in the worse case in 6 jeopardy because the world moves to find the 7 measures that NQF has heretofore offered as 8 insufficient and they turn somewhere else for 9 them. 10 CO-CHAIR JARRIS: There are already, you know major players in the 11 12 Catholic Health Association that talks about "community building," which is safe housing, 13 14 job creation, things like that. So there's some who get this. But I mean I think we just 15 16 have to move at a pace and my sense is that 17 NOF will be a relatively conservative pace, which is fine. 18 19 MS. MAINO-FIKE: I wonder if that 20 is perhaps a fifth strategic area, that being 21 describing the boundaries, those concentric 22 cycles that you were talking about, Helen.

	Page 211
1	What are the boundaries or the circles that
2	this group and NQF wants to play within, given
3	that it's this point in time? Not, Paul, as
4	you said you know it's an evolutionary
5	process. They may be expanded, but to put sort
6	of a stake in the ground. I wonder if that's
7	one of the strategic objectives that needs to
8	be decided?
9	Matt?
10	MEMBER STIEFEL: So I think the
11	stake in the ground is the intersection. I
12	mean, that requires more thinking about what
13	that intersection is.
14	Thinking about income. It's hard
15	to imagine NQF would ever be endorsing a high
16	school graduation rate measure. But that
17	caused me to think about the community health
18	needs assessment and it's an interesting,
19	maybe use case, because it sits at this
20	intersection. It's a requirement of hospitals
21	to play in the public health arena.
22	Unfortunately, I think hospitals

	Page 21
1	are looking at that as what are the
2	traditional public health measures and
3	actually even KP is looking at that as well,
4	high school graduation rates and availability
5	of parks. But that could be an opportunity to
б	think about what can the health care delivery
7	system contribute to public health in this
8	Community Health Needs Assessment. A
9	reframing. And that may be a very significant
10	opportunity. And so you could think of sets
11	of measures. It's a different approach that
12	the Community Health Needs Assessment would be
13	something that is endorsed or a whole health
14	risk assessment that has lots of measures
15	within it for standardization.
16	CO-CHAIR JARRIS: I agree. I
17	think that the place to emphasize initially is
18	that interface. And I think that HIV measure
19	actually did that quite well. If there are
20	specific measures that can be used for
21	community health assessments by hospitals and
22	community health improvement plans, that would

2

	Page 213
1	be helpful. But I wouldn't set a line to say
2	we don't go beyond here. I would let the
3	methodology do that for us because if some
4	really smart person figured out how to
5	demonstrate a clear evidence link between high
6	school graduation and health that people could
7	say "Wow. They nailed it and they met the
8	criteria." Then let's go for it and take it
9	as opposed to say dismissing it out of hand.
10	Over time, hopefully, people will get smart
11	enough and the evidence-base will develop so
12	we can tie those things in.
13	MS. MAINO-FIKE: Okay.
14	MEMBER STOTO: I would just like
15	to support Matt's point as a starting point.
16	Because I think the critical thing there is
17	that the hospitals already know about NQF and
18	they're about the only ones in this space that
19	we're talking about well, maybe not the
20	only ones. But they're the ones that know NQF
21	the best.
22	MS. MAINO-FIKE: Yes. Yes. So

	Page 214
1	maybe the fifth objective or category might be
2	initial areas or opportunities to move into
3	the public health space?
4	MEMBER STOTO: It's really what I
5	had in mind when I said identify potential
6	users and uses. I mean, I think the Community
7	Health Needs Assessment IRS requirements or so
8	on are the primary one to start with in that
9	area.
10	MS. MAINO-FIKE: Yes. Yes.
11	MEMBER STOTO: It's not something
12	that's not already on the list.
13	DR. BURSTIN: Or just a series of
14	use cases, which I really think is what we're
15	kind of listing out, which I think is very
16	helpful.
17	Also, the Office of the National
18	Coordinator is developing a series, I'm told,
19	of more population health or interested in
20	developing a series of more population health
21	measures for meaningful use stage 3 for 2015.
22	We just met with them this week. So again,

	Page 215
1	they're thinking very prospectively about what
2	they could do differently. So we can
3	certainly explore those options, too.
4	MEMBER STIEFEL: Another one is
5	the Medicare HRA that's required now. That's
6	a set again, it's a set of measures, many
7	of which are very important population health
8	measures.
9	MS. MAINO-FIKE: So I think what
10	we're starting to get into is where are some
11	low-hanging fruit or initial first steps that
12	NQF and this group should move forward on,
13	take as first steps.
14	So I'd appreciate if you wouldn't
15	mind recording just maybe exactly that. Maybe
16	we don't have a fifth category. It's just, you
17	know proposed next steps could include and
18	some of these projects are good examples.
19	MEMBER PESTRONK: I actually like
20	thinking about it as a fifth category because
21	it's sort of a first decision. It's the first
22	decision to make about then how you go about

Page 216 defining the value proposition because you are 1 2 forced to think about who are your initial customers for the products that will come out 3 of NQF. And if in fact it's in the sweet spot 4 5 that Matt has described, then the customer, 6 the traditional customers which are still good 7 customers for NQF are the governmental 8 customers out of HHS who have turned to NOF 9 for these population health measures. And it 10 could be expanded, the value proposition could be expanded to include the state governmental 11 12 customer because they are Medicaid -- and they are Medicaid on a practical basis and those 13 state directors could use these metrics within 14 their own states. 15 16 And then I was thinking about the other governmental customer, before we broke 17 for lunch. as the local customer and the value 18 19 proposition there that I was trying to 20 describe was NOF and its metrics are partners 21 for those local health department director 22 because the metrics that get adopted and
Page 217 1 promoted by NQF influence the practice and 2 operationalization of the health care system in each of those director's communities. And 3 therefore, NQF becomes a partner to leverage 4 5 change that the local health department can't 6 leverage or the director can't leverage on his 7 or her own, which is exactly where people are 8 trying to push the local health department 9 directors and the state health department 10 directors to not think that they have the capacity on their own to create healthier 11 12 communities, but in a time of scarce resources to leverage the resources that exist elsewhere 13 14 to make that happen. 15 And so in my colleague Paul Jarris' jargon what NQF is actually doing is 16 17 trying to leverage through its work the 18 enterprise of the governmental public health 19 system, to leverage its work in both 20 traditional and new ways. 21 CO-CHAIR JARRIS: The Community 22 Health Assessments, I think that's a very rich

	Page 218
1	area to look at because we have, as you said,
2	the public health accreditation requiring all
3	state and local health departments, and tribal
4	and territorial health departments do
5	Community Health Assessments, Community Health
6	Improvement plan. Nonprofit hospitals have to
7	do that. Well, what part of the metrics
8	they're going to use, and wouldn't it be
9	useful to have standardized metrics so when
10	that hospital who covers three communities in
11	this state develops assessments of population
12	health, it's the same set of measures that the
13	three local health departments and the state
14	health department engaged with that hospital
15	are measuring. That would be a very powerful
16	set of tools.
17	MEMBER STIEFEL: And it's evolving
18	not coordinated, not harmonized.
19	MS. MAINO-FIKE: Right.
20	MEMBER STIEFEL: So the community
21	hospitals in the same geographic area are
22	developing their own Community Health Needs

	Page 219
1	Assessment as is the public health entity.
2	So they're like three or four or five
3	different health assessments in the same
4	community.
5	MEMBER PESTRONK: Yes. And you've
6	got new payment methodologies which are meant
7	to address populations rather than
8	individuals. And so those payers need
9	measures to determine whether the needle has
10	moved from one place to another as a result of
11	what they're funding. And that's a federal,
12	state and local opportunity also.
13	CO-CHAIR JARRIS: And the 990 form
14	on an annual basis, a nonprofit hospital has
15	to report on their Community Health
16	Assessment, which priorities they're
17	addressing and which they are not. And if
18	not, why not.
19	So again, let's have some
20	standardized way of looking at this, otherwise
21	it's just going to be meaningless what's
22	coming out.

	Page 220
1	MS. MAINO-FIKE: I want to capture
2	some of this.
3	I'm thinking some of this
4	conversation should go under that value
5	proposition or value equation. I'm also
6	thinking that just so you have something
7	concrete to leave this meeting with, that
8	maybe number five here does go back to
9	identifying potential uses and users. And then
10	we specifically identify where some of those
11	areas are.
12	We already talked about the
13	community hospitals and leveraging what
14	they're doing.
15	So if we could do that reflected
16	here, that would be great. And then let's
17	I know, Matt, you mentioned this. The other
18	thing I'd like to circle back to, people have
19	mentioned this a few times, is coming back to
20	that value equation. We don't need to come up
21	with one value equation, but if we can
22	summarize what that value equation might be,

1	
	Page 221
1	I think that would make good use of the brain
2	power in this room and help NQF look at making
3	their choice points about how they choose to
4	take action going forward.
5	So, let's look at that value
6	proposition. We have A, B I think we
7	should move this to number 5. What are some
8	further ideas about what the value equation
9	was?
10	I know we broke for our lunch
11	when, Robert, you were kind of summarizing
12	what you thought NQF's leverage was.
13	CO-CHAIR JARRIS: One thing we
14	talked about yesterday, which I think would be
15	very helpful, is there are so many surveys out
16	there and data collection tools that all
17	define what they're collecting differently.
18	MS. MAINO-FIKE: Yes.
19	CO-CHAIR JARRIS: And that I think
20	would be tremendously valuable if all those
21	different surveys used the same measure so
22	that there's comparability. You could say,

	Page 222
1	okay, YRBS goes up to age 18, BRFSS starts 18
2	to 64. So guess what? We now know what
3	happens between this age range as opposed to
4	there's a break in your knowledge because it's
5	a different survey question.
6	MS. MAINO-FIKE: So you're seeing
7	that as part of NQF's value equation?
8	CO-CHAIR JARRIS: No, that would
9	be the value of having population measures.
10	You're right. That's not necessarily NQF's
11	MS. MAINO-FIKE: Right. So maybe
12	we can add that under NQF value equation is
13	one of the things it could do is to play a
14	role in harmonizing the could you say that
15	again, Helen?
16	DR. BURSTIN: Harmonizing the
17	national survey system.
18	MEMBER STOTO: And even
19	harmonizing the national surveys among
20	themselves, which
21	DR. BURSTIN: I was a fed for
22	seven years; that's not an easy proposition.

	Page 223
1	We'll be happy to be a partner in that effort.
2	MEMBER STOTO: Well, I know.
3	Right. And then part of the reason is it's
4	difficult for the feds to do is because
5	everybody's got the same voice. If there were
6	an external group
7	DR. BURSTIN: Right.
8	MEMBER STOTO: that could push
9	it, that that might actually make it easier.
10	MS. MAINO-FIKE: Right. Right. So
11	the value equation is being the outside
12	organization that can get parties together and
13	try to get some standardization.
14	MEMBER PESTRONK: Who's the
15	customer? Because the value proposition is
16	about who the customer is and what one is
17	trying to sell. So, who's the customer here or
18	who are the customers?
19	CO-CHAIR JARRIS: In that case
20	it's the users of the survey. Lots of people
21	use it, so I don't how to get more specific.
22	But wouldn't it be nice if the information

i	
	Page 224
1	from those surveys was clearer or more
2	consistent and had more utility? And that
3	could be public health agencies. It could be
4	clinical folks if they're trying to
5	because, you know we have this problem of the
6	public population health doing works at the
7	population level largely through surveys and
8	the clinical sector doing work by adding up
9	individuals. And where will the two ever
10	meet?
11	MEMBER STIEFEL: I think the
12	customers are the public health entities that
13	you describe, probably federal, state, local
14	and the health care organizations. And if you
15	think of defining customers that way, I think
16	that there's value to each: The value to the
17	public health entities is having this rich
18	vein of data from the clinical care delivery
19	system. And the value to the clinical care
20	delivery system is that with harmonized
21	measures you've got benchmarks to measure your
22	performance against.

	Page 225
1	MS. MAINO-FIKE: So you're
2	suggesting the customer would be the three
3	different levels of government as well as then
4	the clinical care delivery systems, and that
5	you all could define what the benefits are to
6	each of those customer groups fairly easily?
7	So can we record that?
8	MEMBER STOTO: Another value to
9	the clinical health care system is that at
10	some point the IRS might say well the measure
11	that you use in your needs assessment
12	improvement plans have to meet some standards,
13	and endorsement by NQF could be that standard.
14	MEMBER STIEFEL: Maybe a standard
15	community health needs assessment?
16	MS. MAINO-FIKE: Yes, Sue?
17	MEMBER PICKENS: Would there at
18	some point be value to funding agencies like
19	the United Way that when people apply
20	community-based grants to that say it meets
21	NQF population health measures?
22	MS. MAINO-FIKE: Could that be a

	Page 226
1	possible next step, or would that be something
2	that you would want to include in a value
3	equation?
4	MEMBER STOTO: It's another
5	customer.
6	MS. MAINO-FIKE: It's another
7	customer. Right. So our customers would be
8	the three different governmental levels. If
9	we're just looking at this in a broad way,
10	there'd be the three different governmental
11	levels, there would be the health care
12	delivery systems and could be what would
13	you call those? Other organizations that are
14	collecting data? How would you describe them?
15	MEMBER PICKENS: Well, they're
16	actually funding the projects. RWJ would be
17	one that would fund projects in community and
18	population health. They fund the Wisconsin
19	project, and lots of things. So I would call
20	them I'd just call them funders.
21	MS. MAINO-FIKE: Project funders?
22	MEMBER PICKENS: Yes.

	Page 227
1	MS. MAINO-FIKE: Okay.
2	MEMBER STIEFEL: And I think it's
3	the three different public health levels as
4	opposed to government. Government sounds too
5	big.
6	MS. MAINO-FIKE: Sounds too Big
7	Brother? So three different how would you
8	rephrase that?
9	MEMBER STIEFEL: Levels of public
10	health organizations.
11	MS. MAINO-FIKE: Okay. Yes. So
12	like a federal, state and then a local. Okay.
13	Good.
14	So that helps us a little bit
15	answer the question of who is the customer.
16	Ron, did you want to add to that?
17	MEMBER STIEFEL: One of the
18	dilemmas with the users of the measure being
19	the primary customer is how do we sell to
20	developers? Because as Mike pointed out
21	earlier, there aren't that many developers of
22	the population measures and so we have

Page 228 1 customers for the measures without necessarily 2 developers. Now, we heard from two: 3 New York City Health Department and California as 4 5 potential, both customer and developer. But I 6 still think there's that gap out there of why 7 should an organization spend its time, its 8 money developing a measure that ultimately 9 will be used by folks. So one set of 10 customers, yes, are the users of the measures. Another set of customers that I don't really 11 12 think we've addressed are the developers of 13 the measures. 14 MS. MAINO-FIKE: I understand. 15 Mike? MEMBER STOTO: I think it's an 16 17 important point. I think that what we think of as developers and what's the other word? 18 19 Owners or --20 DR. BURSTIN: Stewards. 21 MEMBER STOTO: Stewards. Might 22 actually have to be rethought in this realm.

	Page 229
1	So when you have something like say the
2	smoking measure that's used on all kinds of
3	federal surveys and could be used in other
4	places, you know what does it really mean to
5	be the developer or the steward of something
6	like that?
7	MS. MAINO-FIKE: So do you think
8	that that would be an action item is to look
9	at how we define these customer groups?
10	MEMBER STOTO: Yes.
11	MS. MAINO-FIKE: Yes. Maybe we
12	can put that under action items.
13	CO-CHAIR JARRIS: You know, I
14	think there's almost an infinite number. You
15	know, every grant has measures you have to
16	meet of performance and the part of what
17	drives people nuts is they come up with
18	measures that they pull out of the air, that
19	then change six months into the grant. You
20	know, so it would actually be nice to have
21	some valid reliable measures to assess your
22	performance against.

	Page 230
1	MS. MAINO-FIKE: Well, isn't that
2	one of the value equations that NQF brings is
3	creating a market, if you will, a desire for
4	an external standard approval where there
5	isn't one now? There is one from a clinical
6	standpoint, but we're saying NQF could be an
7	organization that helps to create that market,
8	that desire in the public health sector. That
9	is a possible benefit to add to the value
10	equation.
11	MEMBER BIALEK: And it's important
12	for those organizations to have these ever
13	changing, incredibly diverse reporting
14	requirements for pretty much the same thing
15	for them to understand the value in having
16	some consistency. I'm not sure they currently
17	do recognize the value in having that.
18	MS. MAINO-FIKE: Okay. So NQF
19	could create some consistency and
20	standardization where there wasn't one, and
21	that's a way to lessen the burden.
22	And, Mike, you had wanted to say

ſ

	Page 231
1	something? Never mind.
2	Yes, Kurt?
3	CO-CHAIR STANGE: I really like
4	this idea of focusing on the Community Health
5	Needs Assessment in thinking of the hospitals
6	health care systems as one primary audience.
7	They have this new mandate and then the public
8	health community that's trying to do more with
9	less and realizing they have to convene multi-
10	stakeholder groups. That really is a sweet
11	spot. And if you think of that as the core
12	target audience, you start finding secondary
13	ones that people want to get on board, which
14	would be other government agencies and the
15	business community.
16	And what made me think of that is
17	the measure that Helen mentioned that's
18	already NCQA endorsed that's really about
19	social role function for children and days
20	missed of school. So if you take that to the
21	working population, I mean that's how you
22	engage the business community with days of

page 2
absenteeism or presentism. So that really gets
others involved.
And then Paul mentioned anybody

who is funding anything wants these outcome 4 5 I mean, we're making a big pitch in measures. Cleveland to basically all the philanthropic 6 7 community that they fund all these 8 initiatives, and they under fund the 9 evaluation so they never really know if their 10 money is doing any good. These kind of measures could be something that would be if 11 12 you made that the baseline that's always being assessed at the neighborhood level and the 13 14 health care system level in a community, then 15 when they're funding new initiatives and you want to look at what is the impact people 16 being able to go to work, children being able 17 to go to school, health care utilization; if 18 19 those data are already being collected, then 20 that philanthropic community then doesn't have 21 to put as much of their money into evaluation 22 for every little thing in a way that doesn't

> Neal R. Gross & Co., Inc. 202-234-4433

Page 232

	Page 233
1	matter if they invest in a way that's on a
2	community level.
3	So, I think the core constituency
4	are the people who really have to do this
5	Community Health Needs Assessment because then
6	you start bringing lots of other stakeholders.
7	MS. MAINO-FIKE: Okay. I want to
8	record one second. I'm sorry, Matt. Let's
9	record this Community Health Assessment
10	notion. It's been brought up several times as
11	a good maybe first place to start. So maybe we
12	can put that under the proposed next steps.
13	Exploring that, Community Health Assessments,
14	not mandate but action that's already going
15	on.
16	And, Matt?
17	MEMBER STOTO: Well, it's a
18	mandate, it's a law. And then furthermore,
19	it's not just a Community Needs Assessment but
20	it's the improvement plans as well.
21	MS. MAINO-FIKE: Yes.
22	MEMBER STOTO: It's two separate

	Page 234
1	mandates.
2	MS. MAINO-FIKE: Okay.
3	MEMBER STOTO: This requires
4	different kinds of measures.
5	MS. MAINO-FIKE: Matt?
6	MEMBER STIEFEL: Well, to build on
7	that, I think an entire Community Health Needs
8	Assessment would collapse under the weight of
9	the NQF review criteria. Every element of that
10	assessment, that just sounds overwhelming. But
11	perhaps there's some core subset of it. And
12	maybe it's the healthy behaviors, I keep
13	bringing up, that where it's a bite out of it.
14	It's a more tractable subset that NQF could
15	convene, and it could be maybe that group of
16	stakeholders that we talked about of people
17	from public health and people from clinical
18	care delivery measure developers to agree on
19	not the entire thing, but a start, a subset of
20	it.
21	MS. MAINO-FIKE: Yes. That subset
22	could be the healthy behaviors section. And
	Neal R. Gross & Co., Inc.

	Page 235
1	one way to address that which would be to get
2	this group of measure developers, both
3	clinical and public, together to look at that.
4	MEMBER STIEFEL: And the advantage
5	of focusing on that is that is in this
6	intersection sweet spot.
7	MS. MAINO-FIKE: Right.
8	MEMBER STIEFEL: The high school
9	graduation it's harder to make the case.
10	MS. MAINO-FIKE: Right. Well, that
11	goes back to Helen's point of within these
12	concentric circles you know it's easy to make
13	the case that it's a smaller initial
14	concentric circles.
15	Yes, Amir?
16	MEMBER QASEEM: So is it also
17	could be NQF's role be just endorsing of the
18	measures as well, like the performance of the
19	performance measures or evaluation of
20	performance measures. And I don't know is not
21	a conflict of an interplay so that if you
22	endorse the measure, that you should even be

	Page 236
1	evaluating the measures. But I think it's some
2	sort of evaluation in terms of feedback as
3	well whether and I don't know if NQF is
4	planning to go that route or not.
5	DR. BURSTIN: We're doing it in a
6	lot of different ways, not as formal as I'd
7	like. Our new search system, the quality
8	positioning system, the quality measures
9	allows you to give feedback on the measures.
10	We've solicited comments every time a measure
11	that's been endorsed is up for maintenance.
12	We try to do an annual assessment of the
13	overall portfolio of what it's being used for.
14	And our Usability Task Force this
15	year changed our usability criterion so all
16	projects beginning in the fall have a much
17	will need to report on how the measure has
18	proved useful in terms of improvements and
19	also any potential unintended consequences as
20	a result as well. So, we'll start gathering
21	that data as we move forward prospectively.
22	MEMBER QASEEM: In this case I

	Page 237
1	think it's going to be extremely useful
2	because as you've said we've already endorsed
3	some of the measures and I know we're talking
4	about how to make it more attractive to get
5	more measures. But maybe we do need to see
6	what we've already done where it get us.
7	CO-CHAIR JARRIS: I wondered about
8	sort of turning over some rocks such as
9	another place of intersection between the
10	clinical world and the public health world is
11	in vital statistics. And these are hugely
12	unreliable, invalid reams of data being
13	produced that we make national policy
14	decisions on. But it's basically trash.
15	I mean, if you look at what gets
16	into a death record, you're sitting there
17	seeing 30 patients and they bring you a stack
18	like this of records and plop in front of you
19	to say "Your partner's off today, will you
20	fill out this death certificate?" And you're
21	like flipping through this thing saying "Okay.
22	I'll call it diabetes." Well that's not a

Page 238 1 cause of death, but that's what gets in. 2 So, you know, I don't know if 3 anyone would even want to go there but it's frightening the types of decisions that are 4 5 made, or who calls in the birth record. It's a clerk who may have some education after high 6 7 school who is sitting there phoning in or 8 entering into the electronic birth record 9 system the information on the birth. 10 I mean, so I don't know if we want to turn those rocks over, but it is a really 11 12 frightening -- I mean if you actually look at the quality of the data, it's horrible. 13 14 DR. BURSTIN: And actually, one of 15 our child health/perinatal measure emerged out of California's effort to do just that, to 16 17 improve the vital stats data. So they worry 18 but to show the reliability of the data on the 19 work that they've done to try to put those 20 data into a better database. So, you know 21 there are options to do that when there are 22 good data available that could be made better

	Page 239
1	that could be brought to bear for that.
2	MS. MAINO-FIKE: Well, I see that
3	as another piece of NQF's value equation. If
4	NQF and this group is in a position to
5	standard measures around, you know things like
6	that, it could be another piece of the value
7	equation.
8	I know you've been trying to say
9	something, Ron. Sorry.
10	MEMBER BIALEK: I always try to
11	say something.
12	A comment that Kurt made earlier
13	and something that Matt has said, as well as
14	Paul made me think about another potential
15	stakeholder/customer/funder group which would
16	be the conversion foundations. And that
17	they're struggling with how to invest the
18	dollars that they have to invest in
19	communities to make a difference in terms of
20	health. And they go back to traditional
21	measures, but they really I think some of
22	them, a lot of them, would like to get a

	Page 240
1	little beyond the traditional but they really
2	don't know how to do that. They don't really
3	have the metrics. And maybe conversion
4	foundations, some of the larger ones or some
5	of them coming together, might be willing to
6	invest in some efforts that really would look
7	at this intersection, develop some measures
8	that they could use for their funding
9	decisions and for their monitoring.
10	MS. MAINO-FIKE: Right. Good
11	potential partner source.
12	MEMBER STOTO: And they've got an
13	organization, the National Network of Public
14	Health Institutes. Isn't that them?
15	MEMBER BIALEK: Not the conversion
16	foundations. A lot of those belong to grant
17	makers and health.
18	MEMBER STOTO: Okay. That's what
19	I thought that that group was.
20	MEMBER BIALEK: And NNPHI
21	Institutes.
22	MEMBER STOTO: Okay.

1	
	Page 241
1	MEMBER PESTRONK: Quasi-
2	governmental or nonprofit organizations that
3	states or locals create to get their business
4	done or to do work that a governmental entity
5	would have difficulty doing.
6	MS. MAINO-FIKE: Well let me ask
7	this: What you've got here is a nice list of
8	areas that need to be or could be looked at,
9	strategic objectives to improve the likelihood
10	and data of what you would be getting back
11	from any sort of measures or call.
12	MEMBER STOTO: Go ahead, Matt.
13	MS. MAINO-FIKE: Nothing like two
14	Ms.
15	MEMBER STIEFEL: Just one other
16	thought on the value on the value proposition
17	is this idea of leveraging requirements. That
18	historically, I think that's where NQF's value
19	propositions come from is that NCQA values the
20	NQF endorsement in its role to serve as a
21	measure developer and creditor and all the
22	rest. And the same thing can apply here as

	Page 242
1	sort of that that's why the Community Needs
2	Health Assessment came is the health care
3	system is being told to do this.
4	Sarah mentioned the health care
5	organizations are driven by CMS requirements.
б	I mean, that's why we're doing health risk
7	assessments for seniors and that's why we do
8	the HEDIS measures and all, and the Medicare
9	STAR.
10	So, really I think sort of taking
11	advantage of leverage, leveraging
12	requirements.
13	MS. MAINO-FIKE: Thank you.
14	Adding those to the notes?
15	Yes, Michael?
16	MEMBER STIEFEL: I just want to
17	say that at the top of this thing it says
18	here, you know it says this is all assuming
19	that we're going to issue another call. And
20	it strikes me that after we do all these
21	things we may decide that issuing a call is
22	not the right way to proceed, but that there's

1	
	Page 243
1	really a different way of working with this
2	kind of community.
3	MS. MAINO-FIKE: Good point. Well
4	said.
5	You know for purposes of getting
б	this information we said let's assume that
7	we're going to issue another call. What would
8	we do differently? You know, lessons learned.
9	Knowing what we know, what would we do
10	differently?
11	So, the decision has not
12	necessarily been made to issue another call.
13	MEMBER STOTO: My point is that
14	after doing all this work which I think is the
15	right thing to do, we may decide that issuing
16	calls isn't the right way to identify measures
17	to endorse.
18	MS. MAINO-FIKE: Right.
19	MEMBER STOTO: That that way of
20	doing business may not be the right way in
21	this new space.
22	MS. MAINO-FIKE: Right. And so

	Page 244
1	perhaps another way to reframe this work is to
2	say a potential approach to entering I'm
3	just kind of talking off the top of my head
4	here to entering into the measures of the -
5	_
6	MEMBER STOTO: Yes. Presuming NQF
7	will eventually want to endorse population
8	health measures
9	MS. MAINO-FIKE: Okay.
10	MEMBER STOTO: what do we need
11	to do to get to that point.
12	DR. BURSTIN: I think we probably
13	just made too many assumptions that the pump
14	was quite primed, and it clearly was not. So
15	I think there's a lot of lessons learned for
16	us about being you know before we actually
17	did this again being very clear that there
18	would in fact be measures available. But
19	again, and it may not be totally ready yet,
20	but if you think about if we're doing
21	cardiovascular in 2013, which we will be in
22	the early part of the year, there's some great

	Page 245
1	opportunities to potentially bring in some
2	population level cardiovascular health metrics
3	to that project.
4	So, I guess I'd also like this
5	group to help us think through what would we
б	do in a project like that to ensure that some
7	of those really important measures come in at
8	the community level. I mean, we looked at the
9	AHRQ Prevention Community Indicators last
10	year, whatever it was, in the cardiovascular
11	project about hypertension, CAD, issues like
12	that about avoidable hospitalizations in
13	cardiovascular. But, you know maybe there are
14	some other ones. Like I know, you know Peter
15	Briss is looking for a population level blood
16	pressure screening measure for the Million
17	Hearts Campaign. It needs to be done, it
18	needs to be brought in soon. That's something
19	that, obviously, I think you know a
20	Cardiovascular Committee could probably handle
21	if we kind of get some smart folks like you
22	guys potentially at that table. And I'd like

	Page 246
1	to know what you think we'd need to do to make
2	sure that could happen in a project like that.
3	That HIV measures would have flown
4	through our infectious disease projects in two
5	weeks, I can tell you that. No problem. It
6	would have gone right through. There would
7	have been great like the level of analysis
8	at the community, this is perfect, this is
9	really informative. No one would have blinked.
10	So, just some thoughts.
11	MS. MAINO-FIKE: Sarah?
12	MEMBER SAMPSEL: So kind of in
13	response to that, but also you know this is
14	response to what Paul said earlier about, you
15	know kind of NCQA submitted the BMI measure,
16	you know the same old BMI measure.
17	I'm just wondering if, you know
18	when we started last fall we looked at the
19	standard NQF criteria and then adapted it, you
20	know tweaked it a little bit for population
21	health. And, you know I wonder if we did kind
22	of a little bit of a disservice to ourselves

	Page 247
1	by doing that where what we could do is just
2	so for this cardiovascular call, you know kind
3	of make it clear that we're not you know,
4	we're looking for measures that are
5	translatable at a larger population health
б	level and, you know there's a box they check.
7	This is for a specific subgroup or this could
8	be a population health level measure.
9	Something like that, they've got
10	people to think they could choose population
11	health? Okay.
12	DR. BURSTIN: Yes. Our current
13	submission forms clearly allows you to say
14	clinician, health and you know for all the
15	behavior health forms we just brought in on
16	schizophrenia, they all just said state. So
17	that's fine, which is why the Committee was
18	like sure these seem like great metrics to do.
19	I'm not sure if I'd feel comfortable with the
20	risk adjustment at my clinical level, but at
21	state Medicaid level those seem great.
22	So, again, you know that's already

	Page 248
1	an option.
2	MEMBER SAMPSEL: But I'm just
3	wondering if it's clear enough that people
4	understand how to translate that when they're
5	submitting?
6	MS. MAINO-FIKE: It could need
7	some re-emphasizing or clarity around it.
8	MEMBER PESTRONK: So that is the
9	second of the adapting the second of the
10	strategies for use in existing work groups
11	because what we've discovered through this
12	process is that the guidance and the
13	definitions were not helpful enough. They
14	were as good as we could make them at the
15	time, but they weren't good enough. And so if
16	you're going to go back into that blood
17	pressure group, you would want to give that
18	blood pressure group, both the working group
19	and then the customer the measure definers
20	or suggesters, you'd have to give them a whole
21	lot more orientation, right?
22	DR. BURSTIN: Three one-hour

	Page 249
1	telephone calls with them already, yes. There
2	were.
3	MEMBER PESTRONK: Yes.
4	MS. MAINO-FIKE: Okay. Oh. I'm
5	sorry, Kurt?
6	CO-CHAIR STANGE: So what did we
7	learn from your experience with the
8	Disparities Work Group? And what actions
9	proposed, possibly Helen is getting population
10	and disparities groups together. I think a
11	similar crosscutting strategy for the
12	disparities and for population health to just
13	make that part of all calls or
14	DR. BURSTIN: Yes, I mean, it's a
15	very interesting question. I mean much of the
16	work I think we'll do in disparities going
17	forward is in fact stratifying quality
18	measures as opposed to new de novo measures.
19	We brought in measures this time that are more
20	cultural competency, access to language
21	services; things like that. But I think at
22	some point you don't have as many of those

	Page 250
1	crosscutting disparity measures and you really
2	do focus on the stratification of quality
3	measures. So, we are happy to take those
4	measures in any project when they come in.
5	Similarly, resource use. You
б	know, I'd rather not necessarily do another
7	cost specific project, but it's easy to see
8	how you might bring in resource use specific
9	measures in a lot of these different areas
10	going forward.
11	CO-CHAIR STANGE: So that's kind
12	of taking the measure at the current level and
13	stratifying down?
14	DR. BURSTIN: Yes.
15	CO-CHAIR STANGE: Is the
16	population health taking the current measure
17	and stratifying up to a clinical population
18	level but then also thinking about a
19	geographic community level and a system level?
20	I mean, is that one way to would guidance
21	stratifying down and stratifying up be helpful
22	for the other efforts?

	Page 251
1	DR. BURSTIN: A rolling up and a
2	rolling down, yes.
3	MEMBER STIEFEL: Thinking about
4	the call for cardiovascular measures is an
5	extremely interesting potential opportunity.
6	Some of us participated in the NPP group that
7	developed these recommendations to CMS and we
8	came up with that three part frame of
9	interventions at the social, community,
10	economic level. Interventions at the
11	behavioral level. And interventions at the
12	clinical preventive services level. And by the
13	way, that framework was in our call for
14	measures, too. It seemed it was ignored.
15	But that would be really
16	fascinating to apply to the call for
17	cardiovascular measures to have those three
18	categories of the social, environmental,
19	behavioral and clinical preventive services.
20	It might be a great opportunity to further the
21	population health measures through the
22	cardiovascular measures channel.

	Page 252
1	CO-CHAIR JARRIS: So if we did
2	this right, every call for measures would
3	include those three levels? And the other
4	thing which we were unable to get it got
5	sort of rejected by the overall NPP, is we
6	wanted to create some of us wanted to
7	create a goodness and fairness measure so that
8	you have this is the 2001 concept from the
9	World Health Organization. Goodness is the
10	overall performance at that population level.
11	Fairness is the difference between the most
12	healthy and least healthy group on that
13	measure in a population. That was rejected as
14	too new of a concept.
15	We read different stuff, I guess.
16	But I think ideally that would go into every
17	measure to get at health equity. If you're
18	going to put out a cardiovascular measure, you
19	put in the goodness and fairness, okay?
20	What's the rate of MIs among the population
21	and what's the gap between I don't know if
22	it's Caucasian and African-American and the
Page 253 population, whatever the appropriate 1 2 populations are. 3 DR. BURSTIN: And we do require that measures that are for maintenance provide 4 5 back that stratified data. So the 6 Cardiovascular Committee reviewed every single 7 measure stratified by race and ethnicity when 8 the developers had access to it. So all of 9 those CMS core measures were produced, stratified first --10 11 MS. MAINO-FIKE: Excuse me once 12 again. In goodness, fairness, because I 13 14 want to make sure we capture this appropriately on those three different levels, 15 which was behavioral I believe was first and 16 clinical and what was the third? 17 18 MEMBER STIEFEL: Social and 19 environmental. 20 MS. MAINO-FIKE: Okay. But we 21 just want to make sure that that's another 22 area where can we -- it parlays into all other

Page 254 1 measures. 2 DR. BURSTIN: So just to answer Paul's question, so essentially the various 3 cardiovascular measures, aspirin use, beta 4 5 blockers, et cetera, for a measure that was up for maintenance the developers had to submit 6 7 the data showing, like what you looked at 8 yesterday, essentially NCQA stratified it for 9 you by Medicare, Medicaid commercial and you could see those differences laid out for the 10 11 NCQA measures yesterday. 12 CMS has data to be able to in fact 13 pull it out by race. So they were actually 14 able to give the Committee the differences by race and ethnicity, it's 80 percent for 15 16 whites, it's 70 percent for Hispanics and it was 50 percent for African-Americans. 17 And a 18 couple of times a couple of measures we 19 thought were otherwise topped out, in fact 20 when you dived deep there are some populations 21 who are still at risk. Right, absolutely. 22 Yes.

Page 255 MEMBER STIEFEL: It has all kinds 1 2 of interesting I think positive attributes. It makes the case much more clearly about the 3 relevance of the upstream determinants. 4 As 5 opposed to talking in general about population 6 health, we're talking about, you know, very 7 specifically cardiovascular disease. And it 8 may engage people in a different way, and 9 especially if you call for measures in those 10 three categories. CO-CHAIR JARRIS: 11 That's also why 12 we got to get away from -- okay, renal disease, you know, was whatever a specific 13 14 test done on patient's renal disease by this doctor as the measure and go to what is the 15 incident or prevalence of renal disease and 16 17 then break that out by racial and ethnic 18 groups to demonstrate the huge difference with 19 hypertension between African-American renal 20 disease and Caucasian American. But if all 21 you're doing is measuring the did you 22 prescribe a ACE inhibitor or whatever, you're

	Page 256
1	never going to get at that gap in the
2	population.
3	CO-CHAIR STANGE: Helen, what are
4	you doing with multi-morbidity?
5	DR. BURSTIN: It's a tough one.
6	We actually just put out a framework just in
7	the last few months, actually. We should
8	share it with SCRIP. I think they did a nice
9	job with it. Hopkins helped write a
10	background paper for us on how to approach
11	patients with multi-chronic conditions, and it
12	was a lot of getting at some of these big
13	picture issues and also just thinking
14	differently about the sort of single focus
15	diseases and how you might look at that
16	population more in terms of function and
17	health rather than disease by disease.
18	CO-CHAIR STANGE: So that's a ripe
19	population for it?
20	DR. BURSTIN: Yes.
21	CO-CHAIR JARRIS: It occurs to me,
22	it came up earlier is you know, the approach

	Page 257
1	the multi-chronic disease approach. The
2	simplest way to do that is to say multi-
3	chronic disease, that means you have multi-
4	chronic diseases so we'll treat this person as
5	three diseases. Well, does that actually
6	create wellness in a person if you treat their
7	three diseases?
8	And the same thing happens here.
9	If you look at a population, is it simply
10	treating the rates or quality of diseases in
11	that population or is the health of a
12	population something more than a collection of
13	diseases? And that's where we start to get
14	into that concept of well-being in the
15	population health group. But I think that
16	well-being is not diseases, and that's where
17	we miss on all of these.
18	MS. MAINO-FIKE: I'm going to do
19	CO-CHAIR STANGE: The multiple
20	chronic conditions is a fertile ground for
21	making that point. The reason we kind of
22	resisted it as a Committee I think this idea

	Page 258
1	of just doing it a disease a time is exactly
2	that concern, but that this is a way that you
3	could normalize the population health focus
4	with the disease focus. I mean, multiple
5	chronic conditions has an incredible amount of
6	legs right now. So that would be a way of
7	getting the broader whole person focus and
8	then population
9	CO-CHAIR JARRIS: And
10	unfortunately population health was considered
11	outside the scope of that work at HHS. It was
12	clinical. There was a paper put out, an
13	initiative by HHS on multiple chronic diseases
14	and we got very early copies and tried to work
15	with them, and they kept insisting, "No, I'm
16	sorry, population health and public health are
17	outside the scope of this. This is clinical."
18	And it was a huge missed opportunity.
19	MEMBER STOTO: I think that kind
20	of thinking that the population health is
21	clinical and it's separate is a big problem.
22	But, you know it's common and it runs all the

Page 259 way through these. 1 2 MS. MAINO-FIKE: Do we have that 3 up here as the whole notion of providing clarity on definitions that we're using? 4 Is 5 that up here somewhere? Because I think 6 that's another action item that would be 7 important in soliciting or making any calls 8 for measures. 9 MEMBER PESTRONK: In the framework 10 that I had it was part of number two. It was part refining guidance and definitions. 11 12 MS. MAINO-FIKE: Okay. Good. Good. You know, I'm going to do a time 13 check right now. As it stands, I think we've 14 done a good job of discussing what are some of 15 the things that need to change that we could 16 17 do better in sending out a call for measures? 18 Any call for measures, really. It's a fairly 19 broad list. 20 In terms of wrapping things up, 21 what might be useful we talked about is 22 looking at this list and putting together

	Page 260
1	perhaps some chronology of what might need to
2	be done. Some of these items may be able to
3	be done together. But what you want to do at
4	the end of the day is this group has the
5	funding for a couple of more months, if I'm
6	correct. Helen, I'm going to double check
7	with you. So how do you want to use your
8	time? How do you want to use that time? And
9	it may be you can take some action against
10	some of the things on this list.
11	DR. BURSTIN: Some of this is
12	just, you know in our current project. But I
13	think a lot of what we've talked about is what
14	would future initiatives be both specific in
15	this area as well as potentially thinking
16	about how to build this into another projects
17	going forward.
18	MS. MAINO-FIKE: Yes. Do you feel
19	-any thoughts on how you want to use your time
20	as a group over the next couple of months?
21	What are your thoughts there? I'm going to
22	kind of ask the Steering Committee for their

	Page 261
1	thoughts as well.
2	Okay. You're going to let Matt go
3	first?
4	MEMBER STIEFEL: One idea, maybe,
5	would be to review the compilation of measures
6	and maybe start with a subset of measures, but
7	you know to do the side-by-side kind of
8	evaluation not calling for measures, just
9	reviewing the existing set of measures to see
10	where the overlaps and discrepancies are.
11	That could be a very useful contribution.
12	CO-CHAIR JARRIS: I wonder as part
13	of that if some of the measures had potential
14	to be turned into population health measures,
15	whether any feedback could go to those measure
16	developers to say have you thought about this?
17	MS. JACOBSON: This is Dawn.
18	Can I make one comment in
19	reference to the background paper?
20	MS. MAINO-FIKE: Certainly.
21	CO-CHAIR JARRIS: Go ahead.
22	MS. JACOBSON: Okay. And this goes

	Page 262
1	back to the low-hanging fruit question, or
2	need to identify that.
3	We didn't get a chance to talk
4	about this a lot on our previous call, but in
5	December what I did is I took what I
6	considered the 26 kind of go-to indicator sets
7	from health care and public health and I did
8	go through and find the common low-hanging
9	measures. And those are in Tables 2 and 3,
10	sort of by domain and then overall.
11	And just by default, the Committee
12	comes up with a lot of them that are on there.
13	I know that you talk a lot about infant
14	mortality and prenatal care, you know, tobacco
15	obviously is on there and all of the
16	behaviors that are common on the table.
17	But in addition to those tables
18	which, you know that is a qualitative
19	assessment and it was sort of a research
20	approach, and we can talk more about the
21	methods if you want to going forward as to how
22	I got those lists. But then on page 35 as

i	
	Page 263
1	well, and I don't know if you have the whole
2	report there, we did a synthesis table were we
3	took the low-hanging fruit, the measures that
4	are very, very commonly measured from both
5	clinical care system and then sort of the
6	government indicator HealthyPeople type
7	reports and put them next to a column that
8	said who would then potentially lead
9	interventions or health improvement activities
10	for those measures.
11	And so examples are like
12	hospitalizations for cardiovascular disease,
13	timeliness of diagnosis and treatment for
14	cancer within the clinical care realm.
15	Exposure to secondhand smoke in the physical
16	environment, just more a public health sort
17	of, they take on interventions as leaders.
18	So I just want to say that some of
19	that work has been done, it might just be
20	revisiting and talking more about the methods
21	that led to the table to really be comfortable
22	with seeing that it's some of the low-hanging

	Page 264
1	fruit.
2	And then the other second comment
3	I would really like to make is we put a
4	recommendation in our paper to use existing
5	indicator sets. So a lot of what's being
6	discussed today was part of the Federal
7	Advisory Committee for HealthyPeople, was part
8	of what IOM discussions that lead to the
9	indicator reports. It was the same sort of
10	partners that come to the table and talk about
11	that.
12	So I just would like to put out
13	there is the leading health indicators, they
14	have valid data sets. You know it's been
15	thought through before. So rather than
16	recreating the wheel, I'm just wondering if
17	there's a way to keep what already exists that
18	have been put through a prioritization level?
19	MS. MAINO-FIKE: Matt, did you
20	have something you wanted to add to that?
21	MEMBER STIEFEL: I just think it's
22	a great idea. I think as a starting point, I

	Page 265
1	think there could be additional work to go to
2	the next level of review of reviewing the
3	measure specifications. This is still just a
4	kind of side-by-side, but the devil's in the
5	details with these. But it would be a great
6	place to start from, I agree.
7	MS. MAINO-FIKE: Okay.
8	CO-CHAIR JARRIS: So for
9	illustrative purposes it might be helpful to
10	take the three levels that came out of NPP and
11	take the given measures and put them at the
12	level they're at, which would clearly show us,
13	you know one of these that there's very few
14	at those higher levels, but just to point out.
15	And then to maybe take some of them and say
16	"Here would be the potential with this
17	cardiovascular measure to go to these next two
18	levels." That sounds like a great project for
19	a
20	MS. MAINO-FIKE: So let's write
21	that down as our next step for a person. I
22	think that's another option for a next step.

1	
	Page 266
1	I know we have until 2:30. What
2	I'd like to end with is take that time to come
3	up with ideas for what you think those next
4	steps could and should be. Again, another way
5	to say that is how this group might use the
6	rest of its time as a group and make some
7	suggestions. Assuming, you know, we don't
8	have to go until 2:30 if people don't if
9	we're all out of ideas. But we have up until
10	that point to decide how you want to use your
11	time for the next several months.
12	So what else do we have to add to
13	that list?
14	DR. BURSTIN: One suggestion might
15	be, it might be interesting for us to share a
16	couple of calls for measures that are going
17	out shortly in other areas, like infectious
18	diseases and see if there's a way to sort of
19	write that to make sure some of this flavor
20	comes through. And we template those. We add
21	the clinical stuff in, but they're fairly
22	templated. It might just be an opportunity

1	
	Page 267
1	for us to think about how to take the
2	influence of this group to spread it more
3	broadly.
4	MS. KHAN: That sounds like a good
5	idea. I would add that to another future
6	activity. Yes. So take the lessons learned
7	here on other calls that are going out.
8	Yes. Ron?
9	MEMBER BIALEK: I would like for
10	us to think a little bit more about how we can
11	integrate the consensus, HHS consensus
12	document or the Quality Aims for Public Health
13	into what it is that we're requesting measure
14	developers to be thinking about and reporting
15	on.
16	I don't have a real clear idea in
17	my mind, but I think those quality aims do
18	line up fairly well with the health care
19	quality aims and, you know is there some way
20	for us to think about their use in this
21	process?
22	MS. MAINO-FIKE: Okay. So another

Page 268 1 good next step, quality aims integrated with 2 requests for measures. CO-CHAIR JARRIS: 3 We share other calls for measures also. As I understand it 4 included perhaps development of template 5 6 language around population health to be 7 inserted into other measures, other quality 8 measures. 9 MS. MAINO-FIKE: Yes. Right. 10 Good point. All right. Thank you. What other ideas do you have for 11 how this Committee could use its time over the 12 next couple of months? 13 14 CO-CHAIR JARRIS: I would like to 15 hear from the Health Disparities Work Group 16 and compare notes with them. Because they must be having similar issues. 17 18 MS. MAINO-FIKE: Okay. 19 CO-CHAIR JARRIS: Most of what 20 effects health as far as outside of the four 21 walls, it's not just a matter of street to 22 cath time for different populations.

	Page 269
1	MS. MAINO-FIKE: Right. So hear
2	from the Health Disparities Work Group? Good.
3	What their challenges are, how they're
4	approaching them? Okay.
5	What else might you want to do
6	with your time?
7	CO-CHAIR STANGE: Is there a
8	similar opportunity with the multiple chronic
9	conditions group?
10	DR. BURSTIN: It's done.
11	CO-CHAIR STANGE: Okay.
12	MS. MAINO-FIKE: So with the
13	multiple chronic conditions group, what do you
14	think, Helen?
15	DR. BURSTIN: The Committee's
16	done. They've finished their work, the final
17	product is done. We could share the work if
18	you want to talk to the Chairs or something,
19	I'm sure we'd be happy to get that pulled
20	together for you.
21	MS. MAINO-FIKE: Okay.
22	CO-CHAIR JARRIS: What about
	Neal R. Gross & Co., Inc.

	Page 270
1	others folks working in this area, like CMMI,
2	hearing from them, what they're struggling
3	with. And there may be other I mean NCQA
4	looking at this area? Is IHI looking in this
5	area? Anybody else looking at population
6	health and where are they stuck?
7	MEMBER PESTRONK: AHRQ is looking
8	at it through their own lens. NIH is looking
9	at it, you know, through their own lens.
10	DR. BURSTIN: NIH has done a very
11	nice convening activity this last year on
12	healthy behaviors that should be put into
13	primary care practices routinely. That work
14	was really nicely done.
15	MS. MAINO-FIKE: So the action
16	item there would be
17	CO-CHAIR JARRIS: You know, as I
18	understand it, and I understand very little
19	about NQF's structure, but the NPP assists
20	with the partnership division of NQF. So maybe
21	that would be a forum to maybe convene, if we
22	get funding for them to convene these

Page 271 1 different stakeholders for a day and spend a 2 day of that group on population health We could report out and these other 3 measures. 4 groups report out. And then there are a lot 5 of mostly health care people there, but a lot of different organizations that could discuss 6 7 this. 8 MS. MAINO-FIKE: Right. Convene 9 those two groups and maybe have some 10 information sharing, you know report outs might be something that you could do. 11 Yes. 12 CO-CHAIR JARRIS: Report back to the NPP since the first work in NOF I think 13 14 was done there about, okay, here's what we ran into so you can be aware of what's going on in 15 16 this area. And if that process is doing 17 something. 18 DR. BURSTIN: And we all work very 19 collaboratively, something we could do with 20 NPP with Carrie and Wendy. 21 MS. MAINO-FIKE: Well, I see this 22 as something you could call -- you probably do

	Page 272
1	this with all of your working groups, but you
2	know a lessons learned after you've completed
3	your task, that then you share with other work
4	groups regardless of what their topic was
5	because there may be a lot of overlap. So
6	maybe it's formalizing a lessons learned
7	session.
8	CO-CHAIR JARRIS: I also wonder if
9	we have different mechanism then the work
10	group or the Committee here. And one of the
11	ideas from the morning was doing this
12	environmental scan. We've already done a
13	little bit of an internal scan. But not just
14	to do that to get something you can put in a
15	white paper and plot in front of a group, but
16	doing that as an interactive field
17	relationship building process. And if that's
18	something you'd have to configure more sexily
19	and non-fractally, but that's something you
20	could actually get funding to do.
21	I mean, how do you make population
22	health measurement a part of what NQF does on

Page 273 1 multiple levels? How do you bring together 2 these strange bedfellows that actually have some common needs that they don't have a forum 3 for talking with? If you just thought about 4 5 a roving bee going out gathering information, 6 but that's asking the right questions and 7 saying you should talk to this group. And 8 then something would emerge from that. 9 Shouldn't we ask Dawn if she did 10 that? Dawn, if you're still there, did 11 12 you do a project -- because some of your 13 question, I thought it was RAND on reaching 14 out to different stakeholders about population health measures to try to describe what was 15 16 out there? Are you aware of that or was that 17 you that did that? 18 MS. JACOBSON: No. That was not 19 me. 20 CO-CHAIR JARRIS: Thanks. 21 MS. JACOBSON: And I think Nicki 22 Lurie did that before she left.

	Page 274
1	MS. MAINO-FIKE: Yes. So there's
2	that opportunity to put together an
3	environmental scan and gather those folks
4	together.
5	Anything else that you can think
6	of you want to put down as options for how you
7	use the rest of your time together?
8	I feel like Carol Burnett "I'm so
9	glad we had this time together."
10	How do you want to use the rest of
11	it, not that this isn't a good list already?
12	CO-CHAIR JARRIS: But what do we
13	do with this list?
14	MS. MAINO-FIKE: Well, I think the
15	point of creating it is to give the Steering
16	Committee and the Board an opportunity to
17	decide okay, you know let's prioritize, let's
18	see what we have the funding for.
19	DR. BURSTIN: It's been a really
20	rich discussion. I personally have taken
21	what did I take? Twenty what is it 22
22	pages of notes. So, I sort of feel like it's

1	
	Page 275
1	something we need to process, go through all
2	this, see if we can coordinate it a bit. I
3	tend to think while I type. So if I type it,
4	I learn it and think about it.
5	So, you know I think we need to
6	process it, think it, bring back some options
7	to you, talk with HHS, see what options are
8	moving forward.
9	You know, I think there were some
10	great suggestions today of things that I think
11	I'd like to move on, at least. But I think
12	there are some really potential things that I
13	think no one would argue are logically things
14	where NQF could add value.
15	MEMBER STIEFEL: What's the timing
16	for the call for cardiovascular measures?
17	DR. BURSTIN: I don't even know
18	yet. 2013, so it's months and months. It's a
19	fair amount away. Infectious Disease was just
20	put forward. GI/GU is going out shortly. So,
21	you know most of the other clinical projects
22	will start in the fall.

	Page 276
1	MEMBER STIEFEL: Because I don't
2	know if it's listed up there, but one of the
3	things we could do is to kind of create the
4	language for the population health view of all
5	the upcoming calls for measures.
6	DR. BURSTIN: That's what I was
7	suggesting.
8	MS. MAINO-FIKE: Okay. Good.
9	So what you have done today is, as
10	Helen you said, have a very rich discussion
11	regarding what are some of the reasons that
12	the response was lower than you would like for
13	the call for measures. But more broadly, what
14	are some future steps, actions that could be
15	taken to further this discussion around
16	standards and measures in the population or
17	public sector and what might NQF's role be and
18	should and could be in that.
19	You also took a look at what
20	was three? What some of the measures should
21	be, there was some further discussion around
22	that and what the parameters are.

	Page 277
1	And after, it was almost like you
2	needed to have that thorough discussion
3	yesterday and today and get all the ideas and
4	perspectives out, which I think enabled you
5	then to have more of a concrete conversation,
6	that fishbone exercise around what are some
7	we ended up with four or five. I guess we
8	ended up with four specific strategies to not
9	just improve what we would do differently for
10	any future measures call, but for any call for
11	measures that NQF would put together.
12	And against those five strategic
13	areas, we delved into a little more detail
14	against kind of that environmental scan of who
15	is in the environment that we might want to
16	consider as partners.
17	You've also delved into a little
18	more detail around NQF value propositions and
19	how to phrase that for your current
20	constituents as well as some new constituents
21	that you're looking at taking on.
22	And then finally you came up with

	Page 278
1	a list of potential next steps or action steps
2	that this group could take in the time that it
3	has left together.
4	So, I think that's a pretty good
5	job. I applaud all of you. Next steps, as
6	Helen said, was to kind of digest all of that
7	information and decide where you want to go
8	with it, particularly those potential next
9	steps for this group.
10	One thing you will be receiving is
11	a list of this, future activities as well as
12	the five key strategic areas. You'll receive
13	a copy of that.
14	I think you'll receive a copy of
15	the minutes or the notes as well, is that
16	right? Okay. All right.
17	With that, I am going to ask Elisa
18	where you want to go with the program as far
19	as the agenda for the rest of the day. We've
20	worked pretty hard so far.
21	MS. MUNTHALI: We have. And I know
22	we have a hard stop at 3:00 because folks are

Page 279 trying to get out and take flights. 1 2 So the next agenda item that we have was to revisit the recommendations from 3 the Commission Paper. And will put Amir on the 4 5 spot, because he is the Committee member. Ι did warn you, though, that I was going to put 6 7 you on the spot. And he was the Committee 8 member that suggested that we place this on 9 the agenda. And if you don't have a pressing need to revisit --10 11 MEMBER OASEEM: These 12 recommendations, some of them were very good. But I felt like, I think, maybe this is an 13 14 opportunity for NQF to adopt some of them if you feel like some of them are important. 15 Especially I think Kurt was talking about this 16 as well. And I mentioned it a little bit at 17 18 how we're measuring this population health and 19 total population health. And I haven't looked 20 at these recommendations for a while, but 21 there was a recommendation in there about 22 systems or as well as how to look at the total

Page 280
population health. I wish I had I don't
know which one I'm talking about. But
essentially conceptually I do think that we
should look at these.
There are some recommendations
that may actually be missing from this, which
I think would have been part of it. And I
don't know how the group feels about them.
And then of course, if we do
decide to adopt some of these recommendations,
may ned to be rephrased because they're not
really I don't know how to even interpret
some of them. So that's essentially what my
point was.
And I will quickly look at it,
there was a specific point I was okay.
Number 2 and number 3. So that was the ones.
Since the determinants of health
are conceptually envisioned at the total
population level, it is recommended that in a
measurement framework we find that when
determinants of health at the total population

	Page 281
1	as well. The current categorization of
2	clinical care, behavior, social environment,
3	physical environment should be used by
4	organizations interested in improving total
5	population health. And that was sort of a
6	concept that I was talking about this morning
7	as well that, you know the performance
8	measures are at a lot of different levels,
9	structured process blah, blah, blah. And I
10	think we really need to start looking at all
11	of them together rather than separate because
12	I still feel like that's what the folks out
13	there are doing. And just because you're
14	going to improve process is not going to lead
15	to the improvement of total population health.
16	That's it.
17	Sorry, guys. I have to leave. And
18	thank you so much to see you all.
19	DR. BURSTIN: It may be an
20	exercise that people would like, we could just
21	share those recommendations probably and ask
22	people to submit comments as to whether there

	Page 282
1	are ones that they think should be
2	specifically adopted as sort of more oomph
3	than just being in a Commission Paper.
4	MEMBER QASEEM: Because my fear is
5	that this paper is otherwise going to get lost
б	because it's just you know it's an NQF
7	Commission Paper, but if NQF adopts some of
8	the recommendations, it's going to carry much
9	more weight than just
10	DR. BURSTIN: And we will be
11	putting out a phase 2 report, of course, with
12	the measures that you have reviewed this
13	round. So we will have the opportunity to
14	include anything you'd like in there about the
15	process, what we've learned. I mean, I think
16	it would be nice to actually share some of the
17	discussion from today potentially as well, and
18	then you think if there are some of these that
19	you would like to include there as well, we
20	can put that out for comment.
21	MEMBER BIALEK: Helen, do
22	Committees ever submit recommendations to the
	Neel P. Cross & Co. Inc.

	Page 283
1	Board requesting that the Board adopt them?
2	DR. BURSTIN: Yes. So frequently
3	Steering Committees will make a series of
4	recommendations about a given topical area of
5	what should happen moving forward. And those
6	will move forward and CSAC usually discusses
7	them first. And then if it's something that
8	has policy implications, it will go the Board.
9	MEMBER PESTRONK: Is the
10	Commission Paper a public document? Is it
11	available to be distributed broadly, you know,
12	to our own constituencies and to others?
13	DR. BURSTIN: I'm going to defer
14	to Elisa on that one.
15	MS. MUNTHALI: Sorry.
16	DR. BURSTIN: That's okay. What's
17	the status of the public availability of the
18	final Commission Paper?
19	MS. MUNTHALI: Actually, it's
20	done. We should be posting it Monday
21	probably. So we have the final product.
22	MEMBER PESTRONK: Could you email

Page 284 1 us all a copy? 2 MS. MUNTHALI: Yes, we will. We will email it to you. 3 MEMBER PESTRONK: And so then at 4 5 that point we're free to share it and 6 encourage people to read it? 7 MS. MUNTHALI: Yes. 8 MEMBER PESTRONK: Okay. 9 CO-CHAIR JARRIS: Anything else we should discuss? 10 MS. MUNTHALI: Just one thing. We 11 12 just want to give an opportunity to our 13 members and to the public to provide comment, 14 which we're sorry we didn't do before. Anika? 15 OPERATOR: At this time I'd like 16 17 to remind everyone in order to ask a question, 18 press star, then the number one on your 19 telephone key pad. 20 At this time there are no 21 questions. 22 MEMBER PESTRONK: So may I thank

	Page 285
1	the Co-Chairs. Talk about thankless work.
2	Done with fine spirit. Thank you very much.
3	Thank you to the staff as well.
4	MS. MUNTHALI: And just a few last
5	minute items before we leave.
6	Staff is going to follow-up with
7	developers, and that would be Legacy.
8	I just wanted to remind everyone
9	that the Steering Committee recommended four
10	measures for endorsement. So those will go
11	through the consensus development process.
12	And we will follow-up with Legacy,
13	work with Ron to make sure that we can get
14	some responses to the concerns that you have,
15	and we'll make sure that we get back to you
16	with that.
17	As Helen mentioned, we're going to
18	be drafting the technical report for phase 2.
19	And we hope to post that report for our member
20	and public comment on June 21st, and that will
21	be a 30 day comment period.
22	And before we do that we'll make

	Page 286					
1	sure that you see the report so that you have					
2	a few days to give us feedback.					
3	And then we hope to have a					
4	conference call to adjudicate the comments					
5	during the week of July 30th. We'll confirm					
6	that. We send our Survey Monkey with probably					
7	three tentative dates and ask you to select					
8	from that.					
9	And the report will include your					
10	recommendations and the discussion that you					
11	had yesterday and today, the evaluation					
12	ratings and the measures that you didn't					
13	recommend with the rationale, and the measure					
14	specifications for all of the measures.					
15	So, we just wanted to thank you as					
16	staff, and the Co-Chairs as well. This has					
17	been a great meeting for us and we really					
18	appreciate the time that you've taken to be					
19	with us. Thank you very much.					
20	CO-CHAIR JARRIS: And thank you,					
21	Elisa and Kristin and of course Helen for all					
22	the work that you put into this. I don't					

	Page 287
1	think we're always an easy group to handle,
2	but you got us here.
3	DR. BURSTIN: Thank you to
4	Lorraine.
5	(Whereupon, the above-entitled
6	matter went off the record at 2:31 p.m.)
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
l	Neal R Gross & Co . Inc

Page 288

A	56:21 59:16	adding 224:8	affiliated 157:17	air 49:12 229:18
ability 90:15 96:11	181:12	242:14	Affordable 29:22	Alameda 90:19
109:7	ACOs 22:7 54:10	addition 70:16	73:2	alerts 12:20
able 5:2 9:6 24:4	acronyms 10:18	262:17	African-American	align 98:18 105:12
25:18 27:7,8 50:2	Act 29:22 73:2	additional 265:1	252:22 255:19	aligning 68:21
78:12 84:8 101:1	action 75:9 207:8	address 18:3 27:2	African-America	70:21
172:20 176:19	221:4 229:8,12	41:18 76:12 79:15	254:17	alignment 197:20
183:5 191:14	233:14 259:6	85:11 108:19,20	afternoon 131:18	allow 71:2 135:3
200:5 205:18	260:9 270:15	109:5,7 162:15	age 7:21,22 8:11	allows 236:9
232:17,17 254:12	278:1	219:7 235:1	222:1,3	247:13
254:14 260:2	actions 249:8	addressed 45:9,11	agencies 69:8,9	ally 151:10,12
above-entitled	276:14	119:11 228:12	81:14,14 84:13,16	altogether 113:2
123:18 187:7	active 141:17	addresses 113:9	85:1 88:12,22	AMA 180:5
287:5	actively 30:3	addressing 82:8	89:4 224:3 225:18	amazing 146:11
absenteeism	activities 11:7	89:18 112:20	231:14	American 26:21,22
182:16 232:1	43:12,15,17 45:9	219:17	agency 81:21 88:10	30:13 255:20
absolutely 56:7	79:14 80:11	adequate 120:6	98:19 99:4 100:7	America's 158:10
254:21	116:10,12,19	adequately 102:4	102:9 103:14,14	Amir 1:18 26:14
absorbs 29:3	188:9 197:1,15	adjudicate 286:4	103:19 177:18	63:11 177:16
abundance 204:8	263:9 278:11	adjustment 247:20	196:15	235:15 279:4
ACA 74:17	activity 6:20,22 7:1	Administration	agenda 26:6 127:10	amount 64:8,14
academic 152:15	22:11 31:11 45:21	97:20	278:19 279:2,9	65:6 69:6 84:21
156:8 157:3 167:1	82:3 88:19 90:21	administrative	aggregations 89:8	124:6 258:5
169:8 189:18	110:7 117:1	88:6 89:3	ago 15:15 82:12	275:19
academics 155:17	142:13 192:8	Administrator	121:6 169:3	analogous 55:7
AcademyHealth	200:11 267:6	98:17 99:2	185:22	analysis 11:4 94:4
166:14	270:11	admissions 57:14	agree 16:16 31:21	129:4 130:22
acceptable 120:11	actual 31:11 98:18	adopt 279:14	64:7 70:15 118:21	131:11 146:12,15
accepted 96:11	101:5 103:18	280:10 283:1	122:16 144:13	146:19 147:7
access 111:12	104:18	adopted 80:6 90:1	154:18 159:17	150:20 151:17
112:5,5 184:13	actualization 80:14	185:4 216:22	206:4,9,19,20	152:9,13 161:18
249:20 253:8	adapt 177:9	282:2	208:7 212:16	162:2 164:21,22
accomplished	adapted 180:21	adoption 10:6	234:18 265:6	175:22 189:15
123:22 161:1	246:19	adopts 282:7	agreed 74:7 121:22	192:8 246:7
accountability 22:8	adapting 181:15	ads 112:3,3	agreement 59:10	Analyst 1:22
31:13 54:10 59:21	248:9	adult 7:19 8:16	188:22 201:10	analytic 131:4
accountable 22:5,6	add 32:14 51:16	adults 6:21 7:15	agrees 122:4	and/or 176:11
136:10 181:4	119:10 144:18	advance 38:16	Agriculture 89:1	Angeles 10:21
accountant 30:19	155:18 156:11	90:15 107:10	ahead 40:14 83:20	90:20
accounts 183:5	166:13 202:9	203:13	168:12 188:7	angst 56:3
accredit 179:8	204:1 222:12	advantage 37:1	241:12 261:21	Anika 284:15
accreditation 32:15	227:16 230:9	105:6 235:4	AHRQ 152:21	announced 71:13
53:20 54:20 90:2	264:20 266:12,20	242:11	245:9 270:7	announcement
136:10 177:20	267:5 275:14	advice 23:7	Aim 110:7 113:17	48:18
182:7 218:2	added 28:8 65:22	advising 7:1	113:19 136:14	annual 106:14
ACE 255:22	134:16 151:1	Advisory 264:7	aims 267:12,17,19	219:14 236:12
ACO 22:11 39:3	addendum 118:8	Affairs 113:20	268:1	answer 22:13 26:17
L				
٦

65:21 179:14	appropriately 17.7	89:3,5	aggistance 174.6	A70 169.0
227:15 254:2	appropriately 17:7 127:7 188:15	,	assistance 174:6 192:1	AZQ 168:9 A-F-T-E-R-N-O
		arranging 33:21		
antenna 92:22	195:14 253:15	89:7	Assistant 2:13 18:8	188:1
anti-smoking 112:4	approval 11:19	arrival 7:12	assists 270:19	a.m 1:12 4:2
anybody 16:10,15	69:13 230:4	articulate 137:11	associated 122:22	123:19
27:6,7 28:15 77:9	approve 53:8	articulating 19:9	association 30:13	B
122:13 175:13	approved 48:14	176:22	30:14 123:9 153:6	B 86:16 192:8
176:3 179:6 181:3	105:10,22	aside 152:3 168:17	210:12	221:6
232:3 270:5	approximations	asked 54:22 68:9	assume 196:19	
anymore 71:17	116:3	81:7 95:10 98:6	243:6	back 5:13 6:1 27:7
anyway 148:2	April 11:21	125:16 147:21	assumed 185:1	27:8 28:16 29:6
176:20 203:9	arduous 67:17	184:11 198:20	assuming 126:14	39:1 44:1 48:2,8
APHA 144:22	area 40:18,19,20	201:5	127:12 242:18	49:17 56:16 57:1
150:22	40:21 64:4 66:9	asking 23:3 25:4	266:7	59:13 62:10 63:16
apologize 75:22	71:19,20 76:11	70:7 113:7 140:8	assumption 51:7	77:15,16 106:1,10
95:8 97:15 127:16	79:10 110:5	140:9 185:10	126:19	108:5 112:18
apologizes 97:22	118:13 124:12	273:6	assumptions	113:3 114:18
apparent 66:16	129:16 140:17	ASPE 164:10	244:13	123:16 140:3
apparently 196:6	141:13 146:5	aspirational 84:17	asthma 208:11	143:9 149:18
appeal 16:2,10	165:9 174:9 200:4	84:20 85:9,17	attempt 33:5	163:10 165:5
147:10	205:9,9,12 210:20	aspirin 254:4	attend 8:19 9:6	181:17,20 194:7
appealed 16:14	214:9 218:1,21	assemble 130:1	attention 20:21	205:18 208:1
appeals 16:1,6,8	253:22 260:15	assess 121:8 131:13	38:2 55:5	220:8,18,19
applaud 278:5	270:1,4,5 271:16	178:11,11 205:11	attractive 237:4	235:11 239:20
applicable 5:16	283:4	207:6 229:21	attracts 186:15	241:10 248:16
Applications 196:5	areas 10:1 12:16	assessed 114:22	attributable 86:19	253:5 262:1
applied 62:4,5	45:11 68:14	232:13	attributes 255:2	271:12 275:6
65:13	106:15 127:1	assessing 43:20	audience 180:9	285:15
applies 122:18	175:2,17 176:2	123:2	231:6,12	background 9:14
apply 120:9 225:19	189:3 191:6	assessment 7:19	authority 109:6	25:6 43:6 46:3
241:22 251:16	205:11 207:11	31:9 55:4 67:5	authors 11:2	49:5 79:8 87:9
applying 61:10	214:2 220:11	116:21 123:4	availability 212:4	149:3 256:10
appreciate 215:14	241:8 250:9	139:3 190:19	283:17	261:19
286:18	266:17 277:13	204:20 211:18	available 131:22	bane 16:13
appreciated 51:15	278:12	212:8,12,14 214:7	138:8 159:2	bar 15:13
144:16	arena 24:22 63:4	219:1,16 225:11	162:15 175:7	Barb 107:17
approach 53:5 70:7	82:18 168:11	225:15 231:5	180:13 238:22	Barbara 107:19
85:8 158:3 176:13	191:15 211:21	233:5,9,19 234:8	244:18 283:11	barely 28:14
178:18 212:11	argue 151:13	234:10 236:12	average 178:13	barrier 23:15,18
244:2 256:10,22	275:13	242:2 262:19	avoidable 57:14	barriers 19:5
257:1 262:20	argues 163:10	assessments 29:21	245:12	base 49:21 121:18
approaches 27:13	arises 103:2	30:9 32:17 123:1	aware 46:7 106:21	122:22 150:21
169:15	arm 18:22	170:5 212:21	131:17 167:14	191:13
approaching 269:4	arranged 12:8,9	217:22 218:5,11	271:15 273:16	based 23:8 40:9,10
appropriate 25:9	arrangement 89:9	219:3 233:13	awareness 174:20	62:1 86:8 92:9
41:12 106:5 117:4	93:13	242:7	191:11 192:18	114:8 140:9
145:11 253:1	arrangements 88:7	assigned 198:16	194:6 195:6 200:3	161:13 169:16
	-			
	1		1	1

180:12	75:15,16 136:9	135:16 142:17,20	boundary 58:7	208:15 237:17
baseline 232:12	206:15 225:5	146:16 168:20	box 142:14 169:22	245:1 250:8 273:1
basic 80:11	best 49:14 104:11	171:22 205:15	247:6	275:6
basically 84:16	138:22 175:5,6	227:14 246:20,22	brain 221:1	bringing 57:5
87:14 130:11	213:21	267:10 272:13	brainer 208:5	75:14 124:16
139:20 140:19	bet 91:15	275:2 279:17	brainier 60:7	126:11 157:16
182:10 232:6	beta 254:4	bite 234:13	brainstorm 57:7	165:17 176:14
237:14	better 24:9 28:21	blah 281:9,9,9	127:4 152:5 154:6	201:17 204:22
basis 106:14	59:6 64:11 85:22	blanket 25:9	156:15	233:6 234:13
153:20 216:13	97:9 101:15	blasts 12:20	brainstorming	brings 81:16 230:2
219:14	105:12 113:7	bleeding 131:19	159:18 161:21	Briss 2:10 17:18,20
Bay 79:10	116:8 150:9 169:4	blind 121:9 195:21	167:3,10	18:12,13 34:9
bear 239:1	179:6 185:8	blink 77:9,10	branched 92:9	61:1,2 63:19,20
bedfellows 273:2	238:20,22 259:17	blinked 246:9	brand 64:22	63:22 64:1 68:15
bee 273:5	beyond 15:20	blockers 254:5	174:20 191:10	70:15 71:22 77:18
beginning 19:3	34:22 90:12	blood 44:11 245:15	192:18 193:7,15	77:21 245:15
25:14 166:17	110:14 117:8	248:16,18	193:22 195:6	broad 45:20 124:3
236:16	191:15 213:2	BMI 6:10,11,13 7:5	200:3	125:5 156:18
begs 36:15	240:1	7:15,19,21 8:10	branding 51:3,4	157:22 160:22
begun 73:18	BIALEK 1:15 15:4	13:11 16:3 43:20	75:11 76:1,9	162:17 166:22
behalf 64:17	15:11 46:18 108:4	44:10,11 52:2	193:5 207:15	169:13 226:9
behave 25:11	132:5,9,19 133:1	123:3,4,6,7	branding/market	259:19
behavior 116:5	133:5 134:10,14	178:11,11,13	75:2	broaden 180:14
149:2 247:15	156:6 160:15,20	180:2 246:15,16	break 120:13	205:14
281:2	169:10 171:12,17	board 11:20 58:20	123:13,15 128:22	broader 21:14
behavioral 80:13	172:2 181:3	58:22 59:3,6	129:18 144:20	44:19 63:13 75:16
88:17 119:21	205:21 206:6,11	76:11,17 77:11,22	152:3 186:21	102:2 125:11
251:11,19 253:16	230:11 239:10	78:5,7,13 83:5	188:6 191:17	132:6 180:6
behaviors 10:7	240:15,20 267:9	96:12 137:13	222:4 255:17	190:16 191:13
44:6 58:11 70:8	282:21	195:11,13 206:4,8	breaking 97:14	197:19 258:7
80:13 114:18	big 33:8 38:7 82:2	206:18 208:16	169:2	broadly 122:18
115:18 116:8	165:16 227:5,6	231:13 274:16	breaks 87:14	267:3 276:13
117:9,21 118:22	232:5 256:12	283:1,1,8	BRFSS 68:9 158:14	283:11
129:3,6 153:8	258:21	Bobby 30:12 40:14	222:1	broke 216:17
165:17 234:12,22	bigger 23:18 35:7	44:18 94:12 95:15	bridge 209:9,14	221:10
262:16 270:12	38:19	108:17	bridges 204:16	broker 89:3
believe 20:1 253:16	biggest 19:5 55:18	Bobby's 32:19	briefing 14:13	Brother 227:7
belong 240:16	63:5	bone 130:9	briefly 105:7	brought 47:20
benchmarks	biking 81:22	bones 175:19 188:8	bright 112:22	48:16 51:3 89:13
224:21	biomedical 119:14	Bonnie's 198:10	200:15	179:15 198:13
beneficial 54:21	119:18	Boothe 92:14	bring 30:15 37:14	233:10 239:1
benefit 28:9 35:11	birth 7:11 90:13	booths 51:11	39:1 44:1 49:15	245:18 247:15
48:12 55:1 56:9	238:5,8,9	born 7:13	55:13 63:7 106:9	249:19
114:20 118:1	bit 4:9 18:9 38:19	Boston 83:11	126:5 141:7	bucks 203:15
201:3 207:1 230:9	48:10 70:17 75:19	bottom 85:13	144:12 145:10	build 133:22
benefits 48:20 50:4	92:10 111:7	boundaries 77:6	176:11 179:15	140:12 143:11
69:16 70:4 74:22	118:17 128:22	210:21 211:1	191:1 197:18	145:5 165:3 234:6
	•	-	-	

	_	_		
260:16	202:3 210:4	148:19 153:10	118:2,20 121:16	156:15 167:1
building 67:1 142:4	231:15,22 241:3	calling 261:8	122:11 124:17	180:7 251:18
165:15 210:13	243:20	calls 12:21 13:4,18	129:7 133:14	255:10
272:17	businesses 185:7	46:13 141:6 238:5	136:1,10 137:6	categorization
built 58:3 67:5	busloads 204:12	243:16 249:1,13	138:8,19 147:11	159:8,22 281:1
bunch 43:2	busy 21:2 118:14	259:7 266:16	148:13,20 149:5	categorize 72:21
burden 132:12,21		267:7 268:4 276:5	171:22 181:4	189:17
134:3,4 135:7	C	Campaign 245:17	182:17 184:12	category 57:12
174:10 190:8	C 86:16 202:15,17	cancer 263:14	187:4 190:18,22	66:21 72:21 74:2
192:16 230:21	CAD 245:11	capacity 73:18	195:18 208:2	111:12 124:22
bureau 100:21	CAHPS 29:14	217:11	212:6 217:2	125:5,12,15,19,19
101:3,4	California 2:18	Captain 97:21	224:14,18,19	125:20 145:4
bureaus 99:3	34:11 79:18 80:3	capture 35:13 37:7	225:4,9 226:11	154:10 155:11
100:17 101:10	81:1,9 82:15	40:12 46:15 75:7	231:6 232:14,18	156:2,12 162:17
Burnett 274:8	83:18 84:14 88:10	184:18 188:7	234:18 242:2,4	169:11 214:1
BURSTIN 1:22	88:15,20 228:4	191:16 194:9,20	262:7,14 263:5,14	215:16,20
14:22 15:9,12	California's 238:16	220:1 253:14	267:18 270:13	cath 268:22
16:7 17:20 24:10	call 3:3,5 5:5 9:13	captured 37:11	271:5 281:2	Catholic 30:14
29:11 55:7 59:7	9:15,20 10:1,9,19	125:3,14 137:8	carefully 66:22	210:12
69:21 72:20 75:10	11:9,13,14,20	captures 188:14	Carol 274:8	Caucasian 252:22
75:18 76:3 77:3	12:1,4,4,6,17 13:2	201:11	Carrie 271:20	255:20
105:7 107:11,22	13:8 19:19 32:15	capturing 131:7	carry 282:8	causal 43:19 123:2
109:21 121:4	34:5 45:3,8,13,19	card 50:13 113:13	cart 78:8	123:6
142:3 151:19	46:14 48:9 61:5	cardiovascular	carve 176:19	cause 16:12 109:9
165:12 176:5,17	85:20 112:11	244:21 245:2,10	cascading 197:10	238:1
177:10,22 178:21	117:21 124:4,8	245:13,20 247:2	case 65:20 66:4,6	caused 99:10
196:22 198:12	126:15,20 127:13	251:4,17,22	66:11 67:20 69:19	211:17
199:3,13,16,21	128:5,21 129:13	252:18 253:6	74:20 75:13 76:6	causes 34:4 108:21
207:13 214:13	130:6 134:18	254:4 255:7	78:5,10,10,12	causing 30:1
222:16,21 223:7	136:18 146:19	263:12 265:17	118:1 149:8	CDC 2:10 6:16
228:20 236:5	147:4 148:17	275:16	200:13 210:5	7:11,13 8:3,17
238:14 244:12	149:9 156:12	care 7:5 24:19 25:3	211:19 223:19	30:6 34:10 60:21
247:12 248:22	162:10 163:18	25:10 26:18 27:7	235:9,13 236:22	64:1,3,6,17 66:15
249:14 250:14	164:20 165:1	27:11,17,18 28:3	255:3	68:4,9 77:22
251:1 253:3 254:2	168:8 180:17	28:8,20,21 29:22	cases 82:21 88:3	92:14,15,16,17
256:5,20 260:11	188:10,11 189:7	39:12 40:4 54:13	214:14	109:22 149:21
266:14 269:10,15	198:20 199:1,7	54:14 56:1,16,20	casting 63:12	152:20 154:19,20
270:10 271:18	209:12 226:13,19 226:20 237:22	57:22 58:4,8,13	casual 44:9 86:16	156:3 159:4 164:9
274:19 275:17	241:11 242:19,21	59:8,13,22 60:9	catchment 40:18	166:4 169:9
276:6 281:19	243:7,12 247:2	64:12,22 66:12	40:19,20,21	cells 196:16
282:10 283:2,13	251:4,13,16 252:2	70:6 71:2,5 73:2	categories 40:11	center 18:11,22
283:16 287:3	255:9 259:17,18	77:13 78:4 80:17	41:19 45:4,20	20:15 21:19 26:4
business 17:5 54:15	262:4 271:22	80:18 109:12,18	73:5,7 96:21	198:5
54:19 76:14,17	275:16 276:13	110:3,20 112:19	112:17 113:10	certain 53:19 73:5
90:4,9 93:6,16	277:10,10 286:4	114:13 115:4,6,11	124:20 126:2	86:10 87:19 141:2
99:11 155:2 182:7 184:15 193:13	called 91:18 133:12	115:13,20 116:13	127:1,3 132:6	177:16
104.13 193:13	Culleu /1.10 1 <i>33</i> .12	116:14 117:3	152:17 155:6,20	certainly 20:4 24:7
				I

34:17 38:6 69:16	children 7:21 8:11	207:22 244:14	19:1 270:1	113:2 118:15
120:15 127:6	231:19 232:17	247:13 255:3	CMMI's 64:21	120:10 126:22
150:22 166:4	choice 161:20	265:12	CMS 7:6 19:15	129:11 149:6
215:3 261:20	173:4 205:6,7,14	clerk 238:6	20:3 21:11,18	154:13 169:5
certificate 237:20	206:1 221:3	Cleveland 232:6	54:9,18 180:6	178:12 180:16
cessation 112:6	choices 206:18	climate 81:3,9	183:8,15 242:5	181:20 182:10
113:9	209:18	clinic 79:14 185:15	251:7 253:9	184:3 191:7 194:7
cetera 100:11	choked 209:13	clinical 6:11,13	254:12	206:2,16 216:3
208:3 254:5	cholesterol 44:11	13:10 19:6 38:5	coherent 68:22	220:20 229:17
chain 43:19 44:9	choose 74:10 75:3	51:19 52:4 53:5	cohesion 82:20	241:19 245:7
86:16	139:11 162:7	53:15 58:8 64:10	collaboration	250:4 264:10
Chair 166:16	221:3 247:10	65:5 66:12 67:8	163:7	266:2
Chairs 269:18	chronic 153:13,15	69:3 76:19 79:10	collaborative	comes 55:20 61:18
challenge 20:16	257:3,4,20 258:5	86:8,9,11 110:1,3	146:19 147:7	137:2 163:10
64:22 86:7 87:5	258:13 269:8,13	115:13,20 117:3,6	150:19 151:17	181:4,17 193:15
88:2 89:9 101:19	chronology 260:1	118:20 120:4	152:8,12 161:17	205:1 262:12
103:17 128:2	CIA 146:9	122:20 124:10	189:15 192:7	266:20
challenges 60:20	circle 70:19 207:12	128:18 129:7	collaboratively	comfort 31:8,10
85:14 88:5 269:3	220:18	144:11 147:11	271:19	comfortable 35:10
chance 28:16	circles 60:12 178:5	148:12,19 149:5	collaborators 94:5	194:13,14,15
139:14 262:3	207:20 211:1	150:3 165:18	collapse 234:8	195:3 207:9
CHANDLER 1:22	235:12,14	178:17 179:19	colleague 97:11	247:19 263:21
change 31:7,18	circulated 84:18	190:22 191:15	217:15	coming 13:2 19:9
33:9 58:6 81:3	cited 13:22 14:4,18	204:17 205:11	colleagues 36:11	20:17,20 25:17
99:10 104:11	city 7:16 83:3 228:4	208:20 209:8,10	79:6	27:1 101:8 160:17
142:22 182:4	claim 147:14	209:15 224:4,8,18	collect 117:14	206:21,22 219:22
208:19 217:5	clarify 21:17 48:9	224:19 225:4,9	120:22	220:19 240:5
229:19 259:16	203:20	230:5 234:17	collected 115:10	comment 3:8 75:10
changed 236:15	clarifying 36:7	235:3 237:10	232:19	77:19 78:1 108:5
changing 47:10	clarity 248:7 259:4	247:20 250:17	collecting 221:17	110:12 113:16
76:13,14,16,17,18	cleanly 69:19	251:12,19 253:17	226:14	114:6 118:6
230:13	clear 44:12 46:5	258:12,17,21	collection 73:14	160:14 170:8
channel 251:22	59:18,20 80:16	263:5,14 266:21	119:17 130:2	200:8 239:12
chaos 83:8,22	97:7,16 123:7	275:21 281:2	157:14 221:16	261:18 264:2
characterize 177:3	127:5 135:18	clinically 96:4	257:12	282:20 284:13
charge 149:5	159:17 160:16	clinician 247:14	collective 63:1	285:20,21
chart 35:11,14,15	162:4 177:14	clinicians 19:12	65:18	comments 5:20
charts 189:5	198:4,8 213:5	25:3 54:12 55:16	color 41:3	15:3 73:20 96:13
check 17:17 173:2	244:17 247:3	70:6 168:3	column 263:7	125:3,6,13 126:1
247:6 259:14	248:3 267:16	Clinics 79:9	combine 182:17	236:10 281:22
260:6	clearer 136:16	close 56:19	combined 26:21	286:4
checking 18:2	224:1	closed 180:17	combining 182:15	commercial 254:9
chicken 125:17,17	clearly 41:8 46:11	closely 199:17,20	come 18:6 28:4	Commission 3:6
205:2	59:11 109:18,19	closer 58:3,14	35:5 39:12 40:5	10:10,20 209:4
child 100:21	117:5 118:18	71:22 176:14	49:17 68:11 74:8	279:4 282:3,7
180:19 238:15	119:18 121:9	cluster 192:1	85:20 98:7 100:6	283:10,18
childhood 146:5	138:13 154:15	CMMI 18:4,10	105:16 106:1,21	commitment 76:22

99:14	31:9,10,14 32:17	compensation	13:15 37:15 81:3	148:14 204:18
commitments	32:22 37:22 39:17	182:18	81:4 285:14	224:2
98:11	51:6,8 52:8,15,22	competency 121:16	concrete 126:6	Consortium 79:9
committee 1:4,10	55:4 56:14,18	249:20	220:7 277:5	169:12,18
6:9,14 8:2,12,15	57:4,21 60:6	competing 14:5	conditions 61:15	constituencies
9:2,21 11:19,20	64:11,12,20 65:5	competition 145:15	61:19 62:17 80:8	283:12
12:2,8 16:20 17:4	67:5 70:11 71:6	competitive 94:3	80:11 256:11	constituency
26:16 37:19 49:10	76:5 78:7,13 79:9	146:12,15 148:2	257:20 258:5	190:16 191:13
49:13 65:19 84:19	82:16 84:21 85:3	164:21	269:9,13	233:3
84:19 92:21 93:22	99:22 105:5 108:9	competitors 94:5	conducted 11:22	constituents 277:20
97:4 101:20,22	109:17 119:7	147:1	conference 1:10	277:20
102:6 106:8 109:1	120:16,20,21	compilation 261:5	286:4	constitutes 120:11
122:4,8 131:17	121:2 136:9 141:5	compile 130:17	confidentiality	construct 43:12
161:15 245:20	141:18 142:1	131:10	89:4,13	193:10
247:17 253:6	143:11 146:7,17	complete 14:3	configure 272:18	Consultant 1:24
254:14 257:22	163:15 164:4,18	completed 100:10	confirm 286:5	contact 107:3
260:22 262:11	165:7,19,19,20	133:16 190:2	conflict 235:21	contacting 48:19
264:7 268:12	169:12,13,18	272:2	confusing 56:12	contacts 107:9
272:10 274:16	170:10 171:3	completely 64:6	confusion 19:21	content 198:13
279:5,7 285:9	184:10,13,20	122:4 182:16	96:7,9 97:2	context 27:20 66:1
Committees 17:3	185:16,20,21	198:8	connected 197:2	198:19
282:22 283:3	185:10,20,21	completeness 13:16	connection 43:6	continue 22:15
Committee's	191:21 192:10,11	complex 193:9	59:13 84:2 143:9	45:6 151:20
269:15	191:21 192:10,11	compliance 30:19	connections 81:7	continues 29:13
common 5:3 19:9	204:17 210:13	component 164:12	127:5	continuing 22:13
44:2 68:13 71:15	211:17 212:8,12	components 119:19	consensus 11:18	continuous 83:16
72:18 74:17	212:21,22 214:6	140:15 155:1	12:14 19:10	94:20
258:22 262:8,16	217:21 218:5,5,20	composed 84:15	267:11,11 285:11	continuum 80:8
273:3	217.21 218.5,5,20	composite 113:4	consequences	contracting 93:10
commonly 263:4	220:13 225:15	conceivable 160:22	43:21 168:1	contractual 93:10
communicate	226:17 231:4,8,15	concentric 70:19	236:19	contribute 63:18
137:12	231:22 232:7,14	178:5 207:19	conservative	93:14 212:7
		210:21 235:12,14	210:17	
communicated 46:12	232:20 233:2,5,9	concept 19:7 20:1	consider 5:6 26:11	contributed 36:3,4 contributing 94:22
communication	233:13,19 234:7	23:16,19 35:3		-
14:16	242:1 243:2 245:8	<i>'</i>	41:12 94:3 137:18	contribution 261:11
communications	245:9 246:8 250:19 251:9	61:10 105:16,20 139:21 143:18	183:17 191:22 277:16	contributor 60:16
12:19 119:21		139:21 143:18 144:2 252:8,14	considerable 48:7	contributor 60:16 contributors 34:8
communities 41:9	community-based 40:21 85:5 225:20	257:14 281:6		45:12 49:22
			considered 41:5,13	45:12 49:22 control 109:1,4
79:21 82:14 85:3	comorbid 61:15	concepts 46:15	58:22 86:12,20	· · · · · ·
92:7,11 93:17	companies 83:2	143:22 190:12	119:13 141:14,15	controlled 120:7
171:4 217:3,12	comparability	conceptual 11:5	197:13 258:10	convene 148:16
218:10 239:19	221:22	203:7	262:6	205:5 231:9
community 4:19	comparative	conceptually 280:3	consistency 121:11	234:15 270:21,22
10:3 22:9 27:12	146:10	280:19	230:16,19	271:8
27:20 28:22 29:9	compare 268:16	concern 258:2	consistent 30:7	convened 153:18
29:21 30:8 31:1,5	compendium 130:2	concerns 8:21	70:22 124:12	convener 200:17
	I		I	l

convening 150:15	correction 8:10	95:14 97:11,17	164:18 197:8	customers 177:4
166:9 201:1,18	cost 250:7	103:10 107:1	200:13 201:22	185:5 199:11
205:16 270:11	costs 69:16 111:15	118:3,4 119:9	205:5 230:3	216:3,6,7,8
converged 43:5	112:6 116:18	120:14,19 139:16	274:15	223:18 224:12,15
convergence 156:5	Council 12:19	141:12,20 143:20	creation 210:14	226:7 228:1,10,11
conversation 4:13	84:11 85:17 151:3	146:9,18 147:6	creative 147:19	cutting 186:16
21:8,14 33:18	counseling 6:20	149:13 150:14	credibility 54:8,11	cycle 43:1 100:4,8
34:14 35:16 36:9	countries 204:11	152:14 153:11,15	81:16	cycles 210:22
36:15,17 48:4	country 27:14 30:2	153:18 154:11,21	creditor 241:21	C-O-N-T-E-N-T-S
69:7,17 75:4 79:4	51:12 92:1 145:21	155:7,15 156:11	crime 44:5	3:1
95:13 102:15	170:3,5	159:1 163:2 178:6	crisp 78:10,12	
103:8 124:21	county 90:19,20	182:1 183:16	crisper 66:6	
126:5 127:9	106:20 108:11	191:18 192:15,22	criteria 17:2,6	D 86:16
175:12 188:18,19	115:5 149:22	193:20 194:3	32:11 36:10 47:4	data 45:12 73:14
198:19 220:4	156:21 157:18	195:1,19 202:20	47:8 65:11 86:2	87:11,19 88:3,7,8
277:5	158:14	208:18 210:10	107:5 133:12	88:13,14,15,21
conversations	couple 4:18 98:5	212:16 217:21	213:8 234:9	89:10 90:13,14
47:12 104:4 146:1	101:8 102:11	219:13 221:13,19	246:19	92:13 105:2
170:2	133:19 145:9	222:8 223:19	criterion 236:15	115:14 138:8
conversion 239:16	152:5 169:8	229:13 231:3	critical 213:16	139:8 145:16
240:3,15	179:17 254:18,18	237:7 249:6	cross 69:9	146:10 159:2,4
convinced 121:17	260:5,20 266:16	250:11,15 252:1	crosscutting	170:2 178:12
convincing 65:20	268:13	255:11 256:3,18	249:11 250:1	180:12,13 183:5,6
66:4	course 16:19 24:15	256:21 257:19	Cruz 82:15	183:7 189:7
coordinate 275:2	34:13 56:11 110:7	258:9 261:12,21	CSAC 16:22 283:6	221:16 224:18
coordinated 30:8	111:13 112:7	265:8 268:3,14,19	CSCE 166:5	226:14 232:19
218:18	280:9 282:11	269:7,11,22	CSTE 151:3 153:4	236:21 237:12
coordination	286:21	270:17 271:12	cultural 121:16	238:13,17,18,20
121:17	COURT 173:18	272:8 273:20	249:20	238:22 241:10
Coordinator	coverage 39:13	274:12 284:9	curious 26:16	253:5 254:7,12
214:18	covered 39:3 40:1	286:20	55:17	264:14
COPD 61:16	50:17	Co-Chairs 1:12	current 8:16 69:12	database 238:20
copies 51:10	covers 218:10	12:4 285:1 286:16	100:4 104:6	datapalooza
258:14	Co-Chair 1:14,15	со-ор 33:5	142:21 143:12	149:14
copy 278:13,14	4:3 15:2,22 17:8	create 86:22 91:8	177:4 247:12	date 4:15 103:1
284:1	18:1,15 20:8	137:10 141:4,17	250:12,16 260:12	dates 286:7
Corbridge 2:11	21:20,22 22:3,16	165:7 181:18	277:19 281:1	David 107:19
95:3,4,7,8,16	23:2 24:3 26:8,19	184:8 217:11	currently 73:11	Dawn 2:16 261:17
97:15,18,19	29:1,18 30:5,11	230:7,19 241:3	76:19 129:20	273:9,11
103:16	32:19 34:15 37:16	252:6,7 257:6	138:11 166:16	day 3:2 4:4,6,12
core 28:12 54:15,18	38:21 39:15,19	276:3	230:16	5:13 43:11,14
54:20 139:3	40:14 42:19 46:13	created 43:18	customer 216:5,12	260:4 271:1,2
180:18 231:11	50:11,15,18,22	84:16 96:21	216:17,18 223:15	278:19 285:21
233:3 234:11	54:3,18 55:6	202:22 203:2	223:16,17 225:2,6	days 11:21 23:12
253:9	58:16 64:18 68:2	creates 31:12	226:5,7 227:15,19	28:15 208:4
correct 21:20 127:6	71:12 72:14 76:8	203:19	228:5 229:9	231:19,22 286:2
206:5 260:6	91:3 94:1,11 95:5	creating 68:5 91:18	248:19	day-to-day 27:9

de 177:7 249:18	defining 117:5	deputy 84:22	developed 9:21	141:21 145:22
deadline 134:8	216:1 224:15	describe 49:4	49:5 71:15 103:21	147:12 155:12
135:9 190:10	definitely 81:10	190:14 216:20	113:18,21 147:19	165:19 193:14
deal 29:15	201:9	224:13 226:14	203:5 209:7 251:7	199:9 200:13,16
dealing 29:10	definition 27:18	273:15	developer 8:19 9:3	200:22 204:15
158:7,8,9 183:12	74:13 163:14,20	described 174:18	9:3 12:18 17:11	268:5 285:11
deals 153:8,12	definitions 73:13	175:3 186:4 216:5	22:1,2 106:1	developmental
dealt 56:8 169:18	74:18 172:7 174:3	describing 174:15	107:18 228:5	203:6 208:19
169:19	174:8 248:13	175:18 200:11,20	229:5 241:21	209:14
death 44:15 90:13	259:4,11	201:22 210:21	developers 12:21	develops 199:3
151:5,13 184:2	degree 100:3	deserts 44:5	13:12,19 14:16	218:11
237:16,20 238:1	delay 11:10	design 93:19	32:7 47:21 49:22	devil's 265:4
debate 55:19 59:16	deliver 183:21	desirable 49:19	55:12 67:16 74:22	devote 134:6
60:13 77:7 82:5	delivery 57:22 58:4	desire 230:3,8	75:15 103:19	diabetes 61:17
209:1	58:8,13 114:13	desired 36:5	104:18 107:6,9	237:22
decade 28:1 119:5	115:4,6,11,13,20	133:18	129:14 130:11,14	diagnosis 6:16
December 262:5	116:13,14 117:3	detail 14:19 20:19	131:9 132:22	204:5 263:13
decide 99:17	118:2 129:7 138:9	277:13,18	135:1,3,7,13	diagram 94:21
108:18 120:6	138:20 186:18	detailed 18:10	141:2,13 142:9,21	126:9 127:8 132:4
140:2 172:13	190:18 212:6	104:21	143:12,18 144:2	162:9 175:19
175:5 242:21	224:18,20 225:4	details 265:5	144:22 145:2	dialogue 22:12,14
243:15 266:10	226:12 234:18	determinant 38:7	148:18 155:14,19	133:22 135:4
274:17 278:7	delved 277:13,17	42:6 90:17 96:5	156:13 161:20	difference 183:22
280:10	demonstrate 86:18	102:18	174:12,12 176:12	239:19 252:11
decided 48:22	132:14 133:1,3	determinants 11:6	189:12 190:6,8,22	255:18
211:8	135:12 137:9,12	37:21 38:10 42:2	191:6 200:18	differences 131:3
deciding 193:11	213:5 255:18	42:9 43:13 44:22	227:20,21 228:2	254:10,14
decision 16:3 58:18	demonstrating	45:22 58:2,15	228:12,18 234:18	different 4:21
125:9 215:21,22	135:17 201:3	63:14 79:16 81:8	235:2 253:8 254:6	32:16 36:21 40:3
243:11	denominator 22:5	81:17 82:18 83:21	261:16 267:14	41:16,18,19 45:15
decisions 237:14	denominators 44:3	90:7 91:21 93:2	285:7	45:15 47:7 55:9
238:4 240:9	department 2:18	116:11,17 255:4	developing 11:12	56:17 72:16 77:12
deconstructing	7:17 10:22 34:11	280:18,22	68:13 74:17 143:4	93:1 94:18 96:15
85:10	79:18 81:20 88:15	determinative	143:5,6,8 145:14	99:9 100:5 101:15
decreasing 91:8	88:22 89:1 216:21	79:22	146:16 158:12,18	106:14 119:17,22
deep 172:10 175:21	217:5,8,9 218:14	determine 13:20	163:15 164:17	120:1 121:18
176:21 188:16	228:4	83:3 162:21 219:9	170:4 199:5	127:2 130:5
254:20	departmental 91:6	determining 125:1	214:18,20 218:22	142:10 146:16
default 262:11	departments 80:2	develop 5:3,14	228:8	149:10,21,21
defer 283:13	80:3,19 85:4	26:11 30:7 73:13	development 11:10	163:5,17,21,22
deficit 52:19	87:18 90:3,4,10	103:15,22 135:15	11:17 12:15 29:20	175:1 176:13
define 24:8 31:16	90:19 218:3,4,13	141:2 147:16	35:3 47:22 82:19	178:15 180:15
41:8 73:4 164:16	depending 59:7	159:6 160:10	84:10 85:16 86:6	181:6 197:21
166:21 169:4	100:6,8	162:5 163:8 172:4	89:2 99:12 101:21	200:20 201:18
193:4 221:17	depends 160:4	177:7 180:12	102:3 105:5,13	212:11 219:3
225:5 229:9	204:5	184:11 191:2	107:4 108:1	221:21 222:5
definers 248:19	depth 4:8	213:11 240:7	110:19 140:17	225:3 226:8,10

			1	
227:3,7 234:4	discrete 115:7	dispense 55:22	double-blinded	drive 5:16 36:9
236:6 243:1 250:9	discuss 4:8 271:6	disservice 246:22	120:7	98:22 116:5,9,12
252:15 253:15	284:10	distinction 179:19	doubt 83:13 207:21	116:19 121:1
255:8 268:22	discussed 191:17	distributed 283:11	downscaling 87:6	122:5 182:3
271:1,6 272:9	264:6	dive 172:10 175:21	downsides 69:20	driven 29:22 81:2
273:14 281:8	discusses 283:6	176:21 188:16	downstream 43:21	242:5
differentiate 111:6	discussing 6:22	dived 254:20	193:17	driver 58:5
differently 126:16	23:5 178:2 259:15	diverse 230:13	Dr 14:22 15:9,12	drivers 66:17
126:21 127:14	discussion 6:6 9:12	division 270:20	16:7 17:20 18:12	drives 229:17
128:6,10 134:17	9:16 24:13,16	doctor 52:1 178:10	24:10 29:11 55:7	driving 121:2
137:5 162:10	34:3 48:8 74:9	182:22 255:15	59:7 61:1 63:19	182:2 183:14
176:2 188:12	78:8 80:4 98:1,10	doctors 54:12	63:22 68:15 69:21	drop 192:10
215:2 221:17	102:21 104:14	doctor/patient 53:3	70:15 71:22 72:20	dropping 192:5
243:8,10 256:14	123:17 124:3,20	document 14:11	75:10,18 76:3	drugs 29:4
277:9	126:7 131:18	267:12 283:10	77:3,18,21 78:20	duct 35:6
difficult 19:8 113:5	149:18 179:17	doing 18:4,9 28:5	79:1 89:16 91:14	due 11:9 84:9
120:3 223:4	189:2 205:1	38:11 64:13,21	92:5 98:17 105:7	101:13,14,16
difficulty 241:5	274:20 276:10,15	65:21 76:6 83:5	106:16 107:2,11	151:12
digest 278:6	276:21 277:2	83:14 84:4,5 93:1	107:21,22 108:3	dwindling 138:11
digested 17:12	282:17 286:10	93:4,7,17 98:20	109:21 121:4	D.C 1:12
dilemmas 227:18	discussions 43:3	99:11 129:1 143:3	142:3 151:19	
dimension 40:22	46:4 48:19 81:17	145:17,19,21	165:12 176:5,17	E
dimensions 40:16	121:20 264:8	149:8 154:12	177:10,22 178:21	E 192:11
41:5	disease 28:2,5	157:13 163:1,17	196:22 198:12	earlier 36:6 111:18
direct 52:10 143:8	44:11 52:14,19	164:20 166:2	199:3,13,16,21	126:22 133:10
159:13 186:18	62:2,17 101:7	168:10,18 170:4	207:13 214:13	144:13 145:12
direction 13:7	104:15 117:10,10	170:22 175:22	222:16,21 223:7	171:8 174:18
102:10 141:9	153:13,16 246:4	181:10,13 183:3,7	228:20 236:5	191:17 227:21
directions 20:22	255:7,13,14,16,20	184:17 195:12	238:14 244:12	239:12 246:14
directly 56:20	256:17,17 257:1,3	196:12,16 198:16	247:12 248:22	256:22
87:17 207:22	258:1,4 263:12	201:1,2 217:16	249:14 250:14	early 11:21 106:7
director 183:19	275:19	220:14 224:6,8	251:1 253:3 254:2	161:4 185:14
216:21 217:6	diseases 39:16	232:10 236:5	256:5,20 260:11	244:22 258:14
directors 58:20	256:15 257:4,5,7	241:5 242:6	266:14 269:10,15	easier 44:8 127:21
84:22 85:1 195:13	257:10,13,16	243:14,20 244:20	270:10 271:18	186:8 190:13
216:14 217:9,10	258:13 266:18	247:1 255:21	274:19 275:17	223:9
director's 24:4	disease-based	256:4 258:1	276:6 281:19	easily 158:19
217:3	61:11	271:16 272:11,16	282:10 283:2,13	177:11 225:6
disability 182:18	disjointed 113:13	281:13	283:16 287:3	easy 77:16 117:16
disagree 154:17	dismissing 213:9	dollars 239:18	draft 12:4 88:14	222:22 235:12
206:4	disorganized	domain 88:8	191:2	250:7 287:1
discomfort 60:4	183:12	262:10	drafting 285:18	eating 44:7 58:11
disconnect 46:10	disparate 201:17	domains 115:17	dramatically 138:9	114:19 116:16
62:18	disparities 198:14	131:14 149:7	draw 44:9 128:14	echo 66:10
discovered 248:11	249:8,10,12,16	191:3,5	drinking 44:7	economic 10:5
discrepancies	268:15 269:2	Don 43:10	58:12 114:19	80:10 82:19 89:2
261:10	disparity 250:1	double 121:8 260:6	116:16	145:22,22 251:10
			•	-

	I		I	
economics 119:21	emphasize 82:4	218:14	epiphany 185:14	86:13,22 105:20
edge 186:16	212:17	engagement 21:12	equation 138:18	119:12,13,22
educate 192:4	employer 182:13	31:5	139:10 220:5,20	120:2,6,11 121:5
educating 140:13	employers 180:10	engaging 4:12 31:8	220:21,22 221:8	121:8,11,13,18
education 42:8	183:15	31:10	222:7,12 223:11	122:2,6,7,22
82:19 83:5 89:1	empty 145:3	engineering 34:20	226:3 230:10	123:9 213:5
118:12 133:20	enabled 277:4	enlist 151:18 163:6	239:3,7	evidence-base 86:7
135:3 140:14	encourage 47:21	enlisted 151:10	equations 230:2	213:11
190:6 192:2 238:6	284:6	enormous 58:14	equity 71:16 72:10	evidence-based
educational 118:7	encouraged 101:6	64:8,13 65:6	72:19 252:17	108:10
119:1	ended 45:21 277:7	enormously 138:15	ER 29:3,7	evolutionary 211:4
effect 42:2 67:3,7	277:8	ensure 182:21	especially 15:6	evolved 124:14
effects 268:20	endorse 171:19	245:6	19:14 78:3 79:22	136:1
effort 92:18 223:1	203:4 235:22	enter 58:17	114:3 122:18	evolving 218:17
238:16	243:17 244:7	entering 238:8	204:15 255:9	exact 72:12 73:3
efforts 12:3 71:4	endorsed 6:10 7:3	244:2,4	279:16	exactly 19:10 61:8
73:14 161:8 205:3	7:7,18 8:1,14 15:7	enterprise 217:18	essentially 24:21	110:21 125:17
240:6 250:22	15:14 53:19 55:3	entertain 36:17	254:3,8 280:3,13	215:15 217:7
egg 205:2	55:8,20 59:2 68:1	enthusiasm 13:6	establish 79:10	258:1
eight 112:21	99:8 103:21 114:5	65:7	189:13 190:21	example 29:15 60:1
either 69:4 78:13	137:21 177:19	entice 36:12	established 114:4	61:14 64:18 65:4
86:17 144:16	178:1 181:22	entire 11:17 57:12	estimate 81:18	67:4 68:4,6 70:3
163:7 192:17	208:3 212:13	57:18 80:8 115:14	et 100:11 208:2	111:20,21 112:1
203:12	231:18 236:11	146:7 182:21	254:5	122:10 123:3
elaborate 82:22	237:2	197:3 234:7,19	ethnic 41:2 255:17	142:11 143:3
electronic 238:8	endorsement 1:3	entities 93:10	ethnicity 72:22	155:4 156:1 157:3
element 234:9	7:9 15:14,16	100:17 165:18	73:5 253:7 254:15	171:2 173:9 184:9
elements 205:22	53:22 54:16 66:1	224:12,17	Europe 167:13	195:11 208:3
elephant 195:21	66:18 67:1,6,22	entity 84:12 100:7	evaluate 97:2	examples 49:2,3,6
eliminate 56:3	102:21 104:7,21	219:1 241:4	evaluated 6:9	49:7 64:19 83:12
eliminated 198:11	105:11 136:18,19	entree 49:21	evaluating 87:1	133:16 134:22
Elisa 1:23 4:10	202:22 203:10	envelop 42:10	236:1	157:2 174:5 175:2
5:21 8:4 33:11	204:14,16 205:19	environment 44:4	evaluation 65:11	189:19 190:2
198:15 278:17	225:13 241:20	263:16 277:15	96:7 232:9,21	215:18 263:11
283:14 286:21	285:10	281:2,3	235:19 236:2	exceeds 69:19
else's 55:1 email 13:4 154:4,7	endorsements 70:20	environmental 10:5 11:2 38:9	261:8 286:11	excellent 126:6 139:19
162:8 167:6	endorser 22:2	44:22 66:17 85:6	eventually 15:18 244:7	exception 53:6
283:22 284:3	endorsing 15:6	92:8 93:19 116:11	everybody 39:14	90:18 122:2
emails 164:8	211:15 235:17	163:18 164:2,21	59:16,17 67:13	exchanges 13:4
embrace 19:7 20:5	energy 124:3 167:3	175:22 251:18	121:22 122:3	excited 65:2
76:4 79:22	engage 83:1 133:21	253:19 272:12	139:14 146:8	Excuse 92:3 136:19
emerge 124:21	137:13 151:15	274:3 277:14	184:12 188:4	173:12 253:11
273:8	157.13 151.15	envisioned 280:19	everybody's 194:13	exercise 44:7 58:12
emerged 238:15	168:15 231:22	epidemiologists	223:5	75:11 114:19
emergence 29:12	255:8	87:18 151:4,13	evidence 43:19	116:17 129:1,9
emergency 29:2	engaged 26:2	153:5	47:16 55:22 80:5	130:1 149:12
	ingagiu 20.2	133.3	T1.10 JJ.22 00.J	130.1 147.12
				l

F				Page 290
150:10 152:4	E-ZPass 51:11	fear 282:4	figured 213:4	173:17,17 175:1
159:18 161:16		feasibility 65:13	fill 237:20	175:17 176:3
277:6 281:20	F	feasible 133:16	filling 97:20	188:8,8,22 189:3
exist 48:3 217:13	face 60:20	fed 222:21	final 7:4 66:20	189:6 219:2 220:8
existence 16:13	facilitate 35:3,4	federal 98:20	269:16 283:18,21	277:7,12 278:12
existing 11:3 47:18	facilitated 4:13	145:20 170:1	finalize 11:8	flavor 266:19
131:1,20 248:10	9:11 107:9	219:11 224:13	finally 11:21 48:22	flights 279:1
261:9 264:4	facilitating 33:21	219.11 224.13	67:13 277:22	flip 35:10,14,15
exists 68:3 196:4	facilitator 14:21	264:6	find 104:4 210:6	189:5
264:17	22:20 23:5 33:17	feds 223:4	262:8 280:21	flipped 127:16
expand 58:1 205:4	34:2 35:12	feedback 23:8	finding 129:1,2	flipping 237:21
expanded 211:5	fact 15:13 70:7,10	34:13 50:1 116:7	148:11 174:11	Floor 1:10
216:10,11	94:2 107:12 123:4	117:2 124:7 236:2	231:12	Florida 82:14
	167:20 182:20			
expect 21:4	199:6 216:4	236:9 261:15 286:2	fine 16:3 127:3	169:16
expectancy 204:10	244:18 249:17		152:2 195:4	flown 246:3
experience 33:19	254:12,19	feeds 90:2	210:18 247:17	flushed 175:4
111:14 112:1	factor 86:20	feel 55:21 60:11	285:2	focus 10:3 27:19
249:7	factors 10:5 44:21	62:18 67:16 151:10 195:20	finish 95:15 188:21	36:2 38:15 56:4
expert 63:5	62:20 80:14 88:17		finished 269:16	117:5,20 149:1
expertise 103:18	125:1	196:14 247:19	finishing 188:5	162:3 165:16
experts 121:7	Faculty 113:17	260:18 274:8,22	first 4:9 6:15,21	172:15 175:5,6
explain 16:1	failures 29:3,9	279:15 281:12	7:10 11:13 37:2	250:2 256:14
Explaining 190:17	fair 69:1,6 275:19	feeling 195:21	48:4 53:3,7 62:9	258:3,4,7
explicit 53:14	fairly 4:12 66:2	feels 82:10 280:8	64:7 71:18 78:8	focused 38:5,14
explicitly 45:19	225:6 259:18	felt 11:10 279:13	79:2 105:16	42:12 47:6 62:2
73:4 76:9 80:7	266:21 267:18	fertile 257:20	117:20 131:12	65:1 94:18 96:4,5
81:7 155:19	fairness 252:7,11	Feucht 95:9	144:14 150:16	110:3 181:8 200:6
explore 24:8 42:4	252:19 253:13	FHA 153:4	160:11 172:15	focusing 116:22
215:3	fall 111:11 155:5	fictional 49:7	175:6,6 188:13	153:7 168:3 231:4
explored 24:9	155:20 180:1	field 4:22 5:5,15	200:14 205:1	235:5
exploring 27:15		25:1 35:2,4 58:18	215:11,13,21,21	folks 16:2 35:17
233:13	205:18 236:16	62:8 91:6 102:3	233:11 253:10,16	37:7,9 48:3 55:17
Exposure 263:15	246:18 275:22	104:12 107:10	261:3 271:13	60:16 63:6 68:5
extended 199:15	falling 70:11	124:14 141:8	283:7	73:19 80:22 85:7
extends 81:11	familiar 33:22	145:13,16 154:12	fish 175:19 188:8	93:19 106:21
extent 59:4 64:4	71:21 72:8 108:1	163:3 166:2	fishbone 94:21	120:16 133:20
65:1 133:15	families 197:9	197:16 198:15	126:8 127:8 132:4	139:12 143:6,12
177:16 209:17	family 27:20	203:12 272:16	152:4 162:9 277:6	144:7,8 147:1
210:4	far 50:19 59:8 79:4	fifth 174:19 194:8	fit 48:1 49:8 101:15	150:3 156:20
external 12:5,12	80:17 89:18	194:17 200:3	154:20 155:13	160:3,8 168:15
13:1 69:12 223:6	114:14 123:22	210:20 214:1	156:7,15 160:8	169:11,17 176:10
230:4	161:9 193:16	215:16,20	196:17	185:11 188:17
extra 203:15	207:19 208:13,21	fight 151:5	fitting 46:20	199:6 206:7 224:4
extremely 13:13	268:20 278:18,20	fights 163:11	five 6:11 7:8 13:10	228:9 245:21
61:6 63:8 237:1	farther 66:12	figure 34:19 41:11	15:15 123:16	270:1 274:3
251:5	fascinating 251:16	94:14 111:6	162:13 167:21	278:22 281:12
E-I 92:6	fashioned 35:15	120:10 202:13	168:19 173:8,10	follow 161:2

followed 17:6	foundations 239:16	f. ll. 49.11 106.1	acthor 14.2 274.2	34:22 40:14 48:2
follow-up 7:6 69:22		fully 48:11 106:1 108:17	gather 14:2 274:3	
95:11 98:4 116:21	240:4,16 four 6:10 15:15	fun 43:3 174:12	gathered 115:10	50:20 53:1 54:8 56:22 58:21 62:20
165:12 285:6,12	62:17 94:18 95:18	function 231:19	gathering 115:21 120:1 124:6	83:19 90:11,22
food 44:5 177:12		256:16		94:12 95:1 102:10
	95:19 96:20		145:16 147:3	
fora 12:13	115:18 117:21	functional 44:13	173:3 236:20	108:13,14 112:11
force 84:15 85:17	167:21 207:11	functions 28:7 139:4	273:5	115:8 117:8
121:5 236:14	219:2 268:20	fund 163:8 226:17	gauge 12:5	129:12 140:3
forced 216:2	277:7,8 285:9 fourth 96:10		GE 182:6,14,20 183:19 184:2	147:12 150:17
foreign 7:13		226:18 232:7,8		164:14 165:5
forget 73:2 153:9	174:15	fundamentally	general 35:2 47:4	178:16,18 188:7
167:16 f	frame 38:4,11,12	44:16 59:2 200:19	64:4 114:1 196:22	193:8 206:7
form 14:3 30:19	38:15,19 45:16	funded 186:19	255:5	207:20 208:15,20
219:13	48:16 101:21	funders 226:20,21	generally 65:20	208:22 209:5,6
formal 236:6	118:13,22 119:2	funding 25:22	86:5	213:2,8 215:22
formalizing 272:6	126:12,17 134:4	141:1,3 152:15,18	generate 117:1	220:4,8 232:17,18
format 63:1 126:10	134:11 169:1	154:14,22 166:17	177:6	236:4 238:3
forms 115:3 247:13	195:10 251:8	167:1 169:9	geographic 40:18	239:20 241:12
247:15	framework 30:8	174:11 179:3	67:11 87:6 218:21	248:16 252:16
forth 48:8 111:2	43:8 44:1 45:3	189:18 219:11	250:19	255:15 261:2,15
137:15 139:13,21	80:6 87:1 101:19	225:18 226:16	geographical 40:2	261:21 262:8
forthcoming 13:13	102:8 113:20	232:4,15 240:8	Germany 168:9	265:1,17 266:8
fortunate 13:11	129:15 167:15,18	260:5 270:22	getting 16:21 20:5	275:1 278:7,18
forum 1:1,10 62:11	172:3 251:13	272:20 274:18	23:15 68:1 85:9	283:8 285:10
124:18 191:2	256:6 259:9	further 52:12,16	109:8 112:13,14	goal 24:11 61:20
270:21 273:3	280:21	56:22,22 60:11,12	115:1 118:12	goals 44:20 84:17
forums 205:5	frameworks 11:5	78:3 80:19 89:19	137:13 146:3	84:20 85:10,18
forward 5:3 29:13	43:3,4,5 44:2	135:16 142:17,20	150:2 159:9 168:7	goes 5:9 99:19
40:8 49:15 55:13	45:19	205:16 208:22	179:2 186:19	110:14 112:18
55:20 56:4 57:5	framing 45:5	209:6 221:8	206:15 241:10	113:3 222:1
65:8 66:8 71:11	frankly 76:15	251:20 276:15,21	243:5 249:9	235:11 261:22
75:5,9 95:2 99:12	free 284:5	furthering 148:2	256:12 258:7	going 4:16 9:9
105:14,16 106:9	frequently 283:2	furthermore	give 9:14 52:1	14:11 18:6 19:16
121:15,22 122:9	fresh 88:18	233:18	60:15 63:17 102:9	19:17 20:15 24:1
122:14 124:9	frightening 238:4	future 3:4 9:12	151:1 152:14	26:3,4 27:10,14
176:11 189:1	238:12	73:21 74:1,6	171:1 207:1 236:9	31:3,6,18 37:10
197:16,18 207:3	front 28:14 33:9	125:6,10 197:11	248:17,20 254:14	50:10 54:10 55:12
215:12 221:4	43:16 128:9,20	260:14 267:5	274:15 284:12	59:9,9 62:5,19,22
236:21 249:17	198:4 237:18	276:14 277:10	286:2	66:8,13 72:16,18
250:10 260:17	272:15	278:11	given 39:12 64:21	73:12 77:2 78:4
262:21 275:8,20	fruit 47:14,19	G	67:13,17 100:3	80:19 82:1,20
283:5,6	215:11 262:1		101:4 126:6 211:2	83:10,19 86:10
forwarded 12:4	263:3 264:1	gap 11:4 105:19	265:11 283:4	87:9 88:9 89:9
found 27:5 93:20	fruits 88:18	204:16 228:6	giving 72:4 174:5	93:7,14 105:14
104:15 165:14	full 16:4 31:16	252:21 256:1	GI/GU 275:20	106:12 112:8
Foundation 156:22	105:21,21 172:21	gaps 104:1,2	glad 194:19 274:9	113:1 120:2,8,12
158:11	209:3	gas 84:13	go 19:17 31:3,6,14	122:12 126:15
	l	l	I	

127:12 129:1	259:12,12,15	42:4 51:21 52:5	277:7	harder 66:11 178:5
141:9 142:4 144:7	267:4 268:1,10	59:2 64:17 69:15	guidance 49:18	235:9
145:1,13,20 146:2	269:2 274:11	74:7,10 85:7	132:10,16,21	harken 149:18
153:21 161:1	276:8 278:4	92:13 125:7 140:5	133:6 134:16	harmonization
166:8 168:8,17,19	279:12	148:16 151:9	172:6 174:3,8	114:11 129:9
172:14,20 173:16	goodness 252:7,9	153:8,19 155:16	189:22 192:14	137:1 178:3
180:1,15 183:17	252:19 253:13	156:7 161:14	248:12 250:20	harmonized 70:13
184:1 188:15,21	gosh 91:14	163:10 166:15	259:11	84:4 115:19 138:8
191:20 194:17	gotten 66:3 144:10	171:2 176:6	Guide 120:16,20,21	138:19 149:6
196:9,13,16 199:2	government 25:21	179:18 183:17	121:2	218:18 224:20
201:13 204:1	64:9 154:15	192:3 193:1 195:9	guided 198:1	harmonizing 117:5
205:13 209:20,22	155:18 225:3	196:3 197:5 201:1	guidelines 61:14,16	150:9 190:17
210:1 218:8	227:4,4 231:14	206:15,21,22	62:2,2 104:11	222:14,16,19
219:21 221:4	263:6	207:18 208:14	guys 26:17 97:16	head 111:10 152:6
233:14 237:1	governmental	211:2 215:12	144:9 245:22	156:1 168:20
242:19 243:7	64:19 69:9 216:7	223:6 234:15	281:17	175:12 244:3
248:16 249:16	216:11,17 217:18	235:2 239:4,15	H	heads 191:7
250:10 252:18	226:8,10 241:2,4	240:19 245:5	half 104:17 121:6	health 1:3,24 2:15
256:1 257:18	governments 81:13	248:17,18,18	hamster 27:8	2:16,19 3:5 4:4
259:13 260:6,17	91:22	249:8 251:6	hand 16:18 30:21	5:15,17 7:17 9:13
260:21 261:2	go-to 262:6	252:12 257:15	80:21 127:21	10:7,10,20,22
262:21 266:16	graduation 44:5	260:4,20 266:5,6	213:9	11:1,3,6,6 12:16
267:7 271:15	211:16 212:4	267:2 268:15	handful 128:18	13:8 18:7,8,22
273:5 275:20	213:6 235:9	269:2,9,13 271:2	handle 245:20	19:1,3,8,11 20:1,9
278:17 279:6	grant 26:11 84:10	272:10,15 273:7	287:1	21:2,18 22:5,8
281:14,14 282:5,8	85:16 229:15,19	278:2,9 280:8	happen 29:8 31:19	23:16,17,20 25:12
283:13 285:6,17	240:16	287:1	39:12 40:5 77:2	25:13 27:1,13,19
goo 161:13	Granted 142:13	groups 41:2 69:9	186:4 209:22	28:19,22 29:16,21
good 4:3 24:14 26:9	grants 20:16,17	85:6 107:13 153:1	217:14 246:2	30:1,9,15,22 31:1
28:5 32:12 33:8	225:20	164:1 166:5 178:7	283:5	31:12 32:17,22
40:13 45:2 49:2	granularity 83:7	183:3 205:5	happened 6:7	33:5 34:11 36:19
53:7 61:1 62:7	great 15:1 77:11	209:20 225:6	16:11 27:22 82:7	37:21,21 38:6,10
69:12 78:14 83:6	79:1 83:22 117:9	229:9 231:10	119:6,7 128:14	38:17 39:7 41:4
89:14 95:11 119:2 123:12 124:6	220:16 244:22	248:10 249:10	167:20	41:22 42:6,7,13
125:12 124:0	246:7 247:18,21 251:20 264:22	255:18 271:4,9 272:1,4	happening 22:4	42:22 44:12,17
	265:5,18 275:10	<i>'</i>	88:1 168:2 197:14	45:1,21 51:6,6,8 52:5 54:1,9,14,21
138:3,3 145:7 157:21 158:1	286:17	growing 25:14 growth 81:3 84:11	happens 15:20	55:4 56:13,14,14
164:13 165:10	greater 14:19	85:16	115:9 157:9 208:1	56:16,20 57:4,21
167:12 168:10,21	green 84:13	guarantee 59:5	222:3 257:8	57:22 58:2,4,7,7,8
168:21 204:22	0	0	happy 34:1 177:11	58:12 59:8,13,22
205:6 206:14	ground 211:6,11 257:20	guarantees 183:14 guess 51:20 66:20	223:1 250:3	60:9 61:9,20,21
205:0 200:14 215:18 216:6	groundwork 130:7	78:2 82:7 91:5	269:19	62:6 63:15 64:12
221:1 227:13	group 4:5 18:3,19	98:5 120:12	hard 35:7 57:11	64:12,17,20,22
232:10 233:11	19:15 21:7,8,12	137:16 148:17	67:19 125:18	65:1,14,19 66:17
232:10 233:11 238:22 240:10	21:14 23:8 35:1	159:3 160:4 222:2	199:4 211:14	67:5,11 68:5,20
243:3 248:14,15	40:7 41:12,13,21	245:4 252:15	278:20,22	69:2 70:5,8,10
243.3 240.14,13	40.7 41.12,13,21	243.4 232.13	_,	07.2 /0.3,0,10
	I	I	I	

			l	
71:1,5,9,16 72:10	186:15 190:18,20	healthy 10:2 71:13	help 9:9 24:13	213:5 235:8 238:6
72:19 76:5,21	191:1 193:4,22	116:8 117:21	32:10 49:8 70:20	higher 88:4 198:5
77:13 78:4,6 79:6	195:10 196:7,20	118:21 158:4,8	81:15 103:13	265:14
79:16,19,22 80:2	197:12 198:4,21	182:22 204:10	118:12 131:6	highest 207:18
80:3,18,19,22	199:12 200:22	234:12,22 252:12	133:17,21,22	highlight 205:7
81:4,5,12,16,19	203:2,22 205:11	252:12 270:12	141:1 144:9	Hispanics 254:16
82:2,18 83:21	208:2,2,6,8,11,22	HealthyPeople	151:18 165:9	historical 27:16
84:15 85:4 87:18	209:1,5,12 210:12	204:10 263:6	174:21 176:6	historically 180:5
88:16,20 90:3,3,7	211:17,21 212:2,6	264:7	186:6 221:2 245:5	241:18
90:10,11,16,17,19	212:7,8,12,13,21	health/perinatal	helped 48:9 79:9	hit 77:7,17
91:21 93:3 97:19	212:22 213:6	238:15	256:9	hits 169:8
100:21 102:13,18	214:3,7,19,20	hear 4:18 34:8	helpful 21:8 24:14	HIV 6:16 53:6 77:9
106:20 108:9,11	215:7 216:9,21	35:18 36:11 40:8	38:3 40:8 70:1	153:5 212:18
109:12,16,18,20	217:2,5,8,9,18,22	55:18 61:2 63:20	91:4,8 94:2,19	246:3
110:3,8,17,20	218:2,3,4,5,5,12	72:4 78:20 95:4	103:8,11 104:4,16	HIV/AIDS 101:4
111:5,11 113:1,18	218:13,14,22	97:16 201:14	107:16 108:2	hold 8:21 20:10
113:20 114:13,14	219:1,3,15 224:3	268:15 269:1	109:10 140:6	22:18 54:10
114:15,18,21	224:6,12,14,17	heard 9:18 13:17	143:22 150:15	hole 5:8,8,10 46:21
115:4,5,6,10,11	225:9,15,21	71:18 95:20	165:14 168:17	46:21 47:8,9
115:15 116:1,9,13	226:11,18 227:3	140:19 142:2	176:9 199:8 200:5	home 29:13,14
116:13 117:2,6,7	227:10 228:4	152:22 170:9	213:1 214:16	67:21 102:16
117:8,13 118:2,2	230:8 231:4,6,8	228:3	221:15 248:13	honesty 180:20
118:8 119:7,16	232:14,18 233:5,9	hearing 118:19	250:21 265:9	Honore 2:13 18:6
120:5 121:19	233:13 234:7,17	270:2	helping 64:18	18:18 20:12 22:10
124:14,17 129:5,5	237:10 239:20	hearts 28:18 65:3	92:17 102:16	23:10 24:7,17
129:20,22 130:3	240:14,17 242:2,2	245:17	104:22 172:4	25:8,20 72:6 73:1
130:16 131:10,21	242:4,6 244:8	HEDIS 129:8	195:9	hook 118:11
133:8,13 136:1,5	245:2 246:21	179:4 180:20	helps 202:13	hope 99:20 106:13
137:5,6,6,22	247:5,8,11,14,15	181:15 242:8	203:20 227:14	154:22 201:4
138:7,8,10,16,19	249:12 250:16	held 8:2,15 13:18	230:7	285:19 286:3
138:21 139:4	251:21 252:9,17	179:22 180:2	heretofore 210:7	hopefully 5:2 90:21
143:7,13 144:7,8	255:6 256:17	Helen 1:22 12:22	hesitant 89:15	105:4 213:10
145:22 146:4,7,10	257:11,15 258:3	66:10 67:14 69:2	Hester 21:6	hoping 98:13
147:11 148:13,17	258:10,16,16,20	69:22 70:16 104:8	Hey 16:11	Hopkins 256:9
148:19 149:2,5,22	261:14 262:7,7	110:15 114:9	HHS 2:15 24:4	horrible 238:13
153:9 156:21	263:9,16 264:13	128:21 139:17	65:3 71:14,19	horse 78:9
157:18 158:10,14	267:12,18 268:6	150:11 167:7	72:10,15 74:16	hospital 16:12 30:1
161:6,8 163:1	268:15,20 269:2	173:2 176:4 177:2	98:12 99:15	30:13,14 31:14
164:10,12 165:17	270:6 271:2,5	184:7 195:14	102:15 216:8	52:9 55:20 218:10
165:20 166:2,15	272:22 273:15	198:9 201:5	258:11,13 267:11	218:14 219:14
166:18 169:14	276:4 279:18,19	207:12 210:22	275:7	hospitalizations
171:22 177:18	280:1,18,22 281:5	222:15 231:17	Hi 18:12 33:15	245:12 263:12
179:8,20 180:3,9	281:15	249:9 256:3 260:6	63:19 106:16	hospitals 30:22
180:11,13,19	healthcare 19:6	269:14 276:10	hierarchical 86:17	33:1 55:8 211:20
182:5,17 183:20	23:21,22 38:6,14	278:6 282:21	high 44:4 84:22	211:22 212:21
184:18 185:13,14	38:18 39:4 161:6	285:17 286:21	182:11 198:5	213:17 218:6,21
185:19,20 186:5,8	healthier 217:11	Helen's 235:11	211:15 212:4	220:13 231:5

	I	l	I	
hospital's 33:6	268:11 272:11	53:12 57:22 58:5	216:11 226:2	181:15 186:7
hour 104:17	277:3	61:7 63:9 65:17	252:3 282:14,19	245:9 264:13
house 84:13	identified 104:1	71:8,10,19 81:18	286:9	indices 158:20
Housekeeping	125:2 131:20	106:8 109:5	included 13:15	individual 12:12
69:12	identifiers 89:7	121:13 122:1,3	14:12 32:12 195:6	62:1 71:4 80:13
housing 42:8 82:19	identify 97:13	124:7 130:22	268:5	86:20 89:7 181:7
210:13	108:22 109:3	131:3 163:9	includes 27:18	individuals 219:8
Howard 71:12	127:3 131:7	166:11 189:9	139:4 189:22	224:9
HRA 215:5	189:10 203:18	192:19 193:8	193:10	indoor 49:11
HRSA 2:11 95:8	214:5 220:10	200:14 202:10	including 32:3	infancy 19:2
97:12 98:7,12,17	243:16 262:2	215:7 228:17	77:13 91:19	infant 262:13
99:7,21 100:18	identifying 93:8	230:11 245:7	107:13 113:20	infectious 101:7
102:16,19 103:13	130:10 161:16	259:7 279:15	138:1 190:1	104:15 246:4
104:18 109:22	162:17 173:20	impressed 23:11	income 211:14	266:17 275:19
152:22	188:17 202:10	improve 5:4,5 9:12	inconsistency	infinite 229:14
HRSA's 98:15 99:2	220:9	31:1,12 37:12	121:14	influence 80:11,12
99:18 100:20	identity 145:5	38:17 61:21 62:3	incorporate 133:8	109:1,4 118:13
101:4,17 103:17	ignorant 76:10	62:12 113:1 138:9	incorrectly 185:2	184:19 217:1
huge 62:18 70:4	ignore 163:9	185:20 188:9	increase 62:5 81:21	267:2
146:5 255:18	ignored 168:7	238:17 241:9	135:8	influenced 93:18
258:18	251:14	277:9 281:14	increased 165:11	influences 208:1
hugely 182:19	IHI 109:17,22	improved 138:20	increasing 3:4	inform 192:4
237:11	110:7 113:16	190:19	134:11 174:11	information 9:15
Human 18:7	136:14,17 270:4	improvement 10:4	190:9	9:18 14:2 50:8
hundred 92:11	IHI's 114:2	11:7 32:18 37:5	increasingly 115:9	60:8,10,15 73:15
hundreds 83:8,9	II 1:4	43:12,14,16 45:9	incredible 31:17	86:1 116:8 117:10
hurdle 24:2	illustrative 265:9	45:21 56:5 60:10	258:5	117:14 133:18
Hygiene 7:17	imagine 53:18	79:11 83:16 94:21	incredibly 60:7	173:4 189:17
hypertension	102:11 156:19	109:13 114:4	77:12 82:22	223:22 238:9
245:11 255:19	211:15	115:8 116:10,12	165:14 208:5,8	243:6 271:10
	immunization	116:19 122:5	230:13	273:5 278:7
I	39:11,13	128:18 146:4	independently	informative 11:12
Ian 2:11 95:4,7	immunizations	204:19 212:22	68:12	246:9
97:19 105:8 106:3	57:15	218:6 225:12	indicated 16:2	informed 10:9,19
ICLEI 91:16 92:5	impact 63:14 65:12	233:20 263:9	134:21	130:4 135:4
idea 33:8 37:19	82:2 105:19	281:15	indicative 9:5	inhibitor 255:22
38:22 118:6,11	169:14,14 232:16	improvements 5:17	indicator 82:16	initial 37:14 48:4
138:16 165:16	impacts 19:18	236:18	86:6 93:2 262:6	143:17 161:18
196:9 197:9 231:4	implemented 79:14	improving 112:19	263:6 264:5,9	162:5 170:20
241:17 257:22	167:15	186:7 189:7 281:4	indicators 80:1,1	189:19 214:2
261:4 264:22	implication 15:5,8	incentive 26:1	83:11,20 84:8	215:11 216:2
267:5,16	implications 15:16	incentives 32:7	85:10,18 90:6,14	235:13
ideally 86:9 252:16	283:8	incentivize 181:13	91:20,20 93:12,15	initially 23:19
ideas 37:10 75:7	importance 105:17	incident 255:16	108:9,10,11	49:15 171:18
139:13 172:13	important 11:11	include 73:10 74:3	158:18,19 169:12	212:17
183:18 207:1	12:2 29:20 32:1	152:8 166:10	169:13,18 170:11	initiates 25:21
221:8 266:3,9	34:18 38:16 44:16	205:4 215:17	171:3,5,13,14	initiative 24:6 65:3
	1	1	1	1

٦

146:6 258:13	interactive 140:16	interventions 10:4	46:11 78:5 86:4	149:13 150:14
initiatives 20:15	272:16	10:6 81:12 93:8,9	40:11 78:3 80:4 99:19 101:13	152:14 153:11,15
161:9 232:8,15	interchange 114:8	120:5 121:19	124:5 179:1	152:14 153:11,15
260:14	interchangeably	251:9,10,11 263:9	245:11 256:13	155:7,15 156:11
	56:11	263:17	268:17	159:1 163:2 178:6
injury 44:12	interest 13:6 20:13			
inner 70:19		interview 83:2	issuing 61:16	182:1 183:16
innovation 18:11	24:5 25:12,16,18	88:20	162:10 242:21	191:18 192:15,22
18:22 20:15 21:18	25:19 27:6 32:21	interviewing 27:4	243:15	193:20 194:3
26:4,11 64:22	64:9,14 83:18	intimately 22:10	item 109:11 162:9	195:1,19 202:20
121:1	101:12 146:17	introduce 190:12	229:8 259:6	208:18 210:10
innovative 121:12	147:3 166:15	introduced 196:10	270:16 279:2	212:16 217:16,21
innovators 30:21	interested 42:14,15	introductions	items 74:8 75:9	219:13 221:13,19
input 9:22 11:16,18	76:4 79:17 100:19	33:12	88:16 173:17	222:8 223:19
21:10 23:4 42:7	101:3 102:20	intuitive 122:14	229:12 260:2	229:13 237:7
84:21 85:3,8	103:2 116:6	invalid 237:12	285:5	252:1 255:11
126:7	149:20 150:4	invaluable 105:3	it'd 178:19	256:21 258:9
inputs 42:2,17,22	152:20,20,21	invest 83:14,15	it'll 29:11,17	261:12,21 265:8
inserted 268:7	214:19 281:4	233:1 239:17,18	208:19	268:3,14,19
inside 64:9 69:6	interesting 4:12	240:6	I-C-L 92:5	269:22 270:17
142:14	5:13 22:4 29:7,12	investment 67:20	J	271:12 272:8
insisting 258:15	29:17 31:15 33:4	68:1		273:20 274:12
instance 39:8,10	42:3,10 79:4	investments 98:11	Jacksonville 82:14	284:9 286:20
47:6 106:3	109:22 115:12	invite 150:17	83:11	Jason 1:19 129:17
Institute 2:16 11:1	130:1 140:18	invited 82:11	JACOBSON 2:16	jeopardy 210:6
109:12	148:15 149:12	inviting 18:19 79:3	261:17,22 273:18	Jim 21:6,14
Institutes 240:14	211:18 249:15	involve 164:6	273:21	job 28:5 83:6 97:9
240:21	251:5 255:2	involved 22:11	Janet 12:22	150:9 186:7,11
institutional 80:9	266:15	25:6 26:2 67:15	jargon 94:21	210:14 256:9
81:9	interestingly 143:2	110:22 146:4,6,8	217:16	259:15 278:5
institutions 80:21	interests 41:9	164:10 232:2	Jarris 1:12,14 4:3	jobs 172:21
insufficient 210:8	interface 64:11	involvement 21:12	15:2,22 17:8 18:1	Johnson 106:20
insurance 184:14	118:20 212:18	IOM 203:15 264:8	18:15 20:8 21:20	joined 37:18
insured 178:16	intergovernmental	IRS 55:2 74:16	21:22 22:16 23:2	107:19
182:21 184:14	69:7	136:9 214:7	26:8 29:1,18	joins 81:20
insurer 178:14	internal 272:13	225:10	30:11 32:19 34:15	Journal 26:21,22
integrate 10:1	international 92:7	isolating 62:14	38:21 39:15,19	July 286:5
90:16 267:11	interplay 235:21	issue 26:20,21 35:7	40:14 42:19 46:13	jump 182:11,12
integrated 27:11	interpret 280:12	51:3,4,22 56:7,10	50:11,15,18,22	jump-start 201:18
268:1	interrupt 57:9	61:9 63:6 86:4	54:3,18 55:6	jump-starting
integrating 28:6	96:16	91:7 99:22 100:15	58:16 68:2 71:12	200:12,21
170:10	intersection 114:13	104:9 107:14	72:14 76:8 91:3	June 285:20
integration 28:21	114:16,17 117:19	134:18 148:5	94:1,11 95:5,14	justice 42:8 85:6
intelligence 196:14	145:21 148:12	192:18 193:6	97:11,17 103:10	
intended 100:18	150:6 211:11,13	195:7 197:22	107:1 118:3 119:9	K
intensive 181:20	211:20 235:6	198:6,8 202:21	120:19 139:16	Kaiser 158:11
interaction 53:4	237:9 240:7	242:19 243:7,12	141:12,20 143:20	181:10 208:9
179:10	intervention 80:17	issues 4:8,14 29:17	146:9,18 147:6	Karen 199:17

Г

raye Jua	Page	30	4
----------	------	----	---

keep 83:14 106:9	23:13,13,14 25:5	223:2 224:5 229:4	249:20 268:6	47:12 48:3,13
126:17 157:21	25:21 29:5,15	229:13,15,20	276:4	49:10 156:21
176:7 234:12	32:8 33:7 34:18	232:9 235:12,20	large 30:1 38:3	285:7,12
264:17	35:14 37:3 42:22	236:3 237:3 238:2	43:17 84:12 85:1	legitimate 19:22
keeping 173:9	44:4,13 46:19	238:2,10,20 239:5	90:18 92:16	legs 258:6
kept 47:10 258:15	48:16 49:3,10	239:8 240:2	180:10 183:3,15	length 190:9
key 22:22 103:5	50:3 51:10,14,18	242:18 243:5,8,9	largely 51:20	lens 270:8,9
164:4 188:22	53:10 54:13 55:9	244:16 245:13,14	119:14 224:7	lessen 230:21
189:14 201:11	56:15 58:9,17	245:14,19 246:1	larger 36:15 37:17	lessons 168:16
278:12 284:19	59:10,14 61:17	246:13,15,16,17	38:11 98:10,16,22	243:8 244:15
KHAN 267:4	63:5 68:18 69:2	246:20,21 247:2,3	124:5 125:11	267:6 272:2,6
kids 208:4,11	71:16,17 79:6,12	247:6,14,22 250:6	240:4 247:5	letters 33:4
kind 43:5 44:6 46:8	82:8,10 83:10,19	252:21 255:6,13	late 6:16 25:5	let's 48:2,21 49:16
50:5 56:2 65:7	84:7,22 86:10	256:22 258:22	law 233:18	55:21 120:13
67:2 69:12 75:1,6	87:7,15 90:12	259:13 260:12	lay 53:16	123:13,15,21
77:8 83:6 86:22	91:3 92:15 95:10	261:7 262:13,14	layers 57:1 142:15	126:17 134:18
95:12 98:16 99:13	100:17 102:14,22	262:18 263:1	lead 62:19 127:8	144:9 147:4 152:2
99:20 100:13	100:17 102:14,22	264:14 265:13	136:16 263:8	156:11,12 162:3
101:5 110:20	106:19 107:3.17	266:1,7 267:19	264:8 281:14	164:16,16 165:16
127:4 129:8	108:6,8,12 110:21	270:9,17 271:10	leader 178:19	170:19 181:1
131:13 135:22	112:7 120:14	270:9,17 271:10	leaders 60:5 163:6	187:2 188:4 193:8
141:4 150:5 169:4	122:17 126:9,13	275:5,9,17,21	163:14 164:5,19	213:8 219:19
170:1 175:8,21	129:3,10 134:6	276:2 278:21	263:17	220:16 221:5
191:1,6 193:13	135:19 138:4	280:2,8,12 281:7	leadership 12:22	233:8 243:6
195:20 198:2	140:7,9 142:10,19	282:6 283:11	20:3 93:19 113:6	265:20 274:17,17
201:11 205:1,12	143:1,2 145:10	Knowing 243:9	leading 264:13	level 11:14 31:13
214:15 221:11	146:22 147:7	knowledge 222:4	league 92:7	59:12 61:12 71:5
232:10 243:2	148:10,17 149:11	known 79:7	Leapfrog 107:18	71:6,6,7 84:22
244:3 245:21	150:5,21 151:9	knows 67:15 92:16	learn 168:15 249:7	86:12 98:21
246:12,15,21	155:21 156:8	Koh 71:13	275:4	102:19 103:4
247:2 250:11	158:4,13 160:3,5	KP 212:3	learned 51:9 196:8	112:20 114:2
257:21 258:19	160:16 163:20	Kristin 1:22 14:11	243:8 244:15	115:8,14 117:12
260:22 261:7	168:14 169:17	191:19 286:21	267:6 272:2,6	120:11 126:6
262:6 265:4 276:3	174:7 175:15	Kurt 1:12,15 26:19	282:15	146:5 163:5,20
277:14 278:6	179:14,16,18,22	64:7 118:3 120:12	learning 118:10	174:7 175:4
Kindig's 107:19	180:4,5,8,9,9	231:2 239:12	140:17 141:5,18	209:11 224:7
kinds 16:8 29:17	181:10,22 182:9	249:5 279:16	143:14	232:13,14 233:2
30:3 39:9 45:15	183:4,7,10 185:8		leave 89:17 90:22	245:2,8,15 246:7
63:14 65:14 69:8	185:19 186:9	L	220:7 281:17	247:6,8,20,21
74:2,5 83:9 90:13	191:4 196:3,4,15	labeled 129:21	285:5	250:12,18,19,19
116:20 175:7	196:19 201:13	lack 13:22 49:2	leaves 156:18	251:10,11,12
229:2 234:4 255:1	204:6 205:1 206:6		led 263:21	251:10,11,12
Kingdom 167:14	206:17 207:4	laid 4:7 43:7 46:4	LEED 93:18	265:2,12 280:20
know 5:9 6:3,8 9:7	209:2 210:11	47:2 254:10	left 9:4 273:22	levels 77:13 87:13
9:21 13:9 18:13	211:4 213:17,20	language 72:18	278:3	88:19 154:14
19:21 20:11,14,16	215:17 220:17	133:9,11,13,14	leg 110:9	207:18 225:3
21:7,9,13 22:12	221:10 222:2	134:21 162:14	Legacy 9:4,8 12:10	226:8,11 227:3,9
21.1,9,10 22.12	221110 222.2		12.10	22010,11 22110,9
	l	I	I	1

	l			
252:3 253:15	listening 19:14	109:16 121:10,15	lot 4:7 13:5,6 22:12	M
265:10,14,18	79:20 98:1 124:19	125:8 131:19	22:14 27:2 30:2	MADELINE 1:16
273:1 281:8	197:3	132:1 141:1	30:13 47:15,15	main 152:17
leverage 50:7 74:15	listing 214:15	149:22 161:3,5	51:18 56:1,3 63:2	Maino-Fike 2:17
88:11 103:20	lists 125:22 163:22	165:2 169:13	67:17 74:15 77:4	33:14,15 35:9,21
186:3,6 217:4,6,6	262:22	173:5 180:6	87:15 91:5 102:8	40:6 41:6,14
217:13,17,19	little 4:9 18:9 36:6	181:11 182:20	102:9 109:14	42:18 45:7 46:1
221:12 242:11	37:3 38:19 70:17	196:6 205:2,3	110:16 124:2	49:20 57:6 60:14
leverages 36:21	88:13 111:6	218:1 221:2,5	129:19 141:21	61:3 63:11,21
leveraging 220:13	113:13 118:17	229:8 232:16	143:3 148:11	72:3 73:17 75:17
241:17 242:11	128:22 135:16	235:3 237:15	149:17,20 155:11	75:21 77:20 78:14
liberty 20:18	142:17,20 143:15	238:12 240:6	165:8 167:12	78:22 89:12 92:3
life 10:7 27:9 44:20	144:5,19 146:16	256:15 257:9	171:8 181:19	96:16,19 97:5,10
204:10	152:3 168:20	276:19 279:22	196:4 198:15	123:11,21 127:20
lifestyle 10:7	171:22 201:5	280:4,15	203:14 205:12	128:3,7,11,16
likelihood 241:9	205:15 227:14	looked 73:22 102:1	236:6 239:22	130:8 131:6,15
limbo 20:10	232:22 240:1	102:8 111:19	240:16 244:15	132:2,8,17,20
limited 103:18	246:20,22 267:10	170:9 179:21	248:21 250:9	133:3 134:8,13,15
Linde 95:8	270:18 272:13	185:16 208:4	256:12 260:13	135:21 136:3,20
Linde-Feucht	277:13,17 279:17	241:8 245:8	262:4,12,13 264:5	137:7,20 138:1,17
97:21	live 177:15	246:18 254:7	271:4,5 272:5	139:6,9 141:11,19
Linde-Feucht's	living 10:2 80:11	279:19	281:8	142:1 143:16
94:8	load 48:15	looking 21:3 22:6,7	lots 5:14 43:4,18	145:7 146:14,21
line 17:16,18 58:19	local 22:9 80:3 85:4	30:22 36:7 37:17	77:12 87:17	147:17,22 148:21
58:21 94:6,8	87:18 88:3 90:3	38:12 41:1 42:1,5	121:20 145:15	149:15 150:11
199:4 200:15	90:10 146:4	42:16 56:18 62:16	212:14 223:20	152:2 154:6,17
213:1 267:18	185:16,19 216:18	63:13 66:18 67:8	226:19 233:6	155:3,8 156:17
lines 28:14	216:21 217:5,8	75:7 79:13 82:16	love 167:11 176:5	157:1,6,21 159:11
link 213:5	218:3,13 219:12	98:10 104:5	183:10 208:9	160:12,18 161:11
linkage 208:1	224:13 227:12	105:18 112:12	low 19:18 23:14	163:13 164:14
linked 111:17	locals 241:3	124:15 169:1	34:4 35:14 82:9	166:20 168:21
178:4	logical 24:12 84:2	180:10,18 182:15	98:14 124:4 125:1	169:20 170:6,12
linking 64:11	208:14	182:15 193:10	125:2 126:14	170:16 171:7,16
links 70:17 162:4	logically 275:13	194:14 210:2	lower 36:4 276:12	172:1,17,22
list 88:14 111:9	long 4:5 9:18 31:6	212:1,3 219:20	low-hanging 47:14	173:12,15 175:10
119:10 130:18	31:18 32:20 44:14	226:9 245:15	47:19 215:11	175:14,16 176:16
151:20 154:4,7	53:1 123:1 168:11	247:4 259:22	262:1,8 263:3,22	176:18 177:21
159:9 160:1,6,6	185:21	270:4,4,5,7,8	luck 128:13	181:1 186:20
160:17,22 161:18	longer 186:19	277:21 281:10	lucky 84:9	188:3 192:13,20
166:21 167:10	longevity 83:13	looks 28:19	lumped 155:15	194:4,12 195:4
171:4 197:11	look 4:13,14 14:14	loop 117:2	lumping 194:22	200:7 201:8 202:1
202:16,18 214:12	17:10 19:3 27:9	Lorraine 2:17	lunch 127:11 169:2	202:5,15 204:3,21
241:7 259:19,22	27:16,17 34:19,22	33:15 34:16 287:4	176:20 186:22	206:5,10,13
260:10 266:13	36:2,20 39:13	Los 10:21 90:19	187:2,4 188:5	210:19 213:13,22
274:11,13 278:1	40:7 41:19 42:6	lose 28:3 75:8	191:17 216:18	214:10 215:9
278:11	63:9 80:7 103:22	100:13 126:2	221:10	218:19 220:1
listed 172:11 276:2	105:17 108:21	lost 43:6 282:5	Lurie 273:22	221:18 222:6,11
	l		l	l

	1	I		
223:10 225:1,16	map 162:14 196:3	156:4 157:10	110:18 113:4	16:13 19:4,20
225:22 226:6,21	197:7,19 199:21	160:2,4 161:7	123:6 129:16	20:9 21:18 24:22
227:1,6,11 228:14	march 55:12	165:7 176:7 178:3	133:9 134:7 142:8	26:12 28:2 30:3
229:7,11 230:1,18	market 182:2,4	178:22 179:2,13	143:12 144:21	32:2 34:5 36:8,10
233:7,21 234:2,5	230:3,7	182:5 190:9	145:2 148:18	36:19 37:13 38:5
234:21 235:7,10	marketing 57:20	194:10 195:17	155:12,14,19	39:6,6,7 40:1,3,7
239:2 240:10	57:22 74:19	196:22 197:2	159:6 178:10,13	40:9,10,13 41:15
241:6,13 242:13	marriage 143:15	198:13 203:14	180:20 190:12,21	41:16,16,18 42:12
243:3,18,22 244:9	marrying 36:19	204:4 210:5,15	191:5 196:5 199:8	44:10,14,15 45:4
246:11 248:6	materials 14:13	211:12 214:6	200:12,16,18,22	45:4,8,14,20,22
249:4 253:11,20	87:8	229:4 231:21	201:19 203:4	46:6,14 47:13,16
257:18 259:2,12	Maternal 100:21	232:5 237:15	207:22 208:3,7	47:19 48:2,20
260:18 261:20	Matt 1:19 21:9	238:10,12 242:6	211:16 212:18	49:14 50:7 51:18
264:19 265:7,20	29:18 42:19 46:2	245:8 249:14,15	221:21 224:21	51:19 52:6,20
267:22 268:9,18	58:16 59:14 94:12	250:20 258:4	225:10 227:18	53:19 55:3,8,11
269:1,12,21	118:21 127:17	270:3 272:21	228:8 229:2	57:13,16 58:12
270:15 271:8,21	138:5 144:14	282:15	231:17 234:18	59:11,14,20 60:2
274:1,14 276:8	171:20 200:7	meaning 28:9	235:2,22 236:10	61:9,11,21 62:1
maintenance 1:3	211:9 216:5	191:11	236:17 238:15	62:13,16 63:2
236:11 253:4	220:17 233:8,16	meaningful 31:5	241:21 245:16	65:14,22 66:4,19
254:6	234:5 239:13	54:20 76:13	246:15,16 247:8	67:9,11,18 68:1,5
Maizlish 2:18	241:12 261:2	214:21	248:19 250:12,16	68:11,12,14,22
17:18,21 34:10	264:19	meaningless	252:7,13,17,18	70:5 71:1,14,15
78:20 79:1 89:16	matter 49:4 76:7	219:21	253:7 254:5	72:15,17 74:2,3
91:14 92:5 106:16	85:20 123:19	means 33:6 44:19	255:15 261:15	74:14,20 75:14
106:17 107:2,21	140:13 144:6	76:13 88:2 123:14	265:3,17 267:13	76:20,21 77:15
108:3	156:13 187:8	257:3	286:13	79:13 86:9 87:10
major 65:16 66:8	233:1 268:21	meant 219:6	measured 38:1	87:13 90:1 91:10
210:11	287:6	measles 39:19	117:15 209:11	95:21 96:1,8,11
makers 240:17	Matt's 165:15	measure 6:13,15,15	263:4	97:2 98:6,18 99:5
makeup 76:16	213:15	6:17,17,19,19,21	measurement	99:6,8 100:19,22
making 66:3,5	MCHB 106:4	7:2,4,6,11,14,15	25:13 56:4 60:19	101:2,6,7,11,14
68:22 70:18,21	MD 1:14,15,22	7:20 8:1,3,10,13	67:2 71:2,4 100:5	102:13,17 103:4
72:3 73:21 74:19	mean 14:6 23:17	8:18,22 13:11	110:18 113:17	103:15,21,22
78:5 99:6 123:8	41:21 45:2 47:1	14:4,9 15:6,6 16:9	114:3 131:13	105:16 106:2,4
174:12 177:5	47:15 51:20 54:5	16:20 17:11 21:22	164:11 272:22	108:20 109:13,15
179:18 192:7	56:6,16 62:15	22:1,2 32:12	280:21	109:17,19 110:1
193:22 221:2	76:16 77:8 79:17	41:12 47:21,22	measurements	111:5,8,11,22
232:5 257:21	79:20 83:15 84:17	48:14,22 51:22	39:5	112:11,14,14
259:7	89:18 110:2,16	52:1,2 53:6,7 54:6	Measurepalooza	113:3,8,10,18
man 195:21	117:9 118:14,18	54:8,11 55:20	149:15	114:5,17 115:3,9
management	121:1,15 135:16	62:3 63:15 67:16	measures 3:3,5	115:17,20,22
111:14	135:22 136:5	72:16 77:10,11	4:19 5:6,15 6:10	116:1,2,4 117:6
Manager 1:23	140:14 142:20	100:7,9 101:21	6:11,11,12 7:8	117:12,22 118:8
mandate 73:4	144:19 146:11	102:2 103:19	9:14,15,20 11:3	118:15,20 120:4
231:7 233:14,18	150:16 154:1,4,7	105:5,13,18	11:15 12:1,5 13:9	124:5,8,10,11,16
mandates 234:1	155:11,17,18	107:18 108:7	13:10 15:14 16:5	125:13 126:15,20

127:11,13 128:5	251:14,17,21,22	12:20 15:4,11	204:4 205:21	219:6
128:15,19,21	252:2 253:4,9	21:16,21 24:18	206:6,11 209:16	methodologists
129:5,6,13,20,22	254:1,4,11,18	25:16 26:15 29:19	211:10 213:14	13:19
130:3,6,16 131:1	255:9 259:8,17,18	30:6 31:21 38:22	214:4,11 215:4,19	methodology 213:3
131:10,21 132:11	261:5,6,8,9,13,14	39:14,18,21 40:15	218:17,20 219:5	methods 262:21
132:13,15 136:8	262:9 263:3,10	41:7,20 42:21	222:18 223:2,8,14	263:20
137:3,22 141:2	265:11 266:16	45:18 46:2,18	224:11 225:8,14	metrics 181:12
142:12 143:4,6,8	268:2,4,7,8 271:3	50:14,16,19 53:10	225:17 226:4,15	216:14,20,22
145:14 147:3,9,15	273:15 275:16	54:17 55:2 57:10	226:22 227:2,9,17	218:7,9 240:3
149:1,2,4,7,10,19	276:5,13,16,20	57:19 61:4 94:13	228:16,21 229:10	245:2 247:18
150:7 154:13	277:10,11 281:8	94:16 95:18 96:18	230:11 233:17,22	mic 35:18
158:12,13,16,19	282:12 285:10	97:1,6 108:4	234:3,6 235:4,8	Michael 1:20
160:7,9,9,10	286:12,14	110:6 111:3	235:16 236:22	242:15
162:11,16,17,19	measuring 11:5	113:12 119:3	239:10 240:12,15	microphone 35:20
162:21 163:8	37:21 38:3,16	122:16 127:18	240:18,20,22	72:5
165:10,11 168:4,5	39:11 41:3 164:9	128:1,4,8,12,17	241:1,12,15	microphones 6:5
170:11,15 173:21	218:15 255:21	130:20 131:12	242:16 243:13,19	middle 114:15
176:11,14 177:19	279:18	132:5.9.19 133:1	244:6,10 246:12	Mike 31:20 38:21
177:22 178:8	mechanism 272:9	133:5 134:10,14	248:2,8 249:3	40:16 53:9 65:18
179:3,5,8,19,20	Medicaid 18:11	135:15,22 136:4	251:3 253:18	227:20 228:15
179:21 180:2,3,7	143:4,9 179:3	136:21 137:16,21	255:1 258:19	230:22
180:12,16,17,19	180:18,21 183:11	138:6 139:1,2,7	259:9 261:4	Mike's 113:16
181:6,19 185:5,6	185:6 216:12,13	139:15 144:18	264:21 267:9	118:6
185:9 188:11,11	247:21 254:9	145:9 147:8,18	270:7 275:15	million 65:3 203:15
190:2 191:2,8,14	medical 29:13,14	148:9,22 149:16	276:1 279:5,8,11	245:16
197:9,17 198:21	183:18	153:7,13,17	282:4,21 283:9,22	mind 61:8 111:7
199:1,4,5,7 200:6	Medicare 18:11	154:19 155:10,22	284:4,8,22 285:19	126:18 191:19
202:12 203:2,22	183:9 185:6 215:5	156:3,6,14,19	members 12:8 85:4	193:15 200:2
204:7,8,18 205:3	242:8 254:9	157:4,7,12,15,20	284:13	214:5 215:15
205:17 210:3,7	medicine 26:22	158:2,6,17,21	membership 92:10	231:1 267:17
212:2,11,14,20	29:2 184:20	159:3,7,20 160:2	Member/Public	mindset 142:22
214:21 215:6,8	209:15	160:15,20 162:12	3:8	mine 27:3 72:2
216:9 218:12	meet 135:9 190:10	164:7 165:5	Mental 7:17	minor 118:5
219:9 222:9	224:10 225:12	166:13 167:9,17	mention 134:2	minute 17:10 22:19
224:21 225:21	229:16	167:19 169:10,22	mentioned 46:20	123:13,15 144:9
227:22 228:1,10	meeting 1:4 4:5 6:3	170:7,13 171:1,11	85:15 91:11 106:4	285:5
228:13 229:15,18	9:2,6 12:10 14:13	171:12,17 172:2,3	133:20 139:18	minutes 123:15
229:21 232:5,11	35:12 125:21,22	172:18 173:8,14	220:17,19 231:17	125:22 126:4
234:4 235:18,19	144:22 220:7	173:20 175:11,15	232:3 242:4	152:5 169:3,3
235:20 236:1,8,9	286:17	177:1 179:13	279:17 285:17	278:15
237:3,5 239:5,21	meetings 12:8,12	181:3,9 183:2	message 138:13	MIs 252:20
240:7 241:11	12:19,21 23:12	184:6 193:18,21	messiness 43:18	missed 166:11
242:8 243:16	33:21 133:10	194:10,19 195:2,5	met 1:10 12:22	208:5 231:20
244:4,8,18 245:7	150:22 209:4	196:18 198:9,18	17:7,7 213:7	258:18
246:3 247:4	meets 107:5 225:20	199:10,14,19	214:22	missing 155:11
249:18,18,19	member 8:4,8	200:2,9 201:20	metaphor 82:8	280:6
250:1,3,4,9 251:4	10:11,16 12:19,19	202:2,8 203:17	methodologies	missions 87:7
/	. ,		, i i i i i i i i i i i i i i i i i i i	
			•	1

mitigation 84:13	214:2 215:12	196:1 197:4 198:2	185:22 189:21	223:22 229:20
model 50:21 52:20	221:7 236:21	214:17 222:17,19	190:14 191:10	241:7 256:8
87:19 93:6 119:15	275:11 283:6	237:13 240:13	277:2	270:11 282:16
210:4	moved 58:10 99:5	nationally 99:4	needing 69:18	nicely 189:5 270:14
modeling 86:18	121:22 219:10	nations 146:11	needle 219:9	Nicki 273:21
87:16	movement 59:17	naturally 127:9	needs 28:20 29:21	NIH 270:8,10
models 56:17 87:22	61:14 81:2 83:16	navigate 200:17	32:17 55:4 64:20	nimble 104:10
181:16	92:1 163:12	NCQA 7:2,19 8:1	67:5 73:22 74:6	106:11
Moderator 2:17	moves 210:6	8:13 51:3 54:7,14	111:19 125:7	nine 6:9
modest 58:9 117:20	moving 13:7 31:4	129:20 143:2	144:17 170:5	NISHIMI 1:24
modifications	40:8 75:4 99:8,12	156:3 176:12	187:4 206:4,8	131:16
191:19	99:15 102:20	178:7,9 179:15	211:7,18 212:8,12	NNPHI 240:20
modify 5:11 206:12	105:9,14 106:9	180:4,16 231:18	214:7 218:22	Nobody's 89:13
moment 32:6 47:12	120:4 124:9 189:1	241:19 246:15	225:11,15 231:5	noise 55:19 91:5,9
67:20 94:10	275:8 283:5	254:8,11 270:3	233:5,19 234:7	nonprofit 33:1
159:12 197:15	MPH 1:14,15,22,23	neatly 155:13	242:1 245:17,18	218:6 219:14
Monday 283:20	multi 231:9 257:2,3	necessarily 49:18	273:3	241:2
money 228:8	multiple 41:4 61:19	66:18 74:6 122:19	negative 67:3,7	non-fractally
232:10,21	257:19 258:4,13	146:22 154:8	122:7 167:22	272:19
monitoring 87:20	269:8,13 273:1	169:10 222:10	neighborhood	non-HEDIS 79:13
240:9	multi-chronic	228:1 243:12	232:13	noodle 75:19
Monkey 286:6	256:11 257:1	250:6	Neil 2:18 17:14,15	normal 205:19
monthly 12:18	multi-morbidity	necessary 102:4	17:18,20 18:17	normalize 258:3
months 11:8 16:14	256:4	ned 280:11	22:18 33:12 34:10	notes 173:10
101:9 229:19	municipal 81:13	need 15:18 24:20	78:17 106:16	242:14 268:16
256:7 260:5,20	83:4 91:21	27:10,10 28:20	145:14 209:18	274:22 278:15
266:11 268:13	municipalities	29:8 30:9 35:8	Neil's 94:17	noticed 200:7
275:18,18	91:17	39:6 41:5 53:18	net 63:13 99:22	noting 14:15
morbidity 80:15	MUNTHALI 1:23	55:3,8,11 57:2	Network 240:13	notion 31:8 41:15
morning 4:3 18:20	5:22 8:6,9 10:13	62:9,11,13 63:1,9	never 51:12 52:20	63:12 119:12
33:17 34:13 46:9	10:17 15:1 35:19	66:22 81:15,21	66:15 166:3,4	196:11 233:10
61:1 98:2 124:1	278:21 283:15,19	83:22 89:2 102:10	170:9 199:3 231:1	259:3
126:12 127:1	284:2,7,11 285:4	112:12 120:10	232:9 256:1	notions 120:1
197:3 198:19	mutual 114:20	124:11 132:9,12	new 7:16 12:15	novo 177:7 249:18
209:19 272:11	118:1 201:3	132:14 135:12	23:20 25:1 57:11	NPA 72:8
281:6	N	137:10 151:17	58:19 62:8 64:22	NPP 10:3,12 52:18
mortality 80:15		153:2 158:3 176:8	121:12 179:3	196:1 197:4,18
262:14	NACCHO 154:1	176:17 177:19	202:2 205:9,12	199:6 209:7 251:6
motivation 118:16	169:17 NAECLE 1:16	178:1 179:7 219:8	217:20 219:6	252:5 265:10
118:17	NAEGLE 1:16	220:20 236:17	228:3 231:7	270:19 271:13,20
move 29:13 56:3	nailed 213:7 name 92:4 127:15	237:5 241:8	232:15 236:7	NPP's 59:18
58:14 60:10 65:8	name 92:4 127:15 narrow 36:2 161:3	244:10 246:1	243:21 249:18	NQF 1:21,24 3:8
75:9 89:19 102:13		248:6 259:16	252:14 277:20	5:1 9:22 11:14
103:3 106:12	national 1:1,10 10:13,14 15:17	260:1 262:2 275:1	newly 6:12,17 7:11	12:16 24:6,13
116:1 121:14	64:16 71:7 87:10	275:5 279:10	7:14,20 8:3,17	33:20,21 35:5
122:9,13 197:16	98:22 146:1 183:4	281:10	nice 43:7 65:4	38:5 41:8 42:11
207:3 210:16	70.22 140.1 103.4	needed 181:6	118:22 121:7	42:14 48:5,6,8,12
			1	

48:14 50:9 51:3,4	213:20 215:12	obvious 66:13	209:10 213:13	163:14 164:5,19
51:14 53:11,15,19	216:4,7,8,20	159:12 171:22	222:1 227:1,11,12	opinions 207:2
53:22 54:6 55:3	217:1,4,16 221:2	obviously 125:16	230:18 233:7	opportunities 37:5
55:11,13,19 57:5	222:12 225:13,21	245:19 262:15	234:2 237:21	143:14 214:2
57:13 58:3,17	230:2,6,18 234:9	occurred 54:5	240:18,22 244:9	245:1
60:5 62:7,10	234:14 236:3	184:15,16	247:11 249:4	opportunity 30:10
65:11 66:1,18	239:4 241:20	occurs 256:21	252:19 253:20	33:10 37:18 38:4
67:1,6,15,16,22	244:6 246:19	odds 87:8	255:12 259:12	60:17 63:18 75:2
68:4 70:19,20	270:20 271:13	ODPHP 158:5	261:2,22 265:7	78:18 103:2,9
74:7,10 75:1,2,12	272:22 275:14	offense 188:5	267:22 268:18	106:6 142:8
75:12,14 76:11,14	277:11,18 279:14	offer 132:5 191:18	269:4,11,21	143:10 144:2
79:7,12 84:2	282:6,7	offered 210:7	271:14 274:17	161:6 212:5,10
89:22 91:12 94:2	NQF's 118:13	offering 147:9	276:8 278:16	219:12 251:5,20
95:1 96:12 98:11	148:14 171:10	offers 88:10	280:16 283:16	258:18 266:22
99:8,16 100:4	188:20 190:15	Office 2:13 24:5	284:8	269:8 274:2,16
101:7 102:20	191:11 193:3,6,22	214:17	old 35:14 246:16	279:14 282:13
103:4,13 104:6,8	200:11 201:15,16	offices 18:7 99:3	older 6:20 7:16	284:12
104:14,14,16,21	221:12 222:7,10	100:18	OMB 69:10 72:21	opposed 38:17 40:2
105:2 107:6,8	235:17 239:3	official 185:19	once 142:17 188:22	40:4 77:7 192:9
108:1 110:1	241:18 270:19	Oh 91:14 107:2	253:11	204:15 213:9
112:10 113:6	276:17	157:6 170:12	ones 44:8 49:15	222:3 227:4
114:5,12 117:4	NQF-endorsed	249:4	136:8 171:18	249:18 255:5
118:7,19 119:5,13	202:11	okay 5:20 8:6,8	172:12 175:6	option 16:21 248:1
124:9 125:7	NQS 10:2,12 16:2	10:16 15:1,11	185:9 213:18,20	265:22
129:20 136:2,18	NRQ 172:19	17:22 18:5,15	213:20 231:13	options 17:9 215:3
136:19 137:21	number 22:22 85:2	21:21 24:17 26:8	240:4 245:14	238:21 274:6
140:5 142:10	95:21 152:22	35:21 39:6 41:11	280:17 282:1	275:6,7
147:2,14,15,20	153:1 172:12	50:15 51:22 52:2	one-hour 248:22	order 105:2 131:8
149:11 163:1	208:4 220:8 221:7	52:13 63:22 78:21	one-in-one 12:20	137:17 172:16
165:9 171:18	229:14 259:10	79:1 97:5 107:2	one-on-one 51:19	173:7,11 188:9
172:9 173:5 174:4	280:17,17 284:18	107:21 108:3	178:17 205:10	284:17
174:15,20,22	numbered 85:8	109:14 111:3	ongoing 22:12 24:5	organization 33:20
176:11 177:3	nuts 229:17	125:14 127:18	onward 80:14	34:1 48:12 50:8
181:21 185:4	N.W 1:11	128:3 130:8	oomph 282:2	76:18 91:17 92:4
186:3 191:11		131:15 132:8	open 24:20 58:19	92:9,10,16,20
192:19 193:5,8,10	0	134:15 135:10	94:8,9	108:7 116:15
193:12,14,16	obesity 146:6	137:7 138:1 139:6	opening 5:20	136:18 155:4
195:10,11,16,22	178:15	139:9,15 150:12	operating 147:2	185:18 223:12
196:5,12 198:6,22	objective 192:21	152:4,9,11,13	operationalization	228:7 230:7
199:2,3,5,9,12	194:9,18 214:1	154:7,18 156:11	217:2	240:13 252:9
200:15 202:3,22	objectives 36:8	156:18 157:1,20	operationalize	organizational
202:22 203:3,13	170:17 211:7	160:18 167:7,8	198:7	40:19 193:14
203:13 204:1	241:9	168:22 170:18	Operator 17:17,19	organizations 22:6
205:2,8,14 206:1	observation 114:7	172:1 175:10	17:22 22:21 23:3	36:22 67:21 74:13
207:16,18 208:14	114:8	181:20 186:22,22	94:7,10,15 284:16	74:15 80:20 84:5
209:6 210:4,7,17	observations 124:7	194:4 195:4	opinion 16:21	85:5 87:3 89:22
211:2,15 213:17	observing 23:9	199:20 207:5,9	24:18 25:2 163:6	91:11 93:1,5,20

			1	
136:11 148:1,4	252:5,10 262:10	129:13,17 131:17	152:13,15,16,16	219:6
151:22 152:7	overlap 144:15,15	134:3 140:22	152:18 153:3	pay-for 53:20 55:9
153:9,19 159:10	147:11 161:7	141:3 150:14,18	154:12 157:22	PCPI 180:6
159:15 162:3	191:5 208:21	150:19 151:16	161:17,19 164:5	peg 5:7,8,10 46:20
164:1 169:6 171:5	272:5	158:15 159:5	165:1 167:2,4,10	47:7
181:5 189:20	overlaps 261:10	163:14 171:5,10	168:9 169:21	Peggy 2:13 18:2,6
209:20 224:14	oversect 205:11	171:19 181:16,17	170:1,20 173:21	18:16 22:3,17
226:13 227:10	overturn 17:3	182:1 191:22	175:22 185:22	23:7 24:3 26:9
230:12 241:2	overview 20:7	193:11 201:15	186:5 188:17	71:17,21 72:4
242:5 271:6 281:4	overwhelming	203:11 218:7	189:10,14 191:22	Peggy's 72:1
organize 73:20	234:10	222:7 223:3	199:11 216:20	people 5:7 13:6
organized 207:6,7	owned 88:21	229:16 244:22	264:10 277:16	17:11 23:15,22
207:10	owners 88:7,13	249:13 251:8	partnership 10:15	25:14 26:2 27:5
organizing 43:7	228:19	259:10,11 261:12	64:16 163:21	28:13 29:2 31:4
orientation 248:21	owns 88:16	264:6,7 272:22	196:1,5 197:4	31:13 39:11 40:5
oriented 164:9		280:7	270:20	41:2 46:5 53:15
original 126:11	<u> </u>	participants 78:17	partnerships 162:5	54:14 64:3,6
originally 200:10	pace 210:16,17	82:13 89:5	partner's 237:19	66:16 67:19 68:17
ought 42:4 144:1	pad 23:1 284:19	participate 50:3	parts 103:14	71:14 73:7,21
outbreak 39:16	page 262:22	79:3 91:2 101:13	149:21 209:7	77:4 80:15 82:11
52:14	pages 274:22	139:14	party 81:11 82:11	82:17 83:13 89:15
outcome 40:9	paid 38:1	participated 92:13	passed 8:5,11	91:1 92:17 107:14
41:15 42:1,3	palliative 122:11	251:6	102:22	110:17 112:22
52:13 111:8,12,22	paper 3:6 10:10,20	participating 2:22	paternal 180:19	115:2 118:11,14
123:3 232:4	11:1,10 43:6 46:3	60:19 92:12 135:5	path 5:3	133:17,21 134:5
outcomes 39:5,7	49:5 87:9 129:10	participation 34:12	pathway 123:2,6	137:13 140:2,7,14
42:13 43:13 44:9	149:3 256:10	particular 62:4	patient 61:18	141:7,13 145:3
44:17 45:22	258:12 261:19	129:14 173:11	179:10 181:8	149:20 150:3
112:16,19 116:18	264:4 272:15	195:8	209:11	151:21 154:12
123:7 125:20	279:4 282:3,5,7	particularly 12:15	patients 28:10	157:9,13,17,19
167:17 168:4	283:10,18	24:12 73:19 86:3	52:10 122:15	158:4,8 159:14
outcome-based	papers 27:2,3 49:6	118:17 166:14	237:17 256:11	160:8 165:8
74:4	112:3	198:1 278:8	patient's 255:14	174:10,16,22
output 42:7	paradigm 80:4	particulars 175:20	Paul 1:12,14 18:18	177:5 184:18
outputs 42:15	parameters 276:22	parties 82:6 89:8	30:4 46:19 61:5	185:12 186:15
outreach 11:22	parking 14:22	201:17,18 223:12	63:7 64:20 69:14	190:17 192:3,4
12:3 14:11 17:11	parks 44:6 212:5	partly 79:8 84:9	72:8 77:21 92:15	198:13 199:18
76:15 107:12,12	parlays 253:22	91:6	98:3 150:13	210:1 213:6,10
150:16 159:14	part 6:21,22 7:1	partner 81:5,15	165:13,20 211:3	217:7 220:18
165:22 174:21	11:9 24:10 28:1	154:22 155:5	217:15 232:3	223:20 225:19
199:15 200:4	32:3,20 35:11	159:14,16 161:1	239:14 246:14	229:17 231:13
outs 271:10	37:8 38:11 44:21	166:22 169:7	Paul's 207:14	232:16 233:4
outside 23:20 52:9	51:21 56:2 60:4	186:9 203:13	254:3	234:16,17 247:10
59:8 64:9 81:12	79:16 81:5,22	217:4 223:1	pay 55:5	248:3 255:8 266:8
169:22 223:11	83:15,19 91:22,22	240:11	payers 219:8	271:5 281:20,22
258:11,17 268:20	93:7 97:3,3	partners 12:5 13:1	paying 181:14	284:6
overall 62:6 236:13	108:15 128:9,13	63:17 145:19	payment 67:2	people's 150:17

165:22 193:15	215:19 219:5	picture 256:13	plethora 28:2	19:8,10 20:1,9
perceived 117:13	223:14 241:1	pie 76:2	plop 237:18	21:2,17 23:17,20
percent 254:15,16	248:8 249:3 259:9	piece 75:19 76:2	plot 272:15	25:12,13 27:12,19
254:17	270:7 283:9,22	87:3 89:13 130:22	plug 12:11	29:16 36:19 37:22
perfect 35:21 49:21	284:4,8,22	131:4 134:2 178:3	plugged 209:8	38:17,18 39:2,3,4
68:21 69:3,10	Peter 2:10 17:13,15	178:4 184:7 186:2	plus 67:9	39:14 40:4 41:4
175:17 186:21	17:17,19,20 18:15	239:3,6	point 19:2 20:10	44:16,20 47:3
246:8	22:18 33:12 34:9	pieces 47:2 137:15	22:14 23:4 39:21	51:6 52:4,21 53:5
perfectly 76:4	60:22 61:2,3	197:21	65:9,16,17 66:13	54:21 56:14 59:12
performance 24:21	63:19,22 66:14	piggyback 120:15	70:17,18 78:14	60:16 61:9,12,20
53:21 55:10 87:20	68:2 69:21 71:12	pilot 105:9	89:14 91:4 102:12	61:22 62:6,12,21
113:8 168:5	77:18,22 113:13	pilots 27:14	103:12 110:6	62:22 63:15 64:16
170:11,14 183:13	114:9 197:6	pioneers 19:15	117:18 118:5	65:1,14 67:11
204:19 224:22	245:14	pitch 232:5	121:4 124:13	68:5 71:9 76:5,20
229:16,22 235:18	Peter's 120:15	place 7:10 9:16	126:8 144:19	81:3 82:2 86:19
235:19,20 252:10	Petter 18:12	60:3 70:4 104:5	145:7 147:13	102:13 103:3
281:7	phase 1:4 139:20	139:19 144:14	150:6 157:21	110:8 111:5,11,13
period 15:20	179:21 197:8	160:11 163:19	158:1 159:3 162:2	111:14,14,15,19
285:21	282:11 285:18	185:13 212:17	168:1,22 171:8	112:1,2,5,7,8,15
periodic 141:6	phenomenally	219:10 233:11	177:2 204:22	112:15,20 113:1
periodically 90:11	151:15 183:19	237:9 265:6 279:8	205:6,7,14 206:14	113:18 116:4
permission 127:19	philanthropic	places 162:19	206:17 207:14	117:12 118:8
person 25:9 213:4	154:16 232:6,20	174:21 200:4	211:3 213:15,15	119:16 120:5
257:4,6 258:7	philosophy 114:2	229:4	225:10,18 228:17	124:11,17 129:19
265:21	148:14	plan 31:11 72:10	235:11 243:3,13	129:19,22 130:3
personalizing 28:7	phone 34:9 35:18	82:1 143:7 178:12	244:11 249:22	130:16 131:9,21
personally 274:20	36:12 37:9 50:1	180:13 181:18	257:21 264:22	133:8 136:5 137:6
perspective 16:4	73:19 95:9,17	182:6 184:15,19	265:14 266:10	137:22 143:13
36:14 47:4 98:15	97:14,22 110:12	208:2 218:6	268:10 274:15	144:8 147:21
99:21	phoning 238:7	planning 81:13,20	280:14,16 284:5	162:22 164:11
perspectives 3:4	phrase 277:19	169:15 176:19	pointed 227:20	178:14,16 179:20
277:4	physical 6:20,22	187:1 236:4	pointed 227120	180:3,21 182:21
pertussis 39:17	7:1 44:4,22 82:2	plans 32:18 54:9	points 31:22 69:8	185:4 195:10
PESTRONK 1:17	88:19 142:13	115:11 143:9	80:16 98:5,9	196:7,20 197:12
40:15 41:7,20	263:15 281:3	179:8 180:9,11	103:5 125:9 173:4	198:4,21 199:12
94:13,16 95:18	physician 142:19	183:3 185:10	206:1 221:3	200:22 203:2,21
96:18 97:1,6	physicians 24:19	212:22 225:12	policy 27:4 84:15	208:6 209:11,12
147:8,18 155:22	25:10 29:7 185:10	233:20	237:13 283:8	214:19,20 215:7
162:12 165:5	Physiology 44:10	play 113:6 137:4	political 40:20	216:9 218:11
167:17 171:1,11	pick 21:5 94:20	191:14 205:8	119:20	222:9 224:6,7
172:3,18 173:8,14	110:11 129:2,3	211:2,21 222:13	politically 151:9	225:21 226:18
173:20 175:11,15	picked 177:20	played 12:2	poor 96:2	227:22 231:21
177:1 184:6	178:1	player 166:11	population 1:3,24	244:7 245:2,15
194:10,19 195:2,5	PICKENS 1:17	players 109:4	3:5 4:4 5:15,17	246:20 247:5,8,10
196:18 198:18	50:14,16,19 57:10	210:11	9:13 10:10,20	249:9,12 250:16
199:10,14,19	145:9 169:22	playing 203:12	11:3,5,14 12:16	250:17 251:21
200:2 209:16	225:17 226:15,22	please 6:4 95:6	13:8 18:22 19:1,3	252:10,13,20
				, ,
			I	

253:1 255:5 256:2	136:7,13,17	preliminary 88:14	227:19 231:6	proceed 242:22
256:16,19 257:9	137:18 138:2	premise 128:2	270:13	process 5:1,11
257:11,12,15	147:9 152:13	premium 87:9	primed 244:14	11:17 13:12 16:1
258:3,8,10,16,20	155:4 159:13	prenatal 262:14	prior 9:2 11:22	16:6,10,15,16
261:14 268:6	161:5,17,19	preparing 103:14	12:3	17:1,6 19:16
270:5 271:2	162:13,19 165:1	preposition 174:16	priorities 10:14	30:20 31:7,18
272:21 273:14	174:2,9,17 201:16	prescribe 255:22	14:5 64:16 162:14	33:2,9 34:20 35:5
276:4,16 279:18	202:11,16,18	PRESENT 1:13 2:8	172:5,14 173:1	38:13 39:22 40:10
279:19 280:1,20	214:5 220:9 228:5	presentation 94:17	196:1 197:4	41:16 51:15 52:18
280:22 281:5,15	236:19 239:14	195:11 209:19	219:16	56:2 67:15,16
populational	240:11 244:2	presentations	prioritization	68:3,6,13 81:15
195:22	251:5 261:13	151:1	172:16 264:18	85:12 98:12 99:16
populations 40:1,2	265:16 275:12	presented 11:2	prioritize 274:17	100:4 102:21
41:1,17 42:13	278:1,8	presentism 232:1	prioritizing 28:7	103:4 104:7,10,21
80:12 219:7 253:2	potentially 37:20	presents 80:8	priority 10:1 88:4	105:3,11,15 107:5
254:20 268:22	42:11,14,15 46:6	presiding 1:12	98:17 99:2 101:14	108:10,13,15
portfolio 131:20	57:14 91:13	press 22:21 94:15	172:11 174:2	109:15,17,19
165:11 181:11	138:14 162:15	284:18	194:11 195:17	110:18,19 111:8
236:13	163:22 176:13	pressing 279:9	198:5,6	111:12,22 112:15
portfolios 129:21	185:6 210:5 245:1	pressure 44:11	private 64:15 83:1	119:13 120:22
position 62:8 85:22	245:22 260:15	245:16 248:17,18	183:22 197:20	137:2 139:18
88:11 198:11,11	263:8 282:17	Presuming 244:6	probably 9:5 19:18	140:16 147:13
239:4	power 80:9 221:2	pretend 64:5	23:17,18 43:8	161:12,14 184:1
positioning 236:8	powerful 151:15	pretty 44:12,16	46:11 65:17 66:5	190:11 193:14
positive 33:19	153:21 218:15	56:19 79:4 85:7	69:15 72:7 73:8	196:4,12 200:13
116:7 117:2	practical 71:10	89:22 193:16	85:21 98:13 99:15	200:22 201:19
126:13,17 148:7	203:8 216:13	230:14 278:4,20	99:17 102:12	203:10 208:19
255:2	practice 142:2	prevalence 8:17	105:14 116:10	211:5 248:12
possibilities 30:17	152:16 153:3	49:11 88:18	144:14 153:14	267:21 271:16
possibility 110:13	154:11 155:2,16	255:16	166:3 171:4 179:5	272:17 275:1,6
possible 70:22	156:12 163:15	prevent 29:9 89:6	179:20 204:9	281:9,14 282:15
124:9 125:9	164:4,18 165:8	preventable 52:14	224:13 244:12	285:11
136:22 139:10	167:1 169:21	preventative 7:5	245:20 271:22	processes 39:8 42:2
157:22 226:1	184:10,19 185:12	Prevention 245:9	281:21 283:21	90:2,9
230:9	185:14 186:5	preventive 26:22	286:6	processing 175:12
possibly 72:7 162:4	189:14,18 191:21	251:12,19	problem 88:9	process-based 74:4
249:9	192:10,11 217:1	previous 262:4	94:14 95:1,22	produced 237:13
post 125:19 285:19	practiced 27:19	previously 7:2,7,18	96:6,10 97:8	253:9
posted 11:21	practices 104:12	7:22 8:13 15:7	108:18,20 114:21	product 58:19,21
posting 12:3	270:13	pre-contemplative	128:13 140:21	269:17 283:21
283:20	practitioners 28:10	199:22	162:15 165:6	production 88:18
post-meeting 162:8	80:18	primarily 66:3	171:12 204:5	productive 4:6
potential 12:9 13:5	precision 86:5	primary 24:19 25:3	224:5 246:5	productivity
13:12 30:12 31:16	preconceptual	25:10 26:18 27:7	258:21	182:16
32:2 69:20 75:9	197:8	27:11,17,18 28:3	problems 94:19	products 216:3
95:19 114:10	predictive 87:22	28:8,21 80:17	95:19,19 96:15	profound 116:17
129:19 130:3	preference 49:12	184:12 214:8	203:7,8	program 25:22
	_			
		•		

I				
26:1 68:11 79:11	202:18,21 203:1	139:4 144:7	67:10 81:6 181:3	198:2 236:7,8
102:16 183:9	203:20,21 204:14	147:10 148:13,17	put 11:14 12:11	238:13 249:17
278:18	206:1,3,8 207:15	148:19 149:4	33:2 74:5 87:2,10	250:2 257:10
programmatic	216:1,10,19 220:5	156:4 161:6,8	101:20 119:10	267:12,17,19
68:14	221:6 222:22	165:20 166:2,15	134:18 136:15	268:1,7
programs 15:18,19	223:15 241:16	166:18 177:17	137:15 138:17	quantitative 79:10
55:10,11 69:1	propositions	184:1 185:13,14	139:13,21 140:10	quantity 121:10
99:7 112:6	241:19 277:18	186:5,15 190:20	143:22 157:2,4	quarter 187:2
project 1:22,23	prospectively	190:22 193:4,22	188:11 191:7	quarterly 153:19
6:18 14:7 16:19	215:1 236:21	197:20 205:10	192:2 202:6	Quasi 241:1
56:12 83:11,12	proved 236:18	208:21 209:1,5	203:18 211:5	queasiness 87:19
85:19 98:7 100:11	provide 49:18	211:21 212:2,7	229:12 232:21	queasy 87:21
100:17,20 101:8	85:22 133:16	214:3 217:18	233:12 238:19	question 15:5
101:12,15 102:22	134:22 135:2	218:2 219:1 224:3	252:18,19 256:6	22:21 26:15 36:16
104:15 106:22	253:4 284:13	224:6,12,17 227:3	258:12 263:7	38:20 42:3 46:14
157:11 164:9,11	provided 11:4 21:9	227:9 230:8 231:7	264:3,12,18	58:17 69:22 76:9
166:17 170:11	40:5 83:4 99:21	234:17 235:3	265:11 270:12	98:4 108:16
171:3 172:8 174:4	132:10 184:12	237:10 240:13	272:14 274:2,6	109:12 161:12,12
180:18 226:19,21	209:9	258:16 262:7	275:20 277:11	161:13,14 166:1,7
245:3,6,11 246:2	provider 60:9 71:5	263:16 267:12	279:4,6 282:20	179:14 194:21
250:4,7 260:12	178:11	276:17 283:10,17	286:22	198:10 203:11,22
265:18 273:12	providers 55:16	284:13 285:20	putting 13:8 18:4	207:17 208:13
projects 12:15	181:13	publication 14:9	124:15 161:18	210:3 222:5
82:16,20,22 83:9	provides 11:4 26:1	publicly 159:2	259:22 282:11	227:15 249:15
93:2 100:6 105:15	28:9,10	pull 102:4 229:18	puzzle 197:22	254:3 262:1
170:4 215:18	providing 110:13	254:13	P-R-O-C-E-E-D	273:13 284:17
226:16,17 236:16	174:6 190:3,5	pulled 15:18	4:1	questions 8:18 15:2
246:4 260:16	259:3	269:19	p.m 123:20 187:8,9	17:8 22:17 45:15
275:21	public 2:16,18	pulling 37:10 38:8	188:2 287:6	45:16 47:6 68:8
promote 26:4	10:22,22 23:4,16	65:4	Q	103:7 106:18
promoted 217:1	27:1,12 28:21	pump 244:13	QASEEM 1:18	141:8 150:8 182:4
properly 131:7	30:15 32:22 33:5	purchasing 55:10	24:18 25:16 26:15	208:16 273:6
proposal 14:8	34:11 51:6,7 54:1	purely 120:4	61:4 111:3 167:9	284:21
propose 108:7	54:14 55:10 56:9	purpose 35:1 53:13	167:19 235:16	quick 108:4 169:7
proposed 66:6	56:13 57:4,21	53:14 87:20	236:22 279:11	170:8 198:9
215:17 233:12	58:7 65:19 68:20	126:11 147:20	282:4	quickly 152:5 280:15
249:9	69:1 78:6 79:6,19	160:5,6	QF 167:15	quite 92:10 140:7,9
proposing 46:6 proposition 135:19	80:18 81:5,12,19 88:8,15 93:11	purposes 41:8 53:20 178:2 243:5	qualitative 262:18	148:15 188:19
137:11,14 138:7	109:16 110:17	265:9	quality 1:1,10	197:2 199:8
176:7,22 177:4,8	114:14,15,21	pursue 74:7 173:5	10:14 28:2,5	212:19 244:14
181:17 184:7,9,21	114.14,15,21	206:19	37:13 38:18 40:4	212.17 244.14
185:3 186:12,14	117:2,6 118:2	pursued 74:10	44:20 62:12 71:1	R
188:20 190:15	119:7,16 120:5	pursued 74.10 push 42:10 200:15	71:2 79:11 83:16	race 72:21 73:5
193:5,19 200:11	121:19 124:10,17	217:8 223:8	94:20 96:2 98:22	253:7 254:13,15
200:21 201:6,15	129:5 137:5 138:7	pushed 180:5,22	114:4 121:10	racial 41:2 255:17
201:21 202:6,13	138:10,15,21	pushing 20:5 67:8	167:15,17 181:14	racism 80:10
	, - ,	• • • • • • •		
	1		1	1

	1		l	I
raise 5:7 63:8 66:21	ready 18:5 23:6	259:18 263:21	recommended 6:14	regardless 159:15
127:21 191:10,11	100:7,9,12 102:12	264:3 270:14	7:9 8:12 134:21	272:4
200:3	107:15 244:19	274:19 275:12	280:20 285:9	regards 13:3
raised 15:13	real 29:6 30:21	280:12 281:10	reconvene 187:5	region 57:11
raises 58:16 91:7	68:17 83:13 88:2	286:17	188:4	regional 81:13,20
raising 174:19	142:7 186:14	realm 202:3 228:22	record 123:19	registries 117:11
194:5 195:6	267:16	263:14	170:19 187:8	regular 106:13
ran 9:17 185:15	realized 23:19	reams 237:12	225:7 233:8,9	rein 83:21
271:14	realizing 209:13	reason 5:14 65:10	237:16 238:5,8	reinvent 130:18
RAND 156:7	231:9	93:17 147:12,14	287:6	reinventing 167:11
273:13	really 4:7 5:13 17:5	147:15 157:16	recording 173:16	171:9
random 114:22	19:1,7 20:18 25:8	182:8 195:5 209:8	173:18 215:15	reissue 126:15,20
115:16 120:7	27:18 28:6,16	223:3 257:21	records 237:18	127:13
138:12 196:13	29:8 30:2 32:1	reasonable 41:22	recreating 264:16	rejected 123:5
range 185:22 222:3	38:13 39:8 46:6	reasons 13:14	rectangular 47:9	252:5,13
ranging 85:7	47:22 56:8 57:2	14:18 32:5 50:2	redo 17:4	relate 39:8,9
rankings 106:21	58:20 62:13,14	89:19 90:4 276:11	reduce 132:12,21	162:22
108:12 115:5	63:9 65:2 66:22	rebrand 51:5	135:7 190:7	related 68:10 86:15
150:1 156:21	71:8,10 76:7,11	rebranding 51:15	192:16	86:15 106:19
157:18 158:11,14	76:12 81:19 82:3	recall 43:9 72:14	reducing 174:9	156:22 193:19
rarely 17:2	85:12 98:8,10,21	recap 3:2,3 4:10	reenforce 51:2	relates 19:11
rate 19:19 23:14	99:2,5,15,22	6:7	reference 38:15	relation 30:4
34:5,19 36:5	100:15 101:16	receive 278:12,14	261:19	relationship 58:3
37:12 52:3,8,13	102:3 103:20,22	received 11:16 13:9	referenced 40:17	272:17
82:9 98:14 99:18	104:9,20 105:6,17	21:11	referred 140:4	relatively 102:1
101:16 178:15	105:18,20 112:12	receiving 278:10	142:2	210:17
211:16 252:20	112:16 118:4,14	reception 145:1	referring 72:13	relevance 48:6
rates 44:5 56:18	118:19 121:12,13	receptive 81:10	105:8 146:15	193:3 255:4
60:2,7 115:2	121:21 124:13	receptivity 4:22	171:14	relevant 12:7 56:20
212:4 257:10	135:19 140:12	recognition 191:12	refine 132:10,20	57:3 68:4 194:2
rating 91:19	142:6 143:8,11	recognize 230:17	134:16 189:22	207:22
ratings 17:2 93:7	146:3 151:21	recognized 81:4	refined 132:16	reliability 238:18
286:12	157:13 158:22 160:16 161:3	99:5	refinement 11:16	reliable 229:21 relies 87:11 138:11
rationale 286:13 RCTs 121:9	165:21 166:11	recognizes 28:20 recommend 16:20	refining 109:7 172:6,7 174:3,7	rely 128:20
reach 8:20 9:10	172:7 176:9	286:13	192:13 259:11	relying 128:13
170:21 190:15	172.7170.9	recommendation	reflect 66:3	remaining 126:4
reaching 273:13	193:18 197:22	114:7 264:4	reflected 127:7	remember 6:4 92:6
react 101:22	199:22 203:5,19	279:21	207:10 220:15	140:19 162:8
143:18	206:3,14 213:4	recommendations	reflects 64:6	remembered
reaction 118:5	214:4,14 228:11	3:6 5:4 129:11	reframe 244:1	111:10
read 106:7 252:15	229:4 231:3,10,18	130:10 131:8	reframing 212:9	remind 6:2 284:17
284:6	232:1,9 233:4	206:16 251:7	regarding 36:12	285:8
readiness 5:1 35:2	238:11 239:21	279:3,12,20 280:5	37:4,11 89:14	reminding 43:10
79:21 82:6	240:1,2,6 242:10	280:10 281:21	112:3 124:8	remote 60:15 63:17
readmission 16:12	243:1 245:7 246:9	282:8,22 283:4	126:10 127:11	78:17
readmissions 57:15	250:1 251:15	286:10	206:18 276:11	remotely 34:9
	-			-

٦

	04 10 05 15	4 22 17 105 4	50 1 54 15 55 5	104.0.150.14
removes 55:19	84:10 85:15	rest 33:17 105:4	52:1 54:17 56:7	124:9 159:16
renal 255:12,14,16	122:12 156:9,10	112:17 152:1	57:6 61:19 62:17	191:13 195:15
255:19	166:15,19 262:19	241:22 266:6	95:16 97:10,18	197:17 200:17
rephrase 227:8	reserve 95:12	274:7,10 278:19	110:9 119:4	201:16 205:4,6,8
rephrased 280:11	145:20 170:1	restructure 104:6	133:12 134:10	205:14,19 222:14
replace 198:10	residents 83:2	restructuring	136:20 138:2	231:19 235:17
report 72:11,12	resides 79:19	193:12	141:11 147:17,22	241:20 276:17
73:7 105:18 121:7	resisted 257:22	resubmit 188:10	151:7,19 154:9	roll 73:12
164:7 219:15	resonance 148:11	result 10:4,6 74:9	155:7 158:15	rolled 117:11,17
236:17 263:2	resonant 49:14	219:10 236:20	160:1 164:19	rolling 71:3 116:2
271:3,4,10,12	resonate 82:3	results 138:20	171:16 172:8,9,17	251:1,2
282:11 285:18,19	resonated 165:21	170:22 188:10	172:22 175:14	Ron 1:15 9:9,9 12:9
286:1,9	resonating 26:7	190:19	183:8 185:4 186:7	15:3 42:20 46:17
REPORTER	resounds 99:15	resumed 123:20	187:6 188:3	51:2 94:12 144:20
173:18	resource 50:4	187:9	200:19 202:1,1,15	160:14 162:2
reporting 15:17	250:5,8	rethought 228:22	204:3,21 206:10	170:8 171:2 181:2
55:11 73:6 230:13	resources 14:1 33:6	retired 15:19	206:13 218:19	205:20 206:17
267:14	38:8 83:14 87:4	retrospectively	222:10,11 223:3,7	227:16 239:9
reports 72:7 90:11	97:20 100:1	121:3	223:10,10 226:7	267:8 285:13
90:16 263:7 264:9	108:14 131:8	return 67:20	235:7,10 240:10	room 1:11 33:16
represent 77:22	140:21 172:19	revamp 104:6	242:22 243:15,16	55:17 82:5 104:8
representative	175:7 179:1	review 4:10 17:1,1	243:18,20,22	145:3 151:21
60:22 102:19	217:12,13	62:16 102:6 234:9	246:6 248:21	221:2
representatives	respect 98:3 100:16	261:5 265:2	252:2 254:21	root 28:4,12,18
4:19 92:15 193:2	102:15 151:12	reviewed 253:6	258:6 259:14	108:21 109:8
represented 67:12	203:21	282:12	268:9,10 269:1	roots 27:17,21
represents 84:12	respond 104:11	reviewing 261:9	271:8 273:6	round 5:7,8 46:21
requesting 267:13	105:8 135:10	265:2	278:16,16	46:22 282:13
283:1	responded 198:22	revise 134:20	rigor 86:4 107:6	route 236:4
requests 268:2	responding 36:13	revising 174:5	114:3	routine 90:21
require 74:1 121:8	75:1 89:15 110:15	190:1	rigorous 124:15	routinely 107:11
122:19 171:9	134:9,12 135:14	revisit 279:3,10	rigorously 19:13	115:10 117:13
253:3	response 3:4 4:20	revisiting 263:20	rings 59:8	270:13
required 215:5	4:21 5:5 9:13	reworked 133:7	ripe 256:18	roving 273:5
requirement	13:3 19:18 23:14	re-emphasizing	risk 80:13 86:19	rub 171:19
142:16,18 211:20	34:5,19 36:5	248:7	88:17 212:14	rubic 84:8 90:6
requirements	37:12 45:10 66:2	re-engineered	242:6 247:20	Rudolph 107:17
13:17,21 32:21	82:9 98:14 99:18	34:21	254:21	run 102:17
33:1 67:6 73:6	101:16 108:5	rich 217:22 224:17	road 117:13	runs 51:11 258:22
105:1,21 183:13	110:15 113:16	274:20 276:10	Robert 1:17 106:19	RWJ 152:19 157:8
214:7 230:14	115:2 124:4,22	richer 139:8	189:4 194:7	157:8,10,17
241:17 242:5,12	126:14 189:8	richly 169:7	221:11	166:17 226:16
requires 211:12	246:13,14 276:12	right 5:10,10 13:7	Robyn 1:24 198:14	
234:3	responses 125:2	16:7 18:16 26:13	rocks 237:8 238:11	<u> </u>
requiring 180:11	285:14	28:15 35:22 40:6	role 12:2 34:2	s 118:5
218:2	responsibility	41:6 46:3 50:15	36:18 75:4 113:6	safe 210:13
research 47:15	193:1,2	50:18,22 51:10	117:4 118:18	safety 99:21
L				

				Page 51
sales 186:11	258:11,17	208:8 237:5 239:2	178:14	275:20
sample 114:22	scratch 125:17,18	250:7 254:10	serves 53:12	short-circuit 119:8
115:16 138:12	screen 188:7	261:9 266:18	services 18:7 83:3,4	shot 183:1
191:8	screening 7:5,6	271:21 274:18	97:20 111:15	show 111:1 132:3
SAMPSEL 1:18	245:16	275:2,7 281:18	112:8,9 186:18	238:18 265:12
158:6,21 159:3	SCRIP 256:8	286:1	209:9 249:21	showing 254:7
160:2 179:13	Seal 69:13	seed 141:1	251:12,19	side 19:6 55:16
181:9 183:2	search 236:7	seeing 39:20 49:6	serving 195:12	64:15 74:21 90:17
246:12 248:2	second 6:19 7:1,12	90:1 167:22	serving 195.12 session 110:21	90:17 144:11,16
Santa 82:15	16:21 32:3 45:13	180:15 222:6	272:7	183:11
Sarah 1:18 94:6,8	45:16 47:20 48:15	237:17 263:22	sessions 19:14	sides 143:21
94:15 95:8 97:21	61:4 65:9 96:1,17	seen 23:11 33:3	set 40:16 71:15	
	,			side-by-side 261:7
98:8 103:6 159:21	108:15,16 125:5	112:3 142:16	99:9 149:6 179:7	265:4
162:2 177:15	129:17 131:11	sees 27:10 28:16	180:18 181:6	significant 30:10
179:5,12 242:4	133:15 162:1	57:4	185:9 197:1	67:22 122:5 204:7
246:11	172:5 173:13	select 286:7	199:10 204:18	212:9
Sarah's 116:15	174:2 185:1,8	self 117:12	208:15 213:1	similar 142:5
sat 23:12 104:17	233:8 248:9,9	sell 78:11,12	215:6,6 218:12,16	170:17 180:20
saying 16:10 25:1	264:2	223:17 227:19	228:9,11 261:9	249:11 268:17
25:17 32:16 45:17	secondary 231:12	send 92:20 93:21	sets 88:3 212:10	269:8
61:6 66:11 76:1	secondhand 263:15	286:6	262:6 264:5,14	similarities 131:2
144:8,20 165:16	Secretary 2:14	sending 259:17	setting 23:21 85:9	Similarly 250:5
176:7 182:12	18:8	Senior 1:23	197:18	simple 43:11
188:15 201:14	section 73:3 234:22	seniors 242:7	seven 112:21	simplest 257:2
230:6 237:21	sections 198:22	sense 5:3 12:7	222:22	simply 34:2 124:22
273:7	sector 156:4 183:22	14:17 24:15 42:17	sexily 272:18	174:19 257:9
says 55:21 178:13	184:1 224:8 230:8	51:2 70:14 81:9	shame 67:4	single 121:12 253:6
242:17,18	276:17	82:10 83:8 120:18	share 9:1 14:11	256:14
scads 64:19	sectors 197:21	137:3 149:17	60:17 78:18 256:8	sit 206:2
scale 175:18	see 19:5,19 25:12	175:17 194:5	266:15 268:3	site 107:20
scan 11:2 272:12	25:13 29:12,14,17	210:16	269:17 272:3	sites 141:6
272:13 274:3	33:16 41:22 42:16		281:21 282:16	sits 211:19
277:14	49:16 50:5,6,7,12	111:17 112:1	284:5	sitting 111:4 209:3
scanning 164:8	53:15 60:4,18	157:8 164:17	shared 59:21	237:16 238:7
scarce 217:12	76:6 77:5 81:7,14	194:11 195:6,17	143:14	situation 85:13
schizophrenia	83:17 84:1,5	233:22 258:21	SharePoint 141:6	six 16:14 229:19
247:16	86:12,16 89:21	281:11	sharing 89:7 183:6	slightly 60:11
school 44:5 185:17	90:5 93:3 122:12	separating 62:20	271:10	singlify 00.11 small 76:2 84:10
208:5 211:16	127:10,15,22	sequence 172:15	sheet 47:5 49:17	114:22 115:16
212:4 213:6	133:17 135:4	series 19:13 84:16	133:7 134:20	118:11 125:10
231:20 232:18	143:13 159:12	84:19 86:14	174:5 190:1	138:11
235:8 238:7	163:21 170:21	214:13,18,20	sheets 133:17	smaller 235:13
science 119:18	176:18 177:8,18	283:3	shift 38:4,12,14	smart 213:4,10
122:17,17	183:10 189:6	seriously 58:22	shifted 80:4	245:21
sciences 119:17,19	194:17 199:17	serve 113:16	short 21:4 102:1	smells 203:14
119:20,21	200:19 201:19	241:20	shortage 204:7,9	smoke 263:15
scope 87:11 125:11	202:17 205:15	served 5:18 52:4,9	shortly 266:17	smoking 8:16 44:7

58:11 60:3,7	283:15 284:14	170:7,13 198:9	186:21 191:4	32:15 136:10
88:17 111:21	sort 20:10 33:7	speak 6:4 18:19	216:4 231:11	138:19 163:19
112:6 113:8	34:20 43:22 46:4	66:14 95:10,15	235:6 279:5,7	190:18 225:12
114:18 116:16	53:16 55:21 59:13	97:12 103:6,9	spread 267:2	276:16
149:19,20 164:12	60:5 62:13 64:3	104:9 179:5,11	square 5:8,8 46:20	standing 11:20
229:2	64:10 67:1,8,10	speaking 66:14	47:1,7,8	35:10
snag 77:17	68:21 70:13,16,20	special 26:20	squeezing 28:11	standpoint 85:12
social 10:5 38:9	71:3 73:11 78:6	specific 28:2 41:2	squishiness 121:21	98:12 230:6
42:1,6,9 44:3,21	83:6 92:8 111:17	63:6 73:7,11	stability 87:13	stands 26:18 69:10
66:17 79:16 81:17	113:3,4,4 114:6	89:19 93:8 100:16	stack 237:17	259:14
82:18,20 83:1,20	130:12,17 135:2	114:7 133:8 148:9	staff 1:21 8:19 9:3	Stange 1:12,15
90:6,17 91:20	138:18 140:1	174:21 198:13	9:22 13:19 48:9	22:3 24:3 26:19
93:2 96:5 116:11	145:5 149:17	200:4 212:20	104:8,14,16 109:1	30:4,5 37:16
119:19 231:19	163:3,17 165:15	223:21 247:7	131:19 195:10,14	118:4 120:14
251:9,18 253:18	175:18 177:15	250:7,8 255:13	195:22 196:2,20	231:3 249:6
281:2	189:13 194:22	260:14 277:8	285:3,6 286:16	250:11,15 256:3
society 28:11 29:4	197:7,9,16,18	280:16	staffing 14:2 197:5	256:18 257:19
38:8 80:21	207:6 211:5	specifically 22:13	stage 73:10 105:10	269:7,11
solicit 129:12	215:21 236:2	72:15 76:1 98:14	190:11 214:21	star 22:22 91:18
130:11,14 131:8	237:8 241:11	99:17,18 100:20	stages 73:9	94:15 242:9
189:11	242:1,10 252:5	113:7 117:22	stake 211:6,11	284:18
solicitation 130:21	256:14 262:10,19	122:19 195:8	stakeholder 183:17	Starbucks 58:19
solicited 236:10	263:5,16 264:9	220:10 255:7	231:10	STARS 183:9
soliciting 129:14	266:18 274:22	282:2	stakeholders 201:2	start 6:6 9:11 37:3
259:7	281:5 282:2	specifications	233:6 234:16	60:4 68:15 77:14
solid 162:4	sorts 65:11 164:13	98:19 101:5	271:1 273:14	120:3 130:4
solve 94:14 97:8	sound 38:8	105:22 115:22	stakeholder/cust	139:20 142:14
165:6	sounds 123:12	265:3 286:14	239:15	168:20 170:20
solving 97:9	141:21 159:1	specifics 92:21	stand 25:4	180:15 214:8
somebody 107:20	170:17 227:4,6	132:7	standard 90:6	231:12 233:6,11
175:4 186:13	234:10 265:18	specified 106:2	117:15 191:14	234:19 236:20
209:2	267:4	spectrum 30:16	225:13,14 230:4	257:13 261:6
something's 209:22	source 28:8 139:8	31:4 53:2 102:2	239:5 246:19	265:6 275:22
somewhat 33:22	240:11	speed 37:14	standardization	281:10
99:9 104:6	sources 129:2,8	spend 36:6 228:7	74:11,13,14 84:1	started 17:13 28:3
soon 20:18 27:1	130:10 162:18	271:1	89:21 114:10	43:2 61:5 82:11
245:18	space 91:13 94:4	spent 27:4 43:13	124:12 148:5	85:19 92:8 100:12
sophisticated 90:15	95:2 143:13 147:2 147:10,21 166:8	124:6	205:13,17 212:15 223:13 230:20	163:12 167:22
182:14,19	<i>,</i>	spheres 177:15		168:2,3,6 246:18 starting 38:12 62:8
sorry 8:3,6 10:10 10:17 23:2 25:5	166:12 198:17	spirit 285:2	standardize 117:16 208:10	starting 38:12 62:8 70:18 171:21
	202:12 209:21	spirituality 122:10	208:10 standardized 70:7	
48:13 57:9,10 113:12 127:15	213:18 214:3 243:21	split 20:21	115:19 124:16	196:6 213:15 215:10 264:22
132:17 136:19	span 10:8	splitting 194:22 spoken 9:8 64:2	218:9 219:20	starts 100:8 222:1
132:17 136:19	SPANGLER 1:19	98:8		
239:9 249:5	8:4,8 157:7,15	spot 18:5 114:12,16	standardizing 68:7 70:3,21 91:9	state 57:17,18 70:12 71:7 81:14
259:9 249:5	158:2,17 159:20	spot 18:5 114:12,16 116:22 148:12	standards 11:19	84:12,16 85:1,2
230.10 201.17	130.2,17 139.20	110.22 140.12	stanual us 11.17	04.12,10 03.1,2

	1	1		1
88:10,11,12	215:17 233:12	234:3 240:12,18	study 53:5 79:12	successful 210:2
131:13 151:4	266:4 276:14	240:22 241:12	120:8 121:12	sucking 38:7
153:9 183:12,12	278:1,1,5,9	243:13,19 244:6	203:16	sudden 182:8
183:13,13 216:11	steward 229:5	244:10 258:19	stuff 56:1 139:5	Sue 1:17 42:20
216:14 217:9	Stewards 228:20	strange 273:2	164:13 181:12	50:12 59:14 145:8
218:3,11,13	228:21	strategic 84:11	196:9 199:22	225:16
219:12 224:13	Stiefel 1:19 21:9	85:16 162:13,14	205:13 252:15	sufficient 95:20
227:12 247:16,21	29:19 30:6 42:21	172:5,11,14 173:1	266:21	suggest 21:6,13
stateability 92:1	45:18 57:19	175:17 176:2	stumbled 41:10	45:13 108:19
stated 107:6 163:4	113:12 122:16	182:3 188:9	122:21	133:7 147:18
statement 25:10	127:18 128:1,4,8	192:21 194:8,17	subgroup 247:7	161:2 200:5
184:22 185:1	128:12,17 130:20	195:17 196:11,12	submission 14:3	suggested 82:17
states 92:12 216:15	131:12 138:6	209:17 210:20	108:1 247:13	108:18 145:16
241:3	139:1,7 148:9,22	211:7 241:9	submissions 106:13	279:8
statistics 90:12	154:19 155:10	277:12 278:12	submit 13:14 14:7	suggesters 248:20
237:11	156:3,14 159:7	strategies 189:6	14:8 48:5 54:6	suggesting 45:8
stats 238:17	200:9 204:4	201:11 248:10	84:8 100:13 101:1	161:10 171:20
status 20:11 44:13	211:10 215:4	277:8	101:6 103:15	225:2 276:7
90:11,16 108:9	218:17,20 224:11	strategy 10:14	105:2 109:22	suggestion 129:4
113:21 117:10	225:14 227:2,9,17	57:20 99:1 198:2	128:14 129:16	148:10 177:2
185:20 283:17	234:6 235:4,8	249:11	132:11,13,15	266:14
stay 95:17	241:15 242:16	stratification 250:2	158:15 159:5	suggestions 11:16
stead 95:10	251:3 253:18	stratified 253:5,7	160:9,9 174:10,13	49:9 126:1 266:7
stealing 147:20	255:1 261:4	253:10 254:8	178:8 190:8	275:10
148:1	264:21 275:15	stratifying 249:17	192:16 254:6	summarize 123:22
Steering 1:4,10 6:8	276:1	250:13,17,21,21	281:22 282:22	220:22
6:14 8:12 16:19	stop 134:14 278:22	street 1:11 118:10	submitted 6:12,17	summarized 189:4
17:3,4 49:9,13	stopped 21:1	119:2 185:17	7:11,14,20 8:3,17	summarizing 45:7
161:15 260:22	Stoto 1:20 10:11,16	268:21	95:21 96:2,8	221:11
274:15 283:3	21:16,21 31:21	stretch 171:14	109:13 113:19	summary 73:17
285:9	38:22 39:18,21	strict 30:18	134:7 162:16	support 25:22
step 27:7,8 28:16	46:2 53:10 54:17	strikes 110:16	165:10 246:15	26:12,13 37:12
29:6 35:18 52:7	55:2 65:18 110:6	242:20	submitters 12:9	64:14 65:7 86:1
52:12,15 53:3	119:3 135:15,22	strong 20:13 27:10	13:5 97:3	108:17 110:14
58:9,10,14 62:10	136:4,21 137:16	65:10 99:14	submitting 49:1	140:16,22 151:7
71:11 95:9 97:22	137:21 139:2,15	struck 142:7,11	50:8 89:20 100:19	151:18 163:7
117:20 131:11,12	144:18 149:16	144:20	110:4 248:5	174:11 190:3
139:18 162:1	153:7,13,17	structural 80:9	subpopulation	192:5 213:15
200:14 201:9	156:19 157:4,12	structure 73:20	115:14 116:2	supporting 24:5
200:14 201:9 202:10 203:3	157:20 164:7	111:13 270:19	117:17	supposed 169:2
202:10 203:3	166:13 193:18,21	structured 76:19	subpopulations	supposed 109.2 sure 11:15 12:16
268:1	201:20 202:2,8	76:20 111:8 281:9	115:15,21	13:18 17:5 34:7
stepping 151:11	201:20 202:2,0	struggling 59:4	subsequent 116:18	34:12 39:18 40:12
steps 24:12 66:8	214:4,11 222:18	207:14,16 239:17	subset 129:3	41:17 48:11 54:1
73:21 74:6 104:20	223:2,8 225:8	270:2	234:11,14,19,21	72:4 75:11 78:18
125:7,10 189:2	226:4 228:16,21	stuck 178:17 270:6	261:6	78:20 84:3 89:22
207:7 215:11,13	229:10 233:17,22	student 27:3	sub-county 87:12	96:20 98:20 99:3
20111 213.11,13	227.10 233.17,22	50440110 27.5	Sub county 07.12	70.20 70.20 77.3
				Ι

99:6 116:15	70:11 71:5 75:16	221:4 231:20	tape 35:7	256:16 259:20
136:13 138:13	77:13 78:4 79:14	250:3 260:9	taped 6:3	territorial 151:4
139:13 151:6	91:19 110:3 115:5	263:17 265:10,11	target 101:5 231:12	218:4
157:12 164:6	115:6,11,13,16,21	265:15 266:2	targeted 130:11,14	test 255:14
166:10 167:13	116:13,14 117:3	267:1,6 274:21	131:9,14 189:11	tested 100:22 106:2
173:16 177:16	129:7 138:9,10	278:2 279:1	targeting 130:5	106:6,10
188:14,19 194:13	184:11 208:2,9,12	taken 56:1 85:2	task 84:15 85:17	testing 13:15,16,20
200:16 230:16	212:7 217:2,19	274:20 276:15	121:5 236:14	14:3 100:10 105:1
246:2 247:18,19	222:17 224:19,20	286:18	272:3	105:1,21
253:14,21 266:19	225:9 232:14	takes 26:12	taxation 49:11 60:2	tether 57:1 77:15
269:19 285:13,15	236:7,8 238:9	talk 4:20 18:8	team 104:19	77:16
286:1	242:3 250:19	20:18 28:13 32:20	107:20	tethered 56:15
surveillance 138:10	263:5	47:11 59:11	tech 35:14	Texas 57:12,17
138:21 190:19	systems 30:1,2,22	142:19 151:18	technical 65:10	thank 5:22 17:22
survey 45:14,16	58:1,13 64:12,13	157:19 176:6	110:13 174:6	18:17,18 21:21
60:19 70:22 74:17	67:2 70:6 80:18	177:12 201:5	190:3 192:1	26:9 33:14 36:1
83:1 88:21 130:15	138:20 146:7	262:3,13,20	285:18	63:11 78:15 79:2
131:9 150:8	164:10 166:15,18	264:10 269:18	tedious 4:6	95:3 103:8,10
163:18 164:3	225:4 226:12	273:7 275:7 285:1	tee 131:22	242:13 268:10
222:5,17 223:20	231:6 279:22	talked 14:17 39:2	teleconference 2:22	281:18 284:22
286:6	S-E-S-S-I-O-N	40:17 44:18 49:10	telephone 22:22	285:2,3 286:15,19
surveying 163:3	188:1	52:18 59:15 60:2	249:1 284:19	286:20 287:3
surveys 68:8,10	S-T-A-R 91:18	70:2 111:21	tell 13:1 19:4 22:13	thankless 285:1
69:1 70:2,3,9		142:12 145:12,15	25:18 87:17 137:8	thanks 18:17 34:15
71:15 72:16,19	T	166:3,4,4 171:2	147:4 193:8 206:7	187:6 273:20
73:11 89:6 115:1	table 68:17 81:6	204:17 220:12	246:5	themes 35:15 37:6
115:16 138:12	136:9 150:17,18	221:14 234:16	telling 186:13	they'd 154:15
149:22 221:15,21	245:22 262:16	259:21 260:13	template 266:20	184:4
222:19 224:1,7	263:2,21 264:10	talking 21:17 22:4	268:5	thin 66:2
229:3	tables 165:22 262:9	46:8 69:14 73:8	templated 266:22	thing 17:12 28:12
survey-based 87:12	262:17	74:12 75:6 79:20	temporary 59:1	32:9,14 44:6 51:1
suspect 22:15	tags 127:16	82:13 109:8	ten 79:7 120:21	51:17 54:9 55:15
69:17 79:5	tail 183:8	110:22 112:14,16	123:13,15 169:3	55:18 61:17 66:20
sustainability 81:2	take 9:16,17 17:10	112:18 113:11,14	tend 171:13 275:3	78:9 104:3 107:7
84:14	24:1 33:10 37:1	114:9 116:20	tends 38:1	111:2 113:4 118:7
sustainable 92:19	52:7,12 62:9	119:16 128:22	tentative 286:7	119:1,10 120:3
sweet 114:11,16	105:6 111:20	129:18 140:1	tenuous 60:1	127:21 132:18
116:22 148:12	113:2 115:18	144:21 156:5	term 21:5	135:6,11 140:11
191:4 216:4	120:13 123:13,15	158:2 159:21,22	terminology 147:5	144:3 150:16
231:10 235:6	128:8 132:1	163:3,11 173:2,22	terms 4:22 26:18	152:19 166:6
syllogisms 86:14	133:21 142:15,18	182:7 193:3 203:5	36:13 40:12 47:8	191:10 193:19
synergy 116:7	152:2 168:20	210:22 213:19	56:10,13,17 62:21	202:8 207:11
synthesis 263:2	173:1 175:9	237:3 244:3 255:5	73:21 75:3,8	209:14 213:16
synthesized 64:5	176:21 183:5	255:6 263:20	103:13,18 113:6	220:18 221:13
system 28:20 38:13	186:21 187:2,4	273:4 279:16	125:19 147:3	230:14 232:22
56:16,20 58:4	188:4,13 205:16	280:2 281:6	163:6 202:7 236:2	234:19 237:21
59:14,22 60:9	213:8 215:13	talks 210:12	236:18 239:19	241:22 242:17

			_	
243:15 252:4	59:15,19 60:3,6	167:7 168:14,16	thinking 14:8 41:3	225:2 226:8,10
257:8 278:10	60:11,12 61:6,8	169:16,21 176:3,8	46:7,10 58:1	227:3,7 248:22
284:11	62:7,9,10,14,15	176:13 177:8	61:13 97:7 99:11	251:8,17 252:3
things 20:20 21:3	62:21,22 63:1,8	178:21 180:4	118:13 123:9	253:15 255:10
26:10 27:9 32:16	65:10,17 66:1,22	181:5 182:13	136:6,16 139:22	257:5,7 265:10
35:5 36:3 37:17	66:22 67:4,7	183:20 184:8	142:14 154:18	276:20 286:7
47:17 53:11 56:22	69:11 70:3 71:11	186:20 189:4	156:6,9 163:5,13	throttle 80:22
59:20 64:15 73:22	71:22 72:6,9	191:21 192:19	195:7.9 197:8	throw 144:2 151:22
74:2,4,5,11,19,21	73:10 75:12,12,18	193:16,18 194:21	200:10 205:21	158:7
77:8 80:10,12	77:1,3,4,6,7,9,14	195:15,19,20	211:12,14 215:1	throwing 130:12
82:17 83:12 86:18	77:16 78:2,7,9	197:22 198:1,6,7	215:20 216:16	143:17
87:16,22 116:20	83:5,18 84:18	201:2,20 202:12	220:3,6 231:5	THURSDAY 1:6
118:18 121:14	86:6,9 87:3 88:5	204:8,21 206:2	250:18 251:3	ticket 165:17
125:19 136:11	91:4 98:3,9,13	207:2,17 208:6,7	256:13 258:20	tie 98:9 109:19
137:4 139:17	99:13,16,19 100:2	208:13,14,15,18	260:15 267:14	143:16 213:12
142:6 144:12	100:14 101:12,18	209:5 210:15	thinks 25:11 40:7	tied 81:11 83:17
145:10 150:9	102:1,4,7,8 103:1	211:10,17,22	third 65:16 89:8	109:18
156:20,22 164:17	103:16 104:3,22	212:6,10,17,18	96:6,22 97:1	tier 51:21
168:6 170:4 173:6	105:2,3 107:14,20	213:16 214:6,14	125:12 133:19	tie-in 159:13,13
174:13 176:1	109:5,9,14 110:14	214:15 215:9	154:10 174:9	time 9:17 11:13
186:4 189:1 192:4	111:7,16 112:2,10	216:2 217:10,22	185:13 186:2	14:2 15:10,13,20
196:13 207:10	112:12 113:5	221:1,6,14,19	253:17	16:11 18:10 19:2
210:14 213:12	114:11,16 116:4,5	224:11,15,15	thorough 206:16	20:3 24:1 25:21
222:13 226:19	116:6 117:1,19,22	227:2 228:6,12,16	277:2	26:5,6 27:4 28:6
239:5 242:21	118:9,10,19 119:1	228:17,17 229:7	thought 8:4 13:7	31:15 32:20 36:6
249:21 259:16,20	119:3,4,14 120:2	229:14 231:11,16	47:13 51:12 70:2	36:20 48:10,15,17
260:10 275:10,12	120:17 122:17,17	233:3 234:7 236:1	78:1 108:12 126:3	48:22 71:13 84:7
275:13 276:3	123:7,11 127:4	237:1 239:14,21	136:12 143:17	95:11 101:1,20,22
think 4:7,11,20	128:1,12 130:21	241:18 242:10	162:12 169:11	102:4 104:17
5:12 9:4 14:10	131:4 132:9	243:14 244:12,15	171:20 180:2	109:3 115:2
16:5 21:13 23:15	133:19 134:3,7,11	244:20 245:5,19	221:12 240:19	120:20 124:6,13
23:22 24:10,11,19	135:17,17,18	246:1 247:10	241:16 254:19	134:4,4,5,11
25:20 26:4,6 27:6	136:12 137:4	249:10,16,21	261:16 264:15	135:8 136:1
28:4,19 29:19	138:6,15 140:6,8	252:16 255:2	273:4,13	140:20 145:11
30:2,9 31:2,22	140:11,12,15,18	256:8 257:15,22	thoughtful 29:2	150:12 159:12
32:1,4,7,9,10,10	141:10 142:7,22	258:19 259:5,14	thoughts 12:6 29:7	161:21 162:7
34:21 35:8,11	143:10 144:1	260:13 264:21,22	37:15 46:19 60:18	168:11 169:1
36:3,4,5 37:18	145:3,4 146:12,14	265:1,22 266:3	78:19 246:10	172:21 174:11
39:22 40:3,16	147:13 148:4,10	267:1,10,17,20	260:19,21 261:1	176:9,19 181:19
41:5,8,10 43:5,7	148:13,15 149:12	269:14 271:13	thousands 83:2	185:22 190:9
43:22 46:2,9,21	149:16 150:2,5	273:21 274:5,14	204:13,13	208:20 209:1,3
47:10,17 48:8	151:3,16 152:18	275:3,4,5,6,9,10	three 6:14 15:15	211:3 213:10
51:9,17 52:18	153:5 154:3 155:8	275:11,13 277:4	62:17 94:18 100:4	217:12 228:7
53:7,10,13,17	156:5 157:22	278:4,14 279:13	100:14 124:20	236:10 248:15
54:9 56:6,7,9,19	158:10,20 159:7	279:16 280:3,7	139:3 152:15,16	249:19 258:1
57:2,2,19,20,21	160:21 163:2	281:10 282:1,15	156:8 209:7	259:13 260:8,8,19
58:1,5,6 59:7,10	165:15 166:8,19	282:18 287:1	218:10,13 219:2	266:2,6,11 268:12

				Page 521
268:22 269:6	98:9,13 150:21	truckloads 204:12	163:22 164:17	47:3
274:7,9 278:2	touched 99:20	True 157:15,15	169:2 190:11	understanding
284:16,20 286:18	100:2	truly 76:22	192:12 224:9	60:6 134:1
timeliness 263:13	tough 256:5	try 5:14 30:7 35:13	228:3 233:22	understands 20:4
times 19:9 46:21,22	track 208:10	86:21,22 103:20	241:13 246:4	54:2 59:17
47:1 179:17	tracks 146:9	105:12 106:10	259:10 265:17	understood 48:11
220:19 233:10	tractable 234:14	137:12 160:10	271:9	49:4 59:3 138:14
254:18	traditional 23:21	166:8 223:13	twofold 160:6	uneasiness 86:11
timing 84:9 85:20	179:4,9 212:2	236:12 238:19	two-way 118:10	unemployment
99:22 100:3,15	216:6 217:20	239:10 273:15	119:2	29:5
101:13 275:15	239:20 240:1	trying 8:20 9:12	tying 98:21	unfortunate 179:1
title 72:11,12	traditionally 143:7	28:14 30:15 31:16	type 41:15,16 130:5	unfortunately
tobacco 47:13	training 110:21	34:3,7 38:14	144:3 152:19	19:17 211:22
48:13,14 149:21	135:2 140:14	41:11 46:15 58:6	161:4 180:3	258:10
150:1 156:22	190:5 192:2	65:8 69:4 75:7	203:15 263:6	uninsurance 29:5
262:14	trajectory 99:9	77:5 85:11 94:13	275:3,3	unintended 67:7
today 4:8,9,12 6:7	trajectory 99:9 transcribed 6:4	94:14 97:8 103:3	types 41:1 47:16	236:19
24:11 67:22	transformative	104:9 111:5,9,18	49:13 52:5 73:14	unit 39:4
119:12 196:8	37:20	165:6,7,9 169:5	79:22 109:15	United 92:12 146:3
237:19 264:6	translatable 247:5		119:22 133:17	158:10 167:14
275:10 276:9	translate 53:17	170:2,14 177:7 184:8 186:16	238:4	170:3 225:19
277:3 282:17	248:4			
		195:15 197:19	typical 60:5	units 39:9
286:11	translates 177:17	216:19 217:8,17	typically 177:6	University 106:20
today's 98:10 toes 151:11	translation 166:18	223:17 224:4	U	unreliable 237:12
	transportation	231:8 239:8 279:1	ultimately 5:16	unusual 145:19
told 180:1 186:22	42:9 82:1 92:20	Tuesday 180:17	56:15 109:16	unwanted 67:3
209:18 214:18	209:3	turn 85:18 210:1,8	228:8	upcoming 276:5
242:3	trash 237:14	238:11	um 194:20	updated 45:14
toll 51:11	treat 257:4,6	turnaround 101:20	unable 8:19 252:4	upped 15:16
ton 122:12	treating 61:18	turned 128:17	uncertainty 13:16	upside 67:21 69:19
tools 218:16 221:16	257:10	216:8 261:14	67:18	upstream 50:19
top 85:12 111:9	treatment 263:13	turning 237:8	underlying 90:14	58:2,10,15 63:13
152:6 204:9	tremendous 21:10	turnover 9:5	105:19	80:1,7,20 81:8
242:17 244:3	27:5 84:20	TV 112:3	underneath 132:7	86:21 116:10
topic 68:16 272:4	tremendously	tweak 151:5,8	understand 19:7	255:4
topical 106:15	120:3 221:20	tweaked 246:20	20:3,8 23:16	urban 169:15
283:4	trials 86:8 122:20	tweaking 65:15	25:14 48:10 51:8	usability 65:12
topics 65:15 150:4	triangular 46:22	144:6		236:14,15
197:11	tribal 218:3	Twenty 274:21	54:4 56:21 59:6 76:11 77:5 125:18	use 45:6,19 55:21
topped 254:19	trickles 99:1	two 6:21 16:8 17:9		66:7 76:9 82:7
tot 18:19	tried 9:22 125:18	23:11 32:4,16	142:9 174:16,22	120:7 133:13
total 83:7 116:3	141:15 258:14	47:17 72:7 98:9	177:14,17 178:7	134:21 139:11
279:19,22 280:19	Triple 110:7	101:10 105:10	194:1 207:14	150:1 160:5
280:22 281:4,15	113:17,19 136:14	106:18 112:21	228:14 230:15	161:21 162:18,20
totally 21:1 244:19	tripod 110:9	136:22 137:15	248:4 268:4	162:22 163:8
touch 28:3 49:21	trouble 123:8	139:16,18 143:21	270:18,18	165:3 169:3 170:2
72:9 91:15 92:2	troublesome 123:4	144:15 162:16	understandable	173:21 177:5

				Page 322
170.0 101.15	vooino 52.1.14	277.19	wells 269.21	100.7 201.0
179:8 181:15 189:7 200:13	vaccine 52:1,14	277:18 values 57:7 88:9	walls 268:21 want 4:8 5:19 9:14	190:7 201:9 203:18 230:22
203:8 211:19	vaccine-preventa 39:16	136:22 206:22	18:2 31:14,21	252:6,6 264:20
		241:19	,	232:0,0 204:20 285:8 286:15
214:14,21 216:14	valid 229:21		34:17,22 35:6	
218:8 221:1	264:14	variety 46:18	36:2 37:7,13	wants 58:17 211:2 232:4
223:21 225:11	validate 24:13	102:17 169:15	40:12 41:17 48:5	
240:8 248:10	68:12	various 27:4,13	50:20 51:1 55:13	war 33:8
250:5,8 254:4	validated 100:22	79:21 82:6 93:10	58:21 60:15 61:5	warn 279:6
260:7,8,19 264:4	validation 100:10	165:18 254:3	63:7,16 71:9 74:3	Washington 1:11
266:5,10 267:20	validity 65:12 86:5	vegetables 88:19	74:3 79:2,19 82:4	27:5
268:12 274:7,10	86:13	vein 224:18	84:3 94:3 95:12	wasn't 195:7
useful 43:9,22 45:5	valuable 131:5	Vernon 197:3	96:20 97:12	230:20
51:19 60:8,8	138:15 221:20	versus 40:18	108:13 118:9	watch 29:20
77:12 90:8 111:2	value 25:15 28:10	133:13 164:3	125:8 126:12	way 9:8 16:9 21:11
115:4,6 122:15	28:11,16 51:5	203:1	127:3 131:16	23:21 25:11 34:22
150:10 151:21	53:15,22 54:4,6	vicious 181:22	137:9 139:12,13	42:10,22 44:14
162:20 177:13	57:4,17 60:18	Vickie 92:14	139:17 144:5,22	47:22 53:1 54:19
208:6,8 218:9	65:22 75:13 76:6	view 64:5 98:16	151:14 152:8	70:12,14 76:13,14
236:18 237:1	78:10 84:6 88:3	103:12 148:1,4,5	155:18 157:13,19	76:17 81:6 86:20
259:21 261:11	89:21 90:5 102:5	276:4	158:6 163:6,9	91:8 99:10 107:10
usefulness 20:6	102:9 114:10	violence 29:4	164:5,20 165:2	113:15 117:15,16
users 136:7 137:19	132:15 133:2,4	virtual 68:17	166:9 167:5,5	118:22 123:1
138:2 160:7	135:5,13,13,19	vision 196:12	173:5,15 176:10	126:13 134:19
161:19 174:17	136:17 137:9,10	197:19	176:15 177:12	135:8,12 142:10
202:11,16,19	137:14 138:7	visit 21:7 183:1	179:11 182:10,20	145:6 150:6 151:7
203:18 214:6	139:10 174:16	visited 86:13	184:4 188:12	168:12 170:3
220:9 223:20	176:7,22 177:3,8	Visiting 102:16	189:7,11,13	173:9 174:18
227:18 228:10	177:18 178:8,9	visit-based 180:7	194:13 203:9	175:11 183:20,20
uses 32:2,10 36:7	181:16,17 184:7,8	visually 35:13	205:2,4,15 206:19	194:14,16 203:6
46:8 65:12 66:7	184:21 185:2	vital 90:12 237:11	207:3,6,12 220:1	203:10 207:5
136:7,13 137:18	186:12,14 188:20	238:17	226:2 227:16	208:10 219:20
138:2 174:17	190:15 193:5,19	voice 223:5	231:13 232:16	224:15 225:19
202:11,16,18	200:11,20 201:3,6	voted 6:9	233:7 238:3,10	226:9 230:21
203:18 214:6	201:15,21 202:6	voting 8:2,15	242:16 244:7	232:22 233:1
220:9	202:13,17,21		248:17 253:14,21	235:1 242:22
usually 15:19	203:1,19,21	W	260:3,7,8,19	243:1,16,19,20
123:14 283:6	204:13 205:22	wagging 183:8	262:21 263:18	244:1 250:20
utility 224:2	206:3,8,20 207:15	wait 11:11 100:14	266:10 269:5,18	251:13 255:8
utilization 57:16	216:1,10,18 220:4	144:8 185:7	274:6,10 277:15	257:2 258:2,6
116:18 232:18	220:5,20,21,22	waiting 14:21	278:7,18 284:12	259:1 264:17
utilize 190:11	221:5,8 222:7,9	29:14 77:4 94:12	wanted 6:2,7 9:1	266:4,18 267:19
U.S 7:13 146:10	222:12 223:11,15	127:19	11:15 14:6,14	ways 4:7 29:3
167:12 168:18	224:16,16,19	waiver 57:12	18:13 21:16 39:1	45:15 55:18 70:10
	225:8,18 226:2	Wakefield's 98:17	94:7 98:4,8	142:21 146:3
<u> </u>	230:2,9,15,17	walk 176:10	101:12 103:6	159:16 175:3
vaccination 52:3,8	239:3,6 241:16,16	walked 185:15	110:11 119:9	179:14 207:4
56:18	241:18 275:14	walking 81:22	145:10 182:17	217:20 236:6

				_
webinars 12:12,18	144:21 145:1	72:10 85:7 102:17	145:20 147:21	116:9 119:16
12:18 19:14	156:5 160:16	wider 66:15	154:13 155:12	120:9 136:1.5
133:20	165:6 166:16	willing 76:12 240:5	157:10,14 161:7	137:6 143:7 150:4
week 9:3 48:21	167:7,9 168:17	win 161:4	163:1 166:2	150:20 154:2
214:22 286:5	169:2,5 172:20	wind 166:10	167:12 168:10,14	208:20 209:10
weeks 246:5	173:3 178:2	wiring 35:7	171:6,8 172:8,20	210:6 237:10,10
weigh 58:20 199:6	181:13,14 182:7	Wisconsin 106:20	174:5 175:2,8,9	252:9
weight 43:20,21	183:5,6 188:15,19	107:13 156:20	181:19 185:11	worry 159:8 238:17
164:12 234:8	188:20 194:14	157:5,6,8,10	190:1 192:3 195:8	worse 115:1,1
282:9	196:14 198:1	158:9 226:18	197:5,19 198:3,14	210:5
welcome 3:2 6:1	201:6 203:5,7	wish 132:11,13,15	198:15,16 199:2	worth 67:22
wellness 257:6	204:1 207:5,9	171:18 280:1	199:12,16,19	worthwhile 26:5
well-being 10:2	213:19 214:14	withheld 178:12	200:1 217:17,19	wouldn't 149:9
52:21 257:14,16	215:10 226:9	wonder 168:13	224:8 232:17	182:19 213:1
Wendy 197:2	230:6 232:5 236:5	210:19 211:6	238:19 241:4	215:14 218:8
199:17 271:20	237:3 242:6,19	246:21 261:12	243:14 244:1	223:22
went 104:20 113:13	243:7 244:20	272:8	248:10 249:8,16	Wow 213:7
123:19 187:8	247:3,4 255:6	wondered 237:7	258:11,14 263:19	wrap 123:16
287:6	259:4 266:9	Wonderful 95:17	265:1 268:15	wrapping 259:20
weren't 23:3 37:8	267:13 279:18	wondering 78:16	269:2,16,17	write 152:10 256:9
84:8 100:22 101:1	284:5,14 285:17	203:11 246:17	270:13 271:13,18	265:20 266:19
159:21 248:15	287:1	248:3 264:16	272:3,9 285:1,13	written 10:21 63:6
we'll 4:9,18 5:2	we've 9:8 13:11	Wood 106:19	286:22	75:22 93:12
18:16 33:12 34:12	14:15,16,17 15:13	word 12:17 72:17	worked 33:20	wrong 72:17 155:9
94:12 111:20	39:2 43:5 45:2	138:22 155:21	148:3 179:6	173:3
123:17 152:3,12	53:13 56:10 61:10	228:18	278:20	wrote 163:16
169:3 177:11	74:11 100:2 117:9	words 32:16 151:8	worker's 182:18	165:13
209:12 223:1	122:9 123:22	work 4:5 11:11	working 9:8 18:21	
236:20 249:16	126:7 145:5	12:7 18:3,9 19:1	19:13 21:2 30:7	X
257:4 285:15,22	155:15 169:19	19:11 20:2,9,22	30:12 57:11 64:3	Xerox 51:10,10
286:5	171:13 172:21	21:5 22:7 26:3	64:10,17 66:16	Y
we're 14:20 18:1,4	175:2,2 185:9	34:3 37:3 43:2,8	84:13 87:17 109:9	
19:17 22:1,2	196:20 204:16	47:5 48:15 49:17	127:10 165:8	year 7:12 39:13
28:11 29:14 31:3	205:12 207:7	50:20 59:1,1 63:3	176:20 178:20,22	85:21 121:6
37:9,17 38:11,12	228:12 236:10	64:14,20 65:5,7	179:2 185:3 187:1	142:17 208:4
39:20 42:1 44:13	237:2,6 248:11	66:21 69:4 70:22	196:2,14,21 197:6	236:15 244:22 245:10 270:11
53:2 58:6,6 59:4	259:14 260:13	71:2 73:4 74:1,15	231:21 243:1	years 7:22 15:15
61:22 62:14,16,19	272:12 278:19	79:18 85:17 87:15	248:18 270:1	79:8 82:12,21
66:7 72:3,4 76:3	282:15	88:12 104:19	272:1	88:1 100:5,14
78:4 83:19 84:4	wheel 27:8 130:19	105:12,13 109:2	works 93:11 111:1	102:11 107:19
87:2 94:12,14	167:11 171:10	110:10 112:22	175:13 177:14	111:10 120:21
98:20 99:11	264:16	113:22 114:3,12	224:6	167:21 168:19
105:13 106:12	wheelhouse 72:1	120:16 121:5,15	workshop 151:1	222:22
109:8 110:19	white 129:10	122:10 133:7,17	world 42:5,6 53:15	yesterday 4:6,11
116:6 118:19	272:15	134:20 140:1,4	54:1,22 66:15	6:8 8:5 9:6,16
120:8 126:14	whites 254:16	141:15 142:8,21	69:3 86:12 110:17	16:2 37:4,11 39:1
140:7,9 141:9	wide 16:12 63:13	143:4 144:4,11,14	110:20 114:21	40:17 41:10 43:11
	I	I	l	10.17 11.10 10.11

51:17 54:5 62:15	2012 1:7	9		
77:10 98:4 102:15	2012 1.7 2013 105:14 244:21			
105:10 116:21	275:18	9th 1:10		
122:21 123:5	2014 7:10	990 30:19 219:13		
142:12 149:19	2015 214:21			
178:10 179:17	2013 7:12			
221:14 254:8,11	2010 7:12 2020 8:16 71:14			
277:3 286:11	21st 285:20			
York 7:16 228:3	21st 285.20 22 274:21			
YRBS 68:9 222:1	25 82:12,21			
I KD S 00.7 222.1	26 262:6			
0	278 3:6			
00237:15	273 3.8			
0024 7:21 8:5,10	203 5.0			
0029 6:19	3			
0421 7:4	3 125:15,20 214:21			
	262:9 280:17			
1	3:00 278:22			
1 3:2 51:21 73:10	30 11:21 88:1			
94:15 125:3,19	237:17 285:21			
188:16	30th 286:5			
10:41 123:19	300 171:4			
1030 1:11	31 1:7			
11:04 123:20	33 3:5			
11:45 123:17	35 262:22			
1115 57:12				
12:00 187:3	4			
12:07 187:8	4 3:2 57:12			
12:52 187:9	4b 200:9			
12:53 188:2	45 126:4			
15 123:14				
15th 1:11	5			
15,000 64:6	5 221:7			
1690 7:19	50 254:17			
18 7:16,22 8:11	6			
84:15 222:1,1	6 3:3			
1999 6:15	64 222:2			
2	04 222.2			
	7			
2 4:4 7:21 8:11	70 254:16			
125:20 262:9	700 67:9			
280:17 282:11				
285:18				
2:30 266:1,8	8:30 1:12			
2:31 287:6	8:39 4:2			
20 88:1 113:10	80 254:15			
153:19				
2001 252:8				
	1	1	1	1

CERTIFICATE

This is to certify that the foregoing transcript

In the matter of: Population Health Steering Committee

Before: NQF

Date: 05-31-12

Place: Washington, DC

was duly recorded and accurately transcribed under my direction; further, that said transcript is a true and accurate record of the proceedings.

near A ans f

Court Reporter

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701 325